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Abstract 
There is strong interest in developing novel targeted cancer therapies. It has been known for 
over a century that certain viruses and bacteria can preferentially infect and lyse cancerous 
cells. Clinical utility has lagged behind the initial promise of the idea; however three 
therapeutic agents from the oncolytic virus field are currently in Phase IIB/Phase III clinical 
trials. The development path of such therapies would be substantially smoothed by an ability 
to noninvasively monitor their location in the patient’s body post-administration. This would 
allay fears that viral/bacterial distribution may not be confined to the tumour and provide 
real time information on vector localisation and replication. This could be achieved by 
positron emission tomography (PET) scanning if the vector expressed a reporter protein 
which could activate a PET suitable imaging agent. Furthermore the potency of such 
therapies could be increased by if this reporter protein could also act therapeutically by 
converting a systemically delivered benign prodrug into a potent chemotherapeutic – thus 
targeting the toxicity of the prodrug specifically to cancerous cells. A promising 
enzyme/prodrug combination is the use of bacterial nitroreductase (NTR) enzymes to 
activate DNA damaging prodrugs, such as the dinitrobenzamides CB1954 and PR-104A.  
This thesis presents work aimed at developing the ability to noninvasively image bacterial 
NTR expression so that these enzymes can act as both therapeutic and reporter proteins. The 
primary focus of this study was to achieve this by repurposing pre-existing 2-nitroimidazole 
(NI) PET imaging agents, originally developed for imaging tumour hypoxia. Microplate 
based screening strategies were developed to enable detection of 2-NI bioreductive 
activation by different bacterial NTRs over-expressed heterologously in Escherichia coli, 
and these technologies were used to screen a 58-membered library of nitroreductase 
candidates. Although the most widely studied NTR for enzyme/prodrug therapy - NfsB from 
E. coli - was found to lack activity with 2-NI substrates, numerous NTRs from the NfsA 
family were able to metabolise these molecules to the cell entrapped form required for PET 
imaging. Following this discovery, a directed evolution study was conducted to improve the 
native activity of the enzyme NfsA from E. coli. In this study targeted mutagenesis of active 
site residues was carried out, resulting in identification of several NfsA multi-site mutants 
that were substantially improved in their ability to activate a range of 2-NI imaging agents. 
In addition to repurposing existing PET probes, this work sought to identify and engineer 
NTRs for efficient activation of a next-generation PET probe that is designed to be 
substantially less responsive to hypoxia and hence give a cleaner signal for NTR imaging 
(i.e. low to no background resulting from tumour hypoxia). SN33623, a novel 5-NI analogue 
of the existing 2-NI PET probe EF5, was designed and synthesised by our University of 
Auckland collaborators. It was found that this novel probe was not only activated by NfsA 
enzymes, but also by a subset of NfsB enzymes. Although this subset did not include E. coli 
NfsB, sequence alignment and site-directed mutagenesis were used to identify two key 
mutations that can be introduced into E. coli NfsB (as well as engineered variants thereof) to 
confer high levels of SN33623 activity. 
Finally work was carried out, as part of a wider collaborative project, to generate NfsA 
mutants that retained the ability to metabolise 2-NI imaging agents while also showing 
increased activation of the nitroaromatic prodrug PR-104A. Ongoing evaluation of these 
enzymes will include assessment of their therapeutic effect in preclinical models and their 
ability to be noninvasively imaged (by microPET) when expressed from the tumour targeting 
bacterial strain Clostridium sporogenes.   
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Chapter 1: Introduction 
1.1 Targeted novel anti-cancer therapeutics  
According to the most recent Ministry of Health statistics, cancer is now the leading 
cause of death in New Zealand (29.4% of total) (Ministry of Health, 2012), highlighting 
the need for improved treatment strategies. Conventional treatments for cancer typically 
involve surgery, radiotherapy, chemotherapy, or some combination thereof; and can be 
successful particularly when accompanying early cancer detection e.g. the 5 year survival 
rate of melanoma diagnosed when confined to a primary site is 98.2% versus 15.1% when 
diagnosed post distant metastasis (http://seer.cancer.gov/statfacts/html/melan.html, 
accessed 22/2/13). However, the still unacceptably high rate of cancer mortality points to 
a need for improved treatment strategies. A desire for novel therapies has been 
accompanied by a growing understanding of some of the specific features of the tumour 
micro-environment, such as local immune suppression (De Visser et al., 2006), and 
tumour hypoxia (Dachs and Tozer, 2000), which can make a major contribution to 
treatment failure or relapse. This has raised interest in developing treatments which can 
more specifically target toxicities to cancer cells, while avoiding the often brutal side 
effects of standard chemotherapies (Breitbach et al., 2011a; Denny, 2000; Forbes, 2010). 
One such strategy is to treat patients with viral or bacterial pathogens that can specifically 
target their toxicity towards cancer cells. The use of these experimental and replication 
competent therapies brings attendant safety concerns. As such the ability to track the 
location and behaviour of the therapeutic virus/bacteria inside the patient, and in 
preclinical settings, would be invaluable. This thesis primarily focuses on developing 
such imaging capability. 
1.2 Oncolytic viruses as targeted anti-cancer therapeutics 
It was first observed over 100 years ago that, in certain cases, viral infection of a cancer 
patient could lead to positive therapeutic effect and this was later attributed to the fact that 
some viruses are able to preferentially infect, replicate within, and directly lyse cancerous 
cells over healthy tissues (Kelly and Russell, 2007). In the modern era researchers have 
sought to take advantage of such attributes and various oncolytic viruses from multiple 
classes have been investigated as anti-cancer treatments, including but not limited to 
adenovirus (Garber, 2006), herpes viruses (Kaufman and Bines, 2010), reovirus (Kelly et 
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al., 2012), poxvirus (Breitbach et al., 2011a) and measles virus (Msaouel et al., 2009a). In 
some cases treatment involves unmodified viruses that possess a native ability to 
preferentially infect tumour cells (Gollamudi et al., 2009) although more commonly used 
are oncolytic viruses that have been specifically adapted or engineered for increased 
tumour specificity. Such specificity can be achieved by deleting viral genes which are 
crucial for entry and replication within a healthy cell, but dispensable when infecting 
disregulated cancer cells. For example, deletion of the viral thymidine kinase forces the 
virus to rely on high thymidine pools found in many cancers (McCart et al., 2004). In 
another mechanism, cancer cells that have decreased their sensitivity to interferon 
mediated apoptotic and growth inhibitory regulatory signalling have simultaneously 
sensitised themselves to attack from some viruses, as interferon signalling can be a crucial 
component of a successful cellular anti-viral response (Gollamudi et al., 2009; Stojdl et 
al., 2000).   
Interest in oncolytic viruses is not solely due to their targeted nature but also because of 
the multi-mechanistic ways in which they effect an anti-tumour response. This can be 
effected through direct lysis of infected cells, by stimulation of both innate and adaptive 
anti-tumour immunity (Kaufman et al., 2010) and, for some viruses, by initiation of 
tumour vasculature collapse (Breitbach et al., 2011b). That these mechanisms are distinct 
from the toxicity brought about by traditional, often anti-proliferative, chemotherapies 
suggests that oncolytic viruses may synergise well with current standard treatments 
(Harrington et al., 2010).  
The “gold standard” for such therapies would be efficacy against advanced, treatment-
refractory disease (Breitbach et al., 2010). As this is often metastatic, meeting this 
standard would require that the virus be able to treat multiple, and often inaccessible or 
unidentifiable lesions. To date, however, the majority of clinical trials have involved 
intratumoural delivery (Russell et al., 2012). Some of these have observed that following 
intratumoural injection distal lesions can also show therapeutic response, thought to be 
due to viral dissemination in the blood infecting distal legions (Park et al., 2008) or 
through the development of an anti-tumour immune response (Kaufman et al., 2010). 
Generally speaking though, to effect sustained anti-tumoural response in metastatic 
disease is thought to require systemic, intravenous viral delivery. This in turn requires 
that the virus be able to evade the immune system and disseminate in the blood stream; 
research to improve such capabilities is ongoing (Russell et al., 2012). Use of viruses 
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from classes such as vaccinia, which have evolved for intravenous spread, may also 
confer more efficacious systemic delivery, for example in a Phase I clinical trial 
intravenous delivery of the vaccinia virus JX-594 was demonstrated as safe, and the virus 
showed a dose dependent ability to specifically replicate within tumours (Breitbach et al., 
2011a). In addition to all of the technical challenges, progress in intravenous delivery has 
been slowed by regulatory body safety concerns, which mandate a conservative trial 
escalation to intravenous administration (Harrington et al., 2010).  
Demonstrated clinical utility of oncolytic viral therapies has lagged behind the inherent 
promise and interest in the modality, with only one clinical approval to date; a oncolytic 
adenovirus H101 approved for treatment of head and neck cancers in China (Garber, 
2006). However numerous viral therapies are in active development or early stage clinical 
trials with two field leaders in phase III trials (OncoVex
GM-CSF
 and Reolysin®), and a 
third (JX-594) in Phase IIb.  
1.2.1 OncoVexGM-CSF  
OncoVex
GM-CSF
 is a herpes simplex virus type I that has been engineered to express 
granulocyte-macrophage colony-stimulating factor (GM-CSF), to encourage an anti-
tumour immune response by stimulating recruitment of dendritic cells to the tumour 
(Kaufman et al., 2010). It is currently in Phase III clinical trial for treatment of advanced 
melanoma and head and neck cancer (Kaufman and Bines, 2010). In a Phase II trial for 
treatment of stage IIIc and IV melanoma, detectable disease was completely eliminated in 
eight patients and overall objective clinical responses were seen in 26% of the 50 patients 
treated (Senzer et al., 2009). In Jan 2011, based on the strength of Phase II results, 
BioVex was acquired by  the publicly listed pharmaceutical company Amgen for $425 
million, with the deal containing a potential $575 million more in milestone rewards 
(Schmidt, 2011).  
1.2.2 Reolysin® 
Reolysin®, developed by Oncolytics Biotech Inc, is a replication-competent form of the 
reovirus serotype 3 Dearing strain, which preferentially infects, replicates within, and 
stimulates the apoptosis of cancer cells with activated Ras signalling pathways (Kelly et 
al., 2012; Strong et al., 1998). Reolysin® in combination with paclitaxel and carboplatin 
is currently in Phase III clinical trials for the treatment of platinum refractory head and 
neck cancers. In addition, Reolysin® is in more than 10 ongoing Phase II clinical trials 
4 
 
 
covering 12 different cancer indications including non-small cell lung cancer, glioma, 
sarcoma and melanoma, as either a sole agent or more commonly in combination with 
chemotherapies or radiotherapies (http://www.oncolyticsbiotech.com/clinical-trials 
accessed 19/12/2012).  
1.2.3 JX-594 
JX-594 is a Wyeth strain vaccinia virus engineered to express GM-CSF and developed by 
the private biotherapeutics company Jennerex (Parato et al., 2011). In multiple early stage 
trials (treating over 160 patients combined) JX-594 has been demonstrated as safe and 
associated with anti-tumour response, and a recently completed Phase II randomised dose 
finding trial for treatment of advanced hepatocellular carcinoma reported a difference in 
median survival of high dose and low dose patients (14.1 versus 6.7 months respectively 
(Heo et al., 2013)). JX-594 is now in a multi centre PhaseIIB trial which aims to enrol 
120 patients, in which intratumoural injection will be used to treat patients suffering from 
advanced hepatocellular carcinoma who have failed sorafenib treatment, 
http://clinicaltrials.gov/show/NCT01387555.  
1.3 Bacteria as targeted anti-cancer therapeutics 
Viruses are not the only biological agents known to have innate tumour tropism. In 
preclinical models bacteria from a growing range of genera have been shown to, 
following intravenous delivery, preferentially infect and replicate inside of the tumour 
microenvironment, particularly the central necrotic core (Forbes, 2010). This ability is 
displayed by a number of facultative anaerobes such as Escherichia coli (Brader et al., 
2008) and Salmonella typhimurium (Soghomonyan et al., 2005). Reasons for this are not 
entirely understood but are thought to involve a combinations of factors including the 
immune privileged nature of the tumour microenvironment (Yu et al., 2008), that the 
leaky vasculature and sluggish tumour blood flow aid the ability of blood-borne bacteria 
to adhere to tumour cells (Forbes et al., 2003) and that the increased available local 
supply of certain nutrients due to necrotic cell death promotes chemotaxis of the motile 
bacteria to such regions (Kasinskas and Forbes, 2007). This nutrient pool can be targeted 
to increase tumour specific localisation in these facultative anaerobes by gene-knockout 
to generate auxotroph strains (Zhao et al., 2005), for example the clinically tested 
Salmonella typhimurium VNP20009 strain carries a purI deletion that forces the bacteria 
to rely on external sources of adenine (Toso et al., 2002). 
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For obligate anaerobes such as Clostridium (Liu et al., 2008b) or Bifidobacterium (Li et 
al., 2003) the primary mechanism for tumour targeting is better understood, as these 
bacteria can only replicate at pathologically low oxygen levels i.e. in the hypoxic and 
necrotic core of solid tumours. Therapeutically this is beneficial, as hypoxia is a well 
established negative prognostic factor for tumour treatment, but does not typically occur 
in healthy tissue (with the exception of the bone marrow compartment (Asosingh et al., 
2005)) providing a chance to target toxic therapies specifically to cancerous cells. 
Hypoxia is a state of abnormally low oxygen levels (typically defined as an oxygen 
partial pressure of 2.5-10 mm Hg (Rasey et al., 1999), which arises to at least some extent 
in the majority of solid tumours larger than 1 mm
3
 (Dachs and Tozer, 2000) due to rapid 
tumour growth and irregular vasculature compromising blood supply (Vaupel et al., 
1989). Hypoxic cells are resistant to radiotherapy, which requires generation of oxygen 
free radicals for full effect (Gray et al., 1953). Hypoxia also increases resistance to 
chemotherapeutic treatment as the slow growing nature of many hypoxic cells spares 
these cells from anti-proliferative chemotherapies (Kennedy et al., 1997) and as the 
compromised vasculature associated with hypoxia limits drug delivery (Denny, 2000). 
Hypoxia is also known to alter patterns of cell gene expression to promote a more 
aggressive cancer phenotype (Dachs and Tozer, 2000). As motile bacteria actually 
penetrate deep into the hypoxic/necrotic tumour core (Kasinskas and Forbes, 2007; Umer 
et al., 2012), this provides a method of delivering therapies specifically to problematic 
areas that should synergise well with existing chemotherapies whose diffusion to such 
areas is limited (Forbes, 2010).  
In preclinical models bacteria have been shown to exert direct anti-tumour effects  
(Bettegowda et al., 2003; Weibel et al., 2008; Zhao et al., 2007), however it is primarily 
envisaged that for clinical use these effects would be augmented by engineering the 
bacteria to express proteins that confer enhanced toxicity (Forbes, 2010; Hoffman, 2011). 
One strategy is to engineer the bacteria to express directly toxic proteins such as TNF-
related apoptosis-inducing ligand (Ganai et al., 2009) or to increase immune stimulation 
through expression of cytokines such as interleukin-2 (al-Ramadi et al., 2009).  An 
additional strategy is to “arm” the bacteria to express an enzyme that is capable of 
converting a systemically delivered benign prodrug into a potent chemotherapeutic (King 
et al., 2009; Theys et al., 2006). Broadly speaking this strategy is termed gene directed 
enzyme prodrug therapy (GDEPT).  
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1.4 Gene directed enzyme prodrug therapy 
GDEPT refers to experimental anti-cancer gene therapies in which a tumour targeting 
vector, most commonly viral, is used to deliver a gene specifically to tumour cells, 
wherein the enzyme product of this gene is then expressed. This enzyme is able to convert 
a non-toxic prodrug into a potent chemotherapeutic - thus targeting the toxicity of the 
compound specifically towards cancer cells. Crucially, the activated chemotherapeutic 
should be able to diffuse to and kill closely neighbouring cancer cells, conferring the 
possibility of achieving significant tumour ablation without having to achieve the 
(essentially impossible) aim of transfecting every tumour cell with the delivered gene 
Figure 1-1. This “bystander effect” can provide an attractive adjunct to oncolytic 
virotherapies as it confers an additional mechanism to destroy tumour cells that have not 
been directly infected with the virus (Kirn and Thorne, 2009).  
 
 
Figure 1-1 Schematic showing principle of gene directed enzyme prodrug therapy. A tumour 
tropic vector (in this example a virus), is used to deliver the therapeutic transgene specifically to 
tumour cells, which if transfected will then express the enzyme. When the systemically delivered 
prodrug encounters this enzyme, it is converted to a potent chemotherapeutic which is also able to 
diffuse to neighbouring tumour cells.  
 
A number of possible enzyme/prodrug combinations have been investigated (Altaner, 
2008). The most trialled enzyme/prodrug modality, the use of herpes simplex virus 
thymidine kinase (HSV1-TK) to activate the nucleoside analogue ganciclovir (GCV) is 
described in detail below (section 1.4.1). Other notable modalities include cytosine 
deaminase mediated conversion of 5-fluoroctyosine to the nucleoside analogue 5-
fluorouracil (Freytag et al., 2007), the activation of DNA damaging mustard prodrugs by 
cytochrome P450 variants (Ma and Waxman, 2007) and the modality most relevant to this 
Tumour tropic 
vector carrying 
therapeutic 
transgene Prodrug 
systemically 
delivered
Tumour cells express transgene 
enzyme product Tumour cells killed on chemotherapeutic 
prodrug activation 
Additional killing from bystander effect 
as chemotherapeutic diffuses to 
neighbouring cells  
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thesis, the use of bacterial nitroreductase (NTR) enzymes to activate nitroaromatic DNA-
damaging prodrugs.  
1.4.1 Herpes simplex virus thymidine kinase and ganciclovir  
HSV1-TK/GCV was the first suicide enzyme/prodrug pair suggested (Moolten, 1986) and 
has been the most widely investigated (Duarte et al., 2012). Triphosphorylated GCV can 
cause cell death by interfering with DNA replication via direct inhibition of DNA 
polymerase and by misincorporation into elongating DNA strands. Retroviral delivery of 
HSV1-tk followed by GCV therapy was incorporated in the treatment of glioblastoma 
multiforme in the first GDEPT phase III clinical trial (Rainov, 2000). While in this 
instance no additional therapeutic benefit was observed, clinical research has continued 
using different gene delivery strategies, and a number of Phase I and II clinical trials 
incorporating this treatment have seen responses suggestive of  improvement in patient 
outcome (Freytag et al., 2007; Li et al., 2007; Nasu et al., 2007). In a more recent 
example of application of this therapeutic strategy, a replication competent adenovirus 
expressing both an engineered mutant version of HSV1-tk, a yeast derived cytosine 
deaminase gene, and a viral protein that enhances oncolytic activity is currently in a 
randomised Phase II/III trial for treatment of prostate cancer in combination with 
valganciclovir (a pre-prodrug of gancicovir), 5-fluorocytosine and radiotherapy (Lu et al., 
2011). It should be noted that one disadvantage of the HSV1-TK system is that as the 
chemotherapeutic is a nucleoside analogue only actively dividing cells are targeted (the 
same limitation applies to cytosine deaminase). An added disadvantage is that activated 
GCV is not freely cell permeable, making the bystander effect of the treatment primarily 
dependant on cell-cell contacts such as gap junctions (Mesnil and Yamasaki, 2000), 
which can be down-regulated in the dysfunctional tumour environment (Trosko, 2003).  
1.4.2 Bacterial nitroreductase NfsB and CB1954 
The prototypical NTR/prodrug pair is the E. coli enzyme NfsB and the aziridinyl 
dinitrobenzamide prodrug CB1954. Interest in CB1954 was triggered when it was 
observed as a sole agent to efficiently treat tumours arising from a transplanted Walker-
256 rat carcinoma cell line (Cobb et al., 1969). This potent tumour toxicity was later 
found to stem from CB1954 acting as a tumour activated prodrug, with reduction of 
CB1954 by tumour upregulated rat NQO1 converting the weak monofunctional alkylating 
agent to a 4-nitrohydroxylamine (NHOH) derivative. This derivative, following further 
interaction with intracellular thioesters such as acetyl CoA, (either via non-specific (Knox 
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et al., 1991) or enzymatic means (Mitchell and Minchin, 2008)) becomes a potent DNA-
cross linker (Figure 1-2) .   
 
Figure 1-2 CB1954 reduction by rat NQO1 at the 4-nitro moiety converts the compound to first 
the nitroso (not pictured) and then nitrohydroxylamine derivative. Non-specific reaction of the 
latter product with intracellular thioesters results in a compound that binds to and cross-links 
DNA (Knox et al., 1991).  
 
Unfortunately CB1954 is not suitable for use as a sole chemotherapeutic agent against 
human tumours, which do not exhibit the same CB1954 sensitivity, due to the inability of 
the human form of NQO1 to efficiently reduce the prodrug (Boland et al., 1991). 
However another possible application of CB1954 therapy became apparent when the E. 
coli NTR enzyme NfsB was shown to reduce CB1954 90-fold faster than even rat NQO1 
(Anlezark et al., 1992), suggesting utility as a prodrug for GDEPT. Importantly, the 
reduced cytotoxic metabolites of CB1954 are cell permeable and demonstrate a bystander 
effect  (Bridgewater et al., 1997), thought to be primarily effected by the reduced 
metabolites that arise from reduction of the 2-nitro group (Helsby et al., 2004). NfsB can 
reduce either nitro group with equal efficiency, generating equimolar mixes of the 2-
hydroxylamine and 4-hydroxylamine reduction products (Anlezark et al., 1992).  
Phase I/II trials of CB1954 in conjunction with a replication defective-adenovirus 
expressing E. coli NfsB showed that treatment was safe, and a decline in levels of 
prostate specific antigen in some patients suggested some effect, however overall it was 
deemed that greater therapeutic efficacy would be desirable (Patel et al., 2009). While 
next generation viral vectors would presumably be beneficial to this therapy, trial data 
also suggested that the combination of CB1954 and NfsB may not be optimal. 
Hepatotoxicity in clinical trials limited the maximum tolerated drug dose, and achievable 
peak serum concentrations of CB1954 (6.3 ± 2.8 μM) (Chung-Faye et al., 2001) were less 
than one eightieth of the lowest reported Km for E. coli NfsB (Anlezark et al., 1992). As 
such, a search for both more efficient NTRs and effective prodrugs is warranted.  
22
4 4
NQO1
Thioester eg. 
acetyl CoA 2
4
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1.5 Strategies to improve NTR based GDEPT 
1.5.1 Alternative nitroaromatic prodrugs  
NTR based GDEPT using the prodrug CB1954 does have the advantage of building off 
decades of research, as well as the pharmacokinetic data and compliance with good 
manufacturing practice conferred by phase I/II clinical trials (Chung-Faye et al., 2001; 
Patel et al., 2009). However another drug class also offers the same advantages, the 
hypoxia activated dinitrobenzamide mustards. Of these the lead candidate PR-104 
(Figure 1-3), successfully passed Phase I clinical trial (Jameson et al., 2010; McKeage et 
al., 2011) as a hypoxia-activated therapeutic (i.e. independent of GDEPT application).  
                                 
Figure 1-3 Chemical structure of the dinitrobenzamide mustard PR-104 
 
Activated nitrogen mustards are extremely potent drugs due to their ability to bind to the 
N
7
 position of guanine and subsequently cross-link DNA  (Mattes et al., 1986) (Figure 
1-4), and were in-fact among the first small molecules ever used to treat cancer (DeVita 
and Chu, 2008).  
 
 
Figure 1-4 DNA cross-linking by a nitrogen mustard, shown here with chlorine leaving groups 
(Wardman, 2001).   
 
The molecular basis for the use of dinitrobenzamide mustards as hypoxia activated 
prodrugs is that this potent toxicity can be “harnessed” by attachment of the mustard 
10 
 
 
moiety to an electron withdrawing dinitrobenzamide ring, thus stabilising the molecule. 
However if a nitro group on the dinitrobenzamide ring is reduced, this change in electron 
density converts the dinitrobenzamide ring from an electron withdrawing to an electron 
donating group, re-activating the  inherent toxicity of the mustard (Denny and Wilson, 
1993; Guise et al., 2007a). 
 
Figure 1-5 Reduction of PR-104. PR-104 is administered in “pre-prodrug” form, with an 
attached phosphate that increases solubility in the bloodstream. This is cleaved in vivo by human 
phosphatases to generate the more lipophilic prodrug PR-104A. Reduction of the para nitro group 
to either hydroxylamine or amine form (as per Figure 1-6) converts the dinitrobenzamide ring 
from an electron withdrawing to an electron donating group, activating the latent toxicity of the 
nitrogen mustard substituent.  
 
The basis of hypoxia activation in vivo is that the dinitrobenzamide mustards are 
substrates for a number of endogenous human enzymes (e.g. cytochrome P450 reductase 
(Guise et al., 2007a)) that can carry out reduction in one electron increments. This 
mechanism of reduction produces an unstable one electron radical as the first reduction 
product, which in the presence of oxygen is rapidly back-oxidised to the original prodrug. 
This means that full reduction to a DNA cross-linking metabolite can occur only in the 
absence of oxygen.  In contrast, NfsB and other oxygen insensitive NTRs reduce 
nitroaromatic substrates in simultaneous 2e- increments (Bryant et al., 1981; Koder et al., 
2002; Peterson et al., 1979), meaning production of reduced metabolites in a GDEPT 
context is independent of the presence of oxygen (Figure 1-6). 
PR-104
(Preprodrug)
PR-104A
(Prodrug)
NHOH
Electron 
donating
Electron 
withdrawing
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Figure 1-6 Schematic of hypoxia dependent and independent nitroaromatic reduction, 
proceeding from the parental compound to an amine derivative in 1e
-
 and/or 2e
-
 steps. If the first 
reduction is carried out by a 1e
-
 reductase (e.g. cytochrome P450 reductase (CYPOR)) the full 
reduction can only proceed in the absence of oxygen, otherwise the resulting nitro anion radical is 
back oxidised, regenerating the parental compound in a futile cycle. In contrast if all reduction is 
carried out in 2e
-
 increments, as catalysed by bacterial NTRs (e.g. NfsB), then reduction proceeds 
irrespective of oxygenation status.    
 
Disappointingly, the safe clinical dose of PR-104 was lower than had been anticipated, 
which may limit its efficacy as an independent chemotherapeutic agent (McKeage et al., 
2011). PR-104 was found to undergo off-mechanism aerobic (2e-) reduction by human 
aldo-keto reductase 1C3, going some way to explain this observation (Guise et al., 2010) 
and suggesting that dinitrobenzamide mustards that are not substrates for human aldo-
keto reductase 1C3 may be more suited for sole agent use.  Despite the off-mechanism 
AKR1C3 activity PR-104 is still far more dose potent than CB1954, with an up to 20 
times higher maximum tolerated dose on a molar basis (Jameson et al., 2010). This, 
coupled with the advanced clinical status of PR-104, makes it an attractive (pre)prodrug 
for GDEPT.  
Various NTRs, including NfsB, show better catalytic activity with PR-104A (Prosser et 
al., 2013) and other dinitrobenzamide mustards (Anlezark et al., 1995) than they do with 
CB1954, an observation that also suggests these molecules may prove more appropriate 
prodrugs for GDEPT. Importantly, dinitrobenzamide mustards show substantially greater 
potency and bystander effect in mixed population 3D cell models (which measure the 
level of bystander cell death caused by activated drug diffusing from a small population 
Nitro Nitro anion 
radical
2e-
1e- 1e- 2e- 2e-
Nitroso Hydroxylamine Amine
eg. NfsB
eg. CYPOR
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of NTR expressing cells), largely due to their increased lipophilicity compared to CB1954 
(Atwell et al., 2007; Singleton et al., 2007; Wilson et al., 2002).  This increased potency 
is reflected in vivo, for example mice carrying tumour xenografts containing 10% NfsB 
positive cells showed an increase in median survival of only 11 days following CB1954 
treatment compared to 62 days with a dinitrobenzamide mustard SN28343 (Singleton et 
al., 2007).   
1.5.2 Alternative bacterial nitroreductases for GDEPT  
A different but complementary approach to improving NTR GDEPT is to identify NTRs 
that better activate CB1954 and/or other nitroaromatic prodrugs such as PR-104. This has 
been pursued by researchers investigating the prodrug activating abilities of bacterial 
nitroreductases found in nature, both by examining NfsB homologues (Emptage et al., 
2009; Swe et al., 2012; Theys et al., 2006) and NTRs that share little sequence similarity 
to NfsB such as Bacillus amyloliquefaciens YwrO (Anlezark et al., 2002) and 
homologues (Theys et al., 2006) or an engineered derivative of E. coli YieF (Barak et al., 
2006). NfsB has been shown to be less effective at sensitising tumour cells to CB1954 
than another E. coli enzyme, termed NfsA, (Vass et al., 2009), and at a purified protein 
level NfsA shows a near 10-fold higher specificity constant for CB1954 reduction 
(Prosser et al., 2010). More effective GDEPT NTRs have also been sought by generating 
mutants of NfsB with improved activities towards CB1954 (Guise et al., 2007b; 
Jaberipour et al., 2010). Some of these engineered NfsB derivatives are discussed in more 
detail in Chapter 6 of this thesis.  
1.6 Bacterial nitroreductases 
Bacterial NTRs are a ubiquitous and diverse enzyme class, with the best characterised 
NTRs  belonging to the NfsA (Liu et al., 1997; Nokhbeh et al., 2002; Zenno et al., 1996a) 
or NfsB subfamilies (Anlezark et al., 1992; Bryant and DeLuca, 1991; Koike et al., 1998).  
While there is essentially no sequence identity shared between these two families, both 
types of enzyme function as FMN dependent homodimers. NTRs exhibit bi-bi ping pong 
kinetics, meaning overall substrate reduction proceeds via NADPH binding, transfer of 
2e- from NAD(P)H to reduce the associated FMN cofactor and exit of the NAD(P)+ from 
the active site; followed by binding of the second substrate close to the FMNH2 and 
subsequent transfer of the 2e- to reduce the second substrate (Koder and Miller, 1998; 
Zenno et al., 1996a). NfsA family members typically exhibit a pronounced preference for 
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NADPH (Liu et al., 1997; Morokutti et al., 2005; Nokhbeh et al., 2002), whereas the 
NfsB family can use either co-factor (Koder and Miller, 1998; Zenno et al., 1994). That 
the reduction is carried out in obligate 2e- steps is believed to be because the 1e- reduced 
form of FMN is highly disfavoured while this cofactor is NTR associated (Koder et al., 
2002).  
NTRs are extremely promiscuous enzymes, and due to their broad substrate specificity 
are also under investigation for bioremediation, as they can reduce (and thereby detoxify) 
the pollutant chromate (Ackerley et al., 2004) or nitroaromatic explosives such as TNT 
(Williams et al., 2004). Certain NTR subfamilies can also reduce and cleave azo bonds, 
making them potentially useful in degrading recalcitrant azo-containing commercial dyes 
(Liu et al., 2007).  
It is self evident that while the reduction of anthropogenic substances may be of 
biotechnological interest, it is not for such purposes that this widespread enzyme class 
evolved. As this thesis focuses on the ability of these enzymes to reduce nitroaromatic 
substrates they have been designated throughout with the term nitroreductase; but when 
tested directly they are typically more catalytically active with quinone substrates (Zenno 
et al., 1996a, 1996b). Quinones are prevalent in nature, and oxygen insensitive NTRs 
reduce quinones to their hydroquinone form in two electron steps. This bypasses the 
extremely reactive semi-quinone intermediate and thereby minimises ROS generation. It 
has been suggested that such a protective mechanism may in fact be the primary 
biological role of many of these enzymes (Deller et al., 2008; Liu et al., 2008a; Roldán et 
al., 2008). Consistent with this hypothesis, it has been shown that NfsA from E. coli  is 
part of the soxRS (superoxide response) operon, an operon which includes at least 15 
genes implicated in responding to oxidative stress (Liochev et al., 1999). Moreover, 
nitroreductases in various bacterial strains are induced or prove protective in the face of 
such stressors as H2O2, paraquat and heat shock (Gonzalez et al., 2005; Liochev et al., 
1999; Liu et al., 2008a; Moch et al., 2000; Nokhbeh et al., 2002). In some bioluminescent 
bacteria however, e.g. Vibrio fischeri and Vibrio harveyi, NTRs act to maintain a pool of 
reduced flavin monomers, required for luciferase activity (Zenno et al., 1994; Tanner et 
al., 1996).  
In addition to these known activities, a previously uncharacterised activity of these 
bacterial NTRs may offer the possibility of using these enzymes to noninvasively image 
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the location and behaviour of a therapeutic virus/bacteria inside patients, and in 
preclinical settings. 
1.7 Non-invasive imaging of anti-cancer gene therapy   
It is widely recognised that the ability to non-invasively image the location and spread of 
these novel, complex and in some cases replication competent, therapies would be 
extremely beneficial for their clinical development (Baril et al., 2010; Barton et al., 2008; 
Bhaumik et al., 2011; Chiocca, 2002; Rojas and Thorne, 2012). Such imaging would have 
to encompass the whole body and be sensitive and repeatable to allow for visualization of 
vector location over time.   
Current clinical practices for monitoring location and levels of therapeutic vector 
typically consist of biopsy analysis of treated patients (Adair et al., 2012; Breitbach et al., 
2011a; Patel et al., 2009) and/or PCR based determination of levels of viral DNA/RNA in 
a patients plasma, urine and stool (Gollamudi et al., 2009; Immonen et al., 2004; Nasu et 
al., 2007). This is far from ideal; plasma virus levels give no indication of vector location, 
and in addition to patient discomfort the invasive nature of biopsy precludes the 
possibility of sampling over time and restricts locations where gene delivery can be 
assessed, meaning full determination of vector behaviour over time and detection of any 
off target delivery is near impossible. These considerations are particularly important for 
demonstrating the safety and efficacy of systemically delivered replication competent 
vectors, which offer the best chance to treat advanced metastatic disease (Breitbach et al., 
2011a; Garber, 2006). Non-invasive whole body imaging would also allow a more 
accurate determination of the efficacy of a treatment, as clinicians would be able to assess 
patient response in light of the level of vector delivery achieved. In GDEPT based 
protocols, such imaging would help determine the optimal time point for prodrug 
administration. In addition to clinical utility, vector imaging would of course be 
extremely useful for assessing efficacy in experimental and preclinical settings.  
Non-invasive whole body imaging has been largely pursued by engineering the 
therapeutic vector to carry a reporter gene.  The protein product of this gene is then 
detected, typically by application of an exogenous substrate, a reporter probe, which can 
subsequently be visualized by the appropriate imaging technology. A number of strategies 
for imaging anti-cancer gene therapies are discussed below.  
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1.7.1 Optical imaging  
Optical imaging involves the emission and subsequent detection of a bioluminescent or 
fluorescent signal. Due to its low cost and relative ease of application, optical imaging has 
been widely used to successfully monitor transgene expression and vector localisation in 
both in vitro and small animal studies. When fluorescence is used in reporter gene 
imaging, the gene product can either fluoresce independently, e.g. GFP (Chen et al., 
2010), or can generate a fluorescent signal by converting an exogenously delivered probe 
to a fluorescent form (Bhaumik et al., 2011). An in vivo signal can be best monitored 
when emitted fluorescence is in the red or better yet near-infrared (650-900 nm) 
spectrum, as these light frequencies are better able to penetrate tissue and avoid much of 
the background signal generated by tissue auto-fluorescence at shorter wavelengths 
(Nolting et al., 2011) .  
Bioluminescence, wherein surface light emission due to a reporter gene is captured using 
cooled charged coupled device (CCD) cameras, has been used by a number of 
laboratories to monitor in vivo vector localization in small animal cancer models. 
Bioluminescent imaging can be extremely sensitive, as there is next to no background 
signal, but it suffers from low spatial resolution and is generally used to generate 2D 
images, although 3D reconstruction is possible (Cronin et al., 2012; Kuo et al., 2007). 
Most commonly bioluminescent signal is generated by reporter “luciferase” proteins such 
as firefly or Renilla luciferase which in conjunction with oxygen interact with 
exogenously delivered “luciferin” substrates to generate light emission as a by-product 
(Bhaumik and Gambhir, 2002).  Engineering of a number of bacterial species to carry the 
luxCDABE gene cluster (which allows for continuous self-sufficient light emission) has 
also been used for monitoring bacterial tumour colonisation in small animal models 
(Cronin et al., 2012; Yu et al., 2004).   
Ultimately though, however useful these techniques are in pre-clinical work, they are 
intrinsically unsuited to whole body imaging in a clinical setting as optical signal 
attenuation due to tissue absorption gives a depth limit of centimetres at best (Chen et al., 
2010; Razgulin et al., 2011).  
1.7.2 Magnetic resonance imaging 
Magnetic resonance imaging (MRI) is clinically used to provide non-invasive anatomical 
images, constructed by detecting tissue dependent differences in behaviour of nuclei 
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(typically the hydrogen nucleus) when exposed to the strong magnetic field generated by 
a MRI scanner. MRI can be used to detect reporter gene expression if the protein product 
can affect the behaviour of immediately surrounding nuclei, for example by manipulating 
local concentrations of paramagnetic iron (Hill et al., 2011; Zurkiya et al., 2008). While 
MRI has higher spatial resolution, it is less sensitive i.e. less able to detect low levels of 
reporter probe, than nuclear imaging (discussed below; section 1.7.4), and  it has not yet 
received the same attention, development and validation for imaging of tumour tropic 
vectors (Gilad et al., 2008; Hill et al., 2011).  
1.7.3 Ultrasound imaging 
Ultrasound imaging can be adapted for non-invasive imaging of gene delivery, by co-
delivery of the gene with ultrasound detected microbubbles (Sirsi, 2012), but this 
technique as it stands is not appropriate for the imaging of the in vivo behaviour of 
biological vectors.  
1.7.4 Nuclear imaging 
In nuclear imaging a small amount of radioisotope labelled tracer is administered 
systemically to the patient. The tracer is designed so that interaction with a reporter 
protein causes it to accumulate in the cell, whereas tracer that has not encountered the 
reporter protein is cleared from the body. The location and level of the remaining cell-
sequestered tracer can then be visualized using specialized scanners that detect its 
radioactive decay (Figure 1-7).  
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Figure 1-7 Schematic showing the nuclear imaging of a reporter gene/probe. In this example 
the reporter protein enzymatically modifies the radioisotope labelled probe to a cell entrapped 
form, the signal of which can be detected by PET/SPECT scanners enabling non-invasive 
identification of reporter gene location and thus the location of the tumour tropic vectors.  
 
The radioisotope chosen to label the tracer determines whether positron emission 
tomography (PET) or single photon emission computed tomography (SPECT) is used. In 
PET scanning the radioisotope emits positrons, which quickly collide with electrons as 
they travel through the surrounding tissue. This collision causes two high energy gamma 
rays (511 keV) to be simultaneously released at a precise (near 180°) angle from each 
other. This ‘coincidence’ event is registered by surrounding detectors and used to 
reconstruct a precise tomographical image of the location and level of the reporter probe 
(Briat and Vassaux, 2006; Rahmim and Zaidi, 2008). Radioisotopes detectable by PET 
include 
18
F, 
11
C, 
124
I, 
64
Cu, 
13
N and 
15
O (Waerzeggers et al., 2009). In the late 1990s, 
integrated PET/CT scanners were developed (Beyer et al., 2000) and the vast majority of 
PET scans are now conducted in concert with commuted tomography (CT) scans to give 
anatomical images that are precisely combined with the PET derived functional 
information. SPECT detects radioisotopes such as 
123
I, 
99m
Tc or 
111
In, which directly emit 
low energy gamma rays. These are detected by a gamma camera which is rotated around 
the patient to provide whole body images of the source of this decay. To allow 
localization of the origin of a signal, SPECT cameras are fitted with lead collimators, 
which only allow rays approaching at a precise angle to hit the camera. The consequent 
Radionuclide  signal is emitted from 
cell entrapped imaging agent at site 
of gene transfection and detected 
by PET/SPECT scanners
Cell permeable radionuclide imaging 
agent converted to cell entrapped 
form by reporter protein  in 
transfected cells
Tumour tropic 
vector carrying 
reporter 
transgene
Unmodified imaging agent 
diffuses from body
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blocking of a large proportion of signal means that SPECT is inherently less sensitive 
than PET (Briat and Vassaux, 2006; Min and Gambhir, 2008).  
Nuclear imaging has a number of distinct advantages that have led many commentators to 
suggest it as the most appropriate technology for clinical non-invasive whole body 
imaging (Briat and Vassaux, 2006; Peñuelas et al., 2005a; Ponomarev, 2009). It is highly 
sensitive, quantitative, repeatable, can give reasonable spatial resolution (3-4 mm), and 
has no clinically relevant depth limit (Razgulin et al., 2011; Waerzeggers et al., 2009). 
The primary drawback to nuclear imaging is the often complicated generation and 
handling of radionuclide probes, and the need for specialized dedicated instrumentation 
and personnel. One advantage of SPECT over PET is that radioisotopes suitable for 
SPECT are typically more stable (hour-to-day radioactive half-lives vs minute-to-hour 
half-lives for the more commonly used PET radioisotopes) (Hicks and Hofman, 2012). 
Moreover, synthesis of some of the most common SPECT radioisotopes, such as 
99m
Tc, 
does not require access to a medical cyclotron (Dokić, 2005). However, as previously 
mentioned SPECT is inherently less sensitive than PET, detecting only around 0.01% of 
total photons as opposed to 1% by PET (Rahmim and Zaidi, 2008). PET also offers 
greater spatial resolution and a more quantitative report on probe levels (Hicks and 
Hofman, 2012; Min and Gambhir, 2008).  
While PET-suitable radioisotope synthesis is more challenging, requiring the use of 
medical cyclotrons to bombard stable atoms to create short-lived radioisotopes, clinical 
use of PET is increasing. The number of clinical PET scans conducted p.a. in the USA 
increased over the period 2004-2010 from ~900,000 to >1.7 million and there are ~2200 
clinical PET centres worldwide (Yuin et al., 2012). Increased use generally drives down 
costs, and it is reported that for a high throughput facility the purchasing and operating of 
a PET scanner has seen a >50% decrease in real cost over the last 10 years (Hicks and 
Hofman, 2012). This growth has been largely driven by the clinical adoption of PET/CT 
imaging of [
18
F]FDG bio-distribution for identification of metastases and staging of 
certain cancers (Herrmann et al., 2011). Over 90% of PET scans are conducted to monitor  
[
18
F]FDG (Coenen et al., 2010). However the investment in the infrastructure and 
technology required for [
18
F]FDG production and imaging can be leveraged to support 
more niche applications of 
18
F based PET/CT imaging, such as the monitoring of gene 
therapy vectors.  
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A variety of existing reporter protein/probes are already under investigation and promote 
cell specific localization of radionuclide probes through one of three different 
mechanisms (Briat and Vassaux, 2006). Proteins such as HSV1-TK can enzymatically 
modify a cell permeable probe to a cell entrapped form (Yaghoubi and Gambhir, 2007); 
transmembrane proteins such as human sodium iodide symporter (hNIS) can actively 
cause cells to uptake unmodified probes (Barton et al., 2011); and finally radionuclide 
probes can accumulate by binding to specific cell receptors, such as the human type II 
somatostatin receptor (Kim et al., 2012).  A number of investigated reporter genes such as 
the human type II somatostatin receptor  and the human norepinephrine transporter 
(Brader et al., 2009a) carry the advantage that their nuclear imaging probe counterparts 
have already been clinically used for other imaging applications. However, to date the 
two most prominent reporter genes to have been tested for nuclear imaging of vectors in 
oncology applications are HSV1-tk and hNIS.    
1.7.5  HSV1-TK 
HSV1-TK can phosphorylate and thereby entrap within the host cell a number of 
radiolabelled nucleoside analogues, allowing for nuclear imaging of the location of active 
HSV1-TK.  To date HSV1-tk (both wild type and mutant variants) has been the most 
widely used reporter gene for nuclear imaging. Radiolabelled substrates include the 
SPECT imageable 
125
I-FIAU and PET imageable pyrimidine derivatives such as [
18
F] 
FEAU, [
24
I] FIAU and the acycloguanosine derivative [
18
F] FHBG, which has FDA 
approval as a investigational new imaging agent (Yaghoubi and Gambhir, 2007).  
Non-invasive imaging of HSV1-tk expression was first accomplished by using SPECT to 
monitor [
131
I]FIAU accumulation in tumours expressing HSV1-tk in a rat cancer model 
(Tjuvajev et al., 1996). Nuclear imaging of the expression of HSV1-tk or a mutant 
derivative HSV1-sr39tk (Gambhir et al., 2000) has subsequently been used both to 
support preclinical development of HSV1-TK anti-cancer therapies (Abate-Daga et al., 
2011; Fontanellas et al., 2009) and to investigate the possible detection of tumour 
metastases by imaging of HSV1-tk carrying tumour tropic vectors (Brader et al., 2009b). 
The first report of clinical non-invasive imaging of HSV1-tk was in 2001, where as part of 
a HSV1-TK/GCV trial to treat recurrent glioblastoma, five patients were also delivered 
[
124
I]FIAU and tumour specific accumulation was detected in one patient using PET 
(Jacobs et al., 2001). Subsequently in a Phase I trial involving treatment of hepatocellular 
carcinoma by intratumoural injection of a replication deficient adenovirus carrying HSV1-
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tk, followed by GCV application, it was reported that patients who received a dose of 
over 10
12 
virus particles showed a clear PET imageable accumulation of intravenously 
administered [
18
F]FHBG only in the tumour treated with virus (Peñuelas et al., 2005b). 
HSV1-TK based PET imaging has also been applied to the monitoring of infused 
therapeutic cytolytic T-cells (Yaghoubi et al., 2009) and HSV1-tk delivery through 
cationic liposome vectors (Sangro et al., 2010). It should be noted that there has also been 
one report in which the attempted non-invasive imaging of the replication of a herpes 
simplex virus aimed at treating glioma was unsuccessful, though this has been suggested 
to be a consequence of the less sensitive SPECT modality used to detect 
123
I-FIAU 
accumulation (Dempsey et al., 2006).  
1.7.5.1 Preclinical nuclear imaging of bacterial cancer therapies 
Thymidine kinase activated radionuclide probes have been used to non-invasively image 
tumour targeting bacteria in preclinical studies. The clinically trialled Salmonella 
VNP20009 strain, modified to carry HSV1-tk, can be localised using 
124
I-FIAU and 
microPET (Soghomonyan et al., 2005). Non-invasive imaging of Salmonella would be 
particularly beneficial, as in clinical trial it appeared that the fine needle biopsies taken to 
measure in vivo bacterial colonisation did in some instances not detect bacteria later 
shown to be present, possibly because of the bacteria’s irregular hypoxic/necrotic 
dependent intratumoural localisation (Toso et al., 2002). Interestingly it has also been 
shown that some bacterial species do not require addition of HSV1-tk for imaging, as their 
endogenous thymidine kinases exhibit sufficient phosphorylation of radionucleotide 
probes. This property was used to image the localisation of the non-pathogenic E. coli 
Nissle 1917 strain in tumour bearing mice (Brader et al., 2008) and the tumour specific 
germination in BALB/c mice of the clinically relevant C. novyi-NT following [
125
I]FIAU 
treatment and SPECT/CT imaging (Bettegowda et al., 2005).  
1.7.6 Human sodium iodide symporter  
The human sodium iodide symporter (hNIS) has also been investigated as a reporter for 
non-invasive imaging. The physiological role of this transmembrane protein is to actively 
transport iodine into cells. It is primarily found in thyroid tissue but is also expressed in 
the salivary glands, the stomach and lactating mammary glands (Penheiter et al., 2012). 
As hNIS can also promote intracellular accumulation of radiolabelled iodine and anions 
such as 
99m
TcO4
-
, it has been investigated as both a therapeutic and reporter protein. In a 
therapeutic context it promotes uptake of 
131
I and this uptake by endogenous hNIS is 
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exploited as a standard treatment for thyroid cancer (Spitzweg et al., 2001). Exogenously 
over-expressed hNIS/
131
I has undergone investigation as a suicide enzyme/prodrug pair to 
treat a range of cancers including prostate (Barton et al., 2011; Msaouel et al., 2009b), 
hepatocellular carcinoma (Klutz et al., 2011) and pancreatic cancer (Haddad et al., 2012). 
PET imaging can be used to detect hNIS expression as it can promote the accumulation of 
124
I.
 
  However more commonly hNIS expression is detected by SPECT imaging of 
99m
TcO4
-
 accumulation, as arguably the greatest advantage of hNIS as a reporter gene is 
the ready availability and low cost of 
99m
TcO4
-
 (Hicks and Hofman, 2012).  
The clinical use of hNIS as a non-invasive imaging reporter was first described by Barton 
et al. (Barton et al., 2008) who used it to image a replication competent adenovirus armed 
with the suicide genes yCD and mutTKSR39. Prostate cancer patients were administered 
the virus via intraprostatic injection and then dosed with Na
99m
TcO4. SPECT imaging 
could detect hNIS expression in 7 out of 9 patients who received the trial’s highest dose 
of 1 x10
12
 virus particles, with the mean pixel intensity of the SPECT image of injected 
areas on average 2.3 fold greater than in the uninjected prostate. Repeated imaging was 
sufficiently sensitive to determine that hNIS expression peaked 1-2 days post virus 
injection, was confined to the prostate region and that the initial 1 cm
3
 adenovirus 
deposits spread to an average of 6.6 cm
3
, but within too short a timeframe to be due to 
intratumoural viral replication. A separate research group based out of the Mayo clinic 
have armed an oncolytic measles virus with hNIS and are currently conducting a Phase I 
trial (http://www.clinicaltrials.gov/ct2/show/NCT00450814) for treatment of multiple 
myeloma in which they aim to use repeated SPECT/CT imaging of 
123
I uptake to 
determine the bio-distribution and longevity the therapeutic virus (Msaouel et al., 2009b). 
There has also been one report of unsuccessful non-invasive imaging using hNIS, in 
which a patient treated with intratumoural injection of an adenovirus expressing hNIS 
(Ad5/3-24-hNIS) did not show SPECT imageable tumour accumulation of either 
123
I or 
99m
Tc. However, it was suggested that this may have been due to the rapidly acting 
oncolytic virus lysing infected cells before sufficient intracellular accumulation of 
radioprobe could occur; pointing to a need to select compatible vector and reporter 
gene/probe combinations (Rajecki et al., 2011). 
22 
 
 
1.8 Non-invasive imaging of bacterial nitroreductase enzymes 
1.8.1 Optical imaging  
While nuclear imaging is better suited to clinical applications, the use of significantly 
more accessible optical imaging technology facilitates the preclinical development of 
nitroreductase based therapies. Two different quenched fluorescent reporter probes have 
been used for in vivo imaging of E. coli NfsB. One is 6-chloro-9-nitro-5-oxo-5Hbenzo (a) 
phenoxazine (CNOB), which on nitroreduction is converted to a fluorescent 
aminophenoxazin with an emission wave length of 525 nm that can be detected in small 
animals (Thorne et al., 2009). When mice carrying SiHa tumours were treated with 
Clostridium sporogenes expressing NfsB and co-injected with CNOB, red fluorescence 
emitted from some regions of the tumour, with particular localisation around the central 
necrotic core (Liu et al., 2008a). The second compound is CytoCy5S, a quenched 
fluorophore commercially available from GE Healthcare. This is a freely cell permeable 
compound, which on nitroreduction is converted to a cell entrapped form that emits a red-
shifted fluorescent signal (McCormack et al., 2012). CytoCy5S has been shown to non-
invasively detect stable expression of NfsB from multiple different cancer cell lines in 
mice xenograft models, not only by systemic injection of CytoCy5S, but also by pre-
incubation of the tumour-NfsB cells prior to implantation, as in intact cells the CytoCy5S 
signal persists post-activation for a number of days (Bhaumik et al., 2011). CytoCy5S 
also allowed repeated in vivo monitoring of a HSV1-TK-NfsB fusion protein stably 
expressed from a breast cancer cell line xenograft as part of a GCV/CB1954 tumour 
growth delay study (Sekar et al., 2012).  
1.8.2 Nuclear imaging 
No bacterial NTR reporter probes suitable for nuclear imaging have previously been 
described, rendering non-invasive imaging via this modality currently unfeasible. One 
indirect way through which NTR based GDEPT could be imaged is through a linked gene 
strategy in which the tumour tropic vector would co-express a second reporter protein 
(e.g. HSV1-TK, which could report on levels and location of the therapeutic NTR). In 
such strategies the reporter and therapeutic gene are generally expressed from a 
bicistronic vector in a single promoter driven construct, which through the use of an 
internal ribosome entry site allows co-expression of two separate protein products 
(Tjuvajev et al., 1999). While not unworkable, such imaging would make the output 
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signal independent of the presence of the functional NTR protein product, and would 
require careful experimental validation that the activity of the reporter gene is consistently 
reflective of the NTR expression in all clinical settings (Wang et al., 2005). This potential 
disconnect between levels of NTR and reporter gene expression could be avoided by 
fusion of a NTR and HSV1-TK reporter gene to generate a bi-functional single protein 
product (such as that generated by (Sekar et al., 2012)); while HSV1-TK based PET 
imaging of such a construct would again not report directly on NTR function, it would 
presumably provide a much more reliable indication of expression levels. Moreover, both 
strategies would have the advantage of enabling synergistic therapeutic effects to be 
pursued via simultaneous HSV1-TK and NTR based GDEPT (Sekar et al., 2012); and 
would simplify non-invasive imaging of NTR based therapies as existing imaging 
modalities and compounds would be used. However it should be noted that there is 
another possible strategy that would avoid novel compound generation while allowing for 
direct non-invasive imaging of bacterial NTRs. This could be accomplished by 
repurposing, as direct NTR reporter probes, PET imaging agents that have already been 
independently developed and clinically validated.   
1.8.3 2-Nitroimidazole hypoxia imaging agents  
A class of PET reporter probes wherein cellular accumulation is dependent on reduction 
of a nitro moiety are already in existence - the 2-nitroimidazole (2-NI) hypoxia imaging 
agents. 2-NI compounds have been researched in an oncology context for more than three 
decades. Initial interest focused on use in radiation therapy, investigating their ability to 
act as oxygen mimetics to sensitize hypoxic tumours to ionizing radiation. Drugs trialled 
under this application included the prototypical misonidazole (Kogelnik et al., 1978), and 
its analogues etanidazole and pimonidazole (Bleehen et al., 1991). Unfortunately in large 
scale human trials the compounds demonstrated dose limiting neurotoxicity and failed to 
show clear clinical benefit (Wardman, 2007). However this work led to the observation 
that, following nitro group reduction, these drugs covalently bind to cellular 
macromolecules, becoming cell entrapped. In vivo this reduction occurs only in the 
presence of hypoxia (Varghese and Whitmore, 1980). As with the previously discussed 
hypoxia activated prodrugs, this is because these compounds are substrates for a number 
of oxygen inhibited (i.e. one-electron transferring) human oxidoreductases (Joseph et al., 
1994; Wang et al., 2012).  
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This observation suggested that monitoring the intracellular accumulation of 2-NI 
molecules would enable clinicians to detect tumour hypoxia, an important negative 
prognostic factor. This would enable identification of patients who would benefit from 
more aggressive or hypoxia targeted treatments, particularly in a radiotherapy context 
(Marcu et al., 2012; Mees et al., 2009). The use of 2-NI compounds as reporters for 
clinical non-invasive imaging of hypoxia has most commonly been pursued through 
addition of an 
18
F radioisotope to the 2-NI to enable PET detection. Many of the 
compounds used are radiolabelled analogues of the initial radiosensitizers and include 
[
18
F]F-misonidazole (Rasey et al., 1987) and the etanidazole analogues [
18
F]EF5 (Komar 
et al., 2008) and [
18
F]EF3 (Mahy et al., 2008). Others such as [
18
F]FETNIM  (Ganjoo et 
al., 2011),  [
18
F]HX4 (Loon et al., 2010) and [
18
F]FAZA (Mortensen et al., 2012) include 
novel side groups. The chemical structures of these compounds can be seen in Figure 
1-8. Multiple clinical trials in head and neck cancers have demonstrated that using such 
agents to non-invasively determine tumour oxygenation status provides a prognostic 
indicator of patient outcome (Mortensen et al., 2012; Rajendran et al., 2006; Rischin et 
al., 2006; Thorwarth et al., 2005).   
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Figure 1-8 Structures of 
18
F 2-NI hypoxia imaging agents with prior human use. 
 
Radiolabelled misonidazole derivatives were the first 2-NI compounds investigated for 
detection of in vivo hypoxia (Jerabek et al., 1986; Rasey et al., 1987). [
18
F]F-misonidazole 
has been the most widely used 2-NI PET imaging agent (Marcu et al., 2012), and along 
with [
18
F]FAZA is included in a International Atomic Energy Agency (IAEA) co-
ordinated research project (CRP No. F22047) aimed at expanding and supporting the use 
of 
18
F radiopharmaceuticals (Coenen et al., 2010). Importantly [
18
F]F-misonidazole can 
be can be labelled using nucleophilic fluorination (Lim and Berridge, 1993), a preferred 
radioisotope labelling method that is procedurally similar to preparing [
18
F]-FDG, making 
it easier to adapt [
18
F]FDG existing technology at most medical cyclotrons (Coenen et al., 
2010).  However, as is evidenced by the number of other 2-NI analogues that have also 
been developed, [
18
F]F-misonidazole has a number of features which could be improved 
[18F]F-misonidazole
[18F]FAZA
[18F]HX4
[18F]FETNIM
[18F]EF3
[18F]EF5
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upon, such as high liver uptake and a relatively high lipophilicity which contributes to 
slow clearance time and a modest uptake ratio between hypoxic tumours and comparative 
tissue (blood and/or muscle) (Carlin and Humm, 2012; Padhani, 2006). F-misonidazole 
signal attenuation has also been suggested to occur due to non-specific in vivo break 
down of the parental compound (Rasey et al., 1999).  
More hydrophilic second generation 2-NIs such [
18
F]FAZA or [
18
F]HX4 have been 
designed to promote faster clearance. One [
18
F]HX4 human biodistribution study reported 
low liver uptake, that over a 3.6 h period ∼45% of the injected activity of 18F-HX4 was 
excreted in the urine, and that [
18
F]HX4 remained essentially intact in the blood (Doss et 
al., 2010). A click chemistry based synthesis and nucleophilic radiolabelling of [
18
F]HX4 
makes generation of the PET-ready molecule relatively straightforward (Loon et al., 
2010). An alternative design strategy is that seen with [
18
F]EF5, where the lipophilicity of 
the compound has been purposely increased to instead provide high and near uniform 
tissue penetration and thus stable radiobiological background over the imaging period, 
[
18
F]EF5 being chemically stable in vivo (Koch et al., 2010). The electrophilic 
18
F 
fluorination of EF5 is more challenging than nucleophilic displacement (Koch et al., 
2010), however research to simplify synthesis and increase radiolabelled yields is 
ongoing (Chitneni et al., 2012) and could encourage wider use of the compound (Carlin 
and Humm, 2012).  
It should be noted that, when assigning hypoxic status, both [
18
F]F-misonidazole and 
second generation hypoxia imaging agents typically report tumour/blood or 
tumour/muscle ratios of between 1.3 - 2 (Komar et al., 2008; Loon et al., 2010; 
Mortensen et al., 2012; Rajendran et al., 2006). Given these fairly modest 
hypoxia/normoxia ratios it is not implausible to propose that, if bacterial NTRs 
demonstrate efficient metabolism of these 2-NI compounds, then repurposing of these 
agents for effective in vivo imaging of bacterial NTR expression may be possible.  
1.9 Aims of this study 
The overall goal of this thesis was to progress the ability to noninvasively image NTR 
based oncolytic therapies.  
The first aim was to interrogate the abilities of a range of naturally occurring bacterial 
NTRs to reduce 2-NI compounds, radiolabelled forms of which were originally developed 
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for noninvasive PET imaging of hypoxia. To achieve this, microplate screens were 
developed to enable simple and accurate detection of 2-NI reduction by NTR candidates 
over-expressed in E. coli. This aim was investigated in Chapters 3 and 4. Results 
generated by our collaborators to assess whether this 2-NI activity could be used to detect 
in vivo NTR expression in preclinical models are also discussed.  
A second aim was to apply the microplate screening methods in a directed evolution 
project to improve native levels of 2-NI reduction by a lead NTR candidate. This was 
investigated in Chapter 5.  
As an alternative to re-purposing existing (2-NI) PET probes, a third aim of this research 
was to identify NTRs that can efficiently activate a novel PET suitable compound, 
designed to be less responsive to hypoxia. An important outcome of this work was the 
identification of key mutations that can be introduced into variants of E. coli NfsB to 
improve metabolism of this novel probe molecule. This work is presented in Chapter 6. 
Finally, it was aimed that these and other screens would be used in a collaborative 
directed evolution project, to generate an NTR with improved ability to activate the 
nitroaromatic DNA damaging prodrug PR-104A, while retaining an ability to reduce 2-NI 
compounds. This was to generate evolved NTR(s) to progress for further testing in a 
clinically relevant tumour targeting Clostridium strain. This work is presented in Chapter 
7.  
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Chapter 2: Methods 
2.1 Chemical reagents and enzymes  
The compounds PR-104A, RB6154, EF5, SN33623 and all NTR fluorogenic probes were 
synthesised by various chemists at the Auckland Cancer Society Research Centre and 
provided to this study by our collaborators Dr. Adam Patterson and Dr. Jeff Smaill 
(ACSRC; University of Auckland, New Zealand). All compounds were characterised by 
1
H NMR and mass spectrometry. HX4 was a gift from Prof. Philippe Lambin at the 
University of Maastricht. EF3 was a gift from Prof. Cameron Koch at the University of 
Pennsylvania. Pimonidazole was purchased from Bioscience Research Reagents 
(Temecula, CA, USA) and F-misonidazole from ABX Company (Chemical Division, 
Radeberg, Germany). Unless otherwise stated, stock solutions of all drug and imaging 
agent compounds were made up in DMSO and stored at – 80 °C. Restriction enzymes 
were purchased from New England Biolabs (NEB; Ipswich, MA, USA). BioMix™ Red 
Polymerase Mastermix was purchased from Bioline (London, UK). Phusion™ high-
fidelity DNA polymerase was purchased from Finnzymes (Espoo, Finland). Unless 
otherwise stated all other chemicals and reagents were purchased from Sigma-Aldrich (St. 
Louis. MO, USA) or Thermo Fisher Scientific (Waltham, MA, USA).  
2.2 Oligonucleotide primers  
Oligonucleotide primers used in this study were supplied as lyophilised powders by   
Invitrogen (Carlsbad, CA, USA) or Integrated DNA Technologies (IDT; Coralville, IA, 
USA). Stock solutions of 100 µM were made up in TE (10 mM Tris-Cl pH 8.0, 0.1 mM 
EDTA) and 10 µM working solutions were diluted in autoclaved and filter sterilized ddH-
2O. Working and stock solutions were stored at -20 °C. The sequences of all primers used 
in this study are listed in Table 1-1. 
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Primer Sequence (5'→3')
NTR specific primer 
NfsA_Ec_Fw GGCATATGACGCCAACCATTGAAC
NfsA_Ec_Rv GGGTCGACTTAGCGCGTCGCCCAACCCTG
NfsA_St_Fw GGGGCATATGAGTCCGACCATTGAA
NfsA_St_Rv GGGGTCGACTTAGCGCGTCGCCCAGCC
NfsA_Ck_Fw GGGGCATATGACTCCAACCATTGATTT
NfsA_Ck_Rv GGGGGTCGACTTAGCGCGTCGCCCAA
NfsA_Kp_Fw GGGGCATATGACGCCGACCATTGAG
NfsA_Kp_Rv GGGGTCGACTCAGCGCGTTGCCCACC
NfsA_Ecaro_Fw GGGGCATATGATACCAACTATTGATTTGCTACA
NfsA_Ecaro_Rv GGGGCTCGAGCTAGCGTATCGCCCATCCTTGTTG
NfsA_Es_Fw CCCCCATATGACGCCAACGATTGAGCTGC
NfsA_Es_Rv GGGGCTCGAGTTAGCGTGTCGCCCAGCCCTG
NfsA_Vf_Fw CCCCATATGAACCCTGTTATCGATAC
NfsA_Vf_Rv CCCGTCGACTCACTTAATAGCTAGGC
NfsA_Vv_Fw GGGGCATATGAACGCTGTTATTGAC
NfsA_Vv_Rv GGGGTCGACTTACTTTGTCGCCAAGCC
Frp_Vh_Fw GGGCATATGAACAATACGATTGAAA
Frp_Vh_Rv GGGGTCGACTTAGCGTTTTGCTAGCC
NfrA_Bs_Fw GGGGCATATGAATAACACAATCGAAACC
NfrA_Bs_Rv GGGGGTCGACTTAGTTTTTATTAAAGCCCT
NfsA_Li_Lw_Fw GGGGCATATGAATCAGGCGATAGATGCCATTTT
NfsA_Li_Lw_Rv GGGGGTCGACTTATTTTTGATTTAAATGTTGC
NfsA_Bc_Fw GGGGCATATGAATACTATCATTGAAACGATTCTC
NfsA_Bc_Rv GGGGGTCGACTTACTTTTTATCAAACCCTTGGCGT
NfsA_0199NP_Fw GGCATATGCCTTTACAGATGGAA
NfsA_0199NP_Rv GGGTCGACTTACAGTAGCTTGAA
NfsA_Bth_Fw GGGGCATATGAATGAAATGATACATAAAATGGAG
NfsA_Bth_Rv GGGGGTCGACTCATTTCTTATTTAATCCTCTCTCAT
NfsA_Lsak_Fw GGGGCATATGTCTGATTTAATCGCACAAATGCAAC
NfsA_Lsak_Rv GGGGGTCGACTTATGCTAATGTAAACCCCTGTTTCTT
EcD_Pp_Fw CCCCCATATGAGCCTTCAAGACGAAG
EcD_Pp_Rv CTAGGTCGACTCAGCGCAGGCCGAAAC
YcnD_Bs_Fw CCCCCATATGAATGAAGTGATTAAATC
YcnD_Bs_Rv CCCCGTCGACTTATTTTTCAACTTTAAATC
NfsA_Ms_Fw GGGGCATATGACGGTCATCGCGCGCTACGCAGACGTCGAT
NfsA_Ms_Rv GGGGCTCGAGTCAGCGGATTCCCAGGCCCAACCGCTCG
NfsB_Ec_Fw GGGCATATGGATATCATTTCTG
NfsB_Ec_Rv GGGGAATTCTTACACTTCGGTTAAG
NfsB_Ck_Fw CCCCCATATGGATATCGTTTCTGTCGC
NfsB_Ck_Rv CCCGTCGACTCAGACTTCCGTCAGGGTG
NfsB_St_Fw GGGGCATATGGATATCGTTTCTGTC
NfsB_St_Rv GGGGGTCGACTTAGACTTCCGTCAGTG
NfsB_Kp_Fw GGGGCATATGGATATCGTATCGGTC
NfsB_Kp_Rv GGGGCTCGAGTTAAATCTCGGTAATGGT
NfsB_Vv_Fw GGGGCATATGACTATTGTTCAAGCT
NfsB_Vv_Rv GGGGTCGACTTAGATTTCGGTAAAAACAG
2432_Pp_Fw GGGGCATATGGATACCGTATCGCTG
2432_Pp_Rv GGGGCTCGAGTCAGAGGAAGGTGAACACTT
NfsB_Es_Fw CCCCCATATGAACCTTAATGAGATCATTCGC
NfsB_Es_Rv CCCGTCGACTCAGAGCTGCGTGATCAC
FraseI_Vf_Fw GGGGCATATGACGCATCCAATTATTCA
FraseI_Vf_Rv GGGGGTCGACCTAAAGAATGGTAATTAC
NfsB_Vh_Fw CCCCCATATGTCTCATCAAATCATTACAGAC
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NfsB_Vh_Rv CCCCTCGAGTTAAAGAGTAGTAATTACGTC
YfkO_Bs_Fw GGGGCATATGGCAGATCTAAAGACACA
YfkO_Bs_Rv CTAGGTCGACTTAAACCCACTTCACAACAT
YdgI_Bs_Fw GGGGCATATGATCAAAACAAACGATTTTATGG
YdgI_Bs_Rv GGGGGTCGACTTATTTCCATTCTGCAATTG
5190_Pa_Fw GGGGCATATGCATATCGAAGACGCC
5190_Pa_Rv GGGGGTCGACTCAGAAGCGGTCGCGAATGA
AzoR_Ec_Fw GGGGCATATGAGCAAGGTATTAGTTCTT
AzoR_Ec_Rv GGGGGTCGACTTATGCAGAAACAATGCTGT
AzoR_St_Fw CCCGCATATGAGCAAGGTATTAGTTCTT
AzoR_St_Rv CCCGTCGACTTAAGCGGCCACGAC
AzoR_Vv_Fw CCCGCATATGTCTCGTTTACTAGTATT
AzoR_Vv_Rv CCCGGTCGACTTAAGCTGTTAGCGCTGCAAG
4538_Pp_Fw GGGGCATATGTCCCGCGTACTGATCATC
4538_Pp_Rv GGGGCTCGAGTCAGGCCACCGCTGCCAGCTT
NemA_Ec_Fw CTAGGGATCCATGTCATCTGAAAAACTG
NemA_Ec_Rv CTAGGTCGACTTACAACGTCGGGTAATC
NemA_St_Fw CCCGGATCCATGTCATCAGCAAAACTG
NemA_St_Rv CCCGGTCGACTTACAGAGTAGGGTAGTC
NemA_Kp_Fw CCCCATATGTCGGAAGCAA
NemA_Kp_Rv CCCCTCGAGTTACAGAGTCGGGTAA
NemA_Vv_Fw CCCCATATGAGCAAACTGTTTGAA
NemA_Vv_Rv CCCGTCGACTCACACATGCAAAGCGGT
YwrO_Bs_Fw AAATTTGGATCCATGAAAATATTGGTTTTGGC
YwrO_Bs_Rv CCCGTCGACTTAAACAAAAGGCTGCTG
YwrO_Li_Fw CCCCCATATGAAAACATTAGTTATTAT
YwrO_Li_Rv CCCGTCGACCTAATTTAACGTTTTAATA
YwrO_Vf_Fw AAATTTGGATCCATGACAAGCCCGGCT
YwrO_Vf_Rv CCCGTCGACTTATTCCTTAATAAATTTATC
YieF_Ec_Fw GGGGCATATGTCTGAAAAATTGCAGGTG
YieF_Ec_Rv GGGGGTCGACTTAGATCTTAACTCGCTG
1204_Pa_Fw GGGGCATATGAGCGACGACATCAAG
1204_Pa_Rv  GGGGGTCGACTCAACCGCGCAGGCGGCGCA
MdaB_Ec_Fw GGGCATATGAGCAACATCCTG
MdaB_Ec_Rv GGGGTCGACTTAACCAAAAATTTC
MdaB_Ps_Fw GGGGCATATGAAAAAAGTATTGTTCCTCAAC
MdaB_Ps_Rv CTAGCTCGAGTTACTGCGCACCAAACACTT
WrbA_Ec_Fw GGGCATATGGCTAAAGTTCTGGTG
WrbA_Ec_Rv GGGGTCGACTTAGCCGTTAAGTTT
WrbA_Ps_Fw GGGGCATATGAGCAAACCTTACATTCTGG
WrbA_Ps_Rv CTAGGTCGACTCAGCTGCGTGTTGTGTC
YdjA_Ec_Fw CTAGCATATGGATGCACTCGAACTATTG
YdjA_Ec_Rv CTAGGTCGACTCAGAAATAAGTTACAAACGG
YdjA_Kp_Fw CCCCCATATGGATGCTCTCGATCTACTGC
YdjA_Kp_Rv CCCCGTCGACTCAGAATCGCGTCACAAACG
3720_Pp_Fw GGGGCATATGCTTGTGAATGTACTG
3720_Pp_Rv GGGGGTCGACTCACGTCAGCGGGTACAACG
4975_Pa_Fw GGGGCATATGAACGTACTGATCGTC
4975_Pa_Rv  GGGGGTCGACTCAGCGCGCCAGCGGCTGGA
YcdI_Ec_Fw  CTAGCATATGAACGAAGCCGTTAGCC
YcdI_Ec_Rv CTAGGTCGACTTACAACAGCCCGCAGG
YcdI_Kp_Fw GGGGCATATGAACGACGCGATAAACCA
YcdI_Kp_Rv CTAGCTCGAGTTATGCCAGGCAGGCT
YcaK_Ec_Fw GGGGCATATGCAGTCTGAACGTATT
YcaK_Ec_Rv GGGGGTCGACTTATAGTGCATCTACCATAT
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0853_Pa_Fw GGGGCATATGGTTGAAACCGCCAAGACC
0853_Pa_Rv GGGGGTCGACCTAGACCTGGCTGCCGAGCT
KefF_Ec_Fw GGGGCATATGATTCTTATAATTTATGCG
KefF_Ec_Rv GCCTGAGTCGACGTATGGCTATCCATGATGGG
Primers used in constructing NfsA_Ec site saturation mutagenisis libraries
NfsAEC_40_NNKFwd GCGCCCGTGCGACGTCCAGTNNKAGTTTTTTGCAGTGC
NfsAEC_40_41_Rv ACTGGACGTCGCACGGGC
NfsAEC_41_NNKFwd GCCCGTGCGACGTCCAGTTCCNNKTTTTTGCAGTGCAGTAG
NfsAEC_42_NNKFwd GTGCGACGTCCAGTTCCAGTNNKTTGCAGTGCAGTAGCATT
NfsAEC_42_43_Rv ACTGGAACTGGACGTCGCAC
NfsAEC_43_NNKFwd GTGCGACGTCCAGTTCCAGTTTTNNKCAGTGCAGTAGCATTC
NfsAEC_45_NNKFwd CCAGTTCCAGTTTTTTGCAGNNKAGTAGCATTATTCGCAT
NfsAEC_45_Rv CTGCAAAAAACTGGAACTGG
NfsAEC_83_NNKFwd TCTGGGTGTTCTGTGCCGACNNKAACCGCCATTTACAGATC
NfsAEC_83_Rv GTCGGCACAGAACACCCAGA
NfsAEC_103_NNKFwd GCCTGGCGGAACAACTGTTGNNKGGTGTCGTTGATACG
NfsAEC_103_Rv CAACAGTTGTTCCGCCAGGC
NfsAEC_107_NNKFwd AACTGTTGCTCGGTGTCGTTNNKCGGCAATGATGGCGCAG
NfsAEC_107_Rv AACGACACCGAGCAACAGTT
NfsAEC_134_NNKFwd GTATATATCGGCGGCCTGCGCNNKAATATTGAAGCGGTGACG
NfsAEC_134_Rv GCGCAGGCCGCCGATATATACC
NfsAEC_215_NNKFwd GCCGGGATACCTGGAGCGATNNKATCCGCCGAACAATCATT
NfsAEC_215_Rv ATCGCTCCAGGTATCCCGGC
NfsAEC_224_NNKFwd GCCGAACAATCATTAAAGAANNKCGCCCATTTATTCTGGAT
NfsAEC_224_Rv TTCTTTAATGATTGTTCGGC
NfsAEC_225_Rv CCGTCGACTTAGCGCGTCGCCCAACCCTGTTTGTGCAAATAATCCAGAATAAATGGMNN
GCTTTCTTTA
NfsA EC_41_45 NNK GCCCGTGCGACGTCCAGTTCCNNKTTTTTGCAGNNKAGTAGCATTATTCG
Primers used in construction of NfsA_Ec multi-site mutant library
Reverse primers not shown were identical to those used in construction of site saturation mutagenisis libraries
Combo 12 Fwd GGGGTATCATATGACGCCAACCATTGAACTTATTTGTGGCCATMGCTCCATTCGCC
Combo_40_41_42_fwd GCCCGTGCGACGTCCAGTWCTTVTWTTTTGCAGTGCAGTAGCATTATTCG
Combo_40_41_42_45_fwd GCCCGTGCGACGTCCAGTWCTTVTWTTTTGCAGWTGAGTAGCATTATTCG
Combo_40_41_42_45_rev CAACAGTTGTTCCGCCAGG
Combo_103_fwd CCTGGCGGAACAACTGTTGSTGGGTGTCGTTGATACGG
Combo_134_wt_fwd GGTATATATCGGCGGCCTGCGCAATAATATTGAAGCGGTGACG
Combo_134_A_fwd GGTATATATCGGCGGCCTGCGCGCGAATATTGAAGCGGTGACG
Combo_215_fwd CGGGATACCTGGAGCGATCRTATCCGCCGAACAATCATT
Primers used in construction of NfsB_Ec and NfsB_Es site specific mutants
NfsBesak67A_F Fwd TCCTGCCGGCGCTGATGGACTTCAACCAGGTAAAAGCGA
NfsBesak67A_F Rev GTCCATCAGCGCCGGCAGGA
NfsBesak69Q_E Fwd TCCTGCCGGCGCTGATGGACGCCAACGAGGTAAAAGCGAAA
NfsB EsakY105F Fwd GAGCAGCAGGATGGTCGCTTTGACGGCGAGGAAGCGCG
NfsB EsakY105F Rev GCGACCATCCTGCTGCTC
NfsBesak125N_H Fwd CCGCTTTTTTGTGGGTCTGCACAGCGAAACGCCGGAGCA
NfsBesak125N_H Rev CAGACCCACAAAAAAGCGG
NfsB EC_T41L fwd CAATACAGCCCATCCAGCCTGAACTCCCAGCCGTGGC
NfsB EC_T41L rev GCTGGATGGGCTGTATTG
NfsBEC_F70A Fwd CGCTGCCGGTAATTACGTGGCCAACGAGCGTAAAATG
NfsBEC_F70A Rev CACGTAATTACCGGCAGCG
NfsB EC F70A_N71S CGCTGCCGGTAATTACGTGGCCAGCGAGCGTAAAATGCT
NfsB EC_N71S CGCTGCCGGTAATTACGTGTTCAGCGAGCGTAAAATGCT
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Table 2-1 Primers used in this study 
 
NfsBEC_E72Q CCGGTAATTACGTGTTCAACCAGCGTAAAATGCTTGAT
NfsBEC_F70A_72Q CGCTGCCGGTAATTACGTGGCCAACCAGCGTAAAATGCTTG
NfsB EC_T108Y Fwd GAAGATGCCGATGGCCGCTACGCCACGCCGGAAGC
NfsB EC_T108Y Rev GCGGCCATCGGCATCTTC
Primers used in construction of Gateway constructs
NfsA_Ec_GW_Fw GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAGGAGATAGAACCATGGGCACG
CCAACCATTGAACT
NfsA_Ec_GW_Rv GGGGACCACTTTGTACAAGAAAGCTGGGTCCTAGCGCGTCGCCCAACCCTG
NfsB_Ec_GW_Fwd GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAGGAGATAGAACCATGGGCGAT
ATCATTTCTGTCGCCTT
NfsB_Ec_GW_Rev GGGGACCACTTTGTACAAGAAAGCTGGGTCCTACACTTCGGTTAAGGTGATGT
NfsB_Esak_GW_ Fwd GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAAGGAGATAGAACCATGGGCAAC
CTTAATGAGATCATTCG
NfsB_Esak_GW_Rev GGGGACCACTTTGTACAAGAAAGCTGGGTCCTAGAGCTGCGTGATCACCACAT
Primers used for gene knock out
TolC_KO_Fw ATCGGCCTGAGCCTTTCTGGGTTCAGTTCGTTGAGCTGTGTAGGCTGGAGCTGCTTC
TolC_KO_ext_Fw ATGAAGAAATTGCTCCCCATTCTTATCGGCCTGAGCCTT
TolC_KO_Rv GTTACTGGTGGTAGTGCGTGCGGATGTTTGCTGAACCATATGAATATCCTCCTTAG
TolC_KO_ext_Rv TCAGTTACGGAAAGGGTTATGACCGTTACTGGTGGTAGT
NfsA_KO_Fw GGGCAGAAAGAGAAAAAGATAATGACGCCAACCATTGAATGTGTAGGCTGGAGCT
GCTTC
NfsA_KO_Rv GGGTACATCGACGTGGCGGTTTTAGCGCGTCGCCCAACCCATATGAATATCCTCCTTAG
NfsB_KO_Fw GGGCCCGGCAAGAGAGAATTACACTTCGGTTAAGGTGATTGTGTAGGCTGGAGCTGC
TTC
NfsB_KO_Rv GGGTCACATGGAGTCTTTATGGATATCATTTCTGTCGCCCATATGAATATCCTCCTTAG
AzoR_KO_Fw  TTATGCAGAAACAATGCTGTCGATGGCTGCTTTTGCTGTGTAGGCTGGAGCTGCTTG
AzoR_KO_ext_Fw  CAAACATCTATAAGGAAACACCATGAGCAAGGTATTAGTTC
AzoR_KO_Rv ATGAGCAAGGTATTAGTTCTTAAATCCAGCATCCTGCATATGAATATCCTCCTTAG
AzoR_KO_ext_Rv CCACATCAAGACCGTGTCCGGTTATGCAGAAACAATGCTG
NemA_KO_Fw ATGTCATCTGAAAAACTGTATTCCCCACTGAAAGTGTGTGTAGGCTGGAGCTGCTTC
NemA_KO_ext_Fw ATCACCAGACGACCGGGAGCCTTTATGTCATCTGAAAAACGT
NemA_KO_Rv TTACAACGTCGGGTAATCGGTATAGCCTTCCGCGCCCATATGAATATCCTCCTTAG
NemA_KOext_Rv CTTTACGCCGCTCGCAATGTTGGATTACAACGTCGGGTAAT
Miscellaneous primers
pMMBFw GGCTCGTATAATGTGTGG
pMMBRv GACCGCTTCTGCGTTCTGAT
T7prom TAATACGACTCACTATAGGG
T7term GCTAGTTATTGCTCAGCGG
M13Fw GTAAAACGACGGCCAG
M13Rv CAGGAAACAGCTATGAC
Underlined text indicates restriction sites
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2.3 Strains, cell lines and plasmids used in this study 
2.3.1 Bacterial strains  
All bacterial strains used in this study are described in Table 2-2 and Table 2-3. 
 
Table 2-2 Escherichia coli strains used in the study 
 
 
Lab stocks: 
Escherichia coli W3110 
Pseudomonas aeruginosa PAO1  
Pseudomonas putida KT2440  
Pseudomonas syringae pv. phaseolicola 1448a  
Mycobacterium smegmatis str. MC
2
155 
 
ESR culture collection*:  
Salmonella enterica (typhimurium) Ty2 ATCC19430 
Klebsiella pneumoniae ATCC 13883  
Vibrio vulnificus ATCC 27562 ** 
Vibrio harveyi ATCC 33843 ** 
Vibrio harveyi KCTC 2720 ** 
Vibrio fischeri ATCC7744**  
Bacillus subtilis subsp. subtilis NZ isolate  
Enterobacter (Chronobacter) sakazaki ATCC 29544  
Citrobacter koseri ATCC 27156  
Listeria innocua Clip11262  
Bacillus coagulans ATCC 7050 
Listeria welshimeri ATCC 35897 
Lactobacillus sakei subsp. sakei 23K 
Erwinia carotovora subsp. Atrosepticum SCRI1043 
Bacillus thuringiensis serovar konkukian str. 97-27 
Nostoc punctiforme PCC 73102 
 
* Obtained from Institute of Environmental Science and Research, Porirua, NZ 
** propagated in Marine Broth 
 
Table 2-3 Strains used as sources of oxidoreductases in expanded NTR candidate library 
Strain Relevant characteristics Source
DH5α supE 44 DlacU 169 (Ø80 lacZ  DM5) hsdR 17 Invitrogen
BL21 F
–
 ompT gal dcm lon hsdSB(rB
-
 mB
-
) λ(DE3) Novagen
ADA-510 F lac-6 (del)   (sfiA::lacZ ) (Shapiro and Baneyx 2002)
SOS-R1 ADA-510 Δ nfsA  Δ nfsB (Prosser et al., 2010) 
SOS-R2 SOS-R1 Δ azoR  Δ nemA  Δ tolC (Prosser et al., 2013) 
W3110 F-λ-IN(rrnD-rrnE)1 rph1 Lab stock
6 KO W3110 Δ nfsA Δ nfsB Δ yieF Δ ycaK Δ mdaB ΔazoR  (Horvat, 2012)
7 KO 6 KO  Δ nemA This study
Strains used as a source of bacterial oxidoreductase enzymes in this study
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2.3.2 Mammalian cell line  
HCT-116, an adherent colorectal carcinoma cell line, was purchased from ATCC 
(American Type Culture Collection, Manassas, VA, USA).  
2.3.3 Plasmids  
All plasmids used for transformation of bacterial and mammalian cells are listed in Table 
2-4. Also shown are plasmid maps of the vectors used for expression of bacterial 
oxidoreductase enzymes, both from E. coli (pUCX- Figure 2-1) and HCT-116 (F279-V5-
Figure 2-2). 
 
 
Table 2-4 Plasmids used in this study 
     
  
 
Plasmid Relevant characteristics Source
pUCX Amp
R
 E. coli expression vector. tac promoter, lac operator, pET28A(+) RBS. (Prosser et al., 2010)
pET28A(+) Kan
R 
Expression vector for His6-tagged enzyme expression. T7 promoter. Novagen
pGFP Spec
R
 ChlR, pCloDF13 origin of replication, expresses gfp-mut3  under control of 
sulA/sfiA  SOS promoter. 
Dr. Janine Copp, unpublished1 
pKD4 Amp
R 
Kan
R 
Pir-origin of replication. kan
R
 gene template for KO-PCR (Datsenko and Wanner, 2000)
pKD46
Amp
R
 Heat sensitive origin of replication. Recombinase expression vector. ara 
operon promoter.
(Datsenko and Wanner, 2000)
pCP20 AmpR Heat sensitive origin of replication. Encodes FLP recombinase. (Datsenko and Wanner, 2000)
pDONR221 Kan
R
 Entry vector for Gateway recombination cloning Invitrogen
F279-V5
Destination vector for gateway recombination cloning. Mammalian expression 
vector, Puro
R
 Amp
R
 CMV promoter.
ACSRC, (Prosser et al., 2013)
1constructed by PCR-amplifying the sulA/sfiA  promoter, gfp mut3  and downstream chloramphenicol cassette from pANO1 
(Norman et al., 2005) and cloning this fragment into pCDFDuet-1 (Novagen). 
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Figure 2-1 Plasmid map and multiple cloning site of E. coli expression vector pUCX empty.  
Post insertion of the DNA sequence of various bacterial NTRs into the multi-cloning site this 
vector was used for recombinant bacterial NTR expression from E. coli. The plasmid as pictured 
here was used as the empty plasmid control for all experiments where such a control was needed.   
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Figure 2-2 Plasmid map of F279-V5, the plasmid vector used for NTR expression from 
HCT-116 cells. NTR sequences were inserted in-between recombination sites attR1 and attr2 
using Gateway® (Invitrogen) cloning.   
2.4 Bacterial growth and maintenance  
2.4.1 Growth media 
Unless otherwise stated all media were made up in ddH2O and sterilised by autoclaving at 
121 °C for 30 min. Media were stored at room temperature, or at 4 °C if containing heat 
sensitive reagents.    
2.4.1.1 Liquid Media 
Luria broth (LB)*
 
Tryptone 10 g.L
-1
 
Yeast extract 5 g.L
-1
 
NaCl 5 g.L
-1
 
 
*LB was provided as a premixed powder by manufacturer  
 
SOC* 
Tryptone 20 g.L
-1
 
Yeast extract 5 g.L
-1
 
F279-V5
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NaCl 10 mM 
KCl 2.5 mM 
MgCl2  10 mM**  
Glucose 20 mM** 
 
*Adjusted to pH7.0 using NaOH 
**Filter sterilized and added post-autoclave 
 
GYT Medium* 
10% glycerol 
Yeast extract 1.25 g.L
-1
 
Tryptone 2.5 g.L
-1
 
 
*Filter sterilized  
 
Autoinduction media (ZYP-5052)   
ZY base 919 mL.L
-1
 
20 x NPS 50 mL.L
-1
 
50 x 5052 20 mL.L
-1
 
100 x Metal salts 10 ml.L
-1
 
MgSO4 1 mM* 
 
*filter sterilized and added post autoclave 
 
 ZY base 
 Tryptone 10 g.L
-1
 
 Yeast extract 5 g.L
-1
 
 
 20 x NPS 
 NH4SO2 0.5 M 
KH2PO4 1 M 
Na2HPO4 1 M 
 
50 x 5052 
Glycerol 250 g.L
-1
 
Glucose 25 g.L
-1
  
Lactose 100 g.L
-1
 
 
100x Metal salts 
CaCl2.2H2O 0.1 g.L
-1
 
CoCl2.2H2O 0.04 g.L
-1
 
CuSO4.5H2O 0.02 g.L
-1
 
EDTA 1 g.L
-1
 
FeSO4.7H2O 0.5 g.L
-1
 
MgCl2.6H2O 10 g.L
-1
 
MnCl2.2H2O 0.1 g.L
-1
 
NaMoO4.2H2O 0.02 g.L
-1
 
ZnSO4.7H2O 0.2 g.L
-1
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Marine Broth 
Marine broth was supplied by the manufacture (Sigma-Aldrich) as a ready mixed 
Powder and prepared as per manufacturer’s instructions.  
2.4.1.2 Solid Media 
Agar plates for growth on solid media were made by addition of agar 1.5% (w/v) to LB 
prior to autoclaving. Any necessary antibiotics were added post autoclave once the media 
had cooled to <50 °C.  
2.4.2 Bacterial antibiotics  
Antibiotics were made up in stock solutions at 1000x final concentration (Table 2-5) and 
filter sterilized using a 0.22 µM filter (if made up in ddH2O) and stored in aliquots at -20 
°C.   
  
Table 2-5 Antibiotic concentrations  
2.4.3 Growth and storage 
Unless otherwise stated, bacteria were grown at 37 °C, in a static incubator if on solid 
media or at 200 rpm if in liquid media. For short term storage strains were kept at 4 °C on 
solid agar plates. For long term storage liquid cultures were mixed with 1:1 with 
autoclaved 80% (v/v) glycerol and stored indefinitely at -80 °C.   
2.5 Standard molecular biology protocols 
2.5.1 Isolation of genomic DNA (gDNA) 
Bacterial 3 ml overnight cultures were grown in conditions as appropriate for the strain 
(see Table 2-3) and  gDNA was extracted using the DNeasy™ Blood & Tissue kit 
(Qiagen; GmbH, Germany), following the manufacturer’s instructions.  
Antibiotic Final concentration Solvent
Ampicillin 100 µg.L
-1
dd H2O
Kanamycin 50 µg.L
-1
dd H2O
Spectinomycin 50 µg.L
-1
dd H2O
Chloramphenicol 34 µg.L
-1
100% ethanol
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2.5.2 Isolation of plasmid DNA 
2.5.2.1 Miniprep 
Preparation of plasmid DNA was carried out using either the Zyppy™ Plasmid Miniprep 
kit (Zymo Research; Irvine, CA, USA) or the High-Speed Plasmid Mini Kit (Geneaid 
Biotech Ltd; New Taipai City, Taiwan) according to the manufacturer’s instructions.  
2.5.2.2 Midiprep 
DNA midipreps of plasmid F279:ntr were carried out using the Compact Prep
®
 Plasmid 
Midi Kit (Qiagen, GmbH, Germany) according to manufacturer’s instructions.  DNA 
midipreps to provide large quantities of vector for the cloning of mutant gene libraries 
were prepared using a standard alkaline phosphate midiprep protocol from Sambrook 
(Sambrook and Russell, 2001).  
2.5.3 Polymerase chain reaction (PCR) protocol 
Where PCR products were to be used in downstream cloning applications, amplification 
was carried out using Phusion™ high-fidelity polymerase. For colony screening and 
diagnostic PCR purposes Biomix Red™ was used. Standard amplification was carried out 
as shown in Table 2-6 with PCR components shown in Table 2-7. Protocols for overlap 
PCR are described in section 2.8.  
  
Table 2-6 Standard PCR parameters 
 
Phusion™
Temperature Time
98 °C 1 min
98 °C 15 secs
56 °C 30 secs/kB 30 cycles
72 °C 30 secs/kB
72 °C 5 mins
Biomix Red™
Temperature Time
95 °C 5 mins
95 °C 20 secs
56 °C 30 secs/kB 15 cycles
72 °C 1 min/kB
95 °C 20 secs
52 °C 30 secs 15-20 cycles
72 °C 1 min/kB
72 °C 5 mins
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Table 2-7 Components of Phusion™ and Biomix™ Red PCR reactions 
 
2.5.4  Agarose gel electrophoresis  
When analysis of DNA samples was necessary, e.g. for examining results of PCR 
reactions or restriction digests, aliquots of DNA were run on agarose gels (1% w/v 
agarose in 1 x TAE buffer (40 mM Tris-acetate, 1 mM EDTA), 1 μg/mL ethidium 
bromide) covered with 1 x TAE at 120-140 V for 20-40 min. DNA was visualised under 
UV (ultra violet) light and size determined by comparison to Hyperladder I, (Bioline, 
London, UK). 
2.5.5 DNA product purification 
DNA products were purified using the DNA Clean and Concentrator™-5 Kit (Zymo 
Research; Irvine, CA, USA) according to manufacturer’s instructions. The DNA products 
that required purification included PCR products, DNA following restriction digest for 
cloning reactions and ligations prior to transformation of electrocompetent E. coli.  
2.5.6 Restriction enzyme digest 
When restriction digests were required for standard gene cloning and diagnostic purposes, 
digests were carried out as per manufacturer’s instructions and purified using DNA Clean 
and Concentrator™-5 columns (section 2.5.5). The modified restriction digestion protocol 
used to generate high insert ratio mutant gene libraries is detailed in 2.5.8.  
Phusion™ Biomix™ Red  
Component
Quantity added 
(20 µL reaction)
Component
Quantity added (20 
µL reaction)
5 X Phusion™ HF buffer 4 µL Biomix™ Red 10 µL
10 mM dNTP mix 0.4 µL 10 µM forward primer 1 µL
Phusion™ polymerase 0.2 µL 10 µM reverse primer 1 µL
10 µM forward primer 1 µL Template DNA (< 100 ng/µL)
a
0.5-1 µL
10 µM reverse primer 1 µL ddH2O to 20 µL
Template DNA (< 100 ng/µL)
a
0.5-1 µL
ddH2O to 20 µL
a
For PCR screening of colonies, small piece of colony template was added to reaction using a sterile pippette tip
41 
 
 
2.5.7 Ligation 
Bioline T4 DNA Ligase was used for ligation reactions as shown in Table 2-8. Ligations 
were incubated overnight at 16 °C before being used to transform cells.                                           
 
Table 2-8 Ligation components  
2.5.8 Cloning of high insert ratio mutant gene libraries 
All mutant libraries in this thesis were cloned into a pUCX expression vector. For 
generation of mutant gene libraries, which ideally required >85% of the plasmids to carry 
the mutant gene insert, certain modifications to restriction digest and ligation protocols 
were made. We found that higher insert ratios could be more routinely achieved if the 
vector source was digested pUCX:AzoR_Ec plasmid rather than digested pUCX empty 
(i.e. a “stuffer” region of DNA could be excised to ensure that both restriction sites in the 
vector had been digested). Prior to digestion the vector (~10 µg) was heated to 70 °C for 
10 min before cooling to 37 °C. Vector and insert (~1 µg) were incubated with restriction 
enzymes (10 Units of each enzyme per 1 µg DNA) for 16 h at 37 °C with DNA 
concentration kept < 20 µg.mL
-1
. After 16 h an additional 10 Units of each restriction 
enzyme, and an additional enzyme BamHI-HF, (which cuts once in the AzoR_Ec gene 
sequence but not in the pUCX vector backbone) was added to each digest.  The digests 
were incubated for another hour and then the restriction enzymes heat inactivated 
according to the manufacturer’s instructions. Digested insert was cleaned up on a DNA 
Clean and Concentrator™-5 column (Section 2.5.5) and digested vector DNA was 
cleaned up using three individual Miniprep columns and eluted in pre warmed MQ. DNA 
was stored in single use aliquots at -20 °C or used immediately in ligation protocols.   
2.5.9 DNA quantification 
Where required, purity and concentration of DNA products were determined using a 
NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific; Waltham, MA, USA), 
according to the manufacturer’s instructions. 
Component Quantity
Vector < 40 ng
Insert < 160 ng
10X buffer 2 µL
Ligase (1 U.µL
-1
) 1 µL
ddH20
To make up 
to 20 µL
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2.5.10 DNA sequencing 
Sequencing was carried out by Macrogen Inc. (Seoul, South Korea) to determine the 
sequence of any mutants of interest and verify correct insertion and sequence of every 
NTR gene post insertion into a novel vector backbone.   
2.5.11 Transformation/electroporation of E. coli    
2.5.11.1 Generation of chemically competent cells 
An overnight culture of the strain to be made competent was grown in 3 ml LB amended 
with 10 mM MgCl2 and any relevant antibiotic. The overnight culture was inoculated into 
a 10-50 mL culture of LB + 10mM MgCl2 at a 50-fold dilution and the culture was grown 
until an OD600 of 0.4-0.6 was reached. When this was achieved the culture was placed on 
ice for 15 min, spun down (4000 rpm 4 °C, 15 min), the supernatant removed and the cell 
pellet resuspended in a 0.8 x volume of ice cold TFBI. The culture was then left on ice for 
2 h, spun down (4000 rpm 4 °C , 15 min), the TFBI discarded and the supernatant 
resuspended in 0.1 x volume of ice cold TFBII. Aliquots (50-200 µL) of the cells were 
then transferred into ice cold 1.5 ml microcentrifuge tubes and either immediately 
transformed with plasmid DNA or snap frozen and stored indefinitely at -80 °C.  
TFBI 
Potassium acetate 30 mM 
MnCl2 50 mM 
CaCl2 10 mM 
Glycerol 15% (w/v) 
 
TFBII 
MOPS, pH 7.0 10 mM 
CaCl2 75 mM 
KCl 10 mM 
Glycerol 15% (w/v) 
2.5.11.2  Transformation of chemically competent cells 
Frozen aliquots of cells to be transformed were removed from -80 °C storage and fully 
defrosted on ice. DNA to be transformed into the cells was added and the mix left on ice 
for 15 min. Ligations to be transformed were added to the cells at < 10% of the total cell 
volume. The cells were then heat shocked by incubation in a 42 °C heat block for 90 s 
and placed back on ice for 3-5 min. 900 µL of LB was added to the cell mix and the cells 
allowed to recover at 37 °C, 200 rpm for 45-60 min. Cells were then pelleted (13,000 
rpm, 30 s), the supernatant removed, cells resuspended in 200 µL of LB and spread onto 
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an agar plate containing the appropriate antibiotics. Plates were incubated overnight at 37 
°C.  
2.5.11.3  Generation of electrocompetent cells 
A 10 mL overnight culture of the strain to be made competent was inoculated from 
verified glycerol stocks. This overnight was used to inoculate a 500 mL flask containing 
LB and appropriate antibiotics and the resulting culture was grown at 37 °C, 200 rpm 
until an OD600 of 0.35-0.4 was reached, at which point the culture was transferred into 10 
sterile 50 ml tubes and placed on ice for 15-30 min with occasional swirling. The cells 
were then collected by centrifugation (2500 rpm, 30min, 4 °C) supernatant discarded and 
the pellets resuspended in a total volume of 500 mL ice cold sterile ddH2O by gentle 
pipetting. Following this first washing step the cells were again collected by 
centrifugation (2500 rpm, 30 min, 4 °C) and the resulting pellet resuspended in 250 ml 
ice-cold sterile 10% v/v glycerol. The cells were again pelleted by centrifugation (2500 
rpm, 30min, 4 °C) and the resulting pellet resuspended in 125 ml ice cold sterile 10% v/v 
glycerol. The cells were again collected by centrifugation and the pellet resuspended in 
500 µL ice cold sterile GYT. The OD600 of a 1/100 dilution of the cell mixture was then 
determined and GYT added to give a final concentration of 2-3 x 10
10
 cells/mL (OD600 
1.0 = 2.5 x 10
8
 cells/ml). 40 µL aliquots were then distributed into pre-chilled 1.5 mL 
microcentrifuge tubes on ice. Cell aliquots were then snap-frozen using a metal tube 
block cooled to -80 °C. Frozen aliquots of cells were stored at -80 °C until needed.  
2.5.11.4  Electroporation of electrocompetent cells 
Aliquots of frozen cells (40 µL) were defrosted on ice. DNA to be electroporated was 
first purified and eluted in ddH2O.   Then 25-50 ng of DNA added to the cells, mixed, and 
the cells left on ice for a further 15 min.  The cells were then moved to ice cold 0.2 mm 
gap electroporation cuvettes and electroporated using a Bio-Rad GenePulser Xcell™ 
(Hercules, CA, USA). The cells were pulsed (2500 V, 25 µF, 200 Ω) and 1 mL of room 
temperature SOC added immediately after. Cells were allowed to recover for 60 min at 37 
°C, 200rpm before plating on the appropriate antibiotic agar plate to select for positive 
transformants. Modifications to this protocol when used for the generation of large 
mutant libraries which were to be assessed by FACS are presented in section 2.15. 
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2.6 Gene knockout in E. coli    
Genes were knocked out using the FLP/FRT recombinase system developed by Datsenko 
and Wanner (2000). Firstly a primer pair were designed that contained, at the 5’ ends, 30 
nt extensions homologous to the 30 bp at beginning and end of the gene to be removed, 
with the 3’ ends of the primers able to act as a priming sequence and allow amplification 
of a ~1500 kb section of the plasmid pKD4. This PCR amplified pKD4 sequence 
contained a kanamycin resistant (Kan
R
) cassette, flanked by flippase recognition target 
(FRT) excision sites.  Through homologous recombination at the 30 nt regions of 
homology, the targeted gene is replaced with the exogenous Kan
R
 cassette. To allow this 
homologous recombination to occur, the strain in which the gene is to be removed is first 
transformed with the bacteriophage plasmid pKD46, which when expressed by E. coli 
allows for the homologous recombination of short linear DNA. Upon L-arabinose 
dependent induction of pKD46, followed by electroporation, the pKD4 fragment is 
inserted into the genomic DNA, knocking out the gene of interest. To remove the Kan
R
 
cassette cultures were grown at 42 °C to allow for removal of heat sensitive pKD46 
followed by transformation of the strain with the plasmid pCP20. pCP20 contains an 
ampicillin resistant cassette and encodes for a FLP recombinase which, on temperature 
dependent induction, recognizes the FRT excision sequence and removes the Kan
R
 
cassette. Further high temperature culturing eventually cures the strain of the heat 
sensitive pCP20 leaving only a ~200 bp “scar” in place of the knocked out gene.  
2.7 NTR candidate library 
The 58 bacterial oxidoreductase enzymes tested for activity with various nitroaromatic 
substrates are shown in Table 2-9. Each was individually PCR amplified from gDNA 
preparations of indicated bacterial species and cloned using restriction digest into the 
pUCX expression vector before transformation into specialised E. coli assay strains.  
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Gene Organism NTR originated from Family % ID/Sim
a Accession number 
NfsA_Ec Escherichia coli NfsA 100/100 AP_001482
NfsA_St Salmonella enterica NfsA 87/95 NP_455401
NfsA_Ck Citrobacter koseri NfsA 86/92 YP_001453815*
NfsA_Kp Klebsiella pneumoniae NfsA 83/92 YP_001334548
NfsA_Es Enterobacter sakazakii NfsA 82/94 YP_001438568
NfsA_Ecab Erwinia carotovara NfsA 65/82 YP_050771*
NfsA_Vf Vibrio fischeri NfsA 52/68 YP_002158635*
NfsA_Vv Vibrio vulnificus NfsA 51/65 NP_763284*
Frp_Vh Vibrio harveyi
c NfsA 51/65 AAM73721*
CO-Frp_Vh Vibrio harveyi
c NfsA 51/65 AAA21331
NfrA_Bs Bacillus subtilis NfsA 39/62 CAB15837*
NfsA_Lw Listeria welshimeri NfsA 41/60 YP_849114
NfsA_Li Listeria innocua NfsA 39/60 NP_470273
NfsA_Bc Bacillus coagulans NfsA 38/60 ZP_01697274*
NfsA_Np Nostoc punctiforme NfsA 38/59 ZP_00110199
NfsA_Bt Bacillus thuringiensis NfsA 35/58 YP_035832*
NfsA_Ls Lactobacillus sakei NfsA 40/57 YP_396325*
EcD_Pp Pseudomonas putida NfsA 35/57 AAL09699
YcnD_Bs Bacillus subtilis NfsA 35/56 CAB12194*
NfsA_Ms Mycobacterium smegmatis NfsA 36/54 YP_887240
NfsB_Ec Escherichia coli NfsB 100/100 AP_001223
NfsB_Ck Citrobacter koseri NfsB 88/95 YP_001454141*
NfsB_St Salmonella enterica NfsB 88/91 NP_806031.
NfsB_Kp Klebsiella pneumoniae NfsB 84/93 YP_001334233*
NfsB_Vv Vibrio vulnificus NfsB 61/75 NP_762888*
NfsB_Pp Pseudomonas putida NfsB 52/71 NP_744580
NfsB_Es Enterobacter sakazakii NfsB 46/66 YP_001437964*
FraseI_Vf Vibrio fischeri NfsB 34/53 BAA04595
NfsB_Vh Vibrio harveyi NfsB 30/48 ZP_01985918*
YfkO_Bs Bacillus subtilis NfsB 29/46 CAB12612*
YdgI_Bs Bacillus subtilis NfsB 25/47 CAB12385*
NfsB_Pa Pseudomonas aeruginosa NfsB 24/42 NP_253877
AzoR_Ec Escherichia coli AzoR 100/100 AP_002037
AzoR_St Salmonella enterica AzoR 87/95 NP_805329. 
AzoR_Vv Vibrio vulnificus AzoR 56/73 NP_761189*
AzoR_Pp Pseudomonas putida AzoR 48/66 NP_746647
NemA_Ec Escherichia coli NemA 100/100 AP_002272
NemA_St Salmonella enterica NemA 92/96 NP_805105*
NemA_Kp Klebsiella pneumoniae NemA 86/92 YP_001335650*
NemA_Vv Vibrio vulnificus NemA 47/65 NP_762994*
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       Table 2-9  58 oxidoreductase enzymes in the expanded NTR candidate library, cloned 
into E. coli expression vector pUCX. Where applicable previously published enzyme names are 
used, otherwise names indicate the enzyme family followed by a two letter abbreviation from the 
genus and species of bacteria the enzyme originated from. Strains used as NTR sources are as 
indicated in Table 2-3.  
2.7.1 Bioinformatics 
Protein homology searches were carried out using the National Centre for Biotechnology 
Information (NCBI) protein database using the algorithm protein-protein BLAST (blastp; 
http://blast.ncbi.nlm.nih.gov/)  
2.8 Overlap PCR 
Mutant NTR genes were created using overlap PCR. For each mutation to be made, two 
internal gene primers were designed. The “Fwd” primer was comprised of three parts, 
first a ~18 nt section homologous to the gene section immediately upstream of the 
YwrO_Bs Bacillus subtilis YwrO 70/82
d
NP_391480*
YwrO_Li Listeria innocua YwrO 42/57
d
NP_471232*
YwrO_Vf Vibrio fischeri YwrO 47/62
d
YP_002157853
YieF_Ec Escherichia coli YieF 100/100 AP_004074
YieF_Pa Pseudomonas aeruginosa YieF 45/60 NP_249895
MdaB_Ec Escherichia coli MdaB 100/100 AP_003578
MdaB_Ps Pseudomonas syringae MdaB 60/74 YP_273002
WrbA_Ec Escherichia coli WrbA 100/100 AP_001635
WrbA_Ps Pseudomonas syringae WrbA 39/55 YP_275866
YdjA_Ec Escherichia coli YdjA 100/100 AP_002384
YdjA_Kp Klebsiella pneumoniae YdjA 79/89 YP_001334868
NQO1_Pp Pseudomonas putida NQO1 37/56
e
NP_745853
NQO1_Pa Pseudomonas aeruginosa NQO1 41/54
e
NP_253662
YcdI_Ec Escherichia coli YcdI 100/100 AP_001639
YcdI_Kp Klebsiella pneumoniae YcdI 76/85 YP_001334699
YcaK_Ec Escherichia coli YcaK 100/100 AP_001531
YcaK_Pa Pseudomonas aeruginosa YcaK 27/48 NP_249916
KefF_Ec Escherichia coli KefF 100/100 AP_000710
b
Three letter species abbreviation to differentiate from NfsA_Ec
c
Frp and CO-Frp from Vibrio harveyi  strains KCTC 2720 and ATCC 33843 respectively 
e
Sim. and ID values are relative to Rattus norvegicus  NQO1/DTD 
a
ID and % Sim. indicate amino acid identity and similarity, (as calculated by the blastp 
program “identities” and “positives”, respectively) of each NTR to the E. coli  orthologue 
within enzyme family unless otherwise stated
d
Sim. and ID values for all YwrO family enzymes are relative to B. amyloliquefaciens  YwrO
*Due to differing strain isolate exact NTR protein sequence slightly differs from Accession number and can be found 
in Appendix 1
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mutation site, next the actual mutant codon and finally ~15 nt homologous to the gene 
region immediately after the mutation site. The “Rev” primer was the reverse 
complement of the first ~18 nucleotides of the “Fwd” primer. An example of such 
primers can be seen in Figure 2-3.  
 
Figure 2-3 Example of primers used to generate site directed mutants. Primers designed to 
generate NfsB_Ec T41L mutant from NfsB_Ec wild type. Site of mutation marked in red and 
primer overlap region in blue. Displayed 5’-3’ direction.  
 
A schematic of how such internal primers, in combination with gene specific primers, can 
be used to generate a full length gene using overlap PCR can be seen in Figure 2-4.                               
 
Figure 2-4 Schematic of overlap PCR for generation of site directed mutants 1) Two gene 
fragments are separately amplified using the wild type gene as template with one internal primer 
and complementary gene specific primer in each reaction. The second fragment contains the 
mutation specified by the internal primer. 2) These fragments, which have a ~18 base pair overlap 
due to the specific design of the internal primers are combined. 3) A primer-less PCR reaction is 
commenced and due to this overlap region the fragments self- prime. 4) After a number of PCR 
cycles gene specific primers are added and increase amplification of the full length gene, which 
now contains the specified mutation.   
 
NfsB EC T41L Fwd CAATACAGCCCATCCAGCCTGAACTCCCAGCCGTGG
NfsB EC 41 Rev GCTGGATGGGCTGTATTG
Partial NfsB (E.c) sequence 
(bases 95-145)
-CGCTACTGCAATACAGCCCATCCAGCACCAACTCCCAGCCGTGGCATTTTATTG-
1)
41L
41L
41L
NfsB EC
T41L
41L
2)
3)
4)
5)
T41
41L
41L
T41
NfsB_Ec gene 
template
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The initial gene fragments were amplified in separate PCR reactions from a pUCX: wild 
type NTR gene template (~ 500 pg of plasmid per reaction), using a standard Phusion™ 
protocol (2.5.3). PCR products were then purified, combined in a 1:1 molar ratio and a 
full length gene product amplified using an overlap PCR protocol Figure 2-5. When 
multiple mutations at different gene sites were simultaneously introduced, multiple 
fragments of the gene were amplified and then combined in an overlap PCR reaction, 
with the initial amplification of internal fragments carried out using complementary 
internal gene primers.   
                                                  
Figure 2-5 Overlap PCR protocol Both initial fragment annealing temperature and the number 
of replication cycles post primer addition were occasionally varied to increase yield of a specific 
full length product. 
 
2.9 Generation of mutant NTR libraries 
In addition to being used to introduce specific mutations, overlap PCR was also used to 
construct mutant gene libraries. Here the mutant codon(s) introduced contained redundant 
bases to allow the site to code for any one of multiple amino acids. An NNK codon was 
used in site saturation mutagenesis libraries, and restricted redundancy codons used when 
constructing mutant libraries designed to encompass all possible combinations of a small 
number of preselected mutations. In one instance a mutant gene library was ordered and 
synthesised by GenScript (GenScript, NJ, USA). Post delivery of this library it was 
digested and cloned into our pUCX expression vector as per the gene libraries constructed 
in house.  
Phusion™
Temperature Time
98 °C 2 min
98 °C 10 secs
46-52 °C 20 sec 15 cycles
72 °C 30 secs/kB
Pause Add gene specific primers
98 °C 10 secs
56 °C 20 secs 15-20 cycles
72 °C 30 secs/kB
72 °C 5 mins
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Once the full length mutant gene was constructed for a library it was cloned into the 
pUCX over-expression vector, and the ligations either transformed into chemically 
competent E. coli SOS-R2 cells or electrocompetent E. coli 7KO-pGFP cells as 
appropriate. Entire transformations (SOS-R2 cells) or a 20 µL  aliquot (7KO-pGFP) were 
spread onto solid media + antibiotic  plates for selection of transformed colonies, and 10-
15 random colonies were PCR screened with NfsA insert specific primers to determine 
the gene insert ratio of each library. For SOS-R2 libraries this insert ratio, in conjunction 
with the calculation of the number of possible variants existing in each library, was used 
to determine how many individual colonies would have to be screened to ensure a >95% 
probability that every variant had been tested at least once (Reetz and Carballeira, 2007). 
Libraries with colony numbers not less than this were then picked individually into 
separate media filled wells of 96 well microplates. These plates were grown overnight, 
mixed with glycerol and then stored at -80 °C.  Glycerol plates were used to inoculate day 
cultures for screening of mutants activities with nitroaromatic substrates. Treatment of 
7KO-pGFP libraries which were to be assessed by FACS is further described in section 
2.9.1)   
2.9.1 Modifications to electroporation protocol for the generation of mutant 
libraries which were to be assessed by FACS 
Here the initial electroporation protocol was identical to that of section 2.5.11, but 
positive transformants were selected by adding cells post the 60 min recovery period to 
50 mL LB, Amp + Spec liquid media and the flasks left overnight with gentle agitation at 
room temperature. The overnight cultures were then spun down and the cell pellet 
resuspended in 1 mL LB + Amp media. The OD600 absorbance of a diluted aliquot was 
read to allow an estimation of the cell number of the library and the remainder mixed in a 
50:50 (v/v) ratio with 80% glycerol and stored in 200 µL aliquots at -80 °C until required 
for assessment of mutant activity using FACS.  
2.10 Protein purification 
2.10.1 Expression using Autoinduction media 
A single colony or small inoculum of E. coli BL21(DE3) carrying pET28a(+):ntr was 
used to inoculate 50 mL ZYP-5052 + Kan. This culture was left to incubate overnight at 
30 °C, 200 rpm for at least 16 h, before chilling on ice for 15 min. The cell pellet was 
then collected by centrifugation (4,000 rpm, 25 min, 4 °C). After discarding the 
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supernatant, the cell pellet was either processed immediately, or stored at -80 °C until 
required. 
2.10.2 Expression using low temperature LB + supplements  
A 1.5 mL volume of overnight culture of E. coli BL21(DE3) carrying pET28a(+):ntr was 
used to inoculate a 50 mL volume of LB + Kan + 2.5 mM Betaine + 1 M D-sorbitol 
media. This culture was grown at 37 °C, 200 rpm until an OD600 of ~0.5 was reached. 
Following this the temperature was lowered to 18 °C and after 45 min 0.5 mM IPTG 
added to induce NTR over-expression. Cultures were left to grow for ~40 h before the 
cell pellet was collected as per 2.10.1.  
2.10.3 Enzyme purification 
Cell pellets were lysed by the addition of 4 mL Bugbuster® (Novagen; Merck Millipore, 
MA, USA) for every 50 mL of initial culture. The pellets were resuspended and incubated 
at room temperature on an orbital shaker for 20 min prior to removal of the insoluble 
fraction by centrifugation for 15 min at 4 °C, 12,000 rpm. Purification of His6- tagged 
proteins from the soluble fraction was carried out using a Novagen Hisbind™ Ni-NTA 
chromatography kit (Merck Millipore, MA, USA), according to the manufacturer’s 
instructions. The final settled-bed resin volume per column was ~ 1 mL. Proteins were 
eluted in 500 µL fractions and the three most yellow fractions by eye were pooled and 
incubated with excess (1 mM) FMN or FAD cofactor as appropriate for 1 h on ice. 
Buffer-exchange into 40 mM Tris-Cl pH 7.0 was then conducted using a 5 mL HiTrap™ 
Desalting column (GE Healthcare, Chalfont St. Giles, UK) according to the 
manufacturer’s instructions. Only 1 mL of column flow-through was collected upon 
elution to minimize potential contamination with excess free FMN.  
In one instance His6-tagged NfsA_St was prepared by passage through a French press. 
Here cell pellets were resuspended in ice cold 10-20 mL 1 × His•Bind™ Binding buffer 
(Novagen Hisbind™ Ni-NTA chromatography kit ) and pressure at 40,000 psi applied 
three times to achieve uniform cell lysis.  
His6-tags were not removed from purified proteins as tag presence had previously been 
determined to not affect the catalytic activity of a wide range of purified NTRs (Prosser, 
2011) .  
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2.10.4 Determining enzyme concentration  
Concentrations of purified protein samples were measured using the DC™ protein assay 
kit (Bio-Rad, Hercules, CA, USA), following the manufacturer’s instructions. Protein 
standards used consisted of Bovine Serum Albumin (BSA) made up in 40 % glycerol, 40 
mM Tris-Cl pH 7.0 and spanning from 0.125-1.5 mg.ml
-1
.  
2.10.5 Enzyme storage 
Immediately post purification samples were mixed 1:1 with 80 % glycerol and stored at -
20 °C until use, typically within a few weeks of purification. Glycerol was found to have 
no detrimental effects on enzyme activity and when tested NTRs have been found to 
retain initial activity > 6 month post storage (results not shown).    
2.11 In vitro purified protein kinetics 
Apparent steady state enzyme kinetics for NTRs and substrates were assessed via 
monitoring decrease in absorbance at 340 nm, with extinction coefficients determined as 
outlined in section 1.11.1. Reactions were carried out in 60 µL volumes in UVettes™ 
(Eppendorf, Hamburg, Germany), using the 2 mm path length, and the wavelength was 
measured using a Helios ɣ UV-Vis spectrophotometer (Thermo Fisher Scientific; 
Waltham, MA, USA). Reactions were in 10 mM Tris-Cl pH 7.0 buffer and consisted of 
200 µM NAD(P)H, 2% DMSO and substrate concentrations ranging from 0-1200 µM. 
Reactions were initiated by addition of 6 µL of an appropriate dilution of enzyme and the 
linear decrease in absorbance monitored for the first 20-40 s post enzyme addition. Where 
possible reaction rates were measured at substrate concentrations ranging from 0.2 – 5 x 
apparent Km, although for some enzymes this was not possible as the sensitivity and linear 
absorbance maxima of the spectrophotometer meant only concentrations ranging from 
6.25 – 1200 µM substrate could be accurately assayed.  Non-linear regression analyses 
and Michaelis-Menten curve fitting was performed using SigmaPlot™ 10.0 (Systat 
Software, Richmond, CA, USA). 
2.11.1 Determination of 2-NI extinction coefficients  
Both the oxidation of NAD(P)H and the reduction of the 2-NI substrates (absorbance 
maximas typically near 320 nm (Grunbaum et al., 1987; Olekhnovich et al., 2009)) 
contributes to the decrease in light absorbance at 340 nm as the oxidoreductase reaction 
proceeds (Varghese and Whitmore, 1980). As such, combined molar extinction 
coefficients encompassing the change in absorbance due to both compounds were derived 
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as previously described (Olekhnovich et al., 2009). These values combined the 340 nm 
extinction coefficient of the 2-NI compound (experimentally determined) with ɛ = 12,440 
M
-1 
cm
-1
 representing the assumed oxidation of two moles of NAD(P)H (2 x ɛ= 6,220 M-1 
cm
-1
)  for every mole of 2-NI reduced. The extinction coefficient for each nitroimidazole 
substrate was experimentally determined by measuring the decrease in 340 nm 
absorbance that occurred when 100 µM of 2-NI was incubated with 300 µM NADPH and 
excess NfsA (purified enzyme) for 30 min. NfsA was used as it possesses low-level 
NADPH oxidase activity, such that it slowly reduces dissolved oxygen in the buffer, 
ensuring the eventual oxidation of all NADPH remaining in the cuvette post full 
reduction of the 2-NI substrate. A list of calculated extinction coefficients is presented in 
Table 2-10.  
                                 
Table 2-10  Experimentally derived extinction coefficients for 2-NI compounds used in this 
study, determined at 340 nm to take into account loss in absorbance that occurs due to both 2-NI 
reduction and NAD(P)H oxidation.  
2.12 Thermal scanning experiments to determine protein melting 
temperatures 
Thermal scanning experiments were performed using a Rotor-Gene 6000 (Corbett 
Research, Concorde, Australia). Experiments were performed as previously published 
((Niesen et al., 2007) and http://thermofluor.org/index.html). In brief, duplicate samples 
containing 5 µg protein and Sypro Orange dye (Sigma-Aldrich, St. Louis, MO,USA) in 
Tris-HCl pH 7 buffer were subjected to a thermal melt cycle (35-95  °C), using a 5 s 
ramp. Temperature induced protein melt was determined by monitoring fluorescence 
intensity. Data was analysed using Rotor-Gene 6000 Series software 1.7 (Corbett 
Research, Concorde, Australia). 
Compound 
Δ 340 nm (cm
-1
)  
when 100 µM 
reduced
Extinction 
coefficient  
(M
-1 
cm
-1
)
EF5 -0.651 19,000
EF3 -0.665 19,100
F-miso -0.65 18,900
Pimo -0.611 18,600
RB6145 -0.706 19,500
HX4 -0.666 19,000
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2.13 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
2.13.1  SDS-PAGE protocol 
For visualisation of proteins, 15% SDS-PAGE gels were cast using a Bio-Rad Protean 
II™ apparatus. Roughly 5 mL of 15% separating gel (see 2.13.2) was applied to the gel 
cast, covered with 1 mL of drum grade 100% isopropanol and left to set for 30 min. The 
isopropanol was then discarded and roughly 1.5 mL of 4% stacking gel poured over and a 
multi-well comb inserted and left to solidify for 30 min.   
Samples to be run on each SDS-PAGE gel were added in a 2:1 ratio to 3 x SDS-loading 
buffer. Samples were boiled at 95 °C for 5 min prior to electrophoresis. Gels were run in 
1 x SDS-Run buffer, at constant voltage (150 V) for ~60 min, roughly corresponding to 
the time at which the SDS load buffer ran off the gel. Protein bands were stained by 
gentle shaking in Coomassie blue stain solution for 30 min. Destaining was carried out by 
washing the gel of all Coomassie blue stain in running tap water, followed by gentle 
shaking in destain solution for as long as necessary to achieve the desired contrast. 
Protein size was determined by comparison to a pre-stained Protein Ladder (10-250 kDa) 
(NEB; Ipswich, MA, USA) 
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2.13.2  SDS-PAGE recipes 
 
SDS-PAGE Recipes
15% Seperating gel (10 mL)
2.5 mL 1.5 M Tris-Cl (pH 8.8)
100 µL SDS
2 mL Bis-Acrylamide
3.65 mL Acrylamide
1.75 mL ddH20
100 μL 10 % APS
6 μL TEMED
4% Stacking gel (3 mL)
750 μL 0.5 M Tris-Cl (pH 6.8)
30 μL 10 % SDS
156 μL 2% Bis-Acrylamide
288 µL Acryalmide
1.77 mL ddH2O 
30 μL 10 % APS
5 μL TEMED
3 x SDS Loading Buffer
150 mM Tris-Cl (pH6.8)
6 % SDS
0.3 % Bromophenol Blue
30 % Glycerol
300 mM β-Mercaptoethanol
10 x SDS Run Buffer (per Litre)
144 g Glycine
30.3 g Tris
10 g SDS
Coomassie Blue Stain (per Litre)
2.5 g/L Coomassie Brilliant Blue
450 mL 100 % Ethanol
100 mL 100 % Acetic Acid
450 mL ddH2O
Destain (per Litre)
400 mL 100 % Methanol
100 mL 100 % Acetic Acid
500 mL ddH2O
Added immediately 
prior to pouring gel
Added immediately 
prior to pouring gel
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2.14 Assays for NTR activity with nitroaromatic substrates 
2.14.1 SOS assay 
2.14.1.1 SOS assay using a lacZ reporter  
Individual 96 microplate wells containing 200 µL LB + Amp + glucose (0.4%) were 
inoculated from glycerol stocks with SOS-R2  pUCX:ntr strains and grown overnight 
(~16 h) at 30 °C, 200 rpm. The next morning 15 µL of each overnight culture was used to 
inoculate 200 µL of assay media (LB + Amp + 0.05 mM IPTG + 0.2% v/v glucose) in a 
96 well microplate and cultures were grown for 3.5 h at 30 °C, 200 rpm. Cultures were 
then split, with 100 µL aliquots inoculated into two fresh microplates, one containing 100 
µL assay media + drug at 2 x challenge concentration and one containing 100 µL assay 
media + DMSO control. The OD600 absorbance for each well was determined using an 
EnSpire 2300 Multilabel Reader (Perkin Elmer, Waltham, MA, USA). The plate was 
returned to 30 °C, 200 rpm for 3-4 h prior to again measuring culture OD600 followed by 
quantification of β-galactosidase induction. This was accomplished by removing a 20 µL 
cell aliquot to 130 µL of ONPG assay buffer (see below) and incubating the plate for 15-
30 minutes without shaking at 37 °C until sufficient colour development as a result of 
ONPG cleavage. This reaction was then halted by addition of 50 µL of 1 M Na2CO3 to 
each well. Aborbance readings at 420 nm and 550 nm were taken and used to calculate 
Miller units using the Miller equation (Miller, 1972). Any drug dependent growth 
inhibition was monitored by comparing the OD600 increase for drug challenged and 
unchallenged cultures.If growth inhibition was observed for any over expression strains 
assays were repeated at lower compound concentrations.   
ONPG assay buffer: 
Fresh ONPG assay buffer was made up prior to each use. This consisted of 9 mL 50 mM 
NaPO4 buffer (pH 7.0), 4 mL Z-buffer and 1 mL T-base per 96 well microplate assayed.  
Z-buffer 
NaH2PO4 0.074 M 
Na2HPO4 0.126 M 
MgSO4 2 mM 
MnSO4 0.4 mM 
CTAB 399 mg.L
-1 
Sodium deoxycholate 199.5 mg.L
-1 
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β-mercaptoethanl 0.174 M* 
             
   
  T-base** 
 
K2HPO4 0.08 M 
KH2PO4 0.044 M 
(NH4)2SO4 15.1 mM 
Tri-sodium citrate 1 g.L
-1 
ONPG 8 mg.mL
-1 
*added to assay buffer immediately prior to use, works out to be 52 µL per 96 well microplate 
** Post ONPG addition stored in single use aliquots at -20 °C 
2.14.1.2  SOS assay using a GFP reporter  
Cultures of 7KO pGFP pUCX:ntr were inoculated from glycerol stocks and grown 
overnight (~16 h) in 96 well plates containing 200 µL LB + Amp + Spec + 0.4% v/v 
glucose at 30 °C, 200 rpm. The next morning 10 µL of overnight cultures was used to 
inoculate 200 µL of assay media (LB + Amp + Spec + 0.05 mM IPTG + 0.2% v/v 
glucose) in a 96 well microplate and cultures were grown for 3 h at 30 °C, 200 rpm. 
Cultures were then split, with 100 µL aliquots inoculated into two fresh microplates, one 
containing 100 µL assay media + drug at 2 x challenge concentration and one containing 
100 µL assay media + DMSO control. OD600 absorbance for each well was determined 
and the plate was returned for further incubation at 30 °C, 200 rpm. At approprite time 
intervals (generally 4-6 h) culture OD600 and GFP-mut3 fluorscence readings (ex/em 
488/510 nm) were recorded and SOS induction determined by dividing raw fluorescence 
of drug challenged cultures by that of unchallenged controls. Any drug dependent growth 
inhibition was monitored for by comparing the OD600 increase of drug challenged and 
unchallenged cultures.   
2.14.2 Growth inhibition assay 
Overnight cultures and initial NTR induction proceeded as per the lacZ SOS assay, with 
the assays diverging when strains came to be challenged with drugs. At this point 40 µL 
aliquots of each strain were moved into a 384 microplate wherein wells contained either 
40 µL assay media (LB + Amp + 0.05 mM IPTG + 0.2% v/v glucose) + drug at 2 x 
challenge concentration or a media + DMSO only control. In each experiment strains 
were assayed in duplicate from seperate day cultures. The density of the cultures (OD600)  
was measured, the plate returned to  30 °C, 200rpm for 4 h and then OD600 measured 
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again. Relative increases in OD600 for challenged vs unchallenged wells were then used to 
calculate percentage growth inhibition.  
2.14.3 IC50 assay 
Overnight cultures were grown as per the lacZ SOS assay. The next morning 50 µL of 
each culture was used to inoculate 1 mL of assay media (LB + Amp + 0.05 mM IPTG + 
0.2% v/v glucose) in separate 15 mL Falcon tubes. These Falcons were incubated at 30 
°C, 200 rpm for 2.5 h before 40 µL aliquots of each culture were added to wells of a 384 
well microplate containing 40 µL of assay media ± 2 x final drug concentration. Each 
culture was exposed, in duplicate, to at least seven wells containing a two-fold increasing 
tiration of drugs and one media only control. Media was supplemented with DMSO as 
appropriate and DMSO in media never exceeded 4%. Percentage growth inhibition at 
each drug concentration was determined as per the growth inhibiton assay and IC50 values 
(the drug concentration which caused 50% strain growth inhibition) were calculated using 
non-linear regression analysis in SigmaPlot, fitting the data to a 4-parameter logistics 
curve. (Systat Software, Richmond, CA, USA). 
2.14.4 NAD(P)H depletion assay 
Overnight cultures and initial NTR induction proceeded as per the lacZ SOS assay. 
Cultures were then incubated at 30 °C, 200 rpm for 6 h. Crude cell lysates were prepared 
by mixing cultures with BugBuster® Protein Extraction Reagent in a 1:1 (v/v) ratio at 
room temperature for 30 min, lysates were then diluted as appropriate using 100 mM 
KPO4 buffer pH 8.0. To monitor cell lysate cofactor consumption, replicate 200 µl 
reactions consisting of 0.25% DMSO, 100 mM KPO4 buffer pH 8.0, 50 µl diluted crude 
cell lysate ± 150 µM substrate were prepared and the reactions initiated by addition of 50 
µL of 800 µM NAD(P)H. Reactions were halted by addition of 50 µl NBT solution (2 
mg.ml
-1
 NBT, 0.3 mg.ml
-1
 phenazine methosulfate, 100 mM KPO4 buffer pH 8.0). 
Phenazine methosulfate was mixed with NBT immediately prior to use. Levels of 
formazan production, corresponding to the amount of NAD(P)H remaining in each well, 
were quantified by measuring absorbance at 590 nm, 3-5 min post NBT addition. The 
range of activities able to monitored by the assay were controlled both by the dilution 
factor of the crude cell lysate and by varying the length of time for which the 
oxidoreductase reactions were allowed to proceed.  
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2.14.5 NTR activation of fluorogenic probes in E. coli 
Cultures of SOS-R2 or 7KO-pGFP were grown as per the lacZ or GFP SOS assay 
respectively until the point of prodrug challenge, whereupon cultures were instead treated 
with fluorogenic probe containing media to a final concentration of 25 µM. Cultures were 
returned to the incubator (30 °C, 200 rpm) and 30 min to 2 h later fluorescence 
determined with appropriate excitation and emission wavelengths using the EnSpire 2300 
Multilabel Reader (Perkin Elmer, Waltham, MA, USA). 
2.15 Fluorescence activated cell sorting of mutant libraries 
Overnight cultures were set up by thawing one 200 µL aliquot of a of 7KO pGFP 
pUCX:ntr mutant library (generation described in section 2.9.1) and using this to 
inoculate 10 wells of a 96 well microplate, each filled with 200 µL of  LB + Amp + Spec 
+ 0.4% v/v glucose. These were then grown overnight at 30 °C, 200 rpm.  The next 
morning cultures from these wells were pooled and 2 x 10 µL aliquots used to inoculate 
200 µL apeice of assay media (LB + Amp + Spec + 0.05 mM IPTG + 0.2% v/v glucose) 
in a 96 well microplate. Cultures were then grown, split and challenged with 1 µM 
RB6145 as described in the standard GFP based SOS assay (Section 2.14.1.2). After 4 h 
incubation with 1 µM RB6145 the 2 x 200 µL of drug challenged culture was collected, 
pooled, spun down in a microcentrifuge (13,000 rpm, 30 s), and the cells washed three 
times in phosphate buffered saline (PBS, pH 7.0) resuspended in 1000 µL PBS then 
diluted (50 µL cells into 1000 µL PBS) in FACS tubes. Samples were analysed on a 
FACS Vantage SE-Diva (Becton Dickinson Biosciences, Bedford, MA) with GFP-mut3 
fluorescence excited using a 100 mW blue laser (488 nm) and detected using a 
photomultiplier tube with a 530/30 nm band pass filter. Gates for sorting were set using a 
culture of 7KO pGFP NfsA_Ec cells challenged with 3 µM RB6145 (positive 
fluorescence) or unchallenged controls (negative fluorescence). Sorted events were 
collected, spun down in a microcentrifuge tube and then resuspended in 1 mL of LB + 
Amp + Spec + 0.4% v/v glucose and allowed to recover at 37 °C 200 rpm for 1 h before 
plating in 100 µL aliquots on solid media plates containing Spec + Amp antibiotics. 
Plates were grown overnight at 37 °C in a static incubator, before colonies were picked 
individually into separate media filled wells of 96 well microplates. These plates were 
grown overnight, mixed with glycerol and then stored at -80 °C until required to inoculate 
day cultures for screening activity with nitroaromatic substrates. 
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2.16 Docking  
This modelling work was carried out in conjunction with Dr Jack Flanagan at the 
ACSRC. Molecular docking was performed using the X-ray crystal structure of NfsB_Ec 
(PDB code 1DS7). In preparing the structures for docking, waters were removed and the 
structures protonated using SYBYL8.0.3 (TRIPOS). After visual inspection of the crystal 
structure the orientation of Asn117 from chain A was manually flipped 180 °C to give a 
favourable interaction with nearby Arg120 and Glu101 residues (this orientation was 
already seen in chain B). SN33623 and CB1954 were docked into the NfsB_Ec active site 
using GOLD v5.1, with a docking cavity of 12 Å centred on N5 of the FMN co-factor. 
The docking was performed using the ChemPLP scoring function, with 20 poses per 
ligand saved. Search efficiency was set at 200%, and diverse solutions were allowed with 
1.5 Å freedom. One H bond constraint was set to the hydrogen of the backbone amide of 
Thr41, as this bond was found in the crystal structure of CB1954 bound in NfsB_Ec  
((Johansson et al., 2003) PDB code 1IDT). In regard to CB1954 docking the solutions 
were visually inspected for poses which recapitulated CB1954 binding as seen in the X-
ray crystal structure 1IDT. The poses returned for SN33623 docking were visually 
inspected for solutions which showed favourable confirmation of the amide bond within 
SN33623 and positioned the NO2 functional group of the ligand directly over the FMN 
cofactor.  
2.17 Generation, maintenance and storage of HCT-116:NTR cell lines 
2.17.1 HCT-116 maintenance 
HCT-116 cell lines were, unless otherwise stated, maintained in α-MEM (Gibco, Grand 
Island, NY) media supplemented with 5% Fetal Calf Serum (FCS) and grown in 
monolayer up to 80% confluency in a humidified incubator (37 °C, 5% CO2). Cells were 
sub-cultured at least every 7 days, and kept in culture for < 3 months post growth from 
frozen stocks confirmed to be mycoplasma free by PCR-ELISA (Roche Diagnostics 
Mannheim, Germany). Cell lines carrying a F279-V5 plasmid were maintained in media 
supplemented with 1 µM puromycin.  
When required, cells were harvested from growth flasks and microplates using a standard 
Trypsin/EDTA protocol. Briefly growth media was aspirated and cells washed once with 
1 x PBS, then warm 0.05% Trypsin/EDTA (Invitrogen Corporation, Carlsbad, CA, USA) 
sufficient to cover flask/well surface and left until cells detached  (typically < 5 min). 
60 
 
 
Trypsin was inactivated by re-suspending the cells in FCS containing media and a cell 
aliquot taken to determine cell count using a Z2 Coulter Particle Count and Cell 
Analyzer, (Beckman CoulterTM,Fullerton, CA, USA). If required for sub-culture, the cell 
volume necessary for cell maintenance was transferred to a new flask containing fresh 
media.   
2.17.2 Storage and recovery from frozen stocks 
For long term storage cells were harvested from T175 flasks, centrifuged for 5 min at 300 
RCF, the media discarded and cells resuspended to a concentration of 1-2 x 10
6
 cells.mL
-1
 
in a solution of FCS containing 10% DMSO. The cell mix was placed in 1 mL aliquots in 
cryotubes and then frozen in 1 °C increments using a Mr. Frosty® Cryo 1 °C Freezing 
Container (Thermo Fisher Scientific; Waltham, MA, USA). When a temperature of -80 °C 
was reached the cryotubes were placed in liquid nitrogen for long term storage. 
Cell recovery was accomplished by removal of cell aliquots from nitrogen storage, 
thawing in a 37 °C water bath and rapid addition of thawed cells to a T175 flask 
containing 40 mL of pre warmed αMEM + 5% FCS.  
2.17.3 Generating F279-V5:ntr construct using Gateway® technology 
2.17.3.1 Generating Gateway® compatible PCR products 
NTR genes to be transfected were amplified using Gateway® compatible primers (see 
Table 2-1). These introduced a mammalian Kozak consensus sequence, a Shine-Dalgarno 
prokaryote consensus sequence and Invitrogen Gateway® BP recombination sites, as well 
as an extra GGC (glycine) codon added to each gene immediately after the ATG start 
codon to ensure a uniform ATGG four-base start sequence, and conversion of all stop 
codons to TAG.  PCR products were confirmed to be of correct size using gel 
electrophoresis and purified using the DNA Clean and Concentrator™-5 Kit (Zymo 
Research; Irvine, CA, USA).  
2.17.3.2  BP clonase  
Recombination of the PCR product into an entry vector, pDONR™221 (Invitrogen 
Corporation, Carlsbad, CA, USA) was accomplished using Gateway® BP Clonase™ II 
enzyme mix (Invitrogen). 150 ng of pDONR221 was mixed with 20-50 fmol of PCR 
product, 1 µL of BP Clonase enzyme mix and TE pH 8.0 buffer to 10 µL and incubated at 
25 °C for 14 h. 1 μl of the 2μg.μl-1 Proteinase K solution supplied with the kit was added 
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to the mixture which was left for a further 10 min at 37ºC. The resulting mix was 
transformed into E. coli cloning strain DH5α, and plated on LB + Kan agar plates. 
Colonies were grown and analysed for insertion of NTR sequence by restriction enzyme 
digest with NheI.  
2.17.3.3  LR Clonase 
Recombination of the NTR construct from pDONR221 into the ACSRC constructed 
mammalian expression vector F279/V5 (Prosser et al., 2013) was accomplished using 
Gateway® LR Clonase™ II enzymes mix (Invitrogen Corporation, Carlsbad, CA, 
USA).150 ng of pDONR221:ntr was mixed with150 ng of F279/V5, 1 µL of LR Clonase 
enzyme mix and TE pH 8.0 buffer to 10 µL and incubated at 25 °C for 14 h. 1 μl of the 
2μg.μl-1 Proteinase K solution was added to the mixture which was left for a further 
10min at 37ºC. The resulting mix was transformed into E. coli cloning strain DH5α, and 
plated on LB + Amp agar plates. Colonies were grown and analysed for insertion of NTR 
sequence by restriction enzyme digest with HindIII. Correct insertion was confirmed by 
DNA sequencing of positive constructs.  
2.17.3.4  DNA isolation 
DNA for transfection was prepared using the Compact Prep® Plasmid Midi Kit (Qiagen, 
GmbH, Germany) according to manufacturer’s instructions. Prior to transfection midiprep 
samples were cleaned using a standard ethanol precipitation protocol (Sambrook and 
Russell, 2001).  
2.17.4 Transfection of HCT-116 cells 
Stable HCT-116:ntr cell lines described in this thesis were transfected with F279-V5 
plasmids using one of the following protocols.  
2.17.4.1 FuGENE 6/X-tremeGENE HP transfection  
150,000 cells in 4 mL media were seeded into each well of a 6 well plate and incubated 
over night for 24 h. For every well to be transfected  a Falcon tube was set up containing 
2 µg of the relevant plasmid DNA diluted in 200 µL of  α-CMEM, not supplemented with 
FCS. Room temperature transfection reagent (2-8 µL per tube) was added directly to 
Falcon tube media, mixed gently and incubated at room temperature for 20- 30 min. 
Transfection reagent was either FuGENE 6 or X-tremeGENE HP DNA Transfection 
reagent (both Roche Diagnostics GmBH, Mannheim, Germany). The transfection/DNA 
mix was then added drop wise to each well, mixed gently by rocking and the plate 
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returned to the incubator. For each strain to be generated 2-6 wells of cells were treated 
with transfection/DNA mixes and cells later pooled.  2-3 days post transfection media 
was aspirated and replaced with media supplemented with 1 µM puromycin. Cell growth 
was then inspected daily using a microscope and media containing dead cells aspirated 
and replaced as required, with puromycin concentration in the media gradually increased 
to 3 µM. When cells reached sufficient quantity they were harvested and maintained in 
T75-T175 flasks. This was continued for 2-4 weeks until all cells displayed puromycin 
resistance and cell populations had grown to a sufficient quantity to both freeze cell-line 
samples for long term storage and maintain the cells in subculture.  
2.17.4.2 Lipofectamine® LTX transfection  
500,000 cells in 2 mL media were seeded into each well of a 6 well plate and incubated 
over night for 24 h. Media was aspirated and replaced with fresh media.  For every well 
to be transfected a Falcon tube was set up containing 2.5-3.75 µg of the relevant plasmid 
DNA diluted in 500 µL of  OptimMem (reduced serum) (Gibco). Plus™ transfection 
reagent (2.5-3.75 µL per tube) was added directly to Falcon tube media, mixed gently and 
incubated at room temperature for 5 min followed by addition of 7.5-15 µL of 
Lipofectamine® LTX transfection reagent (Invitrogen). This was gently mixed, incubated 
at room temperature for 30 min and then added drop wise to cells. Generation of stable 
cell lines then proceeded as in section 1.18.2.1.    
2.17.4.3 Transient transfection 
In some instances nitroreductase expression and activity was assessed following transient 
transfection. This was accomplished using identical initial transfection protocols, but ~24 
h post transfection the cells, which comprised a mixed population of those which had or 
had not taken up the F279-V5 plasmid, were collected and used in subsequent protocols.  
2.18 Western blots 
2.18.1 Sample collection and quantification 
Protein was extracted from 1 x 10
6
 cells. These were adhered in the well of a 6 well plate, 
rinsed once with cold PBS and lysed by exposure to 250 µL Radio Immuno Precipitation 
Assay (RIPA) buffer for 30 min on ice. Lysates were removed from the wells and spun in 
a microcentrifuge for 15 min at 4 °C, 13,000 rpm to pellet remaining cell debris.  The 
clear lysate was removed to a new tube and stored at -20 °C until required.  
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Sample protein concentration was determined using a Bicinchoninic Acid (BCA) Protein 
Assay. Briefly in a 96 well microplate protein samples were diluted 1:3 in 0.1 M NaOH 
and mixed with 100 µL of BCA reagent (prepared from mixing 1 x 4% of CuSO4 with 50 
x BCA). The plate was incubated at room temperature with gentle agitation for 10-15 
minutes and optical absorbance at 562 nm read. Sample protein concentration was 
determined by comparison to identically prepared protein standards of BSA spanning in a 
serial dilution from 0-1000 µg/mL.    
RIPA Buffer 
Tris HCl 50 mM pH 8.0 
NaCl 150 mM 
EDTA 1 mM 
Na Deoxycholate 0.5% 
SDS 0.1% 
β-mercaptoethanol 5% 
Protease inhibitor cocktail 1% (Sigma-Aldrich, St. Louis, MO,USA) 
1% (v/v) Nonidet P40 (Roche Diagnostics, Indianapolis, IN, USA) 
 
2.18.2  Gel electrophoresis separation and transfer of proteins 
Protein samples were thawed and diluted in RIPA buffer to allow for loading of 20 µg of 
protein per well. Samples were mixed with 3 x SDS loading buffer and incubated at 98 °C 
for 4 min. Samples were run on 1.5 mm thick, 10-15 well, NuPAGE® 4-12% Bis-Tris 
gels (Invitrogen Corporation, Carlsbad, CA, USA) using a XCell SureLock™ 
Electrophoresis Mini-Cell system (Invitrogen)  filled with NuPAGE® MES SDS Running 
Buffer. One lane was loaded with 5 µL of Bio-Rad pre-stained MW marker to determine 
protein size. Proteins were separated by running electrophoresis at 150 V for 90 min. 
Following this the gel cast was dissembled and protein transfer onto nitrocellulose 
membrane (Bio-Rad Trans-Blot® Transfer Medium) accomplished using the Bio-Rad 
Mini Trans-Blot® Electrophoretic Transfer Cell system filled with ice cold Transfer 
Buffer with electrophoresis run at 100 V for 70 min.  
Prior to antibody staining the membrane was blocked in Blocking Buffer with gentle 
agitation for 60 min. Blocking solution was removed by decanting and membrane was 
washed by soaking in PBS-T (PBS, Tween-20 0.05%) for 5 min and decanting 3 times.   
Transfer Buffer 
Glycine 14.4 g.L
-1
 
Tris Base 3 g.L
-1
 
Methanol 20% v/v 
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MQ    
 
Blocking Buffer 
PBS 
Tween-20 0.05% 
Milk powder 5% 
 
2.18.3 Antibody detection of proteins 
Incubation with primary antibody was carried out in Blocking Buffer at 4 °C overnight 
with gentle agitation at concentrations as stated in Table 2-11. Membranes which required 
secondary antibody staining were decanted, washed 3 times for 5 min in PBS-T and the 
appropriate secondary antibody added diluted in Blocking Buffer and incubated with the 
membrane at room temperature for 2 h. Following 3 x 5 min washes in PBS-T the 
membranes were incubated with SuperSignal® West Pico Chemiluminescent Substrate 
(Thermo Fisher Scientific; Waltham, MA, USA) for 5 min with gentle agitation. Image 
acquisition was accomplished using a Fujifilm LAS-4000 (Fujifilm, Tokyo, Japan). 
Protein expression was quantified using ImageJ (version 1.46 of the public domain Java 
image processing program) and normalised against β-actin levels. As this required 
sequential staining of the same membrane with two different primary/secondary 
antibodies, the membranes were stripped using Restore™ western blot stripping buffer 
(Thermo Fisher Scientific; Waltham, MA, USA) following collection of the β-actin image.   
                                    
 
Table 2-11 Antibody dilutions for use in western blots 
 
Sheep anti-NfsB serum was raised against purified NfsB by South Pacific Sera (Timaru, 
New Zealand). The NfsA antibody was a generous gift from Dr Peter Searle (University 
of Birmingham). Mouse anti-actin antibody was purchased from Millipore (Merck 
Millipore, MA, USA) and Goat and Rabbit secondary antibodies from Santa Cruz 
Biotechnology, Inc (Santa Cruz Biotechnology, Inc., TX, USA).  
Antibody Dilution
Mouse α-actin 1: 10,000
Sheep α-NfsA 1: 20,000
Sheep α-NfsB 1: 20,000
Goat α-mouse IgG-HRP 1: 10,000
Rabbit α-sheep IgG-HRP 1: 10,000
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2.19 Analysis of activation of fluorogenic probes by HCT-116 cell lines 
2.19.1 FLoid® Cell Imaging Station 
Cells from each HCT-116:ntr expression line to be assessed were harvested and 100,000-
300,000 cells seeded into individual wells of a 6 well plate and incubated with 1 mL 
media containing 50 µM of fluorogenic probe for 2 h. Images were taken using the pre-
set channels (relief phase, blue fluorescence, green fluorescence, and red fluorescence) of 
a FLoid® Cell Imaging Station (Invitrogen Corporation, Carlsbad, CA, USA), with 
identical focus, exposure and overlay settings for each cell line when comparing 
activation of the same fluorophore.  
2.19.2 Flow cytometry 
Cells from each HCT-116:ntr expression line to be assessed were harvested and 0.5 x 10
6
 
cells in 450 µL of media seeded into wells of a non-tissue culture treated 24-well plate 
and returned to the incubator for 30 min to equilibrate to 37 °C . 50 µL of media 
containing the probe FSL 61 was added to each well to give a final concentration of 50 
µM and the plate returned to the incubator for 2 h. Cells were then moved into tubes for 
flow cytometry and placed on ice to halt probe metabolism before immediate analysis of 
the fluorescence of single cell events on a Becton Dickinson LSRII Flow Cytometer 
(Becton Dickinson Biosciences, Bedford, MA). Single cells were gated using forward- and 
side-scatter with a 488 nm laser. Fluorescence was excited using the 355 nm UV laser and 
fluorescence emission monitored at 450 nm ± 25. 
2.20 Analysis of EF5/SN33623 metabolism by HCT-116 cell lines 
Cells from each HCT-116:ntr expression line to be assessed were harvested and 1 x 10
6 
cells seeded into the well of a 6 well plate. Plates were returned to the incubator for 30 
min to equilibrate to 37 °C, appropriate volumes of EF5/SN33623 were then added to 
media and plates were incubated with imaging agent for 1- 2 h. Cells were collected, spun 
down (300 RCF, 5 min) and resuspended in 1 mL PBS + 4% paraformaldehyde for 1 h at 
4 °C to fix cells. Paraformaldehyde was aspirated and cells were spun down and washed 
twice using 1 mL PBS, resuspended in 1 mL blocking solution (20% non-fat milk, 5% 
FCS, 0.3% Tween-20 and 1.5% albumin in PBS) and left overnight at 4 °C.  The next day 
cells were washed once using 1 mL PBS and the cell pellet resuspended in 100 µg.mL
-1
 
Alexa488-ELK5.1 antibody in antibody carrier (PBS, 0.3% Tween-20, 1.5% albumin). 
Post antibody addition, care was taken to protect samples from light and to use pre-cooled 
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reagents. Cells were left overnight at 4 °C. The next day prior to cell analysis cells were 
rinsed twice using 1 mL PBS 0.3% Tween-20 and once using 1 mL PBS before being 
resuspended in 500 µL PBS and transferred to a FACS tube. Fluorescence of single cell 
events was monitored using a Becton Dickinson LSRII Flow Cytometer, with samples 
excited using the 488 nm (blue-green) laser and fluorescence emission monitored at 530 
nm ± 20.  
2.21 Determining in vivo hypoxia dependant metabolism of EF5 and 
SN33623 
Where indicated methods outlined in this section were carried out by collaborators at 
the ACSRC.  
2.21.1 Animal handling  
All animal handling was conducted by Alex Mowday. 
Specific pathogen-free homozygous nude NIH-III (Charles River Laboratories, 
Wilmington, MA, USA) mice were bred by the Vernon Jansen Unit (shared vivarium, 
University of Auckland). They were housed in Techniplast microisolator cages and fed 
Harlan Teklad diet 2018i. All animal studies were approved by the University of 
Auckland Animal Ethics Committee (approval CR830).   
2.21.2 Treatment of mice carrying HCT-116 tumours with imaging agents 
All animal handling was conducted by Alex Mowday. 
Xenograft HCT-116 tumours were established by subcutaneous inoculation of 10 x 10
6
 
HCT-116 cells in 100 µL FCS free media  into the flank of male NIH-III nude mice. 
When tumours reached ~ 10 mm diameter mice were given 60 mg/kg pimonidazole (in 
saline) by intraperitoneal injection. After 60 min they were also treated with either 60 
mg.kg
-1
 EF5 (in PBS) or 60  mg.kg
-1
 SN33623 (in PBS) by intraperitoneal injection. After 
120 min mice were culled and tumours excised and fixed in 10% formalin dissolved in 
PBS (48 h), transferred to 70% ethanol then embedded in paraffin wax.  Tumour section 
were cut (5 µM) and mounted onto glass slides.  
2.21.3 Immunohistochemical staining of tumour sections 
Paraffin was removed and tissue samples were rehydrated. This was accomplished by 
heating cells for 30 min at 58 °C, followed by soaking slides in a number of steps at room 
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temperature Soaking steps were 10 min in Xylene, repeating with fresh Xylene, 2 min in 
100% EtOH, repeating in fresh 100% EtOH, 2 min in 95% EtOH, 5 min in ddH2O and 10 
min in 0.01 M TBS (Tris buffered saline pH 7.4). Antigen retrieval was achieved by 
boiling samples in 10 mM sodium citrate buffer pH 6 for 20 min. Slides were cooled in 
citrate buffer on ice for 10 min then washed once in TBS and washed 3 times for 5 min in 
TBS-T (TBS- 0.1% Tween-20). Samples were blocked for 1 h in 10% goat serum then 
stained overnight at 4 °C with 40 µg.mL
-1
 of anti-pimonidazole antibody FITC-
Hypoxyprobe-1 (Chemicon® International, clone 4.3.11.3) diluted in 5% goat serum 
TBS-T. The next day the antibody was removed by washing 3 x 5 min in TBS-T and the 
samples stained with 75 µg.mL
-1
 of Cy5 conjugated ELK5.1 (anti-EF5/SN33623 
antibody) for 5 h at 4 °C, antibody in 5% goat serum in TBS-T. Slides were washed 2 
times for 5 min in TBS-T and 1 time in TBS, mounted using Prolong Gold antifade 
reagent (Invitrogen) and sealed with nail polish. 
As it has been exhaustively confirmed that this protocol does not result in cross-reactivity 
of the Hypoxyprobe-1 and ELK5.1 antibodies (Dr. Maria Abbattista personal 
communication) single antibody stain controls were not carried out for this study.   
2.21.4 Fluorescence microscopy  
Operation of the confocal microscope was carried out by Dr. Maria Abbattista.  
Images were acquired and overlaid using a Zeiss LSM 710 confocal microscope (Carl 
Zeiss AG, Oberkocken, Germany) and Zen2010 software. FITC fluorescence was excited 
using an argon laser (Excitation/Emission 499/519) and Cy5 fluorescence using a HeNe663 
laser (650/670 nm). 
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Chapter 3:  Evaluation of 11 E. coli oxidoreductase enzymes for metabolism 
of 2-Nitroimidazole imaging agents  
3.1 Introduction 
This research has been part of a larger collaborative effort between Dr. Ackerley’s 
laboratory and researchers at the ACSRC, seeking to translate NTR based GDEPT to 
human clinical trial. This progression would be greatly aided by an ability to 
noninvasively image the NTR in both clinical and preclinical settings.  
This chapter describes the evaluation of 11 phylogenetically diverse bacterial 
oxidoreductases of E. coli origin for their ability to reduce a number of 2-NI probes which 
had been originally developed for the clinical imaging of hypoxia. These agents can 
image hypoxia because they are each reduced to a cell entrapped form, via an oxygen 
sensitive reaction, catalysed by endogenous human NTRs. Areas of hypoxia are then 
identified by biopsy based immunohistochemistry or, if the agents are radiolabelled, by 
noninvasive PET imaging. The central premise of our study was that if it was possible to 
identify oxygen insensitive bacterial NTRs that reduce the same agents, only in a more 
efficient manner, then these 2-NI compounds could potentially be repurposed to act as 
PET reporter probes for noninvasive imaging of bacterial NTRs.  
The first section of this chapter focuses on assessing the 11 E. coli oxidoreductases by 
screening in an E. coli over-expression system, by purified protein kinetics and by a 
microplate based colorimetric NAD(P)H depletion screen.  
3.1.1 Identification of diverse Escherichia coli nitroreductase candidates  
The lack of clinical success of NfsB/CB1954, coupled with the ubiquity and diversity of 
bacterial NTRs, suggests that a wider examination of the enzyme superfamily could 
discover NTRs better suited for GDEPT. As a first step in this examination the Ackerley 
laboratory cloned NfsB and 10 other diverse NTR candidates to create a small E. coli 
over-expression library (Prosser et al., 2010).  These 11 enzymes were all of E. coli 
origin, with the intention being that these would be used as a base to guide later library 
expansion using homologues from different bacterial species.  
NfsB, the prototypical NTR in a GDEPT context, was included as a matter of course.  
However, where as NfsB has been the most studied NTR in a GDEPT context it is the 
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enzyme NfsA which is typically described as the “major” E. coli NTR (Bryant et al., 
1981; Roldán et al., 2008), based on its superior activity with the antibiotic nitrofurazone 
(structure depicted in Figure 6-8). Though NfsB and NfsA share little sequence identity 
they both function as similarly sized FMN dependent homodimers with appreciable 
substrate overlap (Zenno et al., 1996). Furthermore NfsA has been shown to sensitize 
HeLa cells to CB1954 (Barak et al., 2006) and while our study was in progress, was 
further characterised by another group in a GDEPT context (Vass et al., 2009). A third 
enzyme included was YieF, an NAD(P)H dependent oxidoreductase initially described 
for its ability to reduce chromate (Ackerley et al., 2004) included as a YieF mutant 
initially evolved for improved chromate reduction also shows activity with CB1954 
(Barak et al., 2006).  
A further four enzymes were chosen based on reported nitroreductase activity or 
annotation as NTRs in online databases. The first was NemA, originally identified due to 
its ability to reduce  N-ethylmaleimide but added to the library as it can reduce 
trinitrotoluene (TNT) (Williams et al., 2004). A second library enzyme, AzoR, is so 
named for its ability to reductively cleave azo bonds (-N=N-), a property of potential use 
in the degradation of a number of recalcitrant synthetic commercial dyes which contain 
this functional group (Nakanishi et al., 2001). In addition to this a close homologue from 
Rhodobacter sphaeroides has proven nitroreductase activity (Liu et al., 2007) again with 
TNT and various derivatives. Two other enzymes, YcdI (Loh et al., 2006) and YdjA 
(Choi et al., 2008),  were annotated in the NCBI database as nitroreductase enzymes, 
though to the best of our knowledge no experimental data supporting these annotations 
have ever been published. 
The remaining enzymes were chosen due to sequence or structural similarity to known 
CB1954 reducing enzymes. KefF was included as the closest E. coli orthologue of the 
CB1954-reducing NTR YwrO from B. amyloliquefaciens (40% identity across 162 
residues). YcaK was a hypothetical protein included based on its homology to the human 
enzyme NQO1 (44% identity over a 127 amino acid stretch).  The last two enzymes 
WrbA (Patridge and Ferry, 2006)  and MdaB (Adams and Jia, 2006) were quinone 
oxidoreductases that have been observed to share structural similarity to NQO1 (Adams 
and Jia, 2006; Carey et al., 2007). In addition, MdaB (“modulator of drug activity B”) 
was one of two enzymes discovered in a screen for proteins whose over-expression 
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protected E. coli from a nitro-containing bis-naphthalimide drug DMP 840 (the other 
being NfsA, in this work termed MdaA) (Chatterjee and Sternberg, 1995).  
To characterise all NTR candidates and to validate screening strategies for activation of 
DNA damaging nitroaromatic prodrugs these enzymes were first assessed for activity 
with CB1954 (Prosser et al., 2010). This allowed for adaption and optimisation of a tool 
called the SOS assay, a 96-well microplate screen for detecting nitroaromatic prodrug 
activation by NTRs over-expressed in E. coli.  
3.1.2 SOS assay 
To efficiently assess a large number of NTR candidates a simple, accurate and rapid 
screening system is needed. To achieve this the Ackerley laboratory had previously 
developed and optimised a microplate based assay to detect NTR catalysed activation of 
DNA damaging prodrugs (Prosser et al., 2010). The basis of this assay was the SOS 
assay, first developed to assess potential genotoxins by Quillardet et al. (1982).  
 
This assay takes advantage of the SOS response, an endogenous process triggered by 
DNA damage in E. coli. It exists to promote the survival of DNA damaged E. coli  by 
stalling cell division, enabling DNA repair and upregulating error prone polymerases to 
enable replication to proceed in the presence of DNA lesions. The SOS genes that are 
involved in this process are controlled by a dimeric transcriptional repressor termed 
LexA. LexA binds to the “SOS box”, a palindromic DNA motif found in the promoter 
regions of these genes; and with its binding prevents access of RNA polymerase. The 
“trigger” of SOS induction is single stranded DNA (ssDNA) which can arise during 
repair of DNA lesions or at replication forks stalled due to DNA damage. The ssDNA 
binds to a protein called RecA, creating an active nucleoprotein filament which promotes 
autocatalytic cleavage of LexA thus releasing the repression of SOS genes.  
This response can be quantitatively detected in an assay format by placing transcription of 
a reporter gene, typically either lacZ  (Prosser et al., 2010; Quillardet et al., 1982; Shapiro 
and Baneyx, 2002) or the gene for GFP (Norman et al., 2005; Pennington and Rosenberg, 
2007) under control of the promoter of an SOS induced gene. This is often (though not 
exclusively) sfiA (also known as sulA) (Norman et al., 2005) a gene induced late in the 
SOS response and involved in stalling cell division.  In our adaptation of this test, cultures 
of E. coli over-expressing individual NTR candidates are exposed to sub-lethal 
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concentrations of a nitroaromatic prodrug. If NTR catalysed reduction occurs, the 
prodrug’s latent DNA damaging toxicity is activated.  The strains of E. coli we use for 
this assay contain chromosomally-integrated lacZ under the control of a sfiA promoter. 
The lacZ gene encodes the enzyme β-galactosidase which cleaves the reporter substrate 
ortho-nitrophenyl galactoside (ONPG) to yield galactose and the yellow coloured o-
nitrophenol, which directly correlates to levels of DNA damage present, and thus the 
activity of the prodrug activating NTR (Figure 3-1).   
          
 
Figure 3-1 Schematic of the SOS assay used to monitor NTR activity with nitroaromatic 
prodrugs. In specialised E. coli SOS reporter strains the relative abilities of different NTRs to 
activate DNA damaging nitroaromatic prodrugs are quantitatively determined by measuring the 
levels of a β-galactosidase reporter protein, which is induced in the presence of E. coli DNA 
damage (Shapiro and Baneyx, 2002).  
 
In Figure 3-2 can be seen an example of the use of this assay to detect nitroaromatic 
prodrug conversion, wherein Dr Gareth Prosser used it to interrogate the activity of the 11 
E. coli NTR candidates with the prototypical nitroaromatic prodrug CB1954 (Prosser et 
al., 2010).  
NTR
DNA 
damageProdrug
SOS 
response
β-galactosidase
SOS promoter
lacZ
ONPG
o-nitrophenol
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Figure 3-2 CB1954-induced SOS response induction of NTR over-expressing SOS-R1 
strainsSOS-R1 strains over-expressing candidate NTRs were grown in liquid media and 
challenged with the indicated concentrations of CB1954 for 3 h prior to assessment of SOS 
response induction. Data are the average ± 1 SEM of 4 independent assays. Reproduced from 
(Prosser, 2011).  
 
3.1.1 Nitroaromatic compounds designed for imaging tumour hypoxia 
The four 2-NI hypoxia imaging agents that were available to this study when work 
presented in this chapter was carried out are shown in Figure 3-3. All experimental work 
was performed using these “cold” versions of each imaging agent, which have normal F 
atoms in the place of where the PET imaging agent would have the radioisotope 
18
F. 
Pimonidazole differs from the other compounds presented here in that it cannot be used 
for noninvasive imaging. It can however be used for biopsy based detection of in vivo 
hypoxia. This is because there are commercially available fluorescently conjugated 
monoclonal antibodies raised towards the compound, meaning that patients can be given 
pimonidazole, a biopsy taken, tumour sections prepared and the in vivo hypoxia 
dependent pimonidazole binding detected and quantified by immunostaining with the 
monoclonal antibody (Janssen et al., 2004). Monoclonal antibodies are also available and 
well validated for biopsy based detection of hypoxia dependent EF5 (Lord et al., 1993) 
and EF3 (Busch et al., 2000) binding, but not for F-miso. Throughout this thesis screening 
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of NTR activity has focused more heavily on EF5 than the prototypical F-miso, as our 
ACSRC collaborators’ preclinical models can detect EF5 binding using traditional 
immunohistochemistry rather than requiring radiobiological compounds, equipment or 
expertise.  
            
Figure 3-3 Chemical structures of 2-NI hypoxia imaging agents available to this study  
3.2 Aims 
 Interrogate the ability of 11 E. coli NTR candidates to activate 2-NI hypoxia 
imaging agents 
 Optimise microplate based screening methodologies for evaluation of NTR 
activity with these compounds  
 Validate the use of 2-NI’s to detect bacterial NTR over-expression by human 
cancer cells (in this chapter human cell validation was performed by Dr Sophie 
Syddall and Alex Mowday at the ACSRC) 
3.3 Results 
3.3.1 Evaluation of NTR activity with 2-NI imaging agents  
3.3.1.1 SOS assay 
Prior to this work 11 NTR of E. coli origin were cloned into the expression vector pUCX 
(Prosser et al., 2010) and these constructs were then transformed into the E. coli tester 
strain SOS-R2. The precursor of this strain, ADA510 (Shapiro and Baneyx, 2002), was 
kindly supplied by  Dr Francois Baneyx and acts as an SOS reporter due to a genomic 
fusion of the promoter for the SOS inducible gene sfiA with a lacZ reporter gene. In a 
collaborative laboratory effort we further modified this strain by knocking out five genes 
using the recombination based protocol of Datsenko and Wanner (Datsenko and Wanner, 
EF5
EF3
F-misonidazole
Pimonidazole
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2000) described in further detail in section 2.6. Four of these genes were the E. coli  
NTRs  nfsA, nfsB, nemA and azoR, previously identified as able to reduce CB1954 
(Prosser et al., 2010) and hence removed to lower the endogenous ability of the tester 
strain to activate nitroaromatic substrates. The fifth gene, tolC encodes an outer 
membrane protein which is an integral component of the E. coli  efflux pump AcrAB-
TolC (Fralick, 1996). A tolC knockout is known to improve sensitivity of E. coli SOS 
tester strains, particularly with more hydrophobic drugs (Chatterjee and Sternberg, 1995; 
Shapiro and Baneyx, 2002). It should be noted that, within this chapter, all assays used to 
screen for CB1954 activation were carried out using our initial tester strain SOS-R1, 
which contained only the nfsA, and nfsB gene deletions.  
The SOS response induced in NTR over-expression cultures on exposure to titrated 
concentrations of the four 2-NI imaging agents were determined as described in detail in 
section 2.14.1.1. The optical densities (OD600) of the cultures were also monitored to 
detect any growth inhibition. Shown in Figure 3-4A are results with the compound EF5, 
representative of those seen with all four imaging agents. It can be seen that EF5 does not 
trigger an SOS response of sufficient magnitude to allow accurate screening using this 
technique. In the NfsA over-expression culture EF5 does at 200 µM elicit a small SOS 
response, however this is not clearly different than that of the empty control and at this 
concentration the growth of the NfsA culture has been substantially inhibited (Figure 
3-4B). This is in marked contrast to the clear SOS response induced by sub-lethal 
concentrations of CB1954. Typically when a nitroaromatic compound is reduced in 2e- 
increments it becomes intrinsically more toxic (Roldán et al., 2008). This is because the 
increased reactivity of the resulting nitroso and hydroxylamine groups allows binding of 
the compound to biomacromolecules (i.e. proteins (Leitsch et al., 2007), DNA (Whitmore 
et al., 1986) and glutathione (Brezden et al., 1997)), which perturbs normal cellular 
function. That EF5 caused growth inhibition, but only on over-expression of NfsA, did 
provide preliminary evidence that NfsA could reduce the imaging agent.  
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Figure 3-4 E. coli NTR over-expression library exposed to titrated concentrations of EF5  
NTR over-expression strains were grown in 96 well microplates and challenged with indicated 
concentrations of EF5 or CB1954 for 4 hours A) Quantification of SOS response induction by β-
galactosidase assay. Fold induction is derived from the Miller units recorded on drug exposure 
divided by those of unchallenged control wells B) Growth was measured as culture turbidity 
(OD600) pre and post drug challenge. Growth inhibition is presented as the percentage decrease in 
the growth of challenged cultures relative to the unchallenged controls for each strain. Data 
presented here are from one experiment ± SD, and are representative of many similar 
experiments.  
 
When initial testing of 2-NI imaging agents revealed that their reduced toxic forms do not 
induce an SOS response, a fifth compound was added to the testing panel. This was the 2-
NI drug RB6145, a drug which in physiological conditions shows a ~30% conversion to a 
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second compound RSU1069 (Bremner, 1993; Jenkins et al., 1990), both compounds are  
shown in Figure 3-5.  RSU1069 is not an imaging agent but rather was designed as a dual 
function hypoxic cell radiosensitizer and hypoxia activated chemotherapeutic.  
However severe dose limiting gastric toxicity in Phase I trials stymied its clinical 
development and spurred interest in analogues such as RB6145 (Jenkins et al., 1990). 
Similar to CB1954, the presence of the DNA alkylating aziridine ring means nitro 
reduction converts RSU1069 from a weak monofunctional alkylating agent to a potent 
DNA cross linker (Bremner, 1993). 
 
Figure 3-5 Chemical structures of the 2-NI RB6145 (used in this study) and the compound 
RSU1069 to which RB6145 shows ~30% conversion to in physiological conditions (Jenkins et 
al., 1990).  
 
Based on this, we hypothesised that reduction of RSU1069 or RB6145 would be 
detectable by the SOS assay, and this hypothesis was found to be true (Figure 3-6). As 
with the 2-NI imaging agents, only NfsA showed significant activity with RB6145, with a 
2 µM challenge concentration sufficient to generate a near 10-fold increase in SOS 
induction (a response near saturation as evidenced by a doubling of RB6145 
concentration failing to significantly increase the level of SOS induction). While other 
NTR candidates did induce a slight SOS response upon RB6145 challenge this was likely 
due to intrinsic genotoxicity of the parental molecule, with levels of SOS induction not 
significantly greater than those seen with the empty plasmid control.  
RSU1069RB6145
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Figure 3-6 RB6145 induced SOS response of the E. coli NTR over-expression library SOS-
R2 NTR over-expression strains were grown in 96 well microplates and challenged with indicated 
concentrations of RB6145 for 4 hours prior to quantification of SOS response induction by β-
galactosidase assay. Fold induction is derived from the Miller units recorded on drug exposure 
divided by those of unchallenged control wells. Data are the mean of two independent 
experiments ± SEM.  
3.3.1.2 Growth inhibition 
To confirm the apparent ability of NfsA to sensitize E. coli to 2-NI compounds, IC50 
values were determined (Figure 3-7). The IC50 value is the drug concentration required to 
reduce strain growth to 50% of that of unchallenged controls, here determined by 
monitoring the culture density (OD600- the cultures light absorbance at 600 nm) of over-
expression strains exposed to titrated drug concentrations for four hours (described in 
section 2.14.3).  
The only NTRs which showed detectable activity with any of the compounds were NfsA 
and NfsB. NfsA sensitised E. coli  to all five of the 2-NI compounds at readily acheivable 
drug concentrations. The NfsB over-expression strain showed low-level activity with both 
EF3 and F-miso, with the IC50 of these compounds was ~7.5 to ~8 fold higher than that 
seen on NfsA over-expression.  
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Figure 3-7 IC50s of  2-NI compounds for the SOS-R2 E. coli NTR over-expression library  
Drug dependent growth inhibition was monitored by measuring strain turbidity (OD600) 
pre and post four hour incubation with a two-fold dilution series of respective drugs, with 
a top concentration of 1 mM chosen to conserve imaging agent stocks. Percentage growth 
relative to unchallenged controls was determined and used to calculate the concentration 
at which 50% growth inhibition was seen using SigmaPlot™ 10.0.  Data are the average of 
at least two independent assays ± SEM. 
  
3.3.1.3 Purified protein kinetics  
To support the in vivo observations and also to confirm that each of the 2-NI compounds 
was reduced directly by candidate nitroreductases (as opposed to via other intermediate 
substrates) each of the enzymes were purified and their ability to reduce these 2-NI 
compounds was quantified in vitro. All 11 E. coli NTR candidates had been previously 
cloned into the plasmid pET-28a(+), which allows for the expression of N-terminal His6 
tagged proteins that can be purified by nickel affinity chromatography (section 2.10). The 
pET:ntr constructs were each transformed into the E. coli  strain BL:21, and NTRs were 
over-expressed by overnight growth of the strains in autoinduction media at 30 °C. 
Consistent with previous observations (Prosser, 2011) only nine of the 11 E. coli NTRs 
were able to be purified, with YcdI and KefF being found predominantly in the insoluble 
fraction (results not shown). Strategies to improve their soluble over-expression were not 
pursued due to their lack of in vivo activity with 2-NI compounds.   
 
EF5 EF3 F-miso Pimo RB6145
Empty > 1000 > 1000 > 1000 > 1000 > 250
NfsA (E.c) 141 ± 9 83 ± 4 112 ± 1 175 ± 5 14 ± 1
NfsB (E.c) > 1000 685 ± 78 859 ± 22 > 1000 > 250
AzoR (E.c) > 1000 > 1000 > 1000 > 1000 > 250
NemA (E.c) > 1000 > 1000 > 1000 > 1000 > 250
YieF (E.c) > 1000 > 1000 > 1000 > 1000 > 250
MdaB (E.c) > 1000 > 1000 > 1000 > 1000 > 250
WrbA (E.c) > 1000 > 1000 > 1000 > 1000 > 250
YdjA (E.c) > 1000 > 1000 > 1000 > 1000 > 250
YcdI (E.c.) > 1000 > 1000 > 1000 > 1000 > 250
YcaK (E.c) > 1000 > 1000 > 1000 > 1000 > 250
KefF (E.c.) > 1000 > 1000 > 1000 > 1000 > 250
IC50 (µM)
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For the successfully purified NTR candidates, reaction rates were determined using 
spectrophotometry, as both the oxidation of NAD(P)H and the reduction of the 2-NI 
compound causes a decrease in light absorbance at 340 nm which is directly proportional 
to the quantity of compound metabolised by the NTR (section 2.11.1). This allowed 
measurement of the intial reaction rate when purified enzyme, a fixed concentration of 
NADPH, and varying concentrations of 2-NI compound were incubated together.  
            
Table 3-1 Kinetic parameters for the reduction of 2-NI compounds by purified His6-tagged 
NTRs Rates of reduction at varying 2-NI concentrations and a fixed concentration of excess  
NADPH (0.20 mM) were monitored at 340 nm, rates measured in quadruplicate. Apparent Km and 
kcat derived using Sigmaplot 10.0 (Systat Software Inc., Richmond, CA). Extinction coefficients 
used were EF5= 19,000 M
-1 
cm
-1
, EF3 = 19,100 M
-1 
cm
-1
, F-miso = 18,900 M
-1 
cm
-1
, Pimo = 
18,600 M
-1 
cm
-1
, RB6145 = 19,500 M
-1 
cm
-1
 for explanation of determination see section 2.10. 
Due to the lack of co-factor preference exhibited by NfsB and the strong NADPH preference of 
NfsA (Bryant et al., 1981) only apparent kinetic parameters  with NADPH as cofactor were 
determined.  
 
As per the in vivo results only NfsA and NfsB showed any activity with the 2-NI 
compounds, with NfsA substantially more active than NfsB. The highest concentration of 
drug able to be measured was 1200 µM, as above this the spectrophotometer did not 
register a linear relationship between light absorbance at 340 nm and compound 
NTR Compound K m
a
 (µM)
k cat
a            
(s-1)
k cat/ K m 
(mM-1 s-1)
NfsA (E.c) EF5 160 ± 10 12.1 ± 0.2 76
EF3 160 ± 21 10.7 ± 0.4 66
F-miso 480 ± 70 8.8 ± 0.6 18
Pimo 240 ± 26 11.3 ± 0.5 47
RB6145 200 ± 33 2.7 ± 0.2 14
NfsB (E.c) EF5 1800 ± 840 0.4 ± 0.1 0.2
EF3 5800 ± 3700 1.1 ± 0.5 0.2
F-miso 5200 ± 3100 2.1 ± 1.0 0.4
 Pimo, RB6145
AzoR (E.c) EF5, EF3, F-miso, Pimo, RB6145
NemA (E.c) EF5, EF3, F-miso, Pimo, RB6145
YieF (E.c) EF5, EF3, F-miso, Pimo, RB6145
MdaB (E.c) EF5, EF3, F-miso, Pimo, RB6145
WrbA (E.c) EF5, EF3, F-miso, Pimo, RB6145
YdjA (E.c) EF5, EF3, F-miso, Pimo, RB6145
YcaK (E.c) EF5, EF3, F-miso, Pimo, RB6145
a apparent K m and k cat as determined at 0.20 mM NADPH
No detectable activity 
No detectable activity 
No detectable activity 
No detectable activity 
No detectable activity 
No detectable activity 
No detectable activity 
No detectable activity 
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concentration. For this reason the apparent kinetic values for NfsB show a high degree of 
error. Nonetheless, while this error should be noted, the difference between NfsA and 
NfsB activity is substantial. In regards to EF5, NfsA was 400 fold more active (in terms 
of the specificity constant kcat/Km) and even in the case of F-miso, the compound with 
which NfsB showed the greatest activity, the specificity constant of NfsB was still 44 fold 
lower than that of NfsA.  
3.3.2 Optimisation of a microplate based NAD(P)H depletion assay 
Our inability to use the SOS assay to determine NTR activity with each of the 2-NI 
imaging agents led us to pursue other screening options. The requirement for NAD(P)H 
as an electron source for NTR activity pointed to the possibility of using an in vivo 
chemical assay which reported on NAD(P)H depletion. A major advantage of such an 
approach is that it would allow for screening of NTR activity irrespective of substrate.  
While direct measurement of NAD(P)H usage is possible via monitoring 340 nm 
absorbance, doing so in a reproducible and high-throughput microplate screen is 
complicated by the relatively low signal and the background absorbance at this 
wavelength from both the microplate and crude lysates (Mayer and Arnold, 2002).  One 
alternative is to use tetrazolium salts to indirectly report on NAD(P)H levels as, in the 
presence of a phenazine methosulfate (PMS) catalyst, NAD(P)H chemically converts a 
number of tetrazolium salts into formazan products with a concomitant large change in 
absorbance spectra (Luo et al., 2006).  
Essentially a crude lysate of the NTR over-expression culture, the substrate in question 
and NAD(P)H are combined and left for a set period of time, with NAD(P)H being 
depleted if an oxidoreductase reaction occurs. The reaction is then be halted by addition 
of nitroblue tetrazolium chloride (NBT)/PMS and any remaining NAD(P)H then 
chemically reduces NBT to a formazan dye, the production of which is measured by an 
absorbance reading at OD590 and directly correlates to concentration of NADPH that was 
remaining in the reaction at that time (Glieder and Meinhold, 2003). A schematic is 
shown in Figure 3-8.  
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Figure 3-8 NAD(P)H depletion assay A) Schematic showing use of NBT/PMS to determine 
remaining NAD(P)H following an NTR catalysed oxidoreductase reaction B) Photo of application 
in 96 well microplate, taken on measuring reduction of the prodrug substrate PR-104A by a NfsA 
over-expression culture.   
3.3.2.1 Optimisation of assay parameters 
Before the NAD(P)H depletion assay was used to screen for NTR activity with 2-NI 
compounds a number of reaction parameters were optimised (results not shown). These 
included the concentrations of NBT and NAD(P)H used; development of a method for 
reproducibly achieving complete and even cell lysis of the E. coli cultures; identification 
of the substrate incubation periods and cell lysate volumes best suited for detection of 
NTR activity (section 2.14.4).  It was also demonstrated that the possibility of NTR 
catalysed reduction of the nitro-group present in NBT did not interfere with the assay 
(results not shown).  
3.3.2.2 CB1954 reduction- SOS assay vs. NAD(P) H depletion assay 
To validate the NAD(P)H depletion assay it was used to measure the activity of the E. 
coli  NTRs with the prodrug CB1954 and these results were compared to those of a SOS 
assay of the same enzymes as determined by Dr. Gareth Prosser (previously depicted in 
Figure 3-2). Separate assays were carried out using both NADPH and NADH cofactors. 
Initially the reactions were allowed to proceed for only 20 minutes and during this time 
only NfsA, NfsB and NemA showed significant activity. However allowing subsequent 
reactions to run for 80 minutes demonstrated that AzoR EC also utilized both NADH and 
NBT/PMS
(absorbs at OD590)
NAD(P)H 
+ substrate 
NTR
NAD(P)+
+ reduced 
substrate 
Empty 
plasmid 
control
NTR over-
expression
culture
Substrate added
1. Reaction initiated on NAD(P)H addition
2. Reaction halted and residual NAD(P)H 
measured via NBT/PMS addition
NAD(P)H
+ substrate
+ NBT/PMS
A) B)
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NADPH in the presence of CB1954. NfsB was also equally efficient with both cofactors, 
whereas NfsA and NemA showed a preference for NADPH. As such both the NAD(P)H 
depletion assay and the SOS assay identified the same NTRs as able to reduced CB1954 
and ranked their activities (NfsA>NfsB>NemA>AzoR) in an identical manner.  
              
Figure 3-9 NAD(P)H consumption by SOS-R1:ntr cell lysates  in the presence of 
CB1954. Crude cell lysates were incubated with equimolar concentrations of both 
CB1954 and either NADH or NADPH for (A) 20 min or (B) 80 min. Addition of NBT 
post-incubation yielded formazan dye in proportion remaining NAD(P)H, which was 
quantified by measuring absorbance at OD590. Plotted values indicate the extent of 
CB1954 metabolism by each NTR over-expressing strain and were derived by subtracting 
the OD590 of CB1954-challenged lysates (chall) from the OD590 of unchallenged 
duplicate controls (Unchall). Data are the average of three independent assays ± SEM.  
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3.3.3 Evaluation of NTR activity with 2-NI imaging agents using the 
NAD(P)H depletion assay 
 
Following this validation the NAD(P)H depletion assay was used to assess activity of the 
E. coli NTRs with each of the five 2-NI compounds (Figure 3-10A). The assay was left 
for 30 mins to allow potential detection of low levels of NTR activity (however NfsA 
consumed all supplied NADPH within ~5 mins of exposure to EF5 (Figure 3-10B). Not 
surprisingly only NfsA expressing cell lysates showed substantial depletion of NADPH in 
the presence of any of the 2-NI compounds. When NADH was used as the cofactor no 
NTR activity was detected, emphasising the strong cofactor preference of NfsA (results 
not shown). The assay proved somewhat less sensitive than purified protein kinetics as it 
could not detect the very low levels of activity NfsB showed with EF5, EF3 and F-miso, 
irrespective of the conditions employed.          
It should be noted that to minimize the amount of (valuable and supply-limited) imaging 
agent consumed, only 150 µM of each substrate was incubated with 200 µM NADPH. As 
NTRs reduce nitroaromatic compounds to hydroxylamine derivatives in two consecutive 
2e- steps, they oxidise two NAD(P)H molecules for every molecule of compound reduced 
and when 150 µM of 2-NI substrate was used reaction rates were not substantially 
affected (results not shown).   
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Figure 3-10 NADPH consumption by SOS-R2:ntr cell lysates in the presence of 2-NI 
compounds. Crude cell lysates were incubated with 200 µM NADPH and 150 µM stated 
compound for A) 30 mins B) 5 mins. Addition of NBT post-incubation yielded formazan 
dye in proportion to the remaining NAD(P)H, which was quantified by measuring 
absorbance at OD590. Plotted values indicate the extent of 2-NI metabolism by each NTR 
over-expressing strain and were derived by subtracting the OD590 of compound 
challenged lysates (chall) from the OD590 of unchallenged duplicate controls (Unchall). 
Data are the average of two independent assays ± SEM. 
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3.4 Discussion 
The ability to noninvasively image transgenic NTR expression level and localisation 
would be extremely advantageous to preclinical and clinical development of NTR cancer 
gene therapy. Successful demonstration of this technology could also position NTRs to be 
used as reporter enzymes for imaging of GDEPT-independent oncolytic viruses and 
bacteria.  Development of this capability would be facilitated if we could repurpose 
imaging agents that have already undergone independent Phase I validation, namely the 
2-nitroimidazole hypoxia imaging agents.  
As part of a collaborative effort to develop NTR based GDEPT our laboratory generated a 
small E. coli based gene over-expression library of 11 diverse candidate NTRs. Exposure 
of E. coli over-expressing these NTRs to four 2-NI imaging agents demonstrated that one 
enzyme, NfsA, the “major” E. coli NTR could metabolise these agents; whereas the 
prototypical NTR used in GDEPT, NfsB, showed low or no detectable activity with the 
compounds. This reduction was determined to be a result of direct enzyme activity by 
spectrophotometric monitoring of the reaction as carried out by purified proteins.   
E. coli based screening for NTR-catalysed 2-NI metabolism using the SOS assay, which 
reports on DNA damage, was successful only for detecting NTR activation of the nitro-
masked DNA cross-linking agent RB6145. However as the reduced metabolites of 2-NIs 
were found to be directly toxic to E. coli, 2-NI reduction can at least be detected by 
monitoring the 2-NI dependent growth inhibition of different E. coli NTR over-
expression strains. In pursuit of other screening options I investigated the use of a 
microplate based colorimetric NAD(P)H depletion assay. This assay was shown to be 
able to detect NTR reduction of both the nitroaromatic prodrug CB1954 and of 2-NI 
imaging agents. In addition to supporting screening of 2-NIs, such an assay could widely 
applicable in our laboratory as it could be used to monitor NTR activity with other nitro-
triggered prodrugs that would not elicit an SOS response (or any other phenotype in 
bacteria) for example nitro-triggered protein kinase inhibitors.   
To validate this 2-NI metabolism, then PhD student Dr. Sophie Syddall at the ACSRC 
generated 11 HCT-116 (human colon carcinoma) cell lines stably expressing the different 
NTRs and assessed the ability of each transfected cell line to metabolise EF5. EF5 
binding (as determined by fluorescent microscopy and flow cytometry of HCT-116:ntr 
cells exposed first to EF5 and then the fluorescent anti-EF5 antibody) was found, in oxic 
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conditions, to occur only on NfsA expression (Syddall, 2009). This demonstrated that a 
bacterial NTR could metabolise a 2-NI imaging agent to its cell entrapped form in human 
cells, and provided initial validation for our strategy of discovering such NTRs by 
measuring 2-NI dependent growth inhibition and NADPH consumption in E. coli.  
Figure 3-11 shows a later experiment performed by PhD candidate Alex Mowday at the 
ACSRC. This is an example of biopsy based detection of EF5 binding in HCT-
116:NfsA_Ec tumour xenografts from mice, showing that this reduction is substantially 
more efficient than both background activation in hypoxic regions of tumours and 
activation in NfsB expressing tumours. Furthermore Alex Mowday showed that when 
mice carrying mixed HCT-116/HCT-116:NfsA_EC xenografts were treated with both 
PR-104A and EF5, fluorescence of excised tumours correlated with tumour cell kill, an 
important result supporting the possible use of 2-NI imaging agents to predict efficacy of 
NTR based GDEPT (Figure 3-12).  
These results demonstrate that we have the beginnings of a useful tool for detecting NTR 
over-expression in our preclinical models. However while immunohistochemically 
detected 2-NI activation by stably expressed NfsA is distinguishable from the hypoxic 
background, this does not guarantee that PET scanning will be able to detect vector 
mediated NTR expression. The feasibility of this strategy can only be truly determined by 
carrying out microPET in preclinical cancer models and later PET in patients. As such we 
have recently developed a collaboration with researchers at Maastricht University in the 
Netherlands (www.maastrichtuniversity.nl) and experiments to achieve this microPET 
validation are ongoing.  
While we have discovered that NfsA from E. coli can carry out 2-NI metabolism this was 
of the result of screening only a small enzyme library. Restricting further study to the first 
NTR found to display this metabolism, without further assessment of what is a very 
widespread enzyme class, may cause us to overlook NTRs with substantially better 
activity. It is nonetheless promising that NfsA could metabolise all of the 2-NI substrates 
regardless of their exact side chain, as this substrate promiscuity suggests that 2-NI 
metabolism may be a general property of the NfsA NTR subfamily.  
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Figure 3-11 In vivo binding of EF5 in HCT-116:ntr tumour xenografts 
HCT-116 tumours were established in NIH III nude mice via subcutaneous injection of 
10 x 10
6
 cells in 100 µL serum free media. Cells added comprised A) 100% wild type 
HCT-116 cells B) 25% HCT-116:NfsA_Ec cells C) 25% HCT-116:NfsB_Ec cells. Mice 
were treated with 60 mg/kg EF5 by intraperitoneal injection and left for three hours. 
Tumours were then excised and fixed in 10% formalin for 48hrs, then paraffin embedded, 
sectioned and mounted on glass slides for immunohistochemical analysis with anti-EF5 
antibody Alexa-488 ELK3.51 (100 μg/ml). Sections were scanned on a Nikon 2000E 
Inverted microscope. Reproduced with permission from Alex Mowday and Adam 
Patterson (ACSRC).    
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Figure 3-12 Comparison of in vivo PR-104A tumour cell kill and EF5 binding Mixed 
HCT-116 tumour xenografts were established in NIH III nude mice by subcutaneous 
injection of 10 x 10
6
 cells comprised of mixtures of HCT-116 and HCT-116:NfsA_Ec 
cells using fixed ratios of 0%, 1%, 3%, 5%, 10%, 15% or 25% NfsA_Ec expressing cells. 
Mice bearing these established mixed tumours were treated with PR-104 (325 mg/kg; 
intraperitoneal injection). Three hours later EF5 (30 mg/kg, intraperitoneal injection) was 
administered to label cells and after a further two hours tumour tissue was excised and 
subjected to enzymatic disaggregation to form a single cell suspension. Cells were then 
processed in two ways; i) plated in triplicate over a range of cell densities (10
5 
-10
2
 
cells/plate) and surviving colonies were counted on day 10 and used to determine log cell 
kill; ii) fixed in 4% paraformaldehyde, labelled with anti-EF5 antibody Alexa-488 
ELK3.51 (100 µg/ml) and subjected to flow cytometry using a Becton Dickinson LSRII 
Flow Cytometer (Becton Dickinson Biosciences, Bedford, MA). Fluorescence was excited 
using the 355 nm UV laser and fluorescence emission monitored at 450 nm ± 25. 
Reproduced with permission from Alex Mowday and Adam Patterson (ACSRC).    
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Chapter 4: Screening of an expanded bacterial oxidoreductase library for 
enzymes which metabolise 2-nitroimidazole imaging agents 
4.1 Introduction 
The previous chapter presented work evaluating 11 E. coli NTR candidates for their 
ability to metabolise previously developed 2-NI PET imaging agents and showed that the 
enzyme NfsA demonstrated such metabolism. We next sought to interrogate NTR 
candidates from other bacteria to see if we could uncover NTRs with superior activity to 
E. coli NfsA.  
The previous chapter also presented three different strategies for screening for 2-NI 
reduction by E. coli NTR over-expression strains, i.e. measurement of 2-NI dependent 
NADPH consumption by cell lysates, 2-NI dependent E. coli growth inhibition, and use 
of the SOS assay to monitor 2-NI induced DNA damage (this last strategy only useful for 
detecting NTR activity with the analogous 2-NI compound RB6145). In the work 
described in this chapter, these strategies are applied to screening an expanded NTR 
candidate library.  
4.1.1 Expanded NTR candidate library 
Bacterial oxidoreductase enzymes are ubiquitous throughout nature and have a number of 
potential biotechnological applications. As such, numerous researchers in our laboratory 
have collaborated in the construction of an E. coli over-expression library of 58 NTR 
candidate enzymes. Activities for which the enzymes in this library have been screened 
include DNA damaging prodrug activation (Prosser et al., 2013), chromate reduction for 
bioremediation purposes (Robins et al. 2013), the activation of novel NTR activated 
fluorogenic probes (Horvat, 2012) and, as presented here, 2-NI imaging agent 
metabolism.   
The library comprises oxidoreductases derived from 20 different bacterial species and 13 
different enzyme families; orthologs of the 11 E. coli NTR candidates identified in 
Chapter 3, and of two additional enzymes previously shown to metabolise CB1954- the 
rat oxidoreductase NQO1 (Knox et al., 1988) and the enzyme YwrO from B. 
amyloliquefaciens (Anlezark et al., 2002). Based on a range of preliminary studies, strong 
weighting was given to members of the NfsA and NfsB families in the final library, these 
contributing 20 enzymes and 12 enzymes respectively (Figure 4-1). Unless otherwise 
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stated enzymes in this library were expressed in the previously described E. coli tester 
strain SOS-R2 using the expression vector pUCX 
 
Figure 4-1 Phylogeny tree of the 58 oxidoreductases in the expanded NTR candidate library. 
Multiple sequence alignment was performed using Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/) on default settings. Bootstrap values are not shown for 
clarity of presentation. Grouping of enzymes into families was based on the degree of shared 
sequence identity with the closest E. coli representative for all families (>24% protein sequence 
identity) except for YwrO and NQO1, which were assigned family names based on their shared 
identity with B. amyloliquefaciens YwrO and Rattus norvegicus NQO1, respectively. Individual 
NTR names indicate enzyme family, except in some instances where names previously reported 
in the literature have been used i.e. YcnD_Bs. This is followed by a two letter abbreviation for the 
genus and species of bacteria the enzyme originated from i.e. Bs- Bacillus subtilis, Vf- Vibrio 
fischeri (exception – Eca for Erwinia carotovora, to distinguish this from Ec for E. coli).  For 
specific bacterial strain used see Table 2-3 and for levels of amino acid identity and similarity and 
accession numbers see Table 2-9. CO-Frp and Frp are slight variants of the same enzyme, derived 
from two different V. harveyi isolates.   
YcaK
YwrO
KefF
NQO1
MdaB
YcdI
NfsB
NfsA
YdjA
NemA
WrbA
AzoR
YieF
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A handful of the NTR candidates included in this library have been described previously. 
In the NfsA family this includes the NADPH dependent FMN reductase Frp from V. 
harveyi, -the first “NfsA” to be crystallised (Tanner et al., 1996). In addition to a 
demonstrated ability to reduce nitro-compounds (Zenno et al., 1998) it is also a chromate 
reductase (Kwak et al., 2003). B. subtilis contains two different NfsA family members 
NfrA_Bs and YcnD_Bs, which share only 36% amino acid identity. Both enzymes have 
X-ray crystal structures determined (Cortial et al., 2010; Morokutti et al., 2005) . It has 
been  briefly noted that the 2-NI azomycin can be reduced by NfrA_Bs (Cortial et al., 
2010); to my knowledge the only 2-NI activity ever previously described for a bacterial 
NTR. YcnD_Bs, which shares 35% amino acid identity with NfsA_Ec, also shares a very 
similar protein structure - reported as having a root-mean-square deviation of 1.2 Å over 
220 aligned protein backbone carbon atoms when compared to the NfsA_Ec crystal 
structure 1IDT (Morokutti et al., 2005). EcD from Pseudomonas putida has been 
characterised as chromate reductase (Gonzalez et al., 2005a). Both NfsA and NfsB 
homologues from S. typhimurium have received attention due to their ability to activate 
the toxicity of nitro compounds in the S. typhimurium based Ames mutagenicity assay 
(Nokhbeh et al., 2002; Watanabe et al., 1998) and NfsB_St has been further characterised 
as an enoate reductase (Yanto et al., 2010). Additional NfsB family members that have 
been characterized include FRaseI_Vf, the major flavin reductase of the bioluminescent 
V. fischeri species (Zenno et al., 1994) -  the structure of which (Koike et al., 1998) shows 
only a root-mean-square deviation of 1.4 Å over backbone carbon atoms compared to 
NfsB_Ec (Parkinson et al., 2000).  
4.2 Aims 
 Interrogate the ability of enzymes from the expanded NTR candidate library to 
activate the 2-NI PET-capable imaging agents EF5 and F-miso, to identify any 
NTRs with greater activity than NfsA_Ec   
 Compare different microplate based screening methodologies used for the 
evaluation of NTR activity with 2-NI compounds  
 Determine the kinetic parameters of 2-NI active enzymes and compare these to the 
results of microplate based screens, to shed light on the key parameters measured 
in each screen  
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4.3 Results 
4.3.1 Screening of the expanded NTR candidate library by monitoring 2-NI 
dependent growth inhibition 
 
4.3.1.1 EF5 mediated growth inhibition assay 
The ability of enzymes within the expanded NTR candidate library to metabolise EF5 
was first assessed by monitoring EF5 dependent growth inhibition of NTR over –
expression strains. Rather than performing detailed IC50 measurements for each of the 58 
NTR candidate strains across a range of EF5 concentrations, the EF5 metabolism of the 
entire NTR library was first measured by monitoring growth inhibition over four hours in 
the presence of either 130 µM or 400 µM EF5 (130 µM representing a value close to the 
previously determined NfsA_Ec EF5 IC50) (Figure 4-2). Reduction of EF5 was observed 
to be a general property of all NfsA family members, with the exception of the most distal 
NfsA_Ec relative, NfsA_Ms. At the higher EF5 concentration it was apparent that one 
NfsB family member, YfkO_Bs (29% shared amino acid identity to NfsB_Ec), could 
metabolise the compound with substantially higher efficiency than the remaining NfsB 
enzymes.   
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Figure 4-2 EF5 mediated growth inhibition of SOS-R2 E.coli NTR over-expression strains. 
Mid-exponential phase over-expression strains were challenged in 384 well plate format A) 130 
µM or B) 400 µM EF5for 4 hours. Growth was measured as culture turbidity (OD600) pre and post 
drug challenge. Growth inhibition is presented as the percentage decrease in the growth of 
challenged cultures relative to the unchallenged controls for each strain. Data are the average of 
three independent experiments ± S.E.M.  
4.3.1.2 IC50 values for selected E. coli NTR over-expression strains 
challenged with EF5 
Next the EF5 IC50 values were determined for the 20 NTR over-expression strains which 
had shown pronounced growth inhibition in the presence of 400 µM EF5 (Figure 4-3).  It 
appears that, as determined by this measure, NfsA_Ec is actually one of the most 
effective NTRs for metabolism of EF5, although the NfsA_St over-expression strain did 
exhibit the lowest EF5 IC50  (NfsA_Ec 127 µM vs NfsA_St 70 µM).  
 
NTR over-expression strain
N
fs
A
_
E
c
N
fs
A
_
S
t
N
fs
A
_
C
k
N
fs
A
_
K
p
N
fs
A
_
E
s
N
fs
A
_
E
ca
N
fs
A
_
V
f
N
fs
A
_
V
v
F
rp
_
V
h
C
O
-F
rp
_
V
h
N
fr
A
_
B
s
N
fs
A
_
L
w
N
fs
A
_
L
i
N
fs
A
_
B
c
N
fs
A
_
N
p
N
fs
A
_
B
t
N
fs
A
_
L
s
E
cD
_
P
p
Y
cn
D
_
B
s
N
fs
A
_
M
s
N
fs
B
_
E
c
N
fs
B
_
C
k
N
fs
B
_
S
t
N
fs
B
_
K
p
N
fs
B
_
V
v
N
fs
B
_
P
p
N
fs
B
_
E
s
F
ra
se
I_
V
f
N
fs
B
_
V
h
Y
fk
O
_
B
s
Y
d
g
I_
B
s
N
fs
B
_
P
a
A
zo
R
_
E
c
A
zo
R
_
S
t
A
zo
R
_
V
v
A
zo
R
_
P
p
N
e
m
A
_
E
c
N
e
m
A
_
S
t
N
e
m
A
_
K
p
N
e
m
A
_
V
v
Y
w
rO
_
B
s
Y
w
rO
_
L
i
Y
w
rO
_
V
f
Y
ie
F
_
E
c
Y
ie
F
_
P
a
M
d
a
B
_
E
c
M
d
a
B
_
P
s
W
rb
A
_
E
c
W
rb
A
_
P
s
Y
d
jA
_
E
c
Y
d
jA
_
K
p
N
Q
O
1
_
P
p
N
Q
O
1
_
P
a
Y
cd
I_
E
c
Y
cd
I_
K
p
Y
ca
K
_
E
c
Y
ca
K
_
P
a
K
e
fF
_
E
c 
E
m
p
ty
G
ro
w
th
 I
n
h
ib
it
io
n
 (
%
)
0
20
40
60
80
100
120
400 µM 
NfsA family NfsB family
NTR over-expression strain
N
fs
A
_
E
c
N
fs
A
_
S
t
N
fs
A
_
C
k
N
fs
A
_
K
p
N
fs
A
_
E
s
N
fs
A
_
E
ca
N
fs
A
_
V
f
N
fs
A
_
V
v
F
rp
_
V
h
C
O
-F
rp
_
V
h
N
fr
A
_
B
s
N
fs
A
_
L
w
N
fs
A
_
L
i
N
fs
A
_
B
c
N
fs
A
_
N
p
N
fs
A
_
B
t
N
fs
A
_
L
s
E
cD
_
P
p
Y
cn
D
_
B
s
N
fs
A
_
M
s
N
fs
B
_
E
c
N
fs
B
_
C
k
N
fs
B
_
S
t
N
fs
B
_
K
p
N
fs
B
_
V
v
N
fs
B
_
P
p
N
fs
B
_
E
s
F
ra
se
I_
V
f
N
fs
B
_
V
h
Y
fk
O
_
B
s
Y
d
g
I_
B
s
N
fs
B
_
P
a
A
zo
R
_
E
c
A
zo
R
_
S
t
A
zo
R
_
V
v
A
zo
R
_
P
p
N
e
m
A
_
E
c
N
e
m
A
_
S
t
N
e
m
A
_
K
p
N
e
m
A
_
V
v
Y
w
rO
_
B
s
Y
w
rO
_
L
i
Y
w
rO
_
V
f
Y
ie
F
_
E
c
Y
ie
F
_
P
a
M
d
a
B
_
E
c
M
d
a
B
_
P
s
W
rb
A
_
E
c
W
rb
A
_
P
s
Y
d
jA
_
E
c
Y
d
jA
_
K
p
N
Q
O
1
_
P
p
N
Q
O
1
_
P
a
Y
cd
I_
E
c
Y
cd
I_
K
p
Y
ca
K
_
E
c
Y
ca
K
_
P
a
K
e
fF
_
E
c 
E
m
p
ty
G
ro
w
th
 I
n
h
ib
it
io
n
 (
%
)
0
20
40
60
80
100
120
130 µM 
NfsA family NfsB family
A)
B)
EF5
EF5
94 
 
 
 
Figure 4-3 EF5 IC50 values for SOS-R2 E. coli NTR over-expression strains. Drug dependent 
growth inhibition was monitored by measuring strain turbidity (OD600) pre and post four hour 
incubation with a two-fold dilution series of EF5. Percentage growth relative to unchallenged 
controls was determined and SigmaPlot™ 10.0 used to calculate the IC50. Data are the average of 
three independent experiments ± SEM. Graphed strains are ordered by increasing IC50. 
 
4.3.1.3 F-miso mediated growth inhibition and IC50 determination  
Although screening efforts were primarily focused on EF5 for the reasons discussed in 
section 1.1, the metabolism of the prototypical 2-NI imaging agent F-miso was also 
assessed. This was again done by monitoring growth inhibition at 130 µM and 400 µM 
(Figure 4-4) and F-miso IC50 values were determined for all NfsA and NfsB family 
members, with the exception of the non-sensitising NfsB_Pa (Figure 4-5).   
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Figure 4-4 F-miso mediated growth inhibition of SOS-R2 E.coli NTR over-expression 
strains. Mid-exponential phase over-expression strains were challenged in 384 well plate format 
A) 130 µM or B) 400 µM F-miso for 4 hours. Growth was measured as culture turbidity (OD600) 
pre and post drug challenge. Growth inhibition is presented as the percentage decrease in the 
growth of challenged cultures relative to the unchallenged controls for each strain. Data are the 
average of three independent experiments ± S.E.M. 
 
As was the case with EF5, all NfsA family members except NfsA_Ms could readily 
metabolise F-miso. Only three NTRs (YcnD_Bs, NfsA_Eca and NfsA_St) conferred F-
miso IC50 values lower than NfsA_Ec.  
It is possible that the smaller side chain of F-miso (compared to EF5) may facilitate its 
reduction by some NfsB family members, with five NfsB like enzymes (YdgI_Bs, 
FraseI_Vf, NfsB_Vv, YfkO_Bs and NfsB_Pp) conferring F-miso IC50 values that are 
only 2-3 fold higher than that of NfsA_Ec (though still 4-6 fold higher than that of the 
“best” NfsA- NfsA_St).  
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Figure 4-5 F-miso IC50 values for SOS-R2 E. coli NTR over-expression strains. Drug 
dependent growth inhibition was monitored by measuring strain turbidity (OD600) pre and post 
four hour incubation with a two-fold dilution series of F-miso. Percentage growth relative to 
unchallenged controls was determined and SigmaPlot™ 10.0 used to calculate the IC50. Data are 
the average of three independent experiments ± SEM. Graphed strains are ordered by increasing 
IC50. 
4.3.2 Screening of the expanded NTR candidate library using a RB6145 SOS 
assay 
Our laboratory generally screens for NTR activity with DNA damaging prodrugs using 
the medium throughput microplate based SOS assay (Prosser et al., 2010; Swe et al., 
2012). As demonstrated in Chapter 3, RB6145 is the only 2-NI compound in our 
collection that elicits a measurable SOS response following NTR-catalysed activation. 
While this is not itself a PET-capable molecule, for enzyme engineering studies it could 
potentially be useful to increase screening throughput with this assay. To determine 
whether RB6145 might reasonably predict metabolism of the other 2-NI molecules in our 
collection, the expanded NTR candidate library was assessed by RB6145 SOS assay 
(Figure 4-6). The activities of the entire expanded NTR candidate library with RB6145 
were then correlated with EF5 and F-miso in turn (Figure 4-7). It was shown that activity 
with RB6145 correlated strongly with metabolism of both EF5 (R
2
=0.79) and F-miso 
(R
2
=0.76) – and in particular, that every NTR with avid imaging agent metabolism also 
generated an SOS reponse post challenge with RB6145 
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Figure 4-6 RB6145 mediated induction of the SOS response E. coli SOS-R2 NTR over-
expression strains. Over-expression strains were grown in 96 well microplates and challenged 
with indicated concentration of RB6145 for 4 hours prior to quantification of SOS response by β-
galactosidase assay. Fold induction is derived from the Miller units recorded on drug exposure 
divided by those of unchallenged control wells. Data are the average of two independent 
experiments ± SEM.  
                   
Figure 4-7 Linear correlation between the SOS response induced by RB6145 and the growth 
inhibitory effects of EF5 and F-miso in E. coli SOS-R2 NTR over-expression cultures. 
Response of the full library to 4 µM RB6145 SOS assay (Data from Figure 4-6) and 130 µM EF5 
and F-miso growth inhibition assay (Figure 4-2 and Figure 4-4 respectively).  
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4.3.3 Evaluation of EF5 metabolism using the NADPH depletion assay 
As an additional screen the EF5 dependent NADPH oxidation by cell lysates of NTR 
over-expression cultures was measured using the NADPH depletion assay. First the 
activity of the entire expanded NTR library was assessed as seen in Figure 4-8 A. It was 
apparent that, over the time that the assay was allowed to progress, eight of the more 
active NTRs (marked by * in Figure 4-8 A) had when incubated with EF5entirely 
depleted all NADPH supplied. To further distinguish the relative activities of these NTRs 
they were re-assayed using less cell lysate and a shorter reaction time (Figure 4-8 B).   
 
Figure 4-8 NADPH consumption by SOS-R2:ntr cell lysates in the presence of EF5. 
Crude cell lysates were incubated with 200 µM NADPH and 150 µM EF5. Addition of 
NBT post-incubation yielded formazan dye in proportion to the remaining NAD(P)H, 
quantified by measuring absorbance at OD590. Plotted values indicate the extent of EF5 
metabolism by each NTR over-expression strain and were derived by subtracting the 
OD590 of EF5 challenged lysates (chall) from the OD590 of unchallenged duplicate 
controls (unchall). A) Assay run for 30 mins using 12.5 µL cell lysate, the eight NTR 
over-expression strains which oxidised all supplied NADPH in the presence of EF5 are 
marked *. Data are the average of three independent assays ± SEM B) Assay run for 10 
mins using 5 µL cell lysate - showing the * NTR over-expression strains plus empty 
plasmid, YcnD_Bs and Ecd_Pp controls. Data are the average of four independent assays 
± SEM.   
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4.3.4 Inconsistencies between the growth inhibition and NADPH depletion 
assays 
As determined by both the IC50 assay and NADPH depletion assay, only NfsA family 
members show avid metabolism of EF5. However when examining the NTRs within this 
family it became apparent that there is little correlation between the two assays (R
2
=0.014 
for a linear correlation between the activities of NfsA family members as determined by 
IC50 and NADPH depletion assays -result not shown). The greatest outliers in this 
correlation were the enzymes NfsA_St and NfsA_Eca (although even when these NTRs 
were removed from the correlation R
2
 rose to only 0.19- result not shown). As measured 
by IC50 assay, both NTRs show EF5 metabolism comparable or better than that of 
NfsA_Ec; yet when using the NADPH depletion assay negligible EF5 metabolism is 
detected. This was not an issue of cofactor preference – when the expanded NTR library 
was re-assayed using NADH, again little cofactor depletion was observed for these NTRs 
(results not shown). A low level of EF5 dependent NADPH depletion by NfsA_St and 
NfsA_Eca over-expression cultures can eventually be detected, but this requires leaving 
the cell lysate to incubate with EF5 for > 60 mins (results not shown).  
4.3.5 Evaluation of EF5 reduction by purified His6-tagged NTRs  
In an effort to shed some light on this phenomenon, the apparent kinetic parameters of 
EF5 reduction by purified His6-tagged NTRs were determined as previously described. 
The enzymes successfully purified and tested were 12 NfsA homologues spanning a 
range of EF5 activities, including NfsA_St; and the NfsB family members NfsB_Ec and 
YfkO_Bs (Table 4-1) (purification of NfsA_Eca was attempted also, using either 
autoinduction media or low temperature LBK supplemented with betaine and sorbitol, but 
in either case the soluble expression of protein was not sufficient to allow purification).    
When examining the kinetic parameters of EF5 reduction by the NfsA family members it 
can be seen that the apparent Km values for all of the NTRs - with the exception of 
NfsA_St – span only a ~ three fold range (NfsA_Bt = 150 µM, NfsA_Vf = 420 µM) and 
the apparent kcat only a ~ fivefold range (NfsA_Bt = 3.4 s
-1
, NfsA_Vv = 16.9 s
-1
). In 
comparison NfsA_St shows a much lower apparent kcat and Km (respectively ~130 and 
~17 fold lower than those of NfsA_Ec). It was determined that the use of the detergent 
Bugbuster® for cell lysis was not adversely affecting the activity of the purified His6-
tagged NfsA_St as NfsA_St purified after performing cell lysis using a French pressure 
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cell press did not show faster catalytic turnover of either EF5 or the prodrug substrate PR-
104A (results not shown).   
The substantially lower apparent kcat of NfsA_St results in it having the lowest specificity 
constant of all the NfsA homologues tested, even though it was the most active enzyme in 
vivo as determined by EF5 dependent E. coli growth inhibition (Figure 4-3). This 
suggested that enzyme kcat might be the dominant factor influencing results of the 
NADPH depletion assay; but that it might have less influence in the 2-NI dependent 
growth inhibition assays (a hypothesis that makes some intuitive sense given the large 
concentrations of substrate added in the NADPH depletion assay).  
                            
Table 4-1 Kinetic parameters for the reduction of EF5 by purified His6-tagged NTRs. Rates 
of reduction at varying concentrations of EF5 and a fixed concentration of excess NADPH (0.20 
mM) were monitored at 340 nm, rates measured in quadruplicate. Apparent Km and kcat derived 
using Sigmaplot 10.0 (Systat Software Inc., Richmond, CA). Extinction coefficient used was 
19,000 M
-1
cm
-1 
for explanation of determination see section 2.11.1. 
NTR
k cat /K m 
(mM-1 s-1)
NfsA_Ec 160 ± 10 12.1 ± 0.2 76
NfsA_St 9 ± 1 0.1 ± 0.0 11
NfsA_Ck 210 ± 26 14.9 ± 0.6 71
NfsA_Kp 290 ± 23 9.4 ± 0.3 32
NfsA_Es 150 ± 21 9.0 ± 0.4 60
NfsA_Vf 420 ± 45 11.0 ± 0.5 26
NfsA_Vv 290 ± 45 16.9 ± 1.4 58
Frp_Vh 140 ± 6 4.9 ± 0.6 35
CO-Frp_Vh 200 ± 30 11.5 ± 0.5 58
NfrA_Bs 290 ± 15 6.8 ± 0.1 23
NfsA_Bt 150 ± 17 3.4 ± 0.1 22
YcnD_Bs 380 ± 35 5.6 ± 0.4 15
NfsB_Ec 1800 ± 840 0.4 ± 0.1 0.20
YfkO_Bs 1400 ± 320 3.5 ± 0.5 3
a apparent K m  and k cat  as determined at 0.20 mM NADPH
K m  (µM)
a k cat  (s
-1)a
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4.3.6 The ability of the kinetic parameters of purified protein reduction of 
EF5 to predict the results of the NADPH depletion assay and EF5 
dependent growth inhibition.  
To investigate the hypothesis that the NADPH depletion assay and EF5 IC50 
measurements were identifying different NTRs as the most active due to divergent 
enzyme kinetic parameters influencing each assay to a different degree, the results of each 
assay were compared with the apparent kcat,, apparent Km and specificity constant (kcat/Km) 
for each purified enzyme with EF5 (Figure 4-9).  
It can be seen that the activities determined by the NADPH depletion assay do not 
correlate well with either the apparent Km values or specificity constant for each NTR 
(R
2
=0.16 and 0.46 respectively), but did correlate strongly with the apparent kcat 
(R
2
=0.82) (Figure 4-9A). An opposite scenario was observed for the IC50 assay, where 
IC50 values showed no correlation whatsoever with either the specificity constant or 
apparent kcat values (R
2
=0.09 and 0.02, respectively), but did show a moderate correlation 
with the apparent Km (R
2
=0.63; Figure 1-10B).  
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Figure 4-9 Linear correlations between kinetic parameters of NTR catalysed EF5 reduction 
and EF5 reduction as determined by A) the NADPH depletion assay B) IC50 values. Graphs 
shown represent the best correlation for each data set. The R
2
 values for the other relevant 
correlations are presented in inset tables. Kinetic parameters used are from Table 4-1 , IC50 as 
presented in Figure 4-3 and NADPH depletion assay values as shown in Figure 4-8. To derive 
values for the eight NTRs with saturated activity in Figure 4-8A, NADPH depletion as 
determined in Figure 4-8B was taken and adjusted ( increased by a factor of 7.5) to take into 
account the shorter assay time and lower cell lysate volume.  
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4.4 Discussion 
4.4.1 Screening of the expanded NTR library for 2-NI metabolism 
Work presented in this chapter assessed a range of oxidoreductase enzymes from an 
expanded NTR candidate library for the ability to metabolism 2-NI compounds. The 
primary driver behind this screening effort was to try and improve on NfsA_Ec as a 
preclinical candidate for a noninvasive PET imaging reporter gene.  
To achieve this, the enzymes of the expanded NTR candidate library were first assessed 
for 2-NI metabolism by monitoring EF5 and F-miso dependent growth inhibition of E. 
coli NTR over-expression strains. Whereas efficient metabolism of EF5 was restricted to 
enzymes within the NfsA family, F-miso was found to have a wider activation profile, 
with a number of NfsB homologues (those within a range of 25-61% shared amino acid 
identity to NfsB_Ec) demonstrating levels of F-miso metabolism closer to that of the 
NfsA enzymes. While the lack of antibodies able to detect F-miso binding means we 
cannot further test NTR/F-miso imaging capabilities by immunohistochemistry, if in the 
future we are able to conduct a radiobiology based assessment of NTR dependent F-miso 
binding, then the activities of these NfsB family members could warrant further 
investigation.  
When the NTR strains were ranked by decreasing 2-NI IC50, the NfsA_Ec  strain was 
found to be one of the most sensitised, with only NfsA_St conferring a ~2 fold lower EF5 
IC50, and only three NTRs showing a ~ 2 fold lower F-miso IC50. The library was further 
assessed by monitoring the RB6145 induced SOS response, yielding similar results. All 
NTRs that could metabolise an imaging agent could also metabolise RB6145, suggesting 
that RB6145 SOS assays could perhaps be used as a  preliminary screening step for 
identifying NTRs that can metabolise 2-NIs. This observation was of particular 
significance for directed evolution work conducted later in this project, presented in 
Chapter Five.  
Next the NADPH depletion assay was used to assess the activities of the expanded NTR 
candidate library with EF5. Surprisingly the results of this assay showed little correlation 
with the NTR activities determined by EF5 IC50 measurement. The kinetic parameters for 
the reduction of EF5 by His6-tagged purified proteins were then determined for 12 NfsA 
enzymes and compared to the results of the EF5 IC50 and NADPH depletion assays. The 
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specificity constants of the purified protein reactions did not correlate particularly well 
with either assay (better for the NADPH depletion than the IC50 assay, R
2
=0.46 vs.  
R
2
=0.09 respectively). However when the individual kinetic parameters used to derive the 
specificity constant - the apparent kcat and Km – were compared to the results of the E. coli 
based screens, a possible explanation for the discrepancy between the results of the two 
screens began to emerge. The results of the NADPH depletion assay showed good 
correlation with the enzymes apparent kcat i.e. the maximum theoretical rate of reduction 
(R
2
=0.82). In contrast the IC50 values did not correlate at all with the apparent kcat but 
instead showed a moderate correlation with the apparent Km of the reaction; a parameter 
generally considered to indicate the affinity that an enzyme has for a particular substrate.   
While somewhat speculative, these observations suggest that the outcome of each assay is 
primarily driven by a different aspect of NTR enzymatic activity. The IC50 values are a 
measure of the EF5 dependent toxicity generated as a result of sustained activity of the 
NTR over a period of four hours, at intracellular concentrations of EF5 that are 
presumably (due to the permeability barrier of the E. coli outer membrane and possibly 
the action of efflux pumps residing therein (Vaara, 1992)) far lower than those added to 
the extracellular growth medium.  If the imaging agent substrate is substantially lower 
than the Km, then kcat would have less influence than it does at high substrate 
concentrations. In contrast, the NADPH depletion assay measures relatively short term 
metabolism by cell lysates at much higher EF5 concentrations, meaning the theoretical 
maximum rate of reaction should have a greater effect on results of the assay. While 
kcat/Km is generally regarded as the most useful parameter to compare the activities of the 
same enzyme with different substrates, it has been shown that it can be misleading when 
used to compare the activities of different enzymes with the same substrate. An enzyme 
with a higher specificity constant but also a higher Km can, over certain (low) substrate 
concentrations actually catalyse a reaction more slowly than an enzyme that has a lower 
specificity constant but also a lower Km  (Eisenthal et al., 2007). In short, the lower the 
available substrate concentration, the more important the Km parameter becomes. 
A critical question here is which assay is most relevant to this project? Given the 
translational aspirations of this study, the most relevant assay is that which most reliably 
identifies NTRs effective in promoting 2-NI activation in transfected human cells. Our 
collaborators at the ACSRC attempted to address this issue for us. However, their efforts 
were complicated by a non-trivial technical concern. 
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4.4.2 Expression of selected members of the expanded NTR candidate library 
from HCT-116 
To assess the activities of the expanded NTR candidate library in human cells, 15 stably 
transfected NTR-expressing HCT-116 cell lines were generated by our collaborators at 
the ACSRC – encompassing nine NTRs from the NfsA family and six from the NfsB 
family. These were initially generated to assess metabolism of the prodrugs PR-104A and 
CB1954 (as presented in (Prosser et al., 2013)) but were also intended to evaluate 
metabolism of EF5.  
Prior to testing HCT-116:ntr activity the level of NTR expression in each cell line was 
quantified. Monoclonal antibodies which can detect the expression of specific NTRs are 
only available for NfsA_Ec and NfsB_Ec. However the expression of the diverse NTRs 
tested here can be detected using Invitrogen Tag-On-Demand™ technology (Prosser et 
al., 2013; Syddall, 2009). NTRs genes cloned into the F279-V5 vector terminate in a 
TAG stop codon, immediately after which is C-terminus V5 epitope tag. NTR expression 
can thus be quantified by infecting a sample of each cell line with a TAG stop suppressor 
adenovirus (Tag-On-Demand™, Invitrogen, Carlsbad, CA), permitting read through of 
the TAG-terminated NTR gene to give an immunoreactive V5-epitope at the C-terminus 
of the expressed protein, which is then detected by western blot. One testing the 
expression levels of these NTRs a significant technical issue became apparent, in that the 
levels of stable and functional expression of the different NTRs from HCT-116 varied 
dramatically, with some NTRs showing no expression whatsoever Figure 4-10.  
 
Figure 4-10 Expression and functional validation of top nitroreductase candidates in a 
human cancer cell line model. Expression of bacterial nitroreductase genes in stably transfected 
HCT-116 cells was determined by western blotting. Cells were infected with an adenovirus 
encoding a TAG suppressor tRNA that enables transient induction of C-terminal V5 tags (Tag-on-
Demand, Invitrogen, Carlsbad, CA; multiplicity of infection 50, 27 h). Reproduced with 
permission from (Prosser et al., 2013) 
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Furthermore, initial levels of protein expression have been shown to sharply decrease for 
some NTRs over the time period that the cell lines are kept in culture (Christopher Guise 
and Alex Mowday, personal communication, (Mowday, 2010). This was unexpected as at 
the ACSRC long term stable expression of NfsA_Ec and NfsB_Ec had previously been 
observed over the course of multiple in vitro and in vivo experiments, via expression from 
different vector back bones (Syddall, 2009) and (for NfsB) on expression from different 
human tumour cell lines (Singleton et al., 2007). Moreover, to our knowledge no 
problems regarding expression of bacterial NTRs in human cells have previously been 
reported in the literature.   
These issues greatly complicated assessment of NTR activity from HCT-116 cells. Alex 
Mowday did manage to test five NfsA family members (NfsA_Ec, NfsA_St, NfsA_Vv, 
NfrA_Bs and NfsA_Kp) for the ability to metabolise EF5. All cell lines except NfsA_Kp 
(which at time of testing showed only trace levels of expression as determined by western 
blot) showed some level of EF5 binding, as determined by flow cytometry of cells which 
had been incubated with EF5 and then exposed to a fluorescently labelled anti-EF5 
antibody (Mowday, 2010). However, the variability in NTR expression levels from one 
cell line to the next and over time was such that it was not possible to draw sensible 
conclusions regarding relative activity levels in the human cellular environment. 
At this point the exact reasons for these expression issues are unknown but possible 
theories will be advanced in later chapters of this thesis. It should be noted that while the 
variable and time dependent expression levels complicate assessment of NTR activity in 
our current pre-clinical models, which rely on stably transfected HCT-116 cell lines, it 
does not necessarily follow that NTRs unable to be stably expressed in HCT-116 are 
unsuitable for use in GDEPT. For example, viral GDEPT would be expected to be more 
akin to a transient expression scenario; whereas vectors such as Clostridium or 
Salmonella require stable NTR expression, but from a bacterial cell. Thus, these issues do 
point to the need to assess different NTRs in the context of the vector intended for patient 
therapeutic use, as these vectors will have different expression requirements.  
4.4.3 Conclusions regarding further E. coli based screening 
The next step in this research was a directed evolution study, in which mutant NTRs were 
generated and then screened for desired improvements in 2-NI metabolism. For this study 
it was important to determine that the screen used would accurately detect mutant NTRs 
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with improved 2-NI metabolism in transfected human cells. The variable NTR expression 
from HCT-116 cells reported in this Discussion complicated our attempt to assess how 
accurately our E. coli based screens reported on this metabolism. However Alex Mowday 
did show that while the NADPH depletion assay and the purified protein kcat indicated 
negligible EF5 metabolism by NfsA_St,  HCT-116 cell lines expressing NfsA_St could 
metabolise EF5 efficiently, at a level comparable to NfsA_Ec (of note NfsA_St was not 
expressed at a higher level than NfsA_Ec as determined by western blot) (Mowday, 
2010). The EF5 metabolism of this NTR would not have been detected if we had solely 
screened the NTR expanded library using the NADPH depletion assay.   
As such it was decided that future screening would focus on 2-NI dependent growth 
inhibition conferred by the mutant NTRs. This was based in part on our concerns 
regarding the inability of the NADPH depletion assay to detect NfsA_St metabolism; but 
also on indications from other parallel work in the Ackerley laboratory, that 
improvements in mutant NTRs ability to metabolise nitroaromatic prodrugs were often 
being driven by decreases in Km rather than increases in catalytic turnover rate (Swe et al., 
2012).  
 
108 
 
 
Chapter 5: Directed evolution of NfsA_Ec for improved metabolism of 2-
nitroimidazole imaging agents 
5.1 Introduction 
5.1.1 Enzyme engineering 
NTR catalysed reduction of xenobiotic 2-NI imaging agents is a serendipitous outcome of 
the enzymes’ general substrate promiscuity, rather than a reaction which nature has 
specifically tailored them for through evolution. It is therefore highly likely that the 
reaction efficiency could be improved through lab based directed evolution of the NTRs. 
Essentially the idea is that a protein can be changed via random or targeted mutation of 
the DNA encoding it, followed by application of selection or screening strategies to 
identify variant proteins which display the desired property, i.e. increased metabolism of 
2-NI imaging agents. Such enzyme engineering is often employed to improve proteins 
used as biocatalysts (Kumar and Singh, 2012) or therapeutics  (Buchanan et al., 2012). An 
example of this with applications to PET imaging is the mutant HSV1-sr39tk, first 
identified as improved in metabolism of the prodrugs GCV and acyclovir (following 
screening of a mutant gene library generated via random mutagenesis of specific sections 
of HSV1-tk) (Black et al., 1996) and then fortuitously found to better activate a number of 
HSV1-tk reporter probes (Gambhir et al., 2000). In regard to NTR based GDEPT, a 
variant of YieF evolved for improved chromate reduction was found to also have 
serendipitously improved CB1954 metabolism (Barak et al., 2006) and two bacterial 
NTRs have been deliberately evolved for improved CB1954 reduction; FRase I by our 
research group (Swe et al., 2012) and an extensive evolution effort focused on NfsB_Ec  
carried out by Peter Searle’s research group (Grove et al., 2003; Guise et al., 2007; 
Jaberipour et al., 2010). In ongoing work we have also evolved NfsA_Ec mutants for 
improved PR-104A activation, and this work will be overviewed in Chapter Seven.  
This chapter will present efforts to evolve the NTR NfsA_Ec to improve its activation of 
2-NI imaging agents. As shown previously, while the native activity of NfsA_Ec with 
EF5 does enable detection of in vivo NfsA_Ec expression from human cells using 
immunohistochemistry, there is still a level of hypoxia background present (Figure 3-11). 
At this point it is unknown if this background would substantially confound interpretation 
of PET images of NfsA_Ec-catalysed 
18
F-2NI probe binding in a clinical context. The 
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likelihood of this problem arising would be lessened by improvement of the ability of this 
NTR to metabolise EF5.  
Three important considerations for any directed evolution study are how, and to what 
extent, to mutate the protein, and how to then identify any improved variants. The extent 
of protein mutation is often dictated by both the ease with which desirable variants can be 
identified and the extent of structural and functional knowledge available for that protein.  
This is because the majority of mutations will have deleterious or neutral effects on the 
relevant property and finding the rare improved clones becomes exponentially more 
challenging as additional sites are mutated and more variants are generated. This is not 
such a constraint if desired variants can be directly selected for or if an effective high-
throughput screening strategy is available. However, as this is not the case for any screens 
of 2-NI activity developed thus far, it was decided to target mutagenesis to residues most 
likely to have maximal effect i.e. those around the active site. Such targeting is greatly 
facilitated by a solved X-ray crystal structure, as available for NfsA_Ec (Kobori et al., 
2001), NfrA_Bs (Cortial et al., 2010), Frp_Vh (Tanner et al., 1996) and YcnD_Bs 
(Morokutti et al., 2005).  
A thorough search for active site mutations that improve 2-NI metabolism was conducted 
by subjecting certain active site residues to site saturation mutagenesis (in which the 
effect of mutating a target residue to each of the other 19 standard amino acids is tested). 
Further improvements in 2-NI metabolism were then pursued by making multi-site 
mutants, as when individual beneficial residues are combined they can often have 
additive or even synergistic positive effects. One valid strategy for generating beneficial 
multi-site mutants is iterative saturation mutagenesis, a stepwise approach to 
accumulating beneficial mutations in which a gene containing a previously identified 
beneficial mutation(s) is iteratively used as the template for further site saturation 
mutagenesis at a different codon (Reetz and Carballeira, 2007). This stepwise approach 
does however require that all acquired mutations add benefit at every step of this process. 
An alternative approach that stands a greater chance of identifying synergistic mutations 
is to generate gene libraries which randomly combine multiple single mutations, followed 
by screening all resulting variants. The number of mutations to be combined can then be 
aligned with the efficiency of available screening strategies (Bornscheuer and 
Kazlauskas, 2011).   
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5.1.2 Docking of EF5 into the active site of NfsA_Ec 
NfsA_Ec was chosen as the NTR to be evolved due to its available crystal structure, 
relatively high native activity with both F-miso and EF5, and its demonstrated stability of 
expression in HCT-116 cells both in vitro and in vivo. As previously discussed, a lack of 
stable expression from HCT-116 does not necessarily preclude functional expression of 
an NTR from viral or bacterial clinical vectors, however to get to that stage it would be of 
immense value to first assess any improved mutants stably transfected HCT-116 
preclinical models. EF5 was chosen for docking into the NfsA_Ec crystal structure as we 
are able to monitor NTR catalysed binding of EF5 in mammalian cells using 
immunohistochemistry.  
Docking was performed by Dr Jack Flanagan at the ACSRC (Figure 5-1A and B). Two 
distinct orientations of EF5 binding in the active site were predicted. In one mode the 
pentafluorine tail of EF5 points back into the enzyme’s binding pocket, whereas in the 
second the tail is closer to the FMN cofactor, forming a hydrogen bond between the EF5 
amide hydrogen and the first hydroxyl group in the FMN phosphate side chain. From this 
docking Dr Flanagan generated a list of 12 NfsA_Ec residues likely to be involved in EF5 
binding (Figure 5-1 C).  
 
Figure 5-1 Docking of EF5 into the active site of solved crystal structure of NfsA_Ec Shown 
are A) the 1
st
 orientation and B) the 2
nd
 orientation of predicted EF5 binding. Docking was carried 
out by Dr Jack Flanagan at the ACSRC using Gold software (Hermes). Images generated in 
PyMOL (Schrödinger, LLC). and show both EF5 (pink carbons) the FMN co-factor (yellow 
carbons) and the protein residues (cyan or orange carbons) which were determined by Jack as 
involved in EF5 binding, either by direct proximity to EF5 or by packing directly behind those 
residues to hold them in place. C) The residues pictured in A) and B) summarised in table format.  
1st Mode 2nd Mode
Ser-40 Ser-40
Ser-41 Ser-41
Phe-42
Leu-43
Cys-45
Phe-83
Leu-103
Asp-107
Asn-134 Asn-134
His-215
Ser-224
Arg-225 Arg-225
B) C)A)
His215
Phe42
Ser41
Ser40
Arg225
Asn134Arg225
Asn134
Phe83
Ser41
Ser224
Leu43
Cys45
Leu103
Asp107
Ser40
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5.1.3 Aims 
 Identify single residue changes in the NfsA_Ec active site that improve its 
reduction of F-miso and EF5 
 Combine a selection of these mutations to identify additive or synergistic 
combinations of beneficial mutations 
 Assess the ability of these mutants to reduce EF5 when stably expressed from the 
human cell line HCT116  
 Investigate the suitability of a high-throughput FACS based screen for identifying 
clones with improved 2-NI metabolism from large multi-mutant libraries  
5.2 Results I: Directed evolution of NfsA_Ec using targeted site 
saturation mutagenesis  
5.2.1 Construction of targeted single site mutagenesis libraries 
The 12 NfsA_Ec residues predicted to be involved in EF5 binding were individually 
subjected to site saturation mutagenesis. To do this, overlap PCR (as described in section 
2.8) was used to generate an NfsA_Ec gene library which contained the degenerate bases 
NNK at the targeted mutation site. In the standard International Union of Biochemistry 
(IUB) degeneracy code N specifies that any DNA base can be incorporated at that 
position, while K indicates either thymine or guanine. Using NNK meant that the targeted 
mutation site contained any one of 32 different codons (instead of the normal 64) but 
could still code for all of the 20 common amino acids (and only one stop codon). This 
means only 94 individual colonies have to be screened to give >95% certainty that every 
codon has been sampled at least once (Reetz and Carballeira, 2007). 
 These genes were cloned into the pUCX vector, and the resulting plasmids individually 
transformed into SOS-R2. For each library, PCR of 20 random colonies using NfsA_Ec 
gene specific primers was used to estimate the insert ratio (found to range from 50 - 90% 
per library- results not shown) and this was used to calculate the minimum number of 
colonies which had to be screened to give > 95% coverage for each library (105 - 188 per 
library).  For each library a number of colonies not less than this minimum were picked 
into 96 well microplates containing NfsA_Ec wild type and empty plasmid controls, and 
these were subsequently screened for 2-NI metabolism.  
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5.2.2 Screening of 12 site saturation mutagenesis libraries for single residue 
mutations conferring increased 2-NI metabolism 
To minimise consumption of the supply-limited imaging agents it was decided to first 
target screening to clones that retained “generic” 2-NI metabolism.  Activity with the 
more readily available 2-NI compound RB6145 can be assayed for by the medium 
throughput SOS assay using a very minimal drug quantity, and as previously shown 
(Figure 4-7) NTR activity with RB6145 was generally predictive of EF5 and F-miso 
metabolism.  
All libraries were screened by RB6145 SOS assays in duplicate (results not shown) and 
clones which showed SOS induction equal or greater than the NfsA_Ec control were 
selected for further screening (ranging from 12% - 32% of clones for each library). These 
clones were tested by 150 µM EF5 growth inhibition assays (results not shown). “Hits” 
from these assays were validated and quantified by repeated EF5 IC50 assays (Table 5-1) 
and the DNA sequences of the improved clones were determined. The activities of these 
mutants with F-miso were then assayed (results also shown in Table 5-1 ). Almost all the 
mutants selected for their improvement in EF5 reduction also showed an increased ability 
to metabolise F-miso, with only one mutation (N134W) detrimental and a handful of 
others (L43E, C45H, C45D and L103Q) giving neglible improvment.  
Overall 47 clones with improved EF5 metabolism  were identified and when  sequenced  
found to contain 31 different mutations. These were spread over nine of the 12 sites 
targeted; no increase in activity with EF5 were found for any residue changes at positions 
107, 224 or 225. Beneficial mutations were seen at residues involved in both predicted 
modes of binding. 
At four sites (40, 43, 103 and 215) only two possible residue changes were found to 
confer improvement, and each of these resulted in a less than two-fold increase in the 
enzyme’s ability to sensitise E. coli to either imaging agent (as determined by the fold 
decrease in 2-NI IC50 for the mutant NTR compared to NfsA_Ec). Many of these 
mutations were relatively conservative; both the L103V and S40T mutations only 
removed or added a methyl group to the amino acid residue respectively, at site 43 both 
favourable changes were to acidic residues, and at residue 215 mutation of the basic His 
residue was only found to be favourable if substituted by either of the two other basic 
residues, Lys or Arg.   
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Table 5-1 NfsA_Ec single mutants showing increased EF5 and F-miso metabolism on over-
expression in E. coli SOS-R2. Drug dependent growth inhibition was monitored by measuring 
strain turbidity (OD600) pre and post four hour incubation with a two-fold dilution series of drug. 
Percentage growth relative to unchallenged controls was determined and SigmaPlot™ 10.0 used 
to calculate the IC50.  Data are the average of at least three independent experiments ± SEM. 
Displayed are the amino acid residue changes found in improved mutants, the IC50 values for each 
NTR over-expression strain on drug exposure and the fold increase in drug sensitisation compared 
to NfsA_Ec wild type. 
NTR
Original 
amino acid
Mutant 
amino acid
 Fold increase in 
EF5 sensitisation1
 Fold increase in                                               
F-miso sensitisation1
127 ± 2 - -
S40T Ser Thr 81 ± 4 1.6 58 ± 6 1.7
S40W2 Trp 88 ± 6 1.4 53 ± 3 1.8
S41M2 Ser Met 59 ± 4 2.1 34 ± 5 2.9
S41Q Gln 62 ± 6 2.1 37 ± 2 2.6
S41Y2 Tyr 67 ± 6 1.9 38 ± 4 2.6
S41C2 Cys 68 ± 2 1.9 37 ± 2 2.6
S41G Gly 71 ± 6 1.8 60 ± 5 1.6
F42N2 Phe Asn 58 ± 4 2.1 50 ± 9 2.0
F42A2 Ala 62 ± 2 2.0 62 ± 5 1.6
F42I2 Ile 67 ± 0 1.9 44 ± 3 2.2
F42H His 69 ± 3 1.8 59 ± 3 1.6
F42W Trp 71 ± 4 1.8 49 ± 3 2.0
F42R Arg 82 ± 2 1.5 47 ± 2 2.0
L43D2 Leu Asp 91± 5 1.4 74 ± 5 1.3
L43E Glu 100 ± 11 1.3 86 ± 7 1.1
C45H Cys His 57 ± 2 2.2 87 ± 4 1.1
C45M2 Met 58 ± 1 2.2 48 ± 5 2.0
C45E2 Glu 59 ± 5 2.2 57 ± 4 1.7
C45L2 Leu 65 ± 4 2.0 56 ± 6 1.7
C45D Asp 74 ± 2 1.7 89 ± 8 1.1
F83A2 Phe Ala 73 ± 6 1.7 73 ± 7 1.3
F83D Asp 73 ± 3 1.7 46 ± 2 2.1
F83R Arg 76 ± 2 1.7 68 ± 5 1.4
F83G Gly 81 ± 3 1.6 55 ± 6 1.8
L103V2 Leu Val 74 ± 2 1.7 73 ± 6 1.3
L103Q2 Gln 80 ± 4 1.6 85 ± 4 1.1
N134R2 Asn Arg 69 ± 4 1.8 51 ± 2 1.9
N134A Ala 75 ± 2 1.7 42 ± 3 2.3
N134W Trp 81 ± 3 1.6 117 ± 7 0.8
H215R2 His Arg 90 ± 3 1.4 64 ± 3 1.5
H215K Lys 96 ± 3 1.3 62 ± 4 1.6
2 mutation found twice in sequenced improved clones 
1 Derived by dividing IC50 value on NfsA_Ec expression by the  IC50 seen on expression of the 
improved mutant
EF5 IC50 
(µM)
Fmiso IC50 
(µM)
NfsA_Ec
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At other sites a greater number of residues were found to improve activity, ranging from 
three beneficial mutations at site 134 to six at site 42. At each of these sites, at least one 
mutation was identified that conferred a > two-fold increase in the enzyme’s ability to 
sensitise E. coli to at least one of the imaging agents. The largest effect was seen with 
changing Ser to Met at site 41, which conferred a 2.9 fold increase in F-miso 
sensitisation. At these sites the beneficial mutations tended to span a wide range of amino 
acid sidechain properties, for example replacing the polar Cys45 residue with either basic 
(His), acidic (Glu, Asp) or hydrophobic (Met, Leu) residues could improve activity. That 
there is so much variation in these beneficial mutations suggests that at these sites the 
wild type residue may be actively inhibiting 2-NI metabolism.   
5.2.3 Combination of single mutations to generate NfsA_Ec variants further 
improved in 2-NI metabolism 
To further improve metabolism of 2-NI imaging agents by NfsA_Ec, individual beneficial 
mutations were combined to create a library of multi-site mutants. To achieve this, a gene 
library was created where at each mutation site the codon contained degenerate bases 
such that it could designate only the desired mutant residue or the original wild type 
residue. By screening such a library all possible combinations of multiple mutations can 
be sampled. The degenerate base code and theoretical examples of its design are 
presented in Table 5-2.  
 
Table 5-2 Table showing IUB degenerate base code. Two examples of amino acids specified by 
degenerate codons included below. 
 
Ideally any degenerate codons used would be restrictive enough to code only for either 
the wild type or the desired beneficial mutant residue(s), since if any additional residues 
are also “allowed” by the codon it unnecessarily increases the library size. Therefore 
mutants chosen for combination were selected after considering not only the 
 Code N V B H D K S W M Y R
Bases A,C,G,T G,A,C G,T,C A,T,C G,A,T G,T G,C A,T A,C C,T A,G
e.g SSG Codon Amino acid CRT Codon Amino acid
GGG Gly CAT His
CGG Arg CGT Arg
GCG Ala
CCG Pro 
IUB Degenerate Bases Code Table
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improvements in 2-NI metabolism they conferred, but also whether codon restriction was 
possible. For example while at Ser41 the Met mutation conferred the greatest 
improvement in 2-NI metabolism, no redundancy codon for incorporating only Ser and 
Met is possible; so tested at this site instead were the next most active Cys and Tyr 
substitutions. For a number of sites (Ser40, Phe42, Leu103, His215) the most active or 
near most active substitution could be incorporated with appropriate redundancy codons.  
At remaining sites (Leu43, Cys45, Phe83, Asn134) no redundancy codon for 
incorporating only the wild type residue or any beneficial mutant residue existed. 
However using a slightly modified strategy mutations at these sites could be included in 
the library. This was done by designing two separate forward primers for amplification of 
the gene fragments containing these sites, one primer specifying the desired mutant and 
one primer specifying the original sequence, and including both resulting fragments in a 
1:1 ratio when generating the full length gene using overlap PCR. Due to the high activity 
observed with the substitutions N134A and C45L/M (noting that Met and Leu can be 
simultaneously encoded for by one redundancy codon) these mutations were included in 
the library. All possible degeneracy codons can be seen in Appendix 2.   
In summary ten mutations over eight sites were chosen: S40T, S41C, S41Y, F42I, C45L 
C45M, L103V, N134A and H215R and a final mutation R12S (found in separate prodrug 
focused evolution work by Dr. Janine Copp, and shown by me to confer 1.6 and 1.7 fold 
increases in EF5 and F-miso sensitisation - results not shown). The ten mutations were 
able to be combined in 576 possible ways.  
5.2.4 Further assessment of selected beneficial single mutations 
Prior to the construction of the multi-site mutant library the ten selected single mutations 
were further assessed, both by SDS-PAGE visualisation of their relative expression levels 
in E. coli SOS-R2 and by determination of their apparent kinetic parameters with EF5, 
carried out using purified His6-tagged recombinant proteins.  
5.2.4.1 SDS-PAGE of relative protein expression 
Protein expression levels of the mutant variants relative to NfsA_Ec were assessed by 
SDS-PAGE (Figure 5-2). Relative expression of the clones was measured using ImageJ. 
Both NfsA_Ec cultures showed similar expression levels (within 10% of each other) and 
no single mutant cultures showed greater NTR expression than both controls. The only 
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mutants showing notably different expression were S41C and L103V, at 60-70% of wild 
type NfsA_Ec levels.                                                   
                                                                                                       
Figure 5-2 SDS-PAGE gel showing NfsA_Ec single mutant relative protein expression levels 
from SOS-R2 pUXC::ntr constructs. NTR over-expression was induced with 50 µM IPTG for 6.5 
hours, as per IC50 assay protocol, prior to sample collection. Samples were normalised for cell 
density (OD600) and 10 µL of sample loaded per lane.   
5.2.4.2 Reduction of EF5 by His6-tagged purified proteins   
To further investigate the effect of each single mutation on the reduction of EF5 by 
NfsA_Ec the apparent kinetic parameters of the reaction were determined. All 10 
NfsA_Ec single mutant genes were cloned into the plasmid pET-28(a+), each pET:ntr 
construct was individually transformed into the E. coli strain BL:21, and NTR over-
expression was induced by IPTG in LBK media containing betaine and sorbitol at 18 °C 
for 40 hours. Eight of the ten mutants were expressed in sufficient soluble quantities to 
allow purification by nickel affinity chromotography, however F42I and H215R were 
found predominantly in the insoluble fraction and as such purification of these variants 
was not successful. The NfsA_Ec wild type protein was prepared and purified in parallel 
with the mutants. 
The apparent kinetic parameters for the reduction of EF5 by NfsA_Ec wild type and 
mutant proteins can be seen in Figure 5-3. The activity of NfsA_Ec was very similar to 
previous measurements (Table 3-1) Of the mutants only two variants, R12S and N134A, 
showed increased EF5 metabolism as measured by the specificity constant kcat/Km, while 
two further proteins S40T and S41C showed roughly the same activity as NfsA_Ec (52 
mM
-1
 s
-1 
and 53 mM
-1
 s
-1 
versus 56 mM
-1
 s
-1 
respectively). The other four tested mutants 
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all showed decreased activity by this measure. For three of the mutants (S41Y, C45L and 
C45M) this was due to a decrease in apparent kcat.  Overall six of the eight mutants tested 
showed a decrease in apparent kcat, however for all mutants in which this occurred the 
apparent Km was also decreased.  
 
Figure 5-3 Kinetic parameters for the reduction of EF5 by purified (His6-tagged) NfsA_Ec 
single mutants A) Plots of initial rates of reaction/enzyme concentration with varying 
concentrations of EF5 and 0.2 mM NADPH. At each EF5 concentration rates were measured in at 
least triplicate and errors represent ± 1 standard deviation.  B) Apparent Km and kcat at 0.2 mM 
NADPH derived using Sigmaplot 10.0 (Systat Software Inc., Richmond, CA). Reaction rate was 
monitored at 340 nm and an extinction coefficient of 19,000 M
-1 
cm
-1
 used see section 2.11.1. 
5.2.5 Construction of a multi-site mutant NfsA_Ec library 
A mix of full length NfsA_Ec genes comprising all possible combinations of the ten 
selected single mutations was generated via overlap PCR of five fragments of the 
NfsA_Ec gene. These fragments had themselves been PCR amplified from a wild type 
NfsA_Ec gene template using primers with the specifically designed degeneracy codons 
to introduce desired mutations (Figure 5-4).   
This gene library was ligated into pUCX, transformed into SOS-R2 and 10 random clones 
were selected and sequenced to confirm correct assembly (See Appendix 3 for 
sequences). All ten individual mutations were represented within the 10 selected clones. 
PCR screening of 20 colonies revealed that 17 had inserts, enabling the insert ratio to be 
estimated at 85%; based on this, to allow 95% coverage of the library 2024 colonies were 
picked into 96 well micro-plates that also contained empty plasmid, NfsA_Ec wild type 
and S41Y controls on each plate.  
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A) B)
K m  (µM)
a k cat            
(s-1)a
k cat /K m  (mM
-1 s-1)
NfsA_Ec 160 ± 20 8.9 ± 0.3 56
R12S 240 ± 40 23 ± 1.2 95
S40T 100 ± 16 5.2 ± 0.3 52
S41C 38 ±  6 2  ± 0.1 53
S41Y 22 ± 1 0.6 ± 0.0 28
F42I - - -
C45L 69 ± 10 1.9 ± 0.1 27
C45M 76 ± 15 1.8 ± 0.1 23
L103V 270 ±  40 9.2 ± 0.1 34
N134A 20 ± 2 2.7 ± 0.1 140
H215R - - -
a apparent K m  and k cat  as determined at 0.20 mM NADPH
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Figure 5-4 Representation of a multi-site mutant NfsA_Ec gene library for testing of all 576 
possible combinations of ten single mutations found to improve NfsA_Ec metabolism of EF5 and 
F-miso- R12S, S40T, S41C/Y, F42I, C45L/M, L103V, N134A and H215R. Constructed by 
combining five fragments (which contained the various mutations) using overlap PCR. Regions of 
the gene which corresponded to the forward primers used to amplify the individual fragments are 
displayed as blue, the reverse primers displayed as red and where these sequences overlap 
displayed as purple. Mutant codons used are displayed as green. For introducing mutations at site 
45 and site 134, where two different primers be used to separately amplify gene fragments which 
were later mixed, the codon difference in each primer is denoted by a forward slash symbol (/). 
Restriction sites for cloning are underlined.  
5.2.6 Screening of a multi-site mutant NfsA_Ec library for variants with 
improved 2-NI imaging agent metabolism 
RB6145 SOS assays were not used for screening of the multi-site library. We thought it 
possible that the increased specialization of the active site due to multiple mutations could 
cause a larger differentiation between activities with the three compounds. Additionally, 
as single mutants were already more sensitised to EF5 and F-miso than wild type 
NfsA_Ec, growth inhibition screens could be conducted using lower concentrations of 
imaging agent than would have been previously possible.  
Each plate was screened with one growth inhibition assay in which duplicate cultures 
were exposed to either EF5 (60 µM) or F-miso (45 µM). Clones exhibiting equal or 
greater drug dependent growth inhibition compared to the single mutant S41Y were 
retested by a second growth inhibition assay before hits were confirmed via determination 
of drug IC50 values (Figure 5-5). The 12 clones that showed a  > 3.5 fold increase in drug 
sensitisation for at least one of the compounds were sequenced, and collectively found to 
comprise a total of eight different sequences (Table 5-3).  
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Figure 5-5 A) EF5 and B) F-miso IC50 values for SOS-R2 E. coli strains over-expressing 
NfsA_Ec wild type or mutants evolved for improved 2-NI metabolism. Drug dependent 
growth inhibition was monitored and SigmaPlot™ 10.0 used to calculate the IC50. Data are the 
average of at least three independent experiments ± SEM. IC50 values for the single site mutants 
S41Y and N134A were determined as controls. Multi-site mutants are referred to by original plate 
and well position in the mutant library. Graphed strains are ordered by increasing IC50. 
 
 
Table 5-3 Amino acid residue changes found in NfsA_Ec mutants exhibiting improved EF5 
and F-miso metabolism as determined in IC50 assays presented in Figure 5-5.  
 
NTR over-expression strain
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Wildtype
Single mutant
Multisite mutant
FACS mutant
EF5
A)
1 Derived by dividing IC50 value on NfsA_Ec expression by the  IC50 seen on expression of the improved mutant
B)
F-miso
NTR over-expression strain
1
4
_
2
1
8
_
3
1
4
_
4
9
1
4
_
5
9
1
6
_
9
3
1
9
_
4
0
2
_
2
1
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1
3
4
A
N
fs
A
_
E
c
IC
5
0
 (
µ
M
) 
0
20
40
60
80
100
120
140
NTR
Fold increase 
in EF5 
sensitisation1 
NfsA_Ec 138 ± 7 -
S41Y 58 ± 3 2.4
N134A 71 ± 11 1.9
1_56 37 ± 2 3.8
2_2 38 ± 1 3.7
8_3 40 ± 2 3.5
14_21 34 ± 3 4.0
14_49 40 ± 1 3.4
14_59 42 ± 7 3.2
16_93 41 ± 2 3.4
19_40 40 ± 2 3.5
EF5 IC50 
(µM) 
NTR
Fold increase 
in F-miso 
sensitisation1 
NfsA_Ec 114 ± 4 -
S41Y 42 ± 3 2.7
N134A 69 ± 9 1.6
1_56 31 ± 2 3.7
2_2 31 ± 2 3.7
8_3 26 ± 2 4.3
14_21 24 ± 1 4.8
14_49 27 ± 1 4.2
14_59 29 ± 3 3.9
16_93 29 ± 5 3.9
19_40 29 ± 3 3.9
F-miso 
IC50 (µM) 
Mutants Sequence R12S S40T S41C S41Y F42I C45L C45M L103V N134A H215R
# 1_56 * R12S/S40T/S41Y/F42I    
# 2_2 R12S/S40T/S41Y/F42I/N134A     
# 8_3 * S40T/S41Y/L103V/N134A    
# 12_9* S40T/S41Y/N134A   
# 14_21* S41C/L103V/N134A   
# 14_49 S41Y/L103V/N134A   
# 14_59 S40T/S41C/L103V/N134A    
# 16_93 S41Y/F42I/L103V/N134A    
* identical mutant found twice in improved clones 
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There were strong patterns in the mutations found in the improved clones. None of the 
sequences contained changes at the 45 or 215 position. In contrast 7 of the 8 improved 
variants contained the N134A mutation and all were mutated at position 41 with changes 
to Tyr (6/8) favoured over Cys.  For five out of the eight sequences the crucial mutations 
appear to be S41X/L103V/N134A (“X” being either Tyr or Cys). There is no notable 
difference between 14_49 (S41Y/L103V/N134A) and 8_3 (14_49 + S40T) or 16_93 
(14_49 + F42I) and also between 14_21 (S41C/L103V/N134A) and 14_59 (14_21 + 
S40T).  
Three clones were selected for further study; these were 14_21 and14_49, based on the 
predominance of the S41X/L103V/N134A mutations; and clone 1_56, chosen to expand 
the diversity of the mutations examined.  
5.2.7 Further assessment of selected multi-site NfsA_Ec mutants 
5.2.7.1 SDS-PAGE of relative protein expression 
Protein expression levels of the mutant variants relative to NfsA_Ec were assessed by 
SDS-PAGE (Figure 5-6). Both 14_21 and 14_49 expressed at identical levels to wild 
type NfsA_Ec, whereas 1_56 expression was slightly decreased (measured by 
densitometry at ~75% of wild type NfsA_Ec, using ImageJ).  
                           
Figure 5-6 SDS-PAGE gel showing NfsA_Ec relative protein expression levels of multi-site 
mutants, expressed from SOS-R2 pUXC:ntr constructs. NTR over-expression was induced with 
50 µM IPTG for 6.5 hours, as per IC50 assay protocol, prior to sample collection. Samples were 
normalised for cell density (OD600) and 15 µL of sample loaded per lane.    
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5.2.7.2 Reduction of EF5 by His6-tagged purified proteins   
The three NfsA_Ec multi site mutants selected for further study were purified as His6-
tagged proteins as previously described, however 1_56 was found predominantly in the 
insoluble fraction and as such purification was not successful. Apparent kinetic 
parameters with EF5 were determined for 14_21 and 14_49. As can be seen in Table 5-4 
the trend of in vivo high activity enzymes showing substantially lower apparent kcat but 
also substantially lower Km values was again apparent.   
                                
Table 5-4 Kinetic parameters for the reduction of EF5 by purified (His6-tagged) NfsA_Ec 
multi-site mutants. Rates of reduction at varying concentrations of EF5 and a fixed concentration 
of excess NADPH (0.20 mM) were monitored at 340 nm, rates measured in quadruplicate. 
Apparent Km and kcat derived using Sigmaplot 10.0 (Systat Software Inc., Richmond, CA). 
Extinction coefficient used was 19,000 M
-1
cm
-1
;
 
for explanation of determination see section 
2.11.1 . Previously measured apparent kinetic parameters of NfsA_Ec wild type and three single 
mutants are shown for comparison.  
5.2.7.3 Activity with the nitroaromatic prodrug PR104-A and the 5-
NI antibiotic metronidazole 
To assess the effect these mutations had on the ability to metabolise prodrugs, E. coli 
SOS-R2 strains expressing the mutants S41Y, 1_56, 14_21 or 14_49 were exposed to PR-
104A, and IC50 values for each strain determined (Figure 5-7A). In addition, each 
mutant’s activity with metronidazole, a 5-NI compound which is a known NTR substrate, 
was tested (Figure 5-7 B). Pleasingly none of the multi-site mutants had lost any ability 
to sensitise E. coli to PR-104A metabolism. It should be noted though that the single 
mutant S41Y showed the greatest (1.9 fold) increase in sensitisation, suggesting that the 
other individual residue changes in 1_56 and 14_49 (which also contain the S41Y 
mutation) may somewhat reduce activity with PR-104A. In contrast all of the multi-site 
K m (µM)
a k cat            
(s-1)a
k cat /K m 
(mM-1 s-1)
NfsA_Ec 160 ± 20 8.9 ± 0.3 56
Single mutants: 
S41Y 22 ± 1.1 0.6 ± 0.01 28
C45L 69 ± 10 1.9 ± 0.1 27
C45M 76 ± 15 1.8 ± 0.1 23
Multi mutants:
14_21 6.5 ± 1.8 0.23 ± 0.01 36
14_49 12 ± 2.3 0.19 ± 0.01 16
a apparent K m  and k cat  as determined at 0.20 mM NADPH
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mutants showed decreased metabolism of metronidazole compared to NfsA_Ec WT and 
S41Y. 
 
Figure 5-7 PR-104A and metronidazole (Metro) IC50 values for SOS-R2 E. coli strains over-
expressing NfsA_Ec wild type or mutants evolved for improved 2-NI metabolism. Drug 
dependent growth inhibition was monitored as previously described and SigmaPlot™ 10.0 used to 
calculate the IC50. Data are the average of three independent experiments ± SEM. Graphed strains 
are ordered by increasing IC50. 
5.2.8 Activity of previously identified mutants with the novel 2-NI imaging 
agent HX4 
During the course of the research described above our laboratory began collaborating 
with researchers at the University of Maastricht and the experimental 2-NI imaging agent 
HX4 became available to our study (background information and structure available in 
section 1.8.3). The ability of the NfsA_Ec mutants to sensitise E. coli to HX4 was 
therefore tested. Serendipitously, the ten single mutations that had been selected for 
combination all also improved NfsA_Ec in vivo metabolism with HX4 (Figure 5-8A). 
Likewise, the sequenced multi-site mutants showed further increases in HX4 metabolism 
(Figure 5-8B) of a comparable range (3.2-4.2 fold increase) to the improvements seen 
with EF5 and F-miso.  
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Figure 5-8 HX4 IC50 values for SOS-R2 E. coli strains over-expressing NfsA_Ec wild type or 
mutants evolved for improved 2-NI metabolism. Shown are results with both single mutants 
(A) and multi-site mutants (B) Drug dependent growth inhibition was monitored as previously 
described SigmaPlot™ 10.0 used to calculate the IC50.  Data are the average of at least two (A) or 
three (B) independent experiments ± SEM. Graphed strains are ordered by increasing IC50 value.  
5.2.9 Assessment of NfsA_Ec mutants showing improved 2-NI metabolism by 
expression in a human cancer cell line   
The experimental work presented in this section was performed during a short research 
visit to the laboratories of our collaborators at the ACSRC.  
For further characterisation of the 2-NI metabolism of the NfsA_Ec variants described 
above, HCT-116:ntr stable cell lines were generated. Chosen for transfection of HCT-116 
were the single mutant N134A and the three multi site mutants 1_56, 14_21 and 14_49. 
Transfer of the mutant NfsA_Ec genes into the HCT-116 expression plasmid F279-V5 
was carried out using Invitrogen Gateway® technology (section 2.17.3). The F279-V5 
plasmid is homebuilt by the ACSRC, and uses a CMV promoter to transcribe both the 
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inserted gene sequence and a puromycin resistance sequence as a single mRNA 
transcript, with an internal ribosome entry site allowing for separate translation of the 
inserted protein and the puromycin resistance protein. To generate stable expression cell 
lines, HCT-116 cells were transfected with F279-V5 NTR plasmids and cells which had 
taken up the plasmid were selected for by multiple passage cycles in media containing 
escalating concentrations of puromycin. 
 HCT-116 cell lines stably expressing NfsA_Ec and NfsB_Ec from F279-V5 had already 
been generated at the ACSRC and these cell lines were made available for this work.  
5.2.10 Western blot of NfsA_Ec wild type and mutant expression from HCT-
116 
Expression of the four NfsA_Ec mutant proteins compared to NfsA_Ec wild type in 
HCT-116 was assessed by western blotting.  The cell line transfected with mutant 1_56 
showed no NfsA_Ec expression whatsoever. The other three mutants showed decreased 
expression relative to NfsA_Ec wild type. This decreased expression was consistently 
observed in two western blots run using independently collected cell samples, with one 
blot pictured in Figure 5-9. When previously attempting to stably express a range of wild 
type NTRs from HCT-116 we had observed both non-existent and variable NTR 
expression levels (Prosser et al., 2013) but we were not expecting to see substantial 
variations in expression of the mutant NTRs presented here, which each differed from 
NfsA_Ec wild type by fewer than five amino acid residues. While variant 1_56 does not 
express from HCT-116 and is also unable to be purified in sufficient soluble form 
following over-expression from E. coli these two issues were not generally found to co-
occur when examining other wild type or mutant NTRs.   
It should be noted that expression issues were not limited to these four mutants, in parallel 
work conducted by Alex Mowday, heterogeneous expression from HCT-116 was also 
observed for a larger suite of 17 NfsA_Ec variants. This observation will be expanded on 
in the discussion of this chapter.  
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Figure 5-9 Western blot showing expression of NfsA_Ec wild type and mutant proteins from 
stable HCT-116:NTR cell lines. HCT-116 cell samples were taken cells lysed and NfsA_Ec 
expression determined by immunoblot.  β-actin loading control also shown. Relative protein 
expression determined by densitometry using ImageJ.  
5.2.11 Testing for functional NTR expression using NTR activated fluorogenic 
probes 
To test for functional expression of the mutant NfsA_Ec proteins, the cell lines were 
exposed to three NTR activated fluorogenic probes designed and synthesised at the 
ACSRC. These probes were chosen on the basis of their structural diversity (structures 
presented in Figure 1-10) and because N134A, 1_56, 14_21 and 14_49  were all found to 
metabolise these three probes at comparable levels to NfsA_Ec wild type when expressed 
in E. coli (results not shown).   
Four weeks post the initial transfection cells were seeded into a 6 well plate and exposed 
to the blue fluorogenic probe FSL61. Four days later the same cell lines were seeded and 
exposed to the green probe FSL76 and red probe FSL178. Cells were imaged with a 
FLoid® Cell Imaging Station, a bench top imaging device with pre-set relief phase and 
blue, red and green fluorescent channels. As can be seen in Figure 5-10, while the 
NfsA_Ec wild type and N134A cell lines show an ability to metabolise all probes, this 
activity was markedly decreased in the 14_21 and 14_49 cell lines and completely absent 
for 1_56 (the latter being the cell line for which no NfsA_Ec expression could be detected 
by western blot).   
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Figure 5-10 Activation of three different NTR specific fluorogenic probes by HCT-116 cells 
expressing NfsA_Ec wild type and mutant proteins. 300,000 (FSL76 and FSL178) or 100,000 
(FSL61) cells were seeded into each well of a 6 well plate and incubated with 50 µM of probe for 
2 hours at 37° C. Images were taken using a FLoid® Cell Imaging Station, with identical settings 
for each cell line. The relief phase overlay is omitted from images of FSL76 and FSL178 
activation to allow a clearer view of probe activation.  
5.2.12  Metabolism of EF5 by HCT-116: NTR cell lines   
Despite concerns that the lowered levels of NfsA_Ec mutant expression might complicate 
interpretation of results, we sought to determine if the NfsA_Ec mutants were 
metabolising EF5 to a cell entrapped product when expressed in HCT-116.  This was 
done by seeding cells into a 6 well plate, incubating them with EF5, and then fixing the 
cells and staining them with the Alexa 488 conjugated antibody ELK 5.1, which binds to 
FSL178FSL76 FSL61
HCT116
NfsA_Ec
N134A
1_56
14_21
14_49
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EF5-protein adducts. The samples were then run on a flow cytometer, and single cell 
events assessed for Alexa 488 fluorescence.  
Shown are results of incubating the cells with 10 µM-hr EF5 (Figure 5-11). The cell line 
expressing 1_56 showed near a non-detectable ability to metabolise EF5, similar to that 
seen on expression of NfsB_Ec. The other three mutants do at least show an ability to 
metabolise EF5 to a cell entrapped product but it is apparent that this activity is not higher 
than that exhibited by cell lines expressing wild type NfsA_Ec, and if anything show 
slightly lowered activity. Exposing the same cell lines to 1 µM-hr EF5, did not 
substantially separate out the wild type and mutant activities (results not shown). 
 
Figure 5-11 Metabolism of EF5 by stable HCT-116:NTR expression cell lines 1 x 10
6
 cells 
were seeded into a 6 well plate and incubated with 10 µM-hr EF5 at 37°C. Cells were fixed and 
stained with Alexa 488 ELK5.1 antibody (100 µg/ml) and analysed on a Becton Dickinson LSRII 
flow cytometer. Collected data was analysed using FlowJo software and mean fluorescence of 
each cell line determined. This experiment was repeated twice each time showing the same trends 
in enzyme activity but with low replication of raw fluorescence values. Displayed are cell 
population histograms from one representative experiment.   
 
If results are normalised by the levels of NTR over-expression the mutants N134A, 14_21 
and 14_49 appear to show greater EF5 metabolism than NfsA_Ec wild type, however 
such a comparison is not really valid. The protocol used here can quantitatively measure 
the level of in vivo EF5 metabolism in tumour xenografts seeded with low percentages of 
HCT-116:NfsA_Ec cells (an example of which can be seen in Figure 3-12). However, 
considered retrospectively, this protocol has not been optimised for quantitatively 
Fluorescence
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Mean Fluorescence
HCT116 4
NfsA_Ec 253
NfsB_Ec 29
N134A 243
1_56 21
14_21 206
14_49 221
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measuring EF5 metabolism by the 100% HCT-116: NTR cell cultures used here, 
(previously with such in vitro cell cultures this protocol has been typically just used to 
provide a yes/no read out of NTR activity) and it is uncertain if features such as the 
quantity of antibody employed or the level of overall EF5 exposure would enable linear 
detection of EF5 adducts over this activity range. Other potential strategies for assessing 
these mutants will be discussed at the conclusion of this chapter.   
5.3 Results II: Preliminary work investigating a high-throughput 
screen for identification of mutants with 2-NI improved metabolism 
5.3.1 A fluorescence activated cell sorting (FACS) based screening strategy  
In addition to the directed evolution work already presented in this chapter preliminary 
work investigating an alternative strategy for identifying mutants showing improved 2-NI 
metabolism was carried out. As this was more of a pilot study than a large-scale project, 
results will be summarised in brief. This strategy uses an adapted version of the SOS 
assay, in which DNA damage up-regulates expression of GFP rather than β-galactosidase, 
to screen for prodrug activating NTRs (Figure 5-12). This was to enable the use of 
fluorescence activated cell sorting (FACS) to select clones experiencing high levels DNA 
damage, as with FACS theoretically 10
6
-10
8
 mutant clones can be examined in a realistic 
timeframe, in contrast to previously presented microplate screening techniques. This 
system has been successfully used by Dr Janine Copp to find single NfsA_Ec mutants 
with improved PR-104A metabolism from large random mutant libraries generated 
through error prone PCR (described in more detail in Chapter 7).  As 2-NI imaging agents 
do not elicit an SOS response NTR activity with these compounds cannot be directly 
assayed for – instead, the 2-NI compound RB6145, which does generate an SOS response 
on nitro-reduction, was used as a surrogate compound to screen a large NfsA_Ec mutant 
library.  
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Figure 5-12 Schematic of the GFP-SOS assay designed for the screening of large mutant 
libraries using FACS. Assays carried out using specialised E. coli strain 7KO (W3110 based 
strain with seven E. coli oxidoreductase genes knocked out; (see Table 2-2) carrying the plasmid 
pGFP (Table 2-4) which allows for expression of GFP-mut3 under control of the sfiA/sulA SOS 
responsive promoter. E. coli strains are challenged with prodrugs and cells expressing NTRs that 
most efficiently convert this prodrug to a DNA damaging form will trigger the SOS DNA damage 
repair response to the greatest extent, upregulating GFP-mut3. Cultures expressing different 
NTRs can then be assessed for prodrug dependent fluorescence using a plate reader or individual 
fluorescent cells can be enriched using FACS.  
5.3.1.1 Large NfsA_Ec mutant library fully randomised (NNK 
codon) at four amino acid sites 
High-throughput screening would enable assessment of libraries which contain fully 
randomised amino acid identity at more than one site. Such screening could uncover 
mutations which are only beneficial in combination with other mutant residues (Reetz et 
al., 2006). These would not be discovered by the previous strategy of combining only a 
small number of mutations which had all previously yielded improved metabolism at a 
single mutation level. A mutant gene library which contained NNK codons at sites 41, 45, 
83 and 134 was cloned into the pUCX plasmid and validated in a similar manner to that 
described in section 5.2.5 – sequences of five random clones confirming correct library 
assembly can be seen in Appendix 3. This simultaneous randomisation gives 
theoretically 1,048,576 possible variants (calculated using the CASTER mutagenesis tool 
(Reetz and Carballeira, 2007)).  
5.3.1.2 FACS selection of GFP expressing cells post RB6145 challenge 
This plasmid library was electroporated into the 7KO pGFP E. coli strain. 7KO is W3110 
based strain with seven E. coli oxidoreductase genes knocked (Table 2-2) carrying the 
plasmid pGFP (Table 2-4) which allows for conditional expression of GFP-mut3 protein 
under control of the SOS responsive promoter sfiA/sulA. 7KO was used as the host strain 
NTR
DNA 
damage
Prodrug
SOS 
response
SOS promoter
GFP
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instead of SOS-R2 to avoid potential interference from the SOS-R2 genomic 
sfiA/sulA:lacZ phusion. Following plasmid electroporation the 7KO pGFP cells were 
grown as a mixed culture in liquid media containing antibiotics to select for positive 
(pUCX:ntr) transformants, and a portion of  this culture used to establish sub-cultures that 
were then challenged with 1 µM RB6145.  Post 4 hours of challenge cells were collected 
then washed and diluted in phosphate buffered saline (PBS). The most strongly GFP 
expressing cells were then selected by FACS, with 25,000 “events” falling within a gate 
that demarked the top 10% of fluorescent events. The cells giving rise to these events 
were collected and plated on solid media. From this, only ~7000 colonies were recovered, 
a ~25% recovery rate.  
5.3.1.3 Screening the 2-NI metabolism of FACS selected clones 
Colonies (455 in total) were picked into five 96 well microplates, with duplicate wild 
type, and S41Y and 14_21 controls included on each plate. Clones showing greater 2-NI 
metabolism than NfsA_Ec wild type were identified by RB6145 SOS assays followed by 
EF5, F-miso and HX4 growth inhibition assays. The respective pUCX:ntr plasmids for 
the eight clones showing the greatest overall 2-NI dependent growth inhibition were 
transformed into E. coli SOS-R2.  IC50 values for EF5, F-miso and HX4 were determined 
in parallel with NfsA_Ec wild type and the mutants S41Y and 14_21; Figure 5-13. While 
all mutants were better able to sensitise E. coli to the 2-NI imaging agents than NfsA_Ec 
wild type, none were more active than the previously identified 14_21 multi-site mutant 
and the majority were actually less active than the single mutant S41Y. The DNA 
sequence of these eight mutants was determined and mutations are shown in Figure 
5-13B. 
While none of the new mutants were more active with 2-NI imaging agents than those 
previously discovered, the sequences returned do show that this method recovers quite 
different mutants - only seven out of the 32 amino acid residue changes seen had 
previously been identified as improving 2-NI metabolism. It is possible that if the 
RB6145 FACS screening strategy used here is better optimised, variants with greater 
activity could be discovered in the future.  
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Figure 5-13 Mutations and 2-NI metabolism of NfsA_Ec mutants recovered from a FACS 
sort of an NfsA_Ec 41 45 83 134 NNK mutant library. A) EF5, F-miso and HX4 IC50 values 
for SOS-R2 E. coli over-expression strains were determined as previously described. Data are the 
average of two independent experiments ± SEM. B) To illustrate the mutants’ 2-NI metabolism a 
graph of F-miso IC50 values with strains ordered by increasing IC50 value. C) Amino acid residue 
changes found in clones. Any residue changes which had been previously found to increase 2-NI 
metabolism when present as a single mutation are marked in red.  
5.4 Discussion 
The work presented in this chapter was carried out to generate NfsA_Ec variants with 
improved ability to metabolise of 2-NI PET suitable imaging agents. This work has 
generated a number of multi-site NfsA_Ec variants better able to sensitise E. coli to 2-NI 
imaging agents. The underlying rationale was that if this activity carries over to a clinical 
setting, we would be able to image the expression of these NfsA_Ec variants using less 
18
F-2-NI than would be required to image NfsA_Ec wild type, thus decreasing hypoxic 
background signal. However we do not yet know if NTR dependent increased E. coli 
sensitisation to 2-NI imaging agents translates to a measurable increase in 2-NI 
metabolism on application in a clinical context.  
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5.4.1 Generation of NfsA_Ec variants which show improved 2-NI metabolism 
on expression in E. coli  
To generate NfsA_Ec variants with improved 2-NI metabolism, 12 active site residues 
identified as likely to be involved in EF5 binding were individually subjected to site-
saturation mutagenesis, with ten of the most promising single mutations then combined in 
a degenerate gene library. From this eight individual multi-mutant sequences were 
identified which, when expressed in E. coli, conferred a 3.2 – 4.8 fold increased 
sensitisation to EF5, F-miso, and HX4 compared to NfsA_Ec wild type. As discussed 
below five of the eight mutants contained either a S41C/L103V/N134A or 
S41Y/L103V/N134A triple mutation motif.   
5.4.1.1 Fluorescent activated cell sorting of mutant libraries to 
identify 2-NI active clones 
Also presented was initial work involving a high-throughput FACS based screening 
strategy used to assess a portion of a large NfsA_Ec variant library. This screening did 
not produce variants that were more active than previously identified multi-site mutants, 
however it is possible that with optimisation this FACS screening strategy may provide 
more active clones.  
Using current protocols the fold enrichment for 2-NI active clones may not actually have 
been very great. In parallel to the mutant library FACS sort a control experiment was also 
run, in which cultures of cells expressing either NfsB_Ec (which shows negligible 
RB6145 metabolism) or NfsA_Ec were challenged with RB6145, mixed in a 9:1 
NfsB:NfsA ratio and then this mix FACS sorted for GFP positive cells. Post FACS sort 
the NfsA expressing cells now made up ~50% of the tested population, only a five-fold 
enrichment of NfsA compared to NfsB – results not shown.  One feature that could be 
decreasing recovery of active clones is that the extra toxicity exerted on E. coli cells 
throughout the FACs process (i.e. the tagging of cells with electric charge) may be 
preferentially killing cells with highly active NTRs as these will already be experiencing 
stress due to DNA damage and cytotoxicity from reduced RB6145. That at least some 
elements of this protocol are toxic to the E. coli can be seen by the fact that only ~25 % of 
sorted “events” generated colonies post FACS. If it was shown that E. coli carrying the 
most active NTRs are unable to recover post FACS sort this problem could potentially be 
bypassed by following a strategy of “PCR rescue” in which recovered events are 
immediately used post-sort as the PCR template for specific amplification of the 
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recovered NTRs, which could then be re-cloned back into pUCX vectors and 
retransformed back into E. coli for downstream testing.   
Using previously presented microplate technologies the numbers of clones which can be 
screened is in the low 1000’s and this limitation is probably impacting recovery of highly 
active variants as only a limited number of residues can be simultaneously mutated at one 
time. If enrichment ratios using the FACS based protocol can be raised, it is probably 
worth continuing to assess larger mutant libraries using this strategy.   
5.4.2 Models of multi-site mutants improved in 2-NI metabolism 
The mutation motifs S41C/L103V/N134A and S41Y/L103V/N134A recurred in a 
number of the multi-site mutants that exhibited improved 2-NI metabolism. To 
investigate changes these mutations may make to the active site of NfsA_Ec the PyMOL 
mutagenesis wizard was used to generate models of both of these mutants. Possible 
explanations for the beneficial effect of the S41C mutation were not readily apparent 
from the model structure (structure not shown). However pictures of NfsA_Ec wild type 
(Figure 5-14A), the S41Y/L103V/N134A model (Figure 5-14B) and over-laid predicted 
modes of EF5 binding (first shown in Figure 5-1) are shown and discussed. It can be seen 
that in this mutant model the orientation of the Tyr41 residue completely blocks one of 
the predicted modes of binding. However EF5 binding similar to the second predicted 
mode may instead be more favoured following S41Y mutation, as here the aromatic Tyr 
side chain and the FMN could act to sandwich the 2-NI head group in between them. The 
L103V and N134A mutations could plausibly promote this, as the smaller mutant 
residues would provide more space for the bulky aromatic Tyr side chain.  
While this is only a model of the S41Y mutation and of EF5 binding we have some 
indication that a similar orientation may occur in the actual protein. A very recently 
completed crystal structure of the NfsA_Ec S41Y single mutant (overall solved to a high 
resolution of 1.3 angstrom) shows disorder specifically at the S41Y site, suggesting that 
the Tyr41 side chain can adopt multiple conformations. That which appears to best fit the 
densities however is one in which S41Y similarly “sandwiches” a unknown molecule (at 
this stage tentatively identified as fumarate) between itself and FMN, leading us to 
speculate that this sandwich conformation may be favourable, and may also occur on 
binding of aromatic substrates such as PR-104A or EF5 (Dr. Christopher Squire, School 
of Biological Sciences, University of Auckland, personal communication).  
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Figure 5-14 Possible effects of S41Y L103V N134A mutations on predicted EF5 binding 
modes. A) Shown is a representation of the NfsA_Ec crystal structure (PDB code 1F5V) with 
wild type residues Ser41, Leu103 and Asn134 coloured purple and shown in stick format. Also 
shown is EF5 in the two predicted modes of binding (orange and cyan carbons) presented in 
Figure 5-1 and the FMN co-factor (yellow carbons. B) Model of NfsA_Ec S41Y/L103V/N134A 
(NfsA_Ec variant 14_49) with the 2nd predicted mode of EF5 binding overlaid. Mutant model 
and images generated in PyMOL using the mutagenesis wizard - each selected residue from the 
NfsA_Ec crystal structure (1F5V) was mutated and the rotamer which was the most frequently 
occurring and showed no clashes to neighbouring residues selected. (Schrödinger, LLC).  
5.4.3 Apparent kinetic parameters of NfsA_Ec variants 
When apparent kinetic parameters were determined for the improved mutants, six of the 
eight single mutants and both of the multi-site mutants tested showed a decrease in 
apparent Km, with the majority of these mutants also showing a larger decrease in apparent 
kcat such that the specificity constant was lowered overall. Our laboratory had previously 
observed, with mutants of FRase I_Vf evolved for improved CB1954 activation, that 
increases in prodrug metabolism were often driven by decreases in Km rather than 
increases in catalytic turnover rate (Swe et al., 2012). As will be shown in Chapter Seven, 
the same trend was seen for NfsA_Ec variants with improved PR-104A metabolism. 
These observations also fit with those presented in the previous chapter, when assessment 
of a range of wild type NfsA homologues found that purified protein kcat in no way 
correlated with sensitisation of an E. coli host strain to EF5, while a moderate correlation 
between E. coli growth inhibition and apparent Km was observed. It is possible that 
because our screening strategies incorporate the SOS assay, which is run using low sub-
lethal concentrations of compounds, we are favouring identification of variants which can 
A) B)
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operate at these low concentrations.  It should be noted however that there are other 
possible explanations for this lowered kcat/Km phenomenon, which shall be raised in the 
final chapter of this thesis.  
If we are indeed favouring selection of mutants capable of maximal metabolism at low 2-
NI concentrations this may well prove favourable for clinical noninvasive imaging. The 
concentration of 
18
F-2NI imaging agent that a bacterial NTR would be exposed to in a 
clinical context is unknown but it is likely to be very low; PET imaging of hypoxia is 
conducted using approximately 1000 fold lower concentrations of EF5 than that used in 
the mouse xenograft experiments shown in Figure 3-11 (Koch et al., 2010).  
5.4.4 Expression of NfsA_Ec variants from HCT-116 cells 
As discussed in the previous chapter, attempts by our collaborators to generate stable 
HCT-116 cells expressing a range of wild type NTRs were complicated by the fact that 
NTR expression levels were extremely varied, and in many cases decreased over time. 
We had not anticipated this occurring on expression of mutant NfsA_Ec proteins, as wild 
type NfsA_Ec expression was unproblematic. However to date researchers within our 
collaborative group have attempted to generate 21 different HCT-116:NfsA_Ec variant 
cell lines and found that the majority of NfsA_Ec variants tested show either absent or 
lowered expression levels. Four of the 21 NTRs to have been tested are the NfsA_Ec 
variants presented in this chapter; and of these one (mutant 1_56) failed to express at all, 
while the other three showed lower expression than NfsA_Ec.  The 17 other mutants were 
tested by Alex Mowday and comprised ten single and seven multi-site NfsA_Ec mutants 
evolved for increased metabolism of the prodrug PR-104A (generation and screening of 
these mutants will be overviewed in Chapter Seven). The expression and NTR activity of 
these 17 cell lines were tested after the time period in culture (~ 3 weeks) required to 
generate 100% puromycin resistant cell lines, in which all cells should in theory be 
expressing an NfsA_Ec variant. However, six out of ten single mutants and four out of 
seven multi-site mutants showed no/negligible expression; and two single and one multi-
site mutant showed substantially decreased expression compared to NfsA_Ec wild type 
(Alex Mowday, personal communication).  In summary, out of the 21 NfsA_Ec variants 
that have been tested thus far, 11 failed to express and a further six showed lower than 
expected expression levels.  
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While different codon usage patterns between species have been known to hamper 
heterologous protein expression we think it unlikely that the changes at a DNA level have 
caused the variations in NfsA_Ec mutant expression, as in some cases NfsA_Ec 
expression is completely destroyed following only one mutation. Additionally two multi-
mutant NfsA_Ec variants can be expressed even though they carry codon changes which, 
when present in NfsA_Ec single mutants, led to no/substantially lowered NfsA_Ec 
expression from HCT-116 (Alex Mowday - personal communication). It also does not 
appear that lowered expression and activity is a consequence of protein instability, at least 
as measured by thermostability (to be more fully discussed in section 6.2.17 in Chapter 6. 
The varied NTR expression levels are also unlikely to be a result of clonal variation in 
HCT-116 expression levels, as each of our stable cell lines are generated from pooled 
populations of transfected cells.   
The cause(s) of this wide variation in functional expression, brought about in some cases 
by just one amino acid change, are unknown, but one possibility is that the promiscuous 
metabolism of certain of these NTRs is cytotoxic to the HCT-116 cells and thus over the 
weeks that we maintain the cell lines in culture the functional expression of these NTRs is 
disfavoured. Activity and NTR expression from many 100% puromycin resistant cell 
lines has been observed to sharply decrease with time (Alex Mowday, Dr Chris Guise, 
personal communication). Additionally, a number of NTRs that are completely non-
expressed/inactive after the time period of culturing required to generate the 100% 
puromycin resistant cell lines (typically at least 2-3 weeks) will actually show functional 
activity and expression when tested very shortly after transfection (Chris Guise and Alex 
Mowday, personal communication and additionally an example of this will be shown in 
the next chapter). Substrate candidates that the NTRs showing problematic expression 
could be interacting with to generate cytotoxicity could include flavins, quinones (such as 
those involved in essential mitochondrial metabolism) or some other as of yet 
unidentified promiscuous substrate.  
5.4.5 Further testing of the 2-NI metabolism NfsA_Ec variants   
This inability to successfully test mutant NTRs has intensified the need to assess the 
activity of these enzymes on expression from more clinically applicable vectors. As will 
be discussed in Chapter Seven we have pursued this by developing a collaboration to test 
the in vitro and in vivo imaging agent and prodrug activating properties of a number of 
our bacterial NTRs, when expressed from a clinically relevant Clostridium tumour 
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targeting bacterial strain. It is hoped that heterologous NTR expression from a bacterial 
(as opposed to human) host cell will constitute an environment more consistent with the 
E. coli host used to screen and select the improved NTR variants.  
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Chapter 6: Identification and engineering of nitroreductases that activate a 
hypoxia resistant PET probe 
6.1 Introduction 
6.1.1 Design of a de novo NTR imaging agent with decreased hypoxic 
activation 
As discussed in previous chapters, non–invasive clinical imaging of bacterial 
nitroreductase enzymes would greatly aid the development of nitroreductase based 
suicide gene therapy. This was attempted by repurposing 2-nitroimidazole based PET 
suitable imaging agents, which we have shown to be activated in an oxygen insensitive 
manner by a number of bacterial NTRs, primarily those from the NfsA family. While the 
advantage of using clinically advanced compounds for bacterial NTR imaging cannot be 
overstated, it is also counter-productive to use an imaging agent where background 
activation (in this case, by tumour hypoxia) will be in the same location as the ultimate 
NTR target. We have attempted to simplify this potential issue in two ways, the first 
being the evolution of NfsA_Ec for more efficient metabolism of 2-NI compounds, to 
increase the differential activity between human oxygen sensitive NTRs and bacterial 
NTRs. However another option is to redesign the chemical matter so as to decrease 
activation by hypoxia.  
To achieve this requires a compound that is not easily reduced by endogenous human 
one-electron nitroreductases. One predictive measure of this is a compound’s one-
electron reduction potential. This is an experimentally derived value indicating how easily 
the compound gains electrons (typically as compared to a normal hydrogen electrode). A 
higher one-electron reduction potential indicates greater electron affinity and easier 
reduction of the substrate by human oxygen sensitive NTRs  (Olive, 1979; Orna and 
Mason, 1989; Wardman P., 2001).  For a nitro-compound to be well suited for reduction 
under hypoxia it should show a one-electron reduction potential greater than -0.450 mV 
(Denny, 2000). Although other side chains do influence one-electron reduction potential, 
the location of the nitro-group on a heterocyclic ring is typically the largest determining 
factor. For nitroimidazole compounds ease of reduction proceeds as 2-NI > 5-NI > 4-NI 
(Tocher, 1997; Wardman, 1985). As evidenced by their use as hypoxia imaging agents 2-
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NI compounds are within the favourable range for reduction. e.g. misonidazole has a one-
electron reduction potential of -0.389 mV (Wardman, 1985).   
To generate a PET-capable probe our ACSRC collaborator Dr Jeff Smaill designed a 5-
NI analogue of EF5 intended to give higher specificity as a bacterial NTR imaging agent. 
This compound was synthesised and termed SN33623 (Figure 6-1). The identical side 
chain to EF5 was chosen as it was anticipated that the antibodies raised against EF5 
would also detect SN33623 binding – as indeed was found to be the case (Adam 
Patterson, personal communication).  
                                              
Figure 6-1 Chemical structures of EF5 and the de novo potential NTR imaging agent 
SN33623. Position of the functional nitro group marked in red. 
 
Our collaborators at the ACSRC measured the one electron reduction potential of 
SN33623 as being - 0.501 mV, lower than that of EF5 (-0.395 mV) and outside the range 
considered to indicate efficient reduction by human one-electron nitroreductase enzymes. 
When tested in vitro, there were trace levels of SN33623 binding when cells were 
exposed to the compound under strict anoxia but this was far lower than that seen with 
EF5, as detected using fluorescently labelled antibodies.  
6.1.2 Reduction of SN33623 by bacterial NTRs 
This chapter presents work assessing the ability of bacterial NTRs to reduce SN33623, 
when expressed both from E. coli and from the human cancer cell line HCT-116. As will 
be shown, initial testing of NTR activity with SN33623 indicated that while a subset of 
NfsB family members could reduce the compound, NfsB_Ec itself could not. As such our 
EF5
SN33623
2
5
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efforts then turned to creating SN33623 active mutants of NfsB_Ec, using the protein 
sequences of SN33623 active NfsB homologues to guide targeted mutation.  
6.1.3 Aims 
 Assess the ability of members of the 58-NTR library to reduce SN33623 
 Identify key mutations that prevent native NfsB_Ec from reducing SN33623 
 Engineer NfsB_Ec mutants which can reduce SN33623 
 Evaluate the ability of selected NTRs to reduce SN33623 when expressed from 
the human cancer cell line HCT-116  
6.2 Results 
6.2.1 In vivo hypoxia dependent metabolism of SN33623  
This experiment was performed in conjunction with two research collaborators at the 
ACSRC: PhD candidate Alex Mowday (who carried out all animal handling), and Dr. 
Maria Abbattista (who operated the confocal microscope).  
 Prior to commencing this study it was imperative to determine whether the in vivo 
tumour hypoxia metabolism and subsequent binding of SN33623 was indeed markedly 
lower than that of EF5. During a research visit to the ACSRC I was involved in one of the 
experiments designed to assess this. Mice carrying HCT-116 tumours were injected with 
either EF5 or SN33623 at 60 mg/kg. As an internal control to demonstrate levels of 
hypoxia present in each tumour the mice were also treated with pimonidazole. As 
previously stated, pimonidazole is a 2-NI compound that can be used for 
immunohistochemical detection of hypoxia (Varia et al., 1998).  Two hours post 
EF5/SN33623 treatment the tumours were excised, fixed, and tumour sections cut and 
mounted on glass slides. The samples were then co-stained with a Cy5 conjugated 
antibody to detect EF5/SN33623 binding and a FITC conjugated antibody to detect 
pimonidazole binding. It has previously been fully determined that there is no cross-
reaction between these two antibodies (Dr Maria Abbattista, personal communication). 
EF5 or SN33623 binding is in red, pimonidazole in green and any overlap between the 
two when images are overlaid seen in yellow (Figure 6-2).  As shown by pimonidazole 
binding, both tumours have clear hypoxic regions, as would be expected. EF5 binding is 
readily detectable and occurs in the same areas of hypoxia as pimonidazole whereas 
SN33623 exhibits negligible binding due to hypoxia. It should be noted that this 
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experiment as it stands does not determine if SN33623 actually penetrates to the tumour - 
this facet will be elaborated on in the discussion.  
 
Figure 6-2 Hypoxia dependent binding of A) EF5 and B) SN33623 in a mouse HCT-
116 tumour xenograft model. Subcutaneous HCT-116 tumours were established in NIH 
III nude mice and grown to ~ 10 mm diameter. Mice were treated with pimonidazole and 
either EF5 or SN33623 (dosing of all compounds at 60 mg/kg via intraperitoneal 
injection) and tumours excised, fixed, paraffin embedded, sectioned and mounted on glass 
slides for immunohistochemical staining with (40 µg/mL) anti-pimonidazole antibody 
FITC-Hypoxyprobe-1 (Chemicon® International, clone 4.3.11.3) followed by staining 
with (75 µg/mL)  anti-EF5/SN33623 antibody Cy5-ELK5.1 Images were acquired and 
overlaid using a Zeiss LSM 710 confocal microscope (x20 magnification – 1 mm scale 
marked on pimonidazole images) and Zen2010 software.  The separate images taken to 
detect pimonidazole binding (green) and SN33623/EF5 (red) binding are depicted both 
individually (left hand panels) and in overlay (right-hand panels; dual registration 
appearing as yellow).  
  
OverlayPimonidazole
EF5
Pimonidazole
SN33623
Overlay
A)
B)
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6.2.2 Screening of the expanded NTR candidate library with SN33623 
To determine the most appropriate assay(s) to measure the activity of bacterial NTRs with 
the potential NTR imaging agent SN33623, its ability to cause both growth inhibition and 
induction of the SOS response in the core SOS-R2 NTR over-expression library was 
determined.  
6.2.2.1 Growth inhibition 
As shown in Chapter 4, strong activation of 2-NI imaging agents is a property restricted 
to the NfsA enzyme family. In contrast exposing the same NTRs to SN33623 and 
monitoring growth inhibition revealed a wider activation profile (Figure 6-3). The 5-NI 
drug was still reduced by the majority of NfsA enzymes, but comparable activity was also 
seen with five of the 12 NfsB enzymes in the library. 
 
Figure 6-3 SN33623 mediated growth inhibition of SOS-R2 E. coli NTR over-expression 
strains. Mid-exponential phase over-expression strains were challenged in 384 well plate format 
with 150 µM SN33623 for 4 hours. Growth was measured as culture turbidity (OD600) pre and 
post drug challenge. Growth inhibition is presented as the percentage decrease in the growth of 
challenged cultures relative to the unchallenged controls for each strain. Data are the average of 
two independent experiments ± SEM. 
6.2.2.2 SOS response 
In Chapter 3 it was shown that while the reduced forms of the 2-NI imaging agents are 
cytotoxic at high concentrations, they do not evoke a strong E. coli SOS response. 
However this was not the case for the 5-NI compound SN33623 which at sub-lethal 
concentrations could evoke an SOS response in the SOS-R2 NTR library (Figure 6-4). 
NTR activity with SN33623 as determined by growth inhibition and SOS assay induction 
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was closely correlated (R
2 
= 0.91 for a linear trend line when comparing data presented in 
Figure 6-3 and Figure 6-4; not shown).  
 
Figure 6-4 SN33623 mediated induction of the SOS response E. coli SOS-R2 NTR over-
expression strains. Over-expression strains were grown in 96 well microplates and challenged 
with 8 µM SN33623 for 4 hours prior to quantification of SOS response by β-galactosidase assay. 
Fold induction is derived from the Miller units recorded on drug exposure divided by those of 
unchallenged control wells. Data are the average of two independent experiments ± SEM.  
6.2.3 SN33623 metabolism and evolutionary relationships of NfsB family 
enzymes 
While the activation of SN33623 by a subset of NfsB enzymes was novel and interesting, 
NfsB_Ec was clearly unable to metabolise SN33623. This was disappointing as NfsB_Ec 
is the best-studied and most developed NTR for GDEPT, yet it has never been shown to 
be imageable. On examining the relationship between all 12 NfsB family members in our 
library (Figure 6-5) it became apparent that while there was a great deal of diversity 
between the five NfsBs which were active with SN33623, there was a close relationship 
(> 50% shared amino acid identity with NfsB_Ec) between the majority that were 
inactive (all except for the outlier enzyme NfsB_Pa). This observation suggested that 
activation of SN33623 may be a general property of the NfsB family of enzymes, with the 
cluster of NTRs closely related to NfsB_Ec having acquired one or more specific 
mutations that “block” this activity.  If so, we anticipated that it might be possible to 
engineer in SN33623 metabolism to NfsB_Ec by changing the residue(s) at these site(s) 
to the equivalent residue(s) from an SN33623 capable NfsB.  
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Figure 6-5 Relationships between NfsB family enzymes A) Cladogram representing 
relationship between the protein sequences of the 12 NfsB enzymes in our NTR over-expression 
library. Generated using ClustalW2 tool (http://www.ebi.ac.uk/Tools/msa/clustalw2/) on default 
settings B) Activity of the NfsBs with the imaging agent SN33623 as measured by the SOS 
chromotest (as seen in Figure 6-4), with NfsBs labelled as to their homology with NfsB_Ec. 
Homology is defined as % of shared amino acid identity between the sequences. A * marks point 
at which NfsB_Es diverges from the other closer NfsB_Ec homologues, past which we 
hypothesize that mutations blocking SN33623 metabolism occurred.  
6.2.4 Identification of amino acid residues important in SN33623 activation 
To further investigate this idea we compared the protein sequence of the six “NfsB_Ec-
like” NTRs with that of NfsB_Es, the SN33623 active NfsB that shares the greatest 
homology (48% identity) with NfsB_Ec (Figure 6-6 A). As it seemed likely that the 
amino acid(s) responsible for the change in SN33623 activity would be in the enzyme’s 
active site or binding pocket, we examined a solved crystal structure of NfsB_Ec bound 
to the prodrug CB1954 and focused only on amino acids within 9.5 Å of the prodrug 
substrate.  This analysis identified 46 amino acids of interest. Of these, 38 amino acid 
sites could be immediately ruled out as key for SN33623 metabolism, as at these sites 
NfsB_Es had the same amino acid as at least one SN33623-inactive NfsB.  Of the 
remaining eight sites three were simply a “gap” in the NfsB_Es protein sequence, and 
modification of the proteins by insertion or deletion in this loop region was not pursued as 
we decided to first focus on the less disruptive strategy of introducing substitution 
mutations. This left five sites at which a differing amino acid between NfsB_Es and 
NfsB_Ec might play a role in determining the ability to metabolise SN33623 (Figure 6-6 
B). We decided to focus on the last four of these sites as the change at site 13 (between 
the structurally similar Ser and Thr) seemed least likely to have a profound effect. 
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Figure 6-6 Identification of amino acid residues important in SN33623 activation A) Protein 
alignment of seven NfsB family enzymes. Residues highlighted in blue are those within 9.5 Å of 
bound CB1954 in NfsB_Ec (determined using the crystal structure 1IDT and protein viewer 
DeepView (SwissPDB)) and the analogous residues in NfsB_Es. The five residues highlighted in 
red are those from this group which differ between NfsB_Es and any of the SN33623-inactive 
NfsBs. Alignment carried out using ClustalW2-Multiple Alignment Tool 
(http://www.ebi.ac.uk/Tools/msa/clustalw2) on default settings B) Table summarising the five 
differing residues- differing site numbers are due to the three amino acid “gap” present in 
NfsB_Es.  
6.2.5 Identification of residues playing a key role in SN33623 metabolism in 
NfsB_Es  
To determine if any of the four NfsB_Ec amino acids identified in Figure 6-6 B (omitting 
T13) were blocking metabolism of SN33623 we first substituted those amino acids into 
the corresponding residue location in NfsB_Es, and assessed if these changes decreased 
the activity of the resulting NfsB_Es variant with SN33623.  The SN33623 IC50 for E. 
coli over-expressing each of the A67F, Q69E, Y105F and N125H single residue variants 
of NfsB_Es was determined (Figure 6-7). As can be seen, the change which had the 
greatest effect on SN33623 metabolism was A67F, which eliminated nearly all activity 
with SN33623. Two other mutations, Q69E and Y105F, also reduced SN33623 
metabolism, causing ~ 2 fold and ~ 5 fold increases in IC50 values, respectively. The 
fourth mutation, N125H, had no measurable effect on SN33623 metabolism.   
NfsB_Es  MNLNEIIRTRHTSKAYDNSRKLTAEQQQELLDLLRFSPSSVNSQPWHFFAVTTEEGKAQILPALMD---ANQVKAKNAAM 77 
2432_Pp  MDTVSLAKRRYTTKAYDASRRIPQATVDALLEQLRHSPSSVNSQPWHFIVADTAEGKALLAKSTAEGYAYNTQKLLDASH 80 
NfsB_Vv  MTIVQAAQSRYSTKAFDASRKLPEEKVAAVKELIRMSASSVNSQPWHFIVASSEEGKARIAKATQGGFAFNERKILDASH 80 
NfsB_Ec  MDIISVALKRHSTKAFDASKKLTPEQAEQIKTLLQYSPSSTNSQPWHFIVASTEEGKARVAKSAAGNYVFNERKMLDASH 80 
NfsB_St  MDIVSVALKRYSTKAFDPSKKLTAEEADKVKTLLQYSPSSTNSQPWHFIVASTEEGKARVAKSAAGNYTFNERKMLDASH 80   
NfsB_Ck  MDIVSVALKRYSTKAFDPSKQLTADEAEKLKTLLQYSPSSTNSQPWHFIVASTEEGKARVAKSAAGNFVFNERKMLDASH 80 
NfsB_Kp  MDIVSVALKRYSTKAFDATKKLTAGEAEQLKTLLQYSPSSTNSQPWHFIVASTDEGKARVAKAASGTYVFNERKILDASH 80 
         *   .    *:::**:* ::::.      :   :: *.**.*******:.. : **** :  :       *  *  :*: 
 
NfsB_Es  TVVFTIKEELNEAHLLQLLEKEQQDGRYDSEEARAANDKGRRFFVGLNSETPEQQREWMTRQAYLALGFLLLGAAAMGLD 157 
2432_Pp  VIVFCTRTEMTEEHLNAVLDQEAADGRFRDEQARAGQNQSRRHYVNLHRFDQKDVQHWMEKQTYLALGTALLGAAAHGLD 160 
NfsB_Vv  VVVFCAKTSIDEAYLLDLLQSEDKDGRFADVEAKNGMHAGRSFFVNMHRFDLKDAHHWMEKQVYLNVGTLLLGASAMEID 160 
NfsB_Ec  VVVFCAKTAMDDVWLKLVVDQEDADGRFATPEAKAANDKGRKFFADMHRKDLHDDAEWMAKQVYLNVGNFLLGVAALGLD 160 
NfsB_St  VVVFCAKTAMDDAWLQRVVDQEDADGRFATPEAKAANDKGRRFFADMHRVSLKDDHQWMAKQVYLNVGNFLLGVAAMGLD 160 
NfsB_Ck  VVVFCAKTAMDDAWLDRVVDQEDADGRFATPEAKAANNKGRRFFADLHRRDLKDDDQWMAKQVYLNVGNFLLGVAAMGLD 160 
NfsB_Kp  VVVFCAKTAMDDAWLQRVVDQEEADGRFATPDAKAANHKGRTFFADMHRKELKDDDQWMAKQVYLNVGNFLLGVAAMGLD 160 
         .:**  :  : :  *  :::.*  ***:   :*: . . .* .:..::    .:  .** :*.** :*  ***.:*  :* 
 
NfsB_Es  ATPIEGFHPEKMDEVLGLKEKGLCSVVVATIGYRSDADFNATLPKSRLDQDVVITQL 214 
2432_Pp  ATPIEGFDSKVLDAELGLRERGFTSVVILSLGYRSEADFNAGLNKSRLPASQVFTFL 217 
NfsB_Vv  AVPIEGFDAKVLDEEFGLREKGFTSVVIVPLGYHSEDDFNAKLPKSRWPAETVFTEI 217 
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Figure 6-7 SN33623 induced growth inhibition of E. coli SOS-R2 NfsB_Es mutant over-
expression strains. Growing NTR over-expression strains were exposed to serially diluted 
SN33623 for four hours. Shown to the left are growth curves, with growth defined as the 
percentage OD600 increase, compared to unchallenged strain controls, during the drug incubation 
period. Symbols are coloured green (high activity), orange (medium activity) and red (low to no 
activity) to denote the relative ability to metabolise SN33623. Inset is a table showing IC50 values, 
calculated using SigmaPlot™ 10.0. Values represent the average of three independent 
experiments ± SEM. 
6.2.6 Specificity of the decrease in SN33623 metabolism 
To confirm that the observed reductions in NfsB_Es variant activity with SN33623 were 
a consequence of the specific residue substitutions, and not due to a global deleterious 
effect on enzyme stability/activity, the ability of these variants to metabolise other 
compounds was tested. Seen in Figure 6-8 are results with three diverse compounds, the 
nitroaromatic prodrug PR-104A, the antibiotic nitrofurazone and the nitro quenched 
fluorophore FSL41 (also known as SN29884 (Singleton et al., 2007)). These results 
demonstrated that the variant NfsB_Es enzymes retained overall NTR functionality, 
particularly apparent in the case of PR-104A for which the mutations A67F, Q69E and 
Y105F actually improved NfsB_Es metabolism.  
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Figure 6-8 Metabolism of SN33623, PR-104A, Nitrofurazone (NFZ) or FSL41 by  SOSR-2 E. 
coli strains over-expressing NfsB_Es mutants A) IC50  Values were determined as previously 
described. Values are the average of at least two independent experiments ± SEM. SN33623 IC50s 
reproduced from Figure 6 for comparison.  B) NTR over-expression cultures were grown in 96 
well microplates and exposed to 25 µM FSL41 (fluorescent when reduced) for 1 hour before 
culture fluorescence was determined (ex355/em460) and compared to that of unchallenged strain 
controls. Values are the average of two independent experiments ± SEM C) Chemical structures 
of compounds tested. 
6.2.7 Generation of NfsB_Ec mutants that can metabolise SN33623 
As the F67A, Q69E or Y105F mutations in NfsB_Es led to a decrease in SN33623 
metabolism it was hypothesised that the opposite substitutions at the equivalent 70, 72 
and/or 108 sites of NfsB_Ec would generate variants which could activate SN33623. To 
assess this, all seven possible combinations of F70A, E72Q and F108Y NfsB_Ec variants 
(i.e. three single mutants, three double mutants, and one triple mutant) were made and 
tested for SN33623 metabolism (Figure 6-9). It was discovered that changing the amino 
acids at these sites did indeed engineer in SN33623 activity to NfsB_Ec. The single 
mutant with the lowest SN33623 IC50 was NfsB_Ec F70A, followed by F108Y. E72Q 
conferred no improvement in activity as a single mutant, but did lower the SN33623 IC50 
slightly when paired with either of the other two mutations. However the largest 
synergistic effect came from combining F70A and F108Y as, with (IC50 = 38 µM) or 
without (IC50 = 45 µM) an accompanying E72Q mutation, NfsB_Ec F70A/F108Y 
conferred a sensitivity to SN33623 comparable to that of wild type NfsB_Es (IC50 = 37 
µM).  
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Figure 6-9 SN33623 mediated growth inhibition of E. coli SOS-R2 over-expressing 
engineered NfsB_Ec variants. Mid-exponential phase NTR over-expression strains were 
exposed to serially diluted SN33623 for four hours. Shown to the left are growth inhibition 
curves, with growth defined as the percentage OD600 increase relative to unchallenged strain 
controls, during the drug incubation period. Symbols are coloured green (high activity), orange 
(medium activity) and red (no activity) to denote the strains relative abilities to metabolise 
SN33623. Inset is a table indications mutations present in each NTR and strain IC50 values, 
calculated using SigmaPlot™ 10.0 Values represent the average of three independent experiments 
± SEM.  
6.2.8 Metabolism of 2-NI imaging agents by NfsB_Ec mutants engineered for 
activity with the 5-NI SN33623 
The HX4 and EF5 dependent growth inhibition of E. coli strains over-expressing 
NfsB_Ec SN33623 active mutants was tested alongside a strain over-expressing 
NfsA_Ec, to determine if the introduced mutations also had a positive effect on 2-NI 
metabolism (Figure 6-10). It was discovered that the four variants containing the F70A 
mutation had gained a low but nonetheless detectable ability to metabolise EF5 (yielding 
an IC50 of ca. 1 mM, relative to ca. 150µM for NfsA_Ec); whereas the remaining variants 
were essentially indistinguishable from NfsB_Ec or the empty plasmid control. In 
contrast, none of the engineered NfsB_Ec variants were distinguishable from wild type 
NfsB_Ec in terms of conferring sensitivity to HX4 (but all strains expressing these 
variants were markedly more sensitive to HX4 than the empty plasmid control; yielding 
IC50s of ca. 800 µM, relative to ca. 600 µM for NfsA_Ec, and >>1 mM for the empty 
plasmid control). 
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Figure 6-10 A)EF5 and B)HX4 mediated growth inhibition of E. coli SOS-R2 over-
expressing NfsB_Ec mutants engineered for improved SN33623 metabolism Mid-exponential 
phase NTR over-expression strains were exposed to serially diluted EF5 or HX4 for four hours. 
Shown to the left are growth inhibition curves, with growth defined as the percentage OD600 
increase relative to unchallenged strain controls, during the drug incubation period. Values 
represent the average of two independent experiments ± SEM.  
6.2.9 Metabolism of SN33623 by NfsB_Ec mutants evolved for superior 
CB1954 activation.   
Having shown that the amino acid substitutions F70A and F108Y could markedly 
improve metabolism of SN33623 by NfsB_Ec, we next wanted to see if this knowledge 
could be used to confer PET imaging potential to variants of NfsB_Ec that had previously 
been evolved for improved prodrug reduction. For this aspect of the study, two double 
mutants generated by Dr Peter Searle’s research group were chosen, NfsB_Ec 
T41L/N71S and NfsB_Ec T41L/F70A; these have been reported to be 14-17 fold more 
potent than wild type NfsB_Ec at sensitising human cancer cells to CB1954 (Jaberipour 
et al., 2010). We hypothesised that the serendipitous occurrence of the F70A substitution 
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in one of these mutants may have already conferred a moderate level of activity with 
SN33623 to this variant. 
The effect on SN33623 and CB1954 metabolism of adding the mutations F70A and 
F70A/F108Y to Dr Peter Searle’s previously evolved enzymes was tested Figure 6-11. 
  
 
1NfsB_Ec mutant reported by Dr Peter Searle to show improved CB1954 metabolism (Jaberipour et al., 2010) 
Figure 6-11 SN33623 and CB1954 mediated growth inhibition of E. coli SOS-R2 over-
expressing engineered NfsB_Ec mutants A) Mid-exponential phase NTR over-expression 
strains were exposed to serially diluted SN33623 for four hours. Shown are growth inhibition 
curves, with growth defined as the percentage OD600 increase, compared to unchallenged strain 
controls, during the drug incubation period. Symbols are coloured green (high activity), orange 
(medium activity) and red (no activity) to denote the strains relative abilities to metabolise 
SN33623 B) Table showing the IC50s for SN33623 and CB1954. IC50s were derived from the 
SN33623 growth curves in A) and equivalent experiments using CB1954 and calculated using 
SigmaPlot™ 10.0. All values represent the average of three independent experiments ± SEM. 
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When both the F70A/F108Y (“SN33623-improving”) mutations were combined with the 
T41L/N71S (“CB1954-improving”) mutations, this did indeed yield an NTR with 
improved SN33623 metabolism. However, the final IC50 of E. coli over-expressing the 
quadruple mutant was 174 µM, substantially higher than the IC50 for the F70A/F108Y 
double mutant (measured as 41 µM in this set of experiments). The addition of F70A and 
F108Y also compromised CB1954 metabolism, reducing the CB1954 IC50 from 186 µM 
to 322 µM (albeit still slightly better than the native NfsB_Ec IC50 of 376 µM). To 
summarise: when both sets of mutations were combined, the resulting NfsB_Ec variant 
exhibited better SN33623 and CB1954 metabolism than wild type NfsB_Ec; but 
substantially less SN33623 metabolism than the specialised F70A/F108Y variant, and 
substantially less CB1954 metabolism than the specialised T41L/N71S variant. 
The strategy was more successful when it came to the T41L/F70A double mutant, which 
due to the F70A residue change, already had SN33623 activity similar to the NfsB_Ec 
F70A single mutant (IC50s of 199 µM and 192 µM respectively). Adding a F108Y 
mutation to the T41L/F70A double mutant again proved synergistic for SN33623 
metabolism, lowering the IC50 to 78 µM, and this time not impairing the ability to 
metabolise CB1954. While neither of these modified mutants were quite as active with 
SN33623 as the double NfsB_Ec F70A/F108Y, it is possible that the metabolism they do 
show is sufficient for imaging purposes.  
6.2.10 Reduction of SN33623 by His6-tagged purified proteins.  
To validate the activity of the mutants at purified protein level, the gene sequences were 
cloned into pET28a+, and purified using nickel affinity chromatography following 
expression from the E. coli strain BL21. Wild type proteins NfsB_Ec, NfsA_Ec and 
NfsB_Es were also purified and tested. While we had initially intended to derive the 
apparent kinetic parameters for each of the NTRs with SN33623 this was complicated by 
the reduction of SN33623 being extremely slow. Particularly at lower SN33623 
concentrations there was only a small difference between background oxidase activity 
(direct electron transfer from NADPH to dissolved O2 in the reaction medium, measured 
as the amount of enzyme catalysed NADPH depletion observed in the absence of any 
additional substrate) and SN33623 dependent NADPH consumption. Comparable levels 
of slow in vitro activity have been observed by other groups when studying the reduction 
of the 5-NI compound metronidazole by other bacterial NTRs, and it was found that full 
determination of kinetic parameters was only possible when using a chemical oxygen 
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scavenging system to remove the oxygen from the reaction cuvettes to lessen background 
oxidase activity (Olekhnovich et al., 2009) (efforts to reproduce this system are ongoing 
in the Ackerley lab). As a substitute for measuring the full kinetic parameters, the relative 
rates of NADPH consumption at 500 µM SN33623 were determined and these showed 
that, at least by this measure, the mutations F70A and F108Y did indeed confer SN33623 
metabolism to NfsB_Ec.  
                                                            
Table 6-1 NADPH consumption rate in the presence of SN33623 by purified His6-tagged 
NTRs. Purified NTRs were incubated for 1-2 minutes with 500 µM SN33623/EF5 and 200 µM 
NADPH. NADPH consumption was determined by monitoring decrease in light absorbance at 
340 nm using an extinction co-efficient of 6,220 M
−1
cm
−1
. NADPH consumption in the absence 
of SN33623 was determined for each enzyme and subtracted from the final rate value. NfsA_Ec 
reduction in the presence of EF5 is shown in comparison. Reactions were measured in at least 
quadruplicate and errors represent ± one standard deviation.  
6.2.11 Docking of SN33623 and CB1954 into the active mutant NfsB_Es F70A 
To further investigate the ability of the NfsB_Ec mutants to metabolise SN33623 the 
compound was docked in silico into the active site of a model of NfsB_Ec F70A. A 
number of X-ray crystal structures of NfsB_Ec have been solved, both unbound 
(Parkinson et al., 2000) and in complex with other substrates and inhibitors (Johansson et 
al., 2003; Lovering et al., 2001; Race et al., 2005). NTR amino acid residues are not 
believed to directly participate in the chemical reactions through which substrate 
oxidation and reduction occurs. NTRs instead catalyse these by stabilising the charge on 
reduced FMN and by providing binding pockets to hold the NAD(P)H and substrate 
within an appropriate distance for direct hydride transfer with the FMN co-factor (Koder 
et al., 2002; Race et al., 2005).   
NTR EF5
NfsA_Ec 2700 ± 400 40,700 ± 1900
NfsB_Es 2400 ± 200 NM2
NfsB_Ec NM2
NfsB_Ec F70A/F108Y 930 ± 200 NM2
NfsB_Ec T41L NM2
NfsB_Ec T41L/F70A/F108Y 440 ± 150 NM
2
1No activity detected
2Not measured
Substrate  reduced 
(µmoles/min/mg of protein)
SN33623
ND1
ND1
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 The NfsB_Ec F70A structure was generated using a solved crystal structure of NfsB_Ec 
as a template (PDB code 1DS7- (Parkinson et al., 2000)) with residue substitution carried 
out in PyMOL v1.5 (Schrödinger, LLC). It was decided that docking into a F108Y 
structure would not be attempted as this mutation site is further than F70A from the FMN 
binding site and docking into a static model is unlikely to able to detect any effect F108Y 
may have on substrate binding (Jack Flanagan, personal communication).   
NfsB_Ec is a homodimer with two active sites, each formed by residues from both 
monomers. Docking into both active sites of NfsB_Ec was undertaken, though the two 
sites are very similar- showing a root-mean-square deviation of only 0.5 Å for all main 
chain atoms within 5 Å of the FMN molecules (Parkinson et al., 2000).  
Firstly the validity of our docking parameters (described in section 2.16) was assessed by 
docking the prodrug substrate CB1954, to see if we could recapitulate the drug binding 
orientation observed in x-ray crystallography studies (Johansson et al., 2003) - this was 
successful as shown in Figure 6-12, providing some degree of confidence around the 
general modelling strategy as applied to NfsB_Ec.  
 
Figure 6-12 Stereo view of CB1954 docked into the NfsB_Ec F70A model (pink carbons), 
superimposed over X-ray crystal structure of CB1954 bound in NfsB_Ec (PDB code1IDT) (cyan 
carbons). Site of F70A mutation labelled, CB1954 molecules presented in stick format and FMN 
co-factors coloured yellow. NfsB_Ec F70A model generated from X-ray crystal structure 1DS7 
using PyMOLv1.5, images also generated in PyMOL. Docking performed using GOLDv5.1 and 
ranked by scoring function ChemPLP. This image shows the first ranked solution for one active 
site, and similar orientations were seen in the second and fourth ranked solutions for docking into 
the second active site.  
 
F70A
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Next the docking of SN33623 into NfsB_Ec F70A was carried out. Twenty solutions 
were generated for each active site, and ranked by the scoring function ChemPLP. These 
were visually inspected for binding orientations which placed the –NO2 functional group 
of SN33623 close to the FMN cofactor. In the first active site the highest scored solution 
showed such an orientation, while in the second active site this orientation was seen in 
both the second and third ranked solutions. In all three solutions the pentafluorine tail of 
SN33623 was oriented directly toward the space in the structure that arose after mutating 
the bulky aromatic sidechain of Phe to the smaller methyl sidechain of Ala. Two of the 
binding orientations observed, which differ in the exact positioning of the pentafluorine 
tail, can be seen in stereo view in Figure 6-13A. In Figure 6-13C the original NfsB_Ec 
wild type structure is superimposed over these solutions, demonstrating the manner in 
which the Phe wild-type residue might block SN33623 binding.   
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Figure 6-13 Docked structures of SN33623 in NfsB_Ec F70A model A) Stereo images of two 
different docked orientations of SN33623, shown with carbons in either pink or orange. Putative 
hydrogen bonds between SN33623 and protein are marked as dashes. The FMN co-factor is 
coloured yellow. B) Both binding orientations shown in A in a surface representation of the 
NfsB_Ec F70A model, with mutated F70A residue in cyan. C) Surface representation of X-ray 
crystal structure of NfsB_Ec (PDB code 1DS7) superimposed on the binding modes shown in A, 
with Phe70 in cyan. FMN presented in stick form.  NfsB_Ec F70A model generated from X-ray 
crystal structure 1DS7 using PyMOLv1.5. Docking performed using GOLDv5.1. Images 
generated in PyMOL. 
6.2.12 Testing of bacterial NTR activity when expressed by the human cancer 
cell line HCT-116 
We next sought to validate that the F70A/ F108Y mutations introduced into NfsB_Ec 
were truly conferring an ability to metabolise SN33623 to a cell entrapped product and 
moreover, that this activity could occur on expression of the enzyme from a human cell. 
As such SN33623 metabolism was tested for these variants (alongside other NTRs) when 
A)
B) C)
F70A
F70A
F70A
F70
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expressed from the human cancer cell line HCT-116. The NTRs chosen for transfection 
into HCT-116 are shown in Table 6-2, and consisted of three different groups of 
enzymes: 1) wild type NTRs; 2) variants of NfsB_Ec engineered for “NfsB_Es-like” 
metabolism of SN33623; and 3) variants of NfsB_Ec enzymes previously engineered by 
Dr Peter Searle for maximal CB1954 metabolism (including the single mutant NfsB_Ec 
T41L). As a number of these NTRs were new to this study they required generation of 
novel F279-V5:ntr constructs and stable HCT-116 NTR expression cell lines.  
Stable HCT-116 NTR expression cell lines were generated as previously described, by 
transfer of the desired NTR sequence into the F279-V5 puromycin resistant expression 
vector using Gateway™ cloning, transfection of HCT-116 cells, and selection for plasmid 
uptake by multiple passage cycles in media containing escalating concentrations of 
puromycin. HCT-116 NfsA_Ec and NfsB_Ec stable expression cell lines had been 
previously generated at the ACSRC and were made available for this study.    
                                         
Table 6-2 Bacterial NTRs selected for testing of SN33623 metabolism on expression from 
the human cancer cell line HCT-116. NTRs coloured according to the IC50 of SN33623 
challenged E. coli SOS-R2 NTR over-expression cell lines. Green indicates ≤ 70 µM, orange 70-
400 µM and red > 400 µM.    
6.2.13 SN33623 metabolism by stable expression HCT-116:ntr cell lines 
Once stably-transfected cell lines had been generated for all desired NTRs the ability of 
those cell lines to metabolise SN33623 was tested. This was done by seeding cells into a 
6 well plate, exposing them to SN33623 for 2 hours, fixing the cells and then staining 
them with the Alexa 488 conjugated antibody ELK 5.1 (as discussed in Section 6.2.1 this 
antibody recognises both EF5 and SN33623).  The samples were then run on a flow 
Bacterial NTR
NfsA_Ec
NfsB_Ec
NfsB_Es*
NfsB_Ec F70A*
NfsB_Ec F70A/F108Y*
NfsB_Ec T41L*
NfsB_Ec T41L/F70A*
NfsB_Ec T41L/F70A/F108Y*
*New to this study, required generation of F279-
V5 constructs and stable HCT-116 expression 
cell lines
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cytometer, and single cell events assessed for Alexa 488 fluorescence (Figure 6-14). The 
SN33623 activity of the cell lines expressing wild type NTRs was consistent with the 
activity they had demonstrated in E. coli, i.e. NfsB_Ec could not metabolise SN33623 
while both NfsA_Ec and NfsB_Es could. In contrast, when the NfsB_Ec mutants 
engineered specifically for metabolism of SN33623 (NfsB_Ec F70A and NfsB_Ec 
F70A/F108Y) were examined, neither showed any detectable activity with this compound 
(Figure 6-14A). However, the third group (derived from an enhanced CB1954-
metabolising variant previously generated by Dr Peter Searle, all containing the additional 
T14L mutation) were more promising (Figure 6-14B). As expected NfsB_Ec T41L had 
no activity with SN33623 but both NfsB_Ec T41L/F70A, and to a greater extent NfsB_Ec 
T41L/F70A/F108Y, did metabolise the compound.  
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Figure 6-14 Metabolism of SN33623 by stable HCT-116:ntr expression cell lines 1 x 10
6
 cells 
were seeded into a 6 well plate and incubated with 20 µM SN33623 for two hours at 37°C. Cells 
were fixed and stained with Alexa 488 ELK5.1 antibody (100 µg/ml) and analysed on a Becton 
Dickinson LSRII flow cytometer. Collected data was analysed using FlowJo software and mean 
fluorescence of each cell line determined. For clarity results with cell lines expressing the NfsB 
variants containing the T41L mutation are shown separately in B) with results of HCT-116 and 
HCT-116 expressing wild type proteins included for comparison. This experiment was repeated 
three times over the course of four weeks, each time showing the same trends in enzyme activity 
but with low replication of raw fluorescence values. Displayed are cell population histograms 
from one representative experiment.   
 
 
 
 
HCT116 7
NfsA_Ec 438
NfsB_Ec 18
NfsB_Es 244
NfsB_Ec T41L 12
NfsB_Ec T41L/F70A 37
NfsB_Ec T41L/F70A/F108Y 85
Cell lines Mean fluorescence
A)
B)
HCT116 7
NfsA_Ec 438
NfsB_Ec 18
NfsB_Es 244
NfsB_Ec F70A 12
NfsB_Ec F70A/F108Y 12
Cell lines Mean fluorescence
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6.2.14 Western blot analysis of NTR expression from stable HCT-116:ntr cell 
lines 
Immediately prior to SN33623 treatment a subsample of cells was taken and used to 
determine NfsB_Ec protein expression levels. These samples were lysed and a western 
blot carried out, probing for NTR expression using a anti-serum raised against NfsB_Ec 
(Figure 6-15). All of the mutant proteins were found to express at a slightly lower level 
than NfsB_Ec wild type (1.6-3.8 fold lower than wild type NfsB_Ec as measured by 
densitometry). However, the NfsB_Ec mutants that had not demonstrated the expected 
SN33623 metabolism (F70A and F70A/F108Y) were not expressed at a noticeably lower 
level than those that could metabolise SN33623 (T41L/F70A and T41L/F70A/F108Y).  
                                       
Figure 6-15 Western blot showing expression of NfsB_Ec wild type and mutant proteins 
from stable HCT-116:ntr cell lines. HCT-116 cell samples were taken, lysed and NfsB_Ec 
expression determined by immunoblot.  β-actin loading control also shown. This western was 
conducted using protein samples collected prior to exposure to SN33623, results of which can be 
seen in Figure 6-14. This trend in expression levels NfsB_Ec > T41L > the four other NfsB_Ec 
variants were repeated over two western blots of separately taken samples.  
6.2.15 Metabolism of the NTR activated fluorogenic probe FSL61 by HCT-116  
 To further interrogate the inability of the NfsB_Ec F70A and F70A/F108Y mutants to 
metabolise SN33623 all cell lines were tested for an ability to activate the fluorogenic 
probe FSL61 (an analogue of the previously used FSL41 (Figure 6-8) , which is better 
suited for microscopy as it is more cell entrapped post-activation) (Figure 6-16). Cells 
were collected, seeded and exposed to FSL61 in 6 well plates, after which media was 
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replaced and images taken using the bench top FLoid® Cell Imaging Station. The two 
mutants that did not contain the T41L mutation showed a markedly lower ability to 
metabolise FSL61 than the other three mutant proteins, which in turn appeared less avid 
for FSL61 than wild type NfsB_Ec. This strongly suggested that the NfsB_Ec F70A and 
NfsB_Ec F70A/F108Y proteins detected in the respective cell lines (Figure 1-14) were 
non-functional.  
 
 
Figure 6-16 Metabolism of the fluorogenic probe FSL61 by stably transfected HCT-116 
NTR cell lines. 100,000 cells of the indicated strains were seeded into individual wells of a 6 well 
plate and incubated with media containing 50 µM FSL61 at 37 °C for two hours. Images were 
taken in the relief phase and blue fluorescence channel and overlaid using a FLoid® Cell Imaging 
Station, with identical settings for each cell line.  
6.2.16 Transient expression and exposure to SN33623 
To confirm whether the observed inactivity of the HCT-116 NfsB_Ec F70A/F108Y cell 
line was because this NTR is not amenable to long term functional expression in HCT-
116, the ability of the different NTRs to metabolise SN33623 after transient transfection 
was tested. HCT-116 cells were transfected with a F279-V5 plasmid expressing either 
NfsA_Ec wild type, NfsB_Ec wild type, NfsB_Ec F70A/F108Y or NfsB_Ec 
T41L/F70A/F108Y. Post transfection (24 h) the cells were collected and to estimate the 
proportion of cells within each transiently transfected population that were expressing a 
HCT-116 NfsB_Ec NfsB_Ec 
T41L
NfsB_Ec 
F70A
NfsB_Ec 
F70A/F108Y
NfsB_Ec 
T41L/F70A/F108Y
NfsB_Ec 
T41L/F70A
FSL61
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functional NTR an portion of each population (0.5 x 10
6
 cells) were taken, exposed to 
FSL61 and evaluated for single cell fluorescence by flow cytometry (Figure 6-17A). 1 x 
10
6
 of remaining cells were exposed to SN33623 for 2 hours, fixed, and stained with anti 
-EF5/SN33623 antibody.  Post antibody staining the SN33623 treated cells were also 
examined using flow cytometry (Figure 6-17B) and the percentage of each cell 
population which metabolised the compounds compared (Figure 6-17C).  As comparison 
to the transient expression cells from NfsA_Ec and NfsB_Ec stable expression cell lines 
were concurrently exposed to SN33623 and FSL61 and analysed in the same manner.  
While a moderate proportion (25%) of cells transiently transfected with the NfsB_Ec wild 
type plasmid construct were positive for NTR activity (i.e. could metabolise FSL61), only 
3% of these cells were located within the gated region indicating activity with SN33623. 
In contrast, the NfsA_Ec, NfsB_Ec F70A/F108Y and NfsB_Ec T41L/F70A/F108Y 
transiently transfected cell lines all showed a markedly higher proportion of SN33623 
active cells (39%-69%). These results demonstrate that NfsB_Ec F70A/F108Y expressing 
cells can metabolise SN33623 when tested within 24 hours post the initial plasmid 
transfection, but not following the long-term culturing required to generate a stable cell 
line.  
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Figure 6-17 Metabolism of A) FSL61 and B) SN33623 by stable and transient HCT-116 
NTR expression cell lines. 4 x 10
6
 HCT-116 cells were transfected with a F279-V5:ntr construct, 
and after 24 hours collected and exposed to 50 µM FSL61(0.5 x 10
6
 cells) or 20 µM SN33623 (1 
x 10
6 
cells) for 2 hours at 37 °C. Cells from stable expression lines of HCT-116 NfsA_Ec and 
NfsB_Ec were also exposed to the compounds. FSL-61 treated cells were immediately analysed 
on a BD LSRII flow cytometer. SN33623 cells were fixed and stained with antibody Alexa 488 
ELK3.51 (100 μg/ml) before flow cytometer analysis. Collected data were compared using 
FlowJo software. For both data sets a gate was set at the point over which 99% of the NfsA_Ec 
stable cell population showed compound metabolism. Cells from other the other samples also 
within this gate were determined to metabolise FSL61 or SN33623. C) The percentage of each 
cell line which can metabolise either compound is summarised in table format.  
 
A)
HCT116
NfsA_Ec:
Stable
NfsA _Ec: 
Transient
NfsB_Ec: 
Stable
NfsB_Ec: 
Transient
NfsB_Ec  
F70A/F108Y: 
Transient
NfsB_Ec 
T41L/F70A /108Y: 
Transient
0%
99%
48%
99%
25%
28%
54%
FSL61
99%
0%
59%
11%
3%
39%
61%
SN33623B)
HCT116
NfsA_Ec: 
Stable
NfsA_Ec: 
Transient
NfsB_Ec: 
Stable
NfsB_Ec 
Transient
NfsB_Ec  
F70A/F108Y: 
Transient
NfsB_Ec 
T41L/F70A /108Y: 
Transient
Cells 
metabolising 
FSL61  (%)
Cells 
metabolising 
SN33623 (%)
HCT116 0 0
Stable expression:
NfsA_Ec 99 99
NfsB_Ec 99 11
Transient expression: 
NfsA_Ec 48 59
NfsB_Ec 25 3
NfsB_Ec F70A/F108Y 28 39
NfsB_Ec T41L/F70A/F108Y 54 61
C)
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6.2.17 Thermostability 
Although western blotting (Figure 1-14) indicated that there are low levels of both 
NfsB_Ec F70A and NfsB_Ec F70A_F108Y present in stably transfected HCT-116 cell 
lines, the proteins do not appear to be functional following long term expression. One 
possible explanation for this phenomenon was that these two mutant proteins are 
inherently less stable than the NfsB_Ec T41L variants. Of all potential protein stressors, 
stability in response to increases in temperature is the best studied, and it has been shown 
in many cases that enzymes with higher thermal stability are also more resistant to other 
destabilising factors (Burg et al., 1998; Rao et al., 2013). Thermostability can be 
quantified by a protein’s melting temperature (Tm), the temperature at which 50% of the 
protein is unfolded. The Tm values of His6-tagged purified proteins were determined 
using a Protein Thermal Shift™ assay (Invitrogen, Carlsbad, CA, USA). Here real-time 
PCR is used to progressively heat the purified proteins which are co-incubated with a 
Protein Thermal Shift™ Dye. This is a dye which fluoresces only when it binds to the 
hydrophobic protein regions exposed as the heated protein unfolds and from these 
increasing fluorescence levels, measured by the real-time PCR machine, protein Tm can 
be determined (Niesen et al., 2007).  
                                           
Table 6-3 Melting temperatures (Tm) of His6-tagged purified NfsB_Ec and NfsB_Ec mutant 
variants Purified proteins were incubated with Protein Thermal Shift™ Dye and heated in a 
Rotor-Gene 6000  real-time PCR machine. Increasing fluorescence of the protein preparations 
was recorded and Rotor-Gene 6000 Series software 1.7  used to generate Tm values from the 
inflection point.  Each value is the average of duplicate measures of samples from the same His6-
tagged protein preparation ± one standard deviation.   
 
Measured protein melting temperatures were not widely different. It does appear that the 
T41L mutation has a positive effect on protein thermostability, both when present as a 
single mutation and in conjunction with F70A and F70A/F108Y and these results do not 
rule out protein stability playing perhaps a small contributing role in the functional 
NTR
NfsB_Ec 70.0 ± 0.0
NfsB_Ec F70A 69.6 ± 0.1
NfsB_Ec F70A_F108Y 68.3 ± 0.1
NfsB_Ec T41L 73.6 ± 0.1
NfsB_Ec T41L F70A 74.0 ± 0.0
NfsB_Ec T41L F70A F108Y 73.0 ± 0.0
Tm (°C)
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activity of the T41L containing mutants as compared to NfsB_Ec F70A and NfsB_Ec 
F70A/F108Y. However both the F70A and F108Y mutations barely decrease NfsB_Ec 
stability suggesting that decreased protein stability is not the factor causing in the 
inactivity of NfsB_Ec F70A and NfsB_Ec F70A_F108Y on stable expression from HCT-
116.  
6.3 Discussion 
The work presented within this thesis seeks to develop bacterial NTRs as reporter genes 
for clinical noninvasive imaging of tumour tropic vectors. Whereas previous chapters 
have focused on repurposing PET probes that were originally developed to image tumour 
hypoxia, the research described here focuses on a de novo imaging agent, specifically 
designed to be capable of metabolism by bacterial NTRs, but not by human enzymes 
under hypoxia. Clinical development of entirely new chemical matter has the substantial 
disadvantage of requiring expensive preclinical and Phase I clinical trials, whereas 
repurposing existing PET probes would not incur these costs and time delays. However, 
effective new chemical matter may prove necessary if existing 2-NI hypoxia imaging 
agents cannot be successfully repurposed for effective vector imaging. The development 
pathway for novel radiobiological compounds may also become more simple with time, 
due to a push for development of PET imaging agents for more varied applications 
(Coenen et al., 2010) and progress in technologies for miniaturized automated production 
of varied PET probes (Li and Conti, 2010; Yuin et al., 2012).  
6.3.1 Further investigation of hypoxia resistance and NTR labelling  
The de novo compound presented in this chapter is currently named SN33623, and is the 
5-NI analogue of EF5. Critically we showed that SN33623 shows clearly lower in vivo 
binding in a HCT-116 tumour xenograft. However this experiment does not show that 
SN33623 actually penetrates tumours as effectively as EF5, and whether SN33623 still 
retains good ability to give a quantitative measure of NTR expression in vivo. Alex 
Mowday has recently shown that SN33623 in vivo reduction by NfsA_Ec can be readily 
detected by immunohistochemistry in a mouse xenograft model of a human lung tumour 
NCI-H1299, containing approximately 5% NfsA-expressing cells. Such a result does tell 
us that the pharmacokinetics of SN33623 are such that NfsA_Ec over-expression can be 
detected in vivo but for full comparison to the experiment presented in Figure 6-2 this 
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needs to be repeated in HCT-116 tumours seeded with varying levels of NTR - 
experiments to determine this are planned at the ACSRC.   
When drug binding is measured by fluorescently-conjugated antibodies in vitro under 
anoxia there is at least 13 fold more fluorescence in EF5 treated cell samples than in those 
treated with SN33623, however the fluorescence of the SN33623 sample can still be 
distinguished from that of untreated cells – in vitro it is not a completely anoxia “clean” 
compound. It should be noted that there are three groups who have done preclinical work 
developing Gallium-68  or 
99m
Tc labelled 5-NI compounds, with a variety of side chains, 
as possible hypoxia imaging agents (Das et al., 2003; Giglio et al., 2012; Mallia et al., 
2005). These groups do report uptake of the compound in tumours in mice, although 
when it has been directly compared in vivo to [
18
F] F-MISO the actual tumour uptake and 
retention of a 5-NI Gallium-68 labelled compound was significantly lower, with the 
measurable tumour/muscle ratio for the novel imaging agent due to the very rapid 
clearance of unbound hydrophilic compound from muscle as compared to the more 
lipophilic F-miso (Fernández et al., 2013). We are in the preliminary stages of 
investigating the use of 4-NI compounds for NTR imaging, as they have lower one-
electron reduction potentials than even 5-NI compounds. Preliminary results indicate that 
a 4-NI analogue of EF5 shows less binding under anoxia than SN33623 but that the 
compound can still be reduced by NfsA_Ec.  It should be noted that, while ease of 
screening should not determine our choice of drug, an advantage of 5-NI compounds is 
that they elicit an SOS response, something not seen with either 2-NI or 4-NI compounds 
(preliminary work- results not shown). Directed evolution of NTRs for increased activity 
with a 5-NI compound would thus be simpler as substantially less scarce imaging agent 
would be required and active NTRs could be directly assayed for in situations which 
require high-throughput FACS based screening, such as interrogating large error-prone 
mutant libraries.  
6.3.2 Bacterial NTRs and SN33623 
A serendipitous outcome of developing SN33623 was an expansion in the variety of 
NTRs that could potentially be used for noninvasive imaging, as a number of NTRs from 
the NfsB family showed SN33623 activity comparable to that of NfsA_Ec. Irrespective of 
whether further development of SN33623 is successful it should at least prove to be a 
useful pre-clinical tool as it can be activated by a number of NTRs, such as NfsB_Es, 
which cannot metabolise EF5.   
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One NTR that could not metabolise SN33623 was NfsB_Ec. We reasoned that it would 
be highly advantageous to identify specific mutations that could be introduced into 
NfsB_Ec, to leverage the wealth of previous research focused on this enzyme, in 
particular the highly active CB1954 metabolising variants generated by Dr Peter Searle 
using directed evolution (Jaberipour et al., 2010). While NfsB_Es, the SN33623 active 
NTR most closely related to NfsB_Ec, shared only 48% amino acid identity, by aligning 
NfsB_Ec against all the SN33623 metabolising NfsB family members and focusing only 
on residues close to the active site the number of likely target residues for mutagenesis 
was reduced to just four.  Ultimately only two amino acid changes (F70A and F108Y) 
were required to make NfsB_Ec capable of metabolising SN33623. It was shown that 
these mutations also conferred SN33623 metabolism when engineered into two NfsB_Ec 
mutants previously reported by Peter Searle to show increased metabolism of the prodrug 
CB1954. As one of these mutants already serendipitously contained the F70A mutation it 
was already inherently able to metabolise SN33623, but this property was increased by 
F108Y addition.  
6.3.3 Expression of NfsB_Ec mutants from HCT-116  
To validate and further study the NfsB_Ec SN33623 active mutants a number of stably 
transfected HCT-116:ntr cell lines were generated, and NTR function and expression was 
tested. The results of this work (which was performed in parallel with much of the human 
cell work presented in Chapter 5) re-emphasise the heterogeneity and unpredictability of 
NTR expression from HCT-116 cell lines. Particularly dramatic was the strong effect 
single residue changes can have on the long term ability of NfsB_Ec variants to express 
functionally in these cells. For example, it was shown that while the F70A mutation (and 
possibly also the F108Y mutation) had a detrimental effect on long term functional 
expression, this could rescued to a substantial extent by one additional mutation, T41L.  
The apparent expression of F70A and F70A/F108Y in the stable cell lines was 
comparable to the functional variants of these proteins which contained T41L, as depicted 
in the western blot in Figure 1-14.  As such F70A and F70A/F108Y are expressed but 
appear inactive for unknown reasons. One possibility that was tested was if the NfsB_Ec 
F70A and F70A/F108Y mutant proteins were less stable and had a greater propensity to 
unfold, with the addition of the third T41L mutation stabilising them. To determine if this 
was likely the thermostability of each of the purified proteins was measured and while 
T41L was found to be stabilising this was not a to a particularly marked degree. It is 
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perhaps possible that this difference in protein stability, as measured by continuing 
stability on temperature increase ,is exacerbated inside the HCT-116 cellular environment 
in the face of other stressors, but such a conclusion is fairly speculative. It should be 
noted that protein thermostability does not correlate with successful stable expression for 
either the NfsA_Ec variants presented in Chapter 5 (results not shown)  or wild type 
NTRs and the larger set of NfsA_Ec variants for which Alex Mowday attempted to 
generate stable cell lines (Dr Janine Copp, personal communication).   
It is perhaps possible that, if these non-T41L containing NfsB_Ec variants carry out 
metabolism that is unfavourable to the host human cell as discussed in Chapter 5 , that 
this is favouring accumulations of mutations in NfsB_Ec F70A and F70A/F108Y which 
are making the NTRs non-functional.  Another speculative possibility for difference in 
activities between the ± T41L variants is that perhaps they metabolise competing 
substrates, such as quinones, inside the HCT-116 cells to differing degrees - with perhaps 
higher quinone metabolism in the non T41L containing mutants inhibiting the metabolism 
of the exogenously applied FSL61and SN33623 nitro-compounds. This would not 
however explain why NfsB_Ec F70A/F108Y was functional immediately after 
transfection but not on long term culturing.  
Ultimately measuring the ability of the HCT-116 NTR cell lines to metabolise SN33623 
did demonstrate that, in contrast to wild type NfsB_Ec, the NfsB_Ec F70A/F108Y 
mutants could reduce SN33623. This activity could be detected when measured ~ 24 
hours after NTR plasmid transfection of the HCT-116 cells or in stable NTR expression 
cell lines when the mutants also contained the T41L substitution. NTR expression in a 
therapuetic context from a replicating viral vector would likely be more similar to a 
transient style transfection situation. It is promising that these mutations could confer 
metabolism of a potential PET capable probe to previously published CB1954 improved 
NfsB_Ec variants – in one case without decreasing CB1954 metabolism - as this could in 
future allow noninvasive clinical imaging of such variants of NfsB_Ec, the enzyme that 
has been the primary focus of NTR based GDEPT for the past two decades.  
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Chapter 7: Directed evolution of NfsA_Ec variants with improved prodrug 
activation  
7.1 Introduction 
The primary focus of work presented in this thesis has been to develop the noninvasive 
imaging capability of bacterial nitroreductase enzymes. However, research in this chapter 
focuses more on use of directed evolution to generate an optimised PR-104A reducing 
variant of NfsA_Ec, while retaining its native ability to activate 2-NI PET probes. The 
key goal was to generate an optimal nitroreductase for PR-104A GDEPT - that has the 
added capacity to activate PET probes - to facilitate translation of NTR based suicide 
gene therapy to the clinic. The experimental work presented in this chapter was primarily 
conducted in collaboration with Dr Janine Copp (Dr Copp focusing primarily on 
improvement of PR-104A metabolism, while I tested enhanced variants for retention of 2-
NI PET probe metabolism).   
7.2 Clostridium directed enzyme prodrug therapy 
The intended vector for the optimised enzymes generated in this work was Clostridium 
sporogenes. Bacteria found within the Clostridium genera are obligate anaerobes which in 
the presence of oxygen can survive in the form of non-vegetative spores. As such a 
number of non pathogenic Clostridium species have been investigated as biological anti-
cancer agents- the treatment involving the injection of Clostridium spores which are only 
able to germinate within the hypoxic and necrotic cores of solid tumours (Morrissey et al., 
2010; Umer et al., 2012). Early clinical trials of Clostridium treatment demonstrated that 
systemic delivery of the spores was safe, that the bacteria germinated within tumours and 
that in some patients this caused tumour oncolysis – although not to levels sufficient to 
improve patient outcomes (Carey et al., 1967; Heppner and Möse, 1978).  More recent 
investigations have focused on combination treatments. An attenuated strain of 
Clostridium novyi, termed C. novyi-NT showed promising preclinical results when 
combined with both DNA or microtubule targeting chemotherapies (Dang et al., 2001) 
and with radiotherapy regimes (Bettegowda et al., 2003). A phase I trial to assess the 
safety of C. novyi-NT spores in cancer patients is currently recruiting 
(http://clinicaltrials.gov/ct2/show/NCT01118819). Another strategy involves “arming” 
the bacteria with recombinant proteins. This has been made possible by advances over the 
last decade in techniques for the genetic manipulation of recalcitrant species, such as C. 
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sporogenes, which show high inherent tumour colonisation properties (Kuehne et al., 
2011; Liu et al., 2002; Theys et al., 2006). Proteins chosen for expression have included 
those expected to either directly trigger an anti-cancer response, for example interleukin-2 
(Barbé et al., 2005), or else prodrug converting enzymes. Treatment modalities reported 
to cause tumour growth delay in preclinical models have used recombinant C. sporogenes 
as an expression vector and include E. coli derived cytosine deaminase and 5-FC (Liu et 
al., 2002), an NfsB homologue from Haemophilus influenza in combination with CB1954 
(Theys et al., 2006) and NfsB_Ec coupled with either CB1954 or PR-104 treatment (Liu 
et al., 2008). In the latter instance, PR-104 was found to generate a substantially greater 
effect than CB1954 in limiting the growth of NfsB_Ec-labeled mouse xenografts, despite 
being administered at much lower dose relative to the equivalent human MTD (ca. 1.3-
fold the human MTD for PR-104, vs. ca. 50-fold for CB1954; Adam Patterson, personal 
communication). The superiority of PR-104 for nitroreductase GDEPT was therefore 
clearly established. 
7.2.1 Translation of nitroreductase armed Clostridium to a clinical setting  
In partnership with the ACSRC we have joined an international collaboration seeking to 
advance NTR GDEPT to advanced preclinical, and then clinical, trial. It is not possible to 
fully discuss the details of this collaboration, with many aspects of it unable to be 
disclosed due to a confidentiality agreement signed by all parties. A conservative 
approach will be taken to avoid breaching the terms of this agreement, including not 
mentioning the identities or precise roles of the other parties involved. Briefly, we are 
seeking to stably integrate into a C. sporogenes strain an NfsA_Ec variant that has been 
evolved for maximal PR-104A reduction, while retaining the ability to metabolise 2-NI 
PET probes, in particular HX4. This is an exciting opportunity to clinically translate not 
just our work involving nitro-aromatic prodrug activation but also noninvasive imaging, 
as the collaboration will allow microPET studies of the tumour tracking properties of 
Clostridium expressing NfsA_Ec variants to be conducted.  
In addition to PR-104A and HX4 metabolism the abilities of the NfsA_Ec variants to 
metabolise metronidazole will also be assessed. Anti-cancer treatment using Clostridium 
has the advantage that, in the event of adverse events, the bacteria can be cleared from 
patients with the antibiotic metronidazole, commonly used clinically to treat Clostridium 
infections (Zar et al., 2007). Metronidazole is a 5-NI compound which has been used for 
decades in humans, and its toxicity is activated by reduction of its nitro-group (Goodwin 
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et al., 1998; Leitsch et al., 2007). This means that if the NfsA_Ec variant introduced into 
C. sporogenes can also reduce metronidazole the C. sporogenes strain will likely become 
hyper-sensitised to metronidazole treatment - a positive bio-safety control for presentation 
to clinical trial regulatory committees. 
7.2.2 Evolution of NfsA_Ec for improved PR-104A activation  
To decide which NTRs would be integrated in Clostridium we first focused on identifying 
mutants with improved PR-104A metabolism and these were then co-screened for 
retention of activity with HX4. This was done because success of the cancer therapy will 
be intrinsically enhanced by any improvement in the prodrug activating capabilities of the 
NTR, while theoretically imaging will be successful as long as a certain (at this point 
unknown) threshold of NTR activity with HX4 is reached.   
Dr. Janine Copp identified single mutations which could be made to NfsA_Ec to improve 
its metabolism of PR-104A. Beneficial single mutations were found by targeting active 
site residues using site saturation mutagenesis, in a process similar to that described in 
Chapter 5. Additional mutations, at sites not previously modelled as being involved in 
PR-104A binding, were found by screening large random mutation gene libraries 
generated by error-prone PCR and enriching for positive clones through the FACS based 
SOS:GFP system previously described (Section 5.3.1). Improved mutants were identified 
by monitoring for increased SOS response in PR-104A treated E. coli NTR over-
expression strains and by measuring PR-104A IC50s. Ten identified mutations were then 
chosen for inclusion into a synthetically constructed mutant gene library (GenScript, NJ, 
USA) which, through the use of specifically designed redundancy codons, could code for 
all possible 512 combinations of these mutations (Table 7-1).  
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Table 7-1 Single mutations to NfsA_Ec determined by Dr Janine Copp to confer improved 
PR-104A metabolism. 
 
Overall there is little overlap between these ten mutations and those observed in Chapter 
5 to improve 2-NI metabolism, with the one exception being S41Y, which was recovered 
independently in both studies. Thus, it was uncertain whether or not 2-NI metabolism 
would be retained to a substantial degree in NfsA_Ec variants selected for maximal PR-
104A metabolism.  
7.3 Aims 
 Assess the 2-NI metabolism of NfsA_Ec single mutants which show improved 
activity with PR-104A  
 Aid Dr Janine Copp in screening an NfsA_Ec multi-mutant gene library to find 
clones showing improved PR-104A reduction 
 Characterise activity of final selected clones with other drugs of importance, 
principally 2-NI imaging agents.  
7.4 Results 
7.4.1 Evaluation of the activity of wild type NTRs with HX4 
Successful noninvasive imaging of the therapeutic C. sporogenes would require the 
introduced NTR to reduce 
18
F-HX4.  Prior to screening of mutant NTRs the activity of the 
full wild type NTR library with cold HX4 was examined by measuring growth inhibition 
post exposure to 200 µM or 600 µM HX4 (Figure 7-1). Consistent with previously tested 
2-NI compounds the majority of NfsA family members (19/20) showed frank activity 
NfsA_Ec 
Mutation
I5T
S41Y
E99G
L103M
K222E
R225A
R225G
R225P
F227S
L229V
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with the compound. A number of NfsB family enzymes (including NfsB_Ec) also showed 
low levels of activity with the compound.  
To confirm that NfsB_Ec has activity with HX4 the abilities of His6-tagged purified 
NfsA_Ec and NfsB_Ec to reduce HX4 in vitro were measured (Figure 7-2). It can be 
seen that, although substantially less active than NfsA_Ec, NfsB_Ec is far more active 
with HX4 than it is with previously tested 2-NI imaging agents such as EF5.  
 
   
Figure 7-1 HX4 mediated growth inhibition of SOS-R2 E. coli NTR over-expression strains. 
Mid-exponential phase  over-expression strains were challenged in 384 well plate format with 
HX4 at A) 200 µM and B) 600 µM for 4 hours. Growth was measured as culture turbidity (OD600) 
pre and post challenge. Growth inhibition is presented as the percentage decrease in the growth of 
challenged cultures relative to unchallenged controls for each strain. Data are the average of three 
independent experiments ± S.E.M.  
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Figure 7-2 Kinetic parameters for the reduction of HX  by purified His6-tagged NTRs Rate 
of reduction at varying concentrations of HX4 and a fixed concentration of excess NADPH (0.20 
mM) were monitored by decrease in absorbance at 340 nm, rates measured in quadruplicate 
reactions. Apparent Km and kcat derived using Sigmaplot 10.0 (Systat Software Inc., Richmond, 
CA). The extinction coefficient used was19, 000 M
-1 
cm
-1 
for explanation of determination see 
section 2.11.1. 
7.4.2 Metabolism of 2-NI imaging agents by NfsA_Ec single mutants showing 
improved activity with PR-104A 
To assess the effects that the ten identified single mutations favourable for PR-104A 
activation had on 2-NI metabolism, the IC50s with HX4, EF5 and F-miso were determined 
for each of the mutant over-expression (SOS-R2) strains (Figure 7-3). Consistent with 
the results of Chapter 5, the S41Y expression strain was again ~ two fold more sensitised 
to the 2-NIs than NfsA_Ec wild type. This mutation however conferred the only notable 
improvement in activity with EF5 and HX4 - the majority of single-residue mutations had 
little effect or were detrimental, particularly those at site 225 for which up to two fold 
decreases in drug sensitisation were observed. A more uniform activity profile was seen 
with F-miso. However, in no case was 2-NI metabolism completely lost (exact compound 
IC50 values for the SOS-R2 empty plasmid control strain could not be measured due to 
compound solubility limitations, but are > 5 mM; results not shown).  
None of the single mutations were found to completely abrogate HX4 activity, offering 
promise that multi-site mutants selected for improved PR-104A metabolism will retain 
some ability to metabolise HX4.   
 
NTR Compound K m (µM)
a k cat            
(S-1)a
k cat /  Km 
(mM-1 S-1)
NfsA_Ec EF5b 160 ± 10 12.1 ± 0.2 76
HX4 180 ± 25 13.5 ± 0.6 75
NfsB_Ec EF5b 1800 ± 840 0.4 ± 0.1 0.2
HX4 1120 ± 160 29.5 ± 2.4 26
a apparent K m  and k cat  as determined at 0.20 mM NADPH
bparameters previosuly determined for EF5 shown for comparison
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Figure 7-3 2-NI IC50 values of  SOS-R2 E. coli strains over-expressing NfsA_Ec wild type or 
single mutants evolved for improved PR-104A metabolism. Drug dependent growth inhibition 
was monitored by measuring strain turbidity (OD600) pre and post four hour incubation with a 
two-fold dilution series of A) HX4 B) EF5 C) F-miso. Percentage growth relative to unchallenged 
controls was determined and SigmaPlot™ 10.0 used to calculate the IC50. Graphed strains are 
ordered by increasing IC50 , D) Data shown in table format.  Data are the average of three 
independent experiments ± SEM.  
7.4.3 Screening of a multi site NfsA_Ec gene library for mutants exhibiting 
improved PR-104A metabolism 
Generation of an E. coli SOS-R2 pUCX NfsA_Ec multi-site mutant library was 
accomplished and validated in the similar manner to that described in Chapter 5 - with the 
one exception being that degenerate mutant genes were ordered pre-synthesised from 
GenScript rather than being generated by overlap PCR. PCR screening of random 
colonies enabled the gene insert ratio to be estimated at 85%  therefore a library of ~1900 
clones were screened to give 95% coverage of the 512 possible combinations of the ten 
single mutations. Each library plate was first screened with duplicate 10 µM PR-104A 
SOS assays and clones which showed a ≥3 fold higher SOS response than NfsA_Ec wild 
type controls were taken forward for repeat screening with SOS assays using 
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progressively lowered concentrations of PR-104A (results not shown). Ultimately 
improved metabolism was confirmed by PR-104A IC50 assay with results for the ten most 
improved clones shown in Figure 7-4.  
        
Figure 7-4 PR-104A IC50 values of SOS-R2 E. coli strains over-expressing mutants identified 
as showing improved PR-104A activation. IC50 values determined as previously described. 
Strains are graphed by increasing IC50 and also presented in inset table. Data are the average of 
three independent experiments ± SEM. The IC50 value for the SOS-R2 empty plasmid control 
could be determined at readily achievable concentrations of PR-104A and as such is included. 
Note: while I aided with construction and initial screening of the multi-site mutant library the 
experiment in this figure was carried out by Dr. Janine Copp. 
 
The majority of the multi-site mutants only conferred slightly greater PR-104A 
sensitisation than the single mutation S41Y. The one exception was the clone #22, which 
with an IC50 of 60 µM showed an 8.3 fold increase in sensitisation compared to NfsA_Ec 
wild type and a 5.0 fold increase compared to S41Y.  
The DNA sequence of each of these ten clones was determined (Table 7-2). All 
contained two to five mutations. Some mutations were highly represented - for example, 
all clones contained the S41Y mutation, 8/10 the F227S and 9/10 showed mutations at 
Arg225. In contrast the mutation L229V did not appear at all, E99G was present only 
once and K222E twice. 
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Empty plasmid 1340 ± 1 -
NfsA EC 498 ± 23 -
S41Y 302 ± 43 1.6
# 14 245 ± 21 2.0
# 17 252 ± 3 2.0
# 22 60 ± 11 8.3
# 28 242 ± 6 2.1
# 33 247 ± 15 2.0
# 40 220 ± 23 2.3
# 41 249 ± 7 2.0
# 42 266 ± 52 1.9
# 43 260 ± 26 1.9
# 44 274 ± 20 1.8
Fold increase in 
sensitisation1 
PR-104A
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Table 7-2 Amino acid residue changes found in NfsA_Ec mutants exhibiting improved PR-
104A metabolism as seen in Figure 7-4 
7.4.4 Reduction of PR-104A by His6-tagged purified proteins   
 The ten NfsA_Ec multi-site mutants were purified as His6-tagged proteins as previously 
described and where possible apparent kinetic parameters with PR-104A were 
determined. As can be seen in Table 7-3 the trend of enzymes which are highly active in 
vivo showing lower apparent kcat but also substantially lower apparent Km values was 
again seen.   
                                 
Table 7-3 Kinetic parameters of reduction of PR-104A by purified His6-tagged NTRs Rate 
of reduction at varying PR-104A concentrations monitored by decrease in absorbance at 400 nm 
and measured in quadruplicate reactions. Apparent Km and kcat derived using Sigmaplot 10.0 
(Systat Software Inc., Richmond, CA). Where Km PR-104A extinction coefficient = 6000 M
-1 
cm
-1 
(Prosser et al., 2013) (note: kinetic assays with PR-104A conducted by Dr Janine Copp) 
Mutants Sequence I5T S41Y E99G L103M K222E R225A R225G R225P F227S L229V
# 14 I5T/S41Y/L103M/K222E/F227S     
# 17 I5T/S41Y/R225P/F227S    
# 22 S41Y/E99G/L103M/R225G/F227S     
# 28 I5T/S41Y/L103M/R225G/F227S     
# 33 S41Y/L103M/R225A/F227S    
# 40 I5T/S41Y/K222E/R225A    
# 41 S41Y/R225A/F227S   
# 42 S41Y/L103M/R225G/F227S    
# 43 I5T/S41Y/R225A/F227S    
# 44 S41Y/R225A  
k cat /K m                 
(mM-1 s-1)
NfsA_Ec 91 ± 17 8.4 ± 0.62 92
S41Y 32 ± 4 0.96 ± 0.04 30
# 14 < 5b 0.19 ± 0.05 NDc
# 17 7 ± 1 0.35 ± 0.12 54
# 22 < 5b 0.22 ± 0.03 NDc
# 28 < 5b 0.52 ± 0.04 NDc
# 33 < 5b 0.63 ± 0.02 NDc
# 40 < 5b 0.2 ± 0.06 NDc
# 41 < 5b 0.18 ± 0.05 NDc
# 42 < 5b 0.64 ± 0.02 NDc
# 43 < 5
b
0.34 ± 0.07 NDc
# 44 < 5
b
0.58 ± 0.02 NDc
a apparent K m  and k cat  as determined at 0.20 mM NADPH
K m 
(µM)a
k cat  (s
-1)a
b 5 µM of PR-104A was lowest concentration at which 
initial rate of reaction could be accurately determined
cNot determined as apparent K m could not be accurately 
determined
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7.4.5 2-NI metabolism of multi site NfsA_Ec mutants selected for improved 
PR-104A activity  
The 2-NI metabolism of these ten multi site mutants was measured by determining IC50 
values for HX4, EF5 and F-miso (Figure 7-5). Surprisingly (given the number of single-
residue mutations observed to diminish 2-NI activity; Figure 7-3) all multi mutant strains 
showed an unchanged or greater sensitisation to these compounds than wild type 
NfsA_Ec. 
 
            
 
Figure 7-5 2-NI IC50 values of  SOS-R2 E. coli strains over-expressing NfsA_Ec wild type or 
mutants evolved for improved PR-104A metabolism. IC50 values were determined as 
previously described for A) HX4 B) EF5 C) F-miso. Graphed strains are ordered by increasing 
IC50.  D) IC50s shown in table format.  Data are the average of three independent experiments ± 
SEM. 
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F-miso
HX4 EF5
A) B)
C) D)
HX4 EF5 F-miso
NfsA EC 186 ± 3 120 ± 5 94 ± 21 - - -
S41Y 93 ± 13 60 ±1 41 ± 8 2.0 2.0 2.3
# 14 112 ± 17 81 ± 3 61 ± 11 1.7 1.5 1.5
# 17 163 ± 18 113 ± 1 60 ± 9 1.1 1.1 1.6
# 22 76 ± 5 79 ± 9 53 ± 6 2.5 1.5 1.8
# 28 127 ± 5 101 ± 14 67 ± 11 1.5 1.2 1.4
# 33 125 ± 18 88 ± 1 59 ± 5 1.5 1.4 1.6
# 40 97 ± 3 79 ± 2 61 ± 5 1.9 1.5 1.5
# 41 79 ± 10 78 ± 3 55 ± 13 2.3 1.5 1.7
# 42 96 ± 2 114 ± 14 66 ± 8 1.9 1.1 1.4
# 43 85 ± 14 77 ± 4 53 ± 1 2.2 1.6 1.8
# 44 99 ± 21 85 ± 10 59 ± 8 1.9 1.4 1.6
Fold increase in sensitisation 1 
HX4
EF5
F-miso
1 Derived by dividing IC50 value on NfsA_Ec expression by the  IC50 seen 
on expression of the improved mutant
IC50 (µM )
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7.4.6 Metabolism of CB1954 and metronidazole by multi site NfsA_Ec 
mutants selected for improved PR-104A activity  
The ability of the multi site mutants to metabolise the prototypical prodrug CB1954 was 
assessed by IC50 assay (Figure 7-6A). The CB1954 sensitisation conferred by the mutants 
varied widely, with the most sensitised mutant strain (#17- 87 µM) having a 15 fold lower 
IC50 than the least (#22- 1320 µM). Compared to NfsA_Ec wild type only #17 was 
improved. Activity with metronidazole, the 5-NI antibiotic intended for use as a bio-
safety control, was also assessed (Figure 7-6B).  Clone #17 was again improved 
compared to NfsA_Ec, this time showing a 12 fold lowered IC50 – a fold increase in 
sensitisation actually larger than that seen for this strain on PR-104A treatment. The other 
mutants showed more moderate improvements, with the exception of #22 which had 
again lost activity. It should be noted that while #22 strain shows decreased sensitisation 
to these substrates the NTR is still metabolising them - the SOS-R2 pUCX empty strain 
has an IC50 of > 5 mM for both metronidazole and CB1954 (results not shown).  
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Figure 7-6 A) CB1954 and B) metronidazole IC50 values of  SOS-R2 E. coli strains over-
expressing NfsA_Ec wild type or mutants evolved for improved PR-104A metabolism. IC50 
values were determined as previously described and graphed in order of increasing IC50. IC50s also 
shown inset in table format.  Data are the average of three independent experiments ± SEM. 
7.5 Discussion 
Our overall aim with this work is to progress the clinical use of bacterial nitroreductase 
enzymes in the treatment of cancer. The multi institution collaboration established 
represents the first time in which the activity of our NTRs will be assessed in a clinically 
applicable delivery vector - with the added possibility of advancing to clinical trial. Given 
this opportunity we wished to provide an NTR with the greatest possible activity with our 
lead prodrug candidate PR-104A. As noninvasive imaging of the recombinant Clostridia 
by microPET will be attempted we also determined activity of our selected NTRs with 
HX4 (the PET probe preferred by our collaborators) and the additional 2-NI imaging 
agents EF5 and F-miso.  
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7.5.1 Selection of the NfsA_Ec variants to be introduced into C. sporogenes  
Prior to the work described in this chapter Dr. Janine Copp had identified ten mutations 
which, when introduced individually into NfsA_Ec, improved metabolism of PR-104A on 
over-expression in E. coli. To search for multi-site mutants showing further improvement 
we screened, using PR-104A SOS and IC50 assays, a gene library encompassing 
sequences with all possible combinations of these ten single mutations. Subsequent to this 
the ability of the most improved multi-site mutants to sensitise E. coli to 2-NI imaging 
agents, to the DNA damaging prodrug CB1954, and to the antibiotic metronidazole was 
determined.  
Based on these results NfsA_Ec, S41Y, and the multi-site mutants #22 and #17 were 
selected for testing in C. sporogenes and the recombination based introduction of these 
genes into the bacterium has recently been completed. The NTRs chosen represent the 
wild type enzyme, both the single (S41Y) and multi-site mutant (#22)  conferring the 
greatest sensitisation to PR-104A and the multi-site mutant showing the greatest CB1954 
and metronidazole sensitisation (#17).  
7.5.2 MicroPET imaging of Clostridium expressing NfsA_Ec variants 
We are at this point unsure what level of NfsA_Ec activity with 
18
F-HX4 will be required 
for in vivo microPET imaging of recombinant Clostridia. However it is reassuring that 
none of the NfsA_Ec multi-site mutants have lost activity with HX4 and many show a 
moderate improvement in metabolism. This is the case even though these multi-site 
mutants contain residue changes which, when present singly, were found to be 
detrimental to 2-NI activity. However the S41Y mutation was found in all multi-site 
mutants with improved PR1-04A metabolism identified in this chapter and, as S41Y is 
also the only single mutation which clearly improved HX4 metabolism, this suggests that 
it is acting as a dominant mutation in regard to 2-NI metabolism. Alongside the mutants 
presented in this chapter, introduction into C. sporogenes of the mutant 1_56, (which 
shows improved HX4 metabolism as seen in Chapter 5), has been attempted but as yet 
these efforts have been unsuccessful. Even if this strain is not completed in the required 
time-frame for inclusion in microPET 
18
F-HX4 studies, the results from attempted 
imaging of the remaining C. sporogenes-NTR strains will provide valuable data for our 
long term goal of developing noninvasive imaging of bacterial NTRs.  
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In passing it is noted that NfsB_Ec shows a moderate metabolism of HX4, a feature not 
seen when this NTR was tested with other 2-NI imaging agents. In subsequent microPET 
studies it may also be worthwhile to attempt to image NfsB_Ec with 
18
F-HX4. If 
successful, this could provide a means of leveraging the 20+ years of development of 
NfsB_Ec as an enzyme for GDEPT, without the need to develop novel chemical matter as 
per Chapter 6. 
7.5.3 Comparison of the NfsA_Ec variants abilities to metabolise PR-104A 
and CB1954 
Further examination of the mutant proteins generated during this study might provide 
useful information about active site confirmations that promote favourable NfsA_Ec –PR-
104A interactions. While a number of multi-site mutant strains showed improved 
metabolism of PR-104A, #22 was substantially more sensitive to PR-104A than all other 
strains. This apparent increase in metabolism is dependent on the inclusion of the E99G 
mutation, as can be seen by comparing the activities of #22 and the otherwise identical 
#42 (Figure 7-7). Conversely the changes in the active site brought about by this 
mutation were found to substantially impede CB1954 metabolism (section 7.4.6).   
 
         
Figure 7-7 Heat map representation of activities of NfsA_Ec multi site mutants with DNA 
damaging prodrugs PR-104A and CB1954, 2-NI imaging agent HX4 and 5-NI antibiotic 
metronidazole. Individual mutations present in each protein are indicated to the left. Data shown 
to the right is fold increase in sensitisation, compared to NfsA_Ec wild type, derived from 
dividing compound IC50 value for NfsA_Ec wild type over-expression strain by the IC50 seen on 
mutant over-expression.  Values colour coded in activity groups of 0.1- 0.8, 0.9 –1.1, 1.2-2.0, 2.1 
–4.0, > 4.0.  
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# 40    A 2.3 0.5 1.9 2.5
# 41  A  2.9 0.1 2.3 1.8
# 42   G  1.9 0.9 1.9 2.7
# 43   A  1.9 0.2 2.2 1.8
# 44  A 1.8 0.7 1.9 2.5
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The entirely differing effects of the various mutations in promoting CB1954 vs. PR-104A 
metabolism suggest that, even though the two drugs share a common dinitrobenzamide 
core, their requirements for favourable active site binding are very different. A solved X-
ray crystal structure of NfsA_Ec variant #22 would be highly beneficial to elucidating the 
different binding modes of PR-104A and CB1954 in the multi-site mutant binding modes 
and would provide information for further evolution studies. However, although efforts to 
crystallise #22 have been initiated, these efforts have as yet been unsuccessful 
(Christopher Squire, personal communication).  
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Chapter 8: Key findings, conclusions and future directions 
8.1 Research motivation 
The research described in this thesis was part of a multidisciplinary collaboration aimed 
at developing nitroreductase GDEPT, an experimental targeted anti-cancer treatment. My 
project focused on screening and engineering bacterial NTRs with a long-term aim of 
developing the capability to noninvasively image the location and levels of therapeutic 
NTR expression in a clinical setting. Notable clinical success of the NTR/GDEPT 
strategy has yet to be demonstrated but previous research has predominantly used the 
enzyme/prodrug pair of NfsB from E. coli and the nitroaromatic prodrug CB1954. In 
contrast, we and our close collaborators at the ACSRC aim to improve this treatment by 
the use of more potent prodrugs – most immediately, the dinitrobenzamide mustard PR-
104. In parallel we have sought to identify superior enzymes for GDEPT by using E. coli 
over-expression libraries to assay for NTRs better able to activate prodrugs and PET 
probes. Reduction of these probes could enable PET based noninvasive imaging of NTR 
expression. It is well recognised that this capability would be extremely advantageous to 
preclinical and clinical development of NTR cancer gene therapy (Baril et al., 2010; 
Bhaumik et al., 2011; Rojas and Thorne, 2012) but prior to this work no such ability for 
bacterial NTRs has been described.    
8.2 Key findings 
While no PET suitable reporter probes have previously been described for bacterial 
NTRs, there do exist a number of 2-NI PET probes developed independently to enable 
clinical imaging of hypoxia. In the first chapter of this thesis it was shown that, of 11 
diverse E. coli oxidoreductase enzymes, only NfsA could reduce the 2-NI hypoxia 
imaging agents pimonidazole, F-miso, EF3 and EF5.  In contrast NfsB_Ec showed little 
to no ability to reduce 2-NI compounds. NfsA_Ec activity was detected in screens 
monitoring sensitisation of the E. coli over-expression host to 2-NI compounds, as well as 
a colourimetric assay monitoring 2-NI activity dependent depletion of NADPH by E. coli 
cell lysates. Importantly our collaborators went on to show that expression of NfsA_Ec in 
human cells can be detected in vitro and in vivo by using antibodies to detect the 
NfsA_Ec catalysed binding of EF5.   
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When a larger collection of NTR candidates sourced from different bacteria was 
examined, 2-NI reduction was found to generally be a property of only the NfsA 
homologues, although some more distantly related NfsB_Ec homologues showed a 
moderate ability to metabolise F-miso and HX4. Surprisingly, the activities of individual 
NfsAs as measured by either growth inhibition (IC50) or NADPH depletion assays 
showed little correlation. Evaluation of kinetic parameters for the reduction of EF5 by a 
number of purified NfsA enzymes suggested that this discrepancy may be due to each 
assay emphasising a different parameter of enzymatic activity, i.e. the results of the 
NADPH depletion assay showed good correlation with the enzymes’ apparent kcat but not 
the apparent Km; while the opposite scenario was observed for the growth inhibition 
assays.  
To improve NTR activation of 2-NI PET probes, NfsA_Ec was selected for directed 
evolution by site saturation mutagenesis, targeting 12 residues surrounding the NfsA_Ec 
active site. In total, 31 different single mutations were identified that improved F-miso 
and/or EF5 metabolism. Ten of these were combined in a degenerate gene library and 
screened to recover variants containing additive or synergistic combinations of these 
mutations. Eight individual multi-mutant sequences were identified that, when expressed 
in E. coli, conferred a 3.2 – 4.8 fold increased sensitisation to EF5, F-miso, and HX4 
compared to NfsA_Ec wild type. The triple mutation motif S41X/L103V/N134A (where 
X indicates either Cys or Tyr) was strongly represented in these eight variants. From a 
model of the S41Y single mutation variant and preliminary x-ray crystallography data 
generated by a collaborator it appears that the S41Y substitution may favour binding of 
aromatic substrates by promoting stacking of the substrate between the FMN cofactor and 
the aromatic side chain of tyrosine. Disappointingly, no improvements in EF5 metabolism 
by HCT-116 cells expressing any of these variants were observed relative to cells 
expressing wild type NfsA_Ec, although decreased expression of the mutant NfsA_Ec 
variants and/or technical limitations of the assay may have contributed to this outcome. 
As an alternative strategy to improve the sensitivity of NTR PET imaging, our 
collaborators designed and synthesised a 5-NI analogue of EF5, named SN33623. 
Experiments to date (with my involvement) have indicated that SN33623 is substantially 
less responsive to hypoxia than EF5. Screening of a wide range of NTR candidates 
revealed that a subset of NfsB enzymes could readily metabolise this compound but that 
this subset did not include NfsB_Ec. Sequence alignment and site-directed mutagenesis 
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were then used to ultimately identify two key mutations (F70A and F108Y) that can be 
introduced into either NfsB_Ec wild type or previously evolved NfsB_Ec variants to 
confer high levels of SN33623 activity. These variants were also shown to metabolise 
SN33623 (unlike wild type NfsB_Ec) when expressed in HCT-116, though for some 
variants this activity was only evident immediately following NTR transfection, with a 
loss of function observed following long term expression from HCT-116. 
In a final aspect of this study a collaborative directed evolution study was conducted to 
improve PR-104A metabolism by NfsA_Ec while retaining 2-NI metabolism. SOS assay 
screening of a multi-site NfsA_Ec mutant library was conducted to identify variants with 
improved PR-104A metabolism, followed by counter-screening for metabolism of other 
clinically relevant nitroaromatic compounds. Importantly, all mutants were found to 
retain 2-NI metabolism, most likely due to the presence of a dominant S41Y mutation in 
all selected variants. On the basis of activity with (primarily) PR-104A and (secondarily) 
HX4, CB1954 and metronidazole, four promising NfsA_Ec variants were chosen for 
future evaluation in C. sporogenes, targeting human clinical trials.  
8.3 Critical evaluation of the E. coli screens used in this study 
Laboratory strains of E. coli are well studied, fast to grow and highly tractable to genetic 
modification. These and other features underpin the widespread use of E. coli as a protein 
expression system and screening tool in directed evolution studies. However, a critical 
question for this study is whether this screening of NTR catalysed 2-NI growth inhibition 
in E. coli is genuinely predictive of the ability of an NTR to act as a reporter gene in a 
preclinical or clinical context. At the broadest level, it appears that E. coli growth 
inhibition can accurately predict complete absence or presence of imaging agent 
metabolism by HCT-116:ntr strains. This approach accurately identified NfsA_Ec as the 
only one of 11 diverse enzymes capable of metabolising EF5 and also predicted the 
ability of strains of HCT-116:NfsB_Ec and various NfsB_Ec variants to metabolise 
SN33623 (albeit in some cases only upon transient NTR expression). However, we do not 
know the extent to which the E. coli based screening successfully reports on incremental 
degrees of activities with either imaging agents or prodrugs, nor to what extent 
improvements in NTR catalytic activity measured using these screens will carry over to a 
clinical setting - critical points for evaluating the use of E. coli for directed evolution to 
improve such activities.  
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8.3.1 Variations in bacterial NTR expression levels from human cells 
Our collaboration had aimed to assess the validity of the E. coli based screens in vitro and 
in vivo preclinical models of stably transfected HCT-116 cell lines, however accurate 
determination of bacterial NTR activity was confounded by the unpredictable and varying 
levels of functional NTR expression observed. Particularly problematic was that the 
expression and/or activity of some NTRs was found to diminish over time.  
Reasons for the heterogeneous expression of different NTRs, introduced in some cases by 
a single amino acid change, are unknown. One possibility is that the NTRs showing 
problematic expression catalyse metabolic activities that are cytotoxic to human cells, 
such that functional expression of these NTRs is selected against over time. This 
hypothesis could be tested by PCR amplifying and sequencing F279-V5:ntr plasmids 
from cell lines that have lost functional NTR expression over several weeks in culture, to 
determine if the NTR or plasmid regions have developed mutations that are diminishing 
expression of functional NTRs. Investigating whether certain NTRs are indeed perturbing 
HCT-116 metabolism and if so, what cellular processes they are interfering with, would 
be a much more extensive project; but could perhaps be attempted by metabolomic 
studies in which chromatography-mass spectrometry technologies were applied to 
compare the metabolite profiles from wild type HCT-116 versus cells expressing different 
NTRs that are tolerated to various degrees (Bennett et al., 2009). It should be noted that 
other explanations are also possible, for example some unidentified protein level 
instability for which protein thermostability is a poor surrogate measure, or that the 
observed variable NTR expression is a consequence of multiple different factors (which 
could complicate any study to determine the exact underlying reason(s) for this issue).   
It is important to reiterate that most vectors for GDEPT would not be expected to mimic a 
stable transfection / expression scenario, and that our findings emphasise the need to 
evaluate selected NTRs in the context of their intended clinical vector. Our collaboration 
will in the near future be able to assess the expression and activity of a number of 
NfsA_Ec variants in Clostridium, and we hope that this bacterial vector will allow for 
NTR expression more similar to that seen from E. coli rather than the problematic HCT-
116 expression. In the future we hope to also progress testing of a selection of NTRs in 
different viral vectors, either through developing further collaborations or through use of 
viruses which are already available to us (e.g. ONYX-411; Singleton et al., 2007). 
Assessing functional NTR expression across a range of the most clinically relevant 
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vectors will enable us  to evaluate the validity of our E. coli based directed evolution and 
to determine if the currently observed variable NTR expression levels are indicative of a 
greater problem.  
8.3.2 Purified protein activities of evolved NTR variants  
To assess whether our mutant NTRs generated via E. coli based directed evolution studies 
were truly improved in ability to catalyse the targeted reactions, we examined activity at a 
purified protein level – however, our results were not clear cut. In multiple different 
directed evolution projects conducted in our laboratory (FRaseI activation of CB1954 
(Swe et al., 2012) and NfsA_Ec activation of EF5 or PR-104A (this study)) many NTR 
variants selected for increased ability to sensitise E. coli to these compounds counter-
intuitively had, when tested as purified proteins, decreased specificity constants for the 
respective reactions. The apparent Km values for the selected mutants were near 
universally decreased, consistent with improved enzymatic activity; but because the 
apparent kcat values were also decreased (in some cases dramatically) this frequently led 
to a net reduction in specificity constant. As previously discussed, the specificity constant  
kcat/Km can be a poor measure of the relative activities of different enzymes, and these 
kinetic parameters could indicate that the mutants have improved activities with the target 
substrates at very low concentrations, with discovery of such mutants having been 
favoured in the SOS assay. However an alternative possibility is that the mutants confer 
increased in vivo sensitisation to these compounds because they have lost ability to 
metabolise endogenous E. coli substrates that perhaps otherwise compete with the 
prodrug/imaging agent for the NTR active site. This possibility is not without precedent, 
for example the role that competing thymidine metabolism has on modulating HSV1-TK 
phosphorylation of xenobiotic prodrugs and imaging agents is well recognised (Gambhir 
et al., 2000; Kokoris and Black, 2002). In one example, a mutant of HSV1-TK that 
conferred greater in vivo GCV sensitisation than wild type actually had (at a purified 
protein level) a 40 fold decrease in specificity constant for GCV (with both an increased 
Km and a decreased kcat) but also a 3000 fold lowered specificity constant with the 
competing thymidine substrate (Kokoris et al., 1999).   
Deconvolution of the effects that competing endogenous metabolites may have on 
activity of NTRs expressed in E. coli would be difficult as, in contrast to the identified 
thymidine substrate of HSV1-TK, the exact identity of potential competing endogenous 
substrate(s) is unknown and NTRs are known to be promiscuous enzymes (Gonzalez et 
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al., 2005; Roldán et al., 2008; Zenno et al., 1996). Quinones are obvious candidates and 
we could possibly assess the relative abilities of purified NfsA_Ec variants and NfsA_Ec 
wild type to reduce a number of commercially available quinones that are known to 
naturally occur in E. coli (Shestopalov et al., 1997). However such a strategy is not ideal, 
as negative results would not rule out the competing metabolite theory but could simply 
indicate that we were not testing the major competing substrate(s). An alternative strategy 
could be to investigate whether it is possible to inhibit the ability of purified wild type 
NfsA_Ec to reduce PR-104A (a substrate whose reduction can be directly monitored for 
by light absorbance at 400 nm) by co-incubating this reaction mix with E. coli cell lysate. 
If cell lysate is able to act as a competitive inhibitor of purified NfsA_Ec reduction of PR-
104A it should then be possible to determine if cell lysate is less able to inhibit the 
NfsA_Ec variants that slowly reduce PR-104A in vitro but show high PR-104A 
metabolism on expression in E. coli.  
If increases in NTR metabolism of prodrug/imaging agents are being driven not by direct 
improvements to the reaction, but by a reduction in the ability to metabolise competing 
substrates, then this could greatly complicate the use of E. coli based screening for 
directed evolution studies as “improved” catalytic activity would heavily dependent on 
the chemical milieu of the cell in which the NTR is expressed and this could vary widely 
and unpredictably between E. coli and various cancerous cellular environments. This may 
prove to be less problematic for therapies in which the NTR is expressed from a bacterial 
vector such as Clostridium or Salmonella as these may show a more similar chemical 
environment to E. coli. Our ongoing trials in C. sporogenes may shed some light on this 
issue. 
 If in these or other studies it becomes apparent that our “improved” variants are actually 
less efficient than the wild type enzyme, i.e. that the greatly reduced apparent kcat values 
for prodrug/imaging agent reduction do lead to reduced NTR activity in therapeutically 
relevant expression systems, it may be worthwhile to use the NADPH depletion assay as 
a screen for directed evolution projects. In this screen the NTR would be exposed to 
significantly more prodrug/imaging agent than to cellular (potentially competing) 
metabolites, which should reduce the ability of these metabolites to impact on 
prodrug/imaging agent reduction.  
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8.3.2.1 Additional points to consider in assessment of the kinetic assays 
Another possibility that should be briefly investigated is if the NfsA_Ec variants showing 
low apparent kcat values for prodrug/imaging agent reduction are being evaluated in a 
fully active form. NfsA_Ec is active as a homodimer, and it may be possible that some of 
the NTR mutations are weakening the dimeric stability. It has been reported that in 
Frp_Vh (a NfsA homologue with strong structural similarity to NfsA_Ec (Kobori et al., 
2001)) substituting the Glu99 residue for Lys leads to extreme dimer destabilisation and 
greatly lowered in vitro activity (Jawanda et al., 2008). This hypothesis would require that 
the effects of dimer destabilisation primarily occur in the in vitro (and not in vivo) setting. 
While I do not consider this to be particularly likely, I note that Glu99 is one of the 
NfsA_Ec sites at which mutation led to a markedly slower kcat value for PR-104A 
reduction, and the mutated residue Arg255 also sits right at the dimer interface, 
suggesting that it may yet be worthwhile assessing the dimer-monomer equilibriums of a 
sample of NfsA_Ec variants by size exclusion chromatography (Jawanda et al., 2008).   
Finally it should be noted that we have not investigated any potential effects that 
mutations may have had on the NTR interactions with the electron donors NADPH and 
NADH. All purified protein reactions were carried out at high (presumably well in 
excess) concentrations of NADPH, and activities over a range of NAD(P)H 
concentrations could be assessed to determine if changes to these parameters could 
explain the relative activities of the NfsA_Ec variants in vivo.  
8.3.3 Summary 
We cannot draw strong conclusions about the validity of our E. coli based directed 
evolution screening without having tested these NTRs in preclinical models that better 
approximate the desired therapeutic application of these enzymes. We cannot currently 
rule out that activity of our improved NTR variants may be context-dependent, modulated 
by competing E. coli cell metabolites. We also do not yet know if variable NTR 
expression from clinically relevant vectors will occur. It should be noted however that 
others using E. coli to screen for improved NfsB_Ec mutants have recovered variants that 
increase prodrug-mediated cytotoxicity in human cells (Grove et al., 2003; Guise et al., 
2007; Jaberipour et al., 2010). Most relevant to this study are the two NfsB_Ec mutants 
(T41l/N71S and T41L/F70A) generated by Peter Searle’s research group, which on NTR 
delivery to SKOV13 cancer cells (via a replication defective adenoviral vector) provided 
significantly better CB1954 sensitisation than NfsB_Ec wild type both in vitro and in vivo 
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(Jaberipour et al., 2010). It is reassuring for the validity of our own E. coli based 
screening systems that these improved mutants, when tested in this study, yielded a lower 
E. coli CB1954 IC50 relative to NfsB_Ec wild-type. However consideration should be 
given to the fact that these particular mutants were identified through an E. coli screen 
using high (lethal) concentrations of CB1954 (in comparison to the low sub lethal 
concentrations used in the SOS assay) and reportedly possess a decreased CB1954 Km, 
but similar kcat, to wild type NfsB_Ec (Jarrom et al., 2009).  
8.4 Further possible directed evolution studies  
Should the testing of NTR activity in clinically relevant vectors indicate that overall our 
current E. coli based screening strategies are valid, but that further improvement in 
imaging agent metabolism would be desirable, there would be a number of ways to 
pursue this. This thesis presented initial work testing the feasibility of screening large 
libraries for 2-NI improvement using a FACS based enrichment strategy. While some 
enrichment for active clones was seen, future use of this technique would depend on an 
exact determination of the enrichment ratio, how consistent this is and whether it can be 
improved. Firstly we will need to conclusively determine whether the cells that we want 
to select (i.e. those that are expressing active NTRs and therefore experiencing the highest 
levels of DNA damage and GFP upregulation), are less able to survive the FACS process 
than those expressing inactive NTRs. The most straightforward way of doing this would 
be to compare colony survival ratios of NfsA_Ec populations which have been exposed to 
titrated RB6145 concentrations and then subjected to FACS sorting and collection based 
on an arbitrary gate with no GFP selection pressure. If a detrimental effect is seen at 
desirable RB6145 concentrations, it should next be assessed if PCR rescue is able to 
efficiently rescue the DNA sequences of highly GFP expressing cells. Also worthwhile 
would be examining if the currently observed 5-fold enrichment for GFP positive cells 
changes if initial starting concentrations of GFP positive versus GFP negative cells are 
lower (e.g. a 1:99, or 1:999 positive to negative ratio, rather than the 1:9 previously 
tested), as low concentrations of GFP positive cells are more likely to reflect the situation 
in mutant libraries.  
A parallel or alternative approach would be to build on the increased 2-NI metabolism 
already shown by the multi-site mutants such as S41X/L103V/N134A. This could be 
done by using these gene sequences as templates for site saturation mutagenesis of other 
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active site residues, in particular targeting residues such as Phe42, Cys45 or Phe83 at 
which multiple amino acid changes were previously observed to improve NfsA_Ec wild 
type activity. Depending on the success of the FACS approach we could also pursue 
improving these mutants further by mutations outside of the active site through screening 
of random mutagenesis libraries generated by error-prone PCR.  
8.5 Research applications 
8.5.1 The use of diverse NTRs in GDEPT 
Our discovery of novel wild type and engineered NTRs for GDEPT applications removes 
the requirement for all prodrugs or imaging agents to be efficient substrates of NfsB_Ec.  
Appropriate chemical selection for a GDEPT therapy already requires simultaneous 
consideration of many important factors such as previous clinical testing, potential off-
target toxicity, bystander potential, and pharmacokinetic availability. Essentially drug 
design for GDEPT requires balancing many potentially competing features and it would 
be advantageous to be able to focus solely on optimising the chemical criteria, without 
having to also add on the additional selection pressure of picking the best substrate for a 
single enzyme target. A particularly apparent example of the benefit of screening a wide 
range of NTRs is that NfsB_Ec does not reduce any of the clinical 2-NI imaging agents 
(EF5, EF3, F-miso and Pimo) which we intially assessed it against.   
It should be noted that mutant NTRs arising from 2-NI evolution studies will not 
necessarily prove optimal for enzyme prodrug therapy, as residue changes that aid 2-NI 
metabolism will not necessarily improve prodrug metabolism and could quite possibly 
impede it. Nonetheless, it is promising that the NfsA_Ec multi-site mutants selected in 
this study for improved 2-NI metabolism retained or slightly improved PR-104A 
metabolism (Chapter 5), and vice versa for variants selected primarily for improved PR-
104A reduction (Chapter 7). 2-NI directed evolution efforts may also provide valuable 
information about how to engineer in imaging agent activation to NTRs with high 
prodrug activity, analogous to the manner in which SN33623 metabolism was engineered 
into CB1954 improved NfsB_Ec variants (Chapter 6). Additionally, 2-NI evolved NTRs 
could also be useful in preclinical development of GDEPT as testing their 2-NI 
metabolism in a microPET setting would enable us to determine the threshold level of 
bacterial NTR/2-NI activity required for accurate and sensitive PET imaging. 
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8.5.2 Noninvasive PET imaging of NTR based therapy 
Collaborators at the University of Maastricht are in the very early stages of assessing 
whether tumour xenografts stably expressing NfsA_Ec can be noninvasively imaged 
using 
18
F–HX4 microPET. This will provide a valuable initial indication of whether 2-NI 
hypoxia imaging agents can be successfully repurposed as noninvasive reporter probes to 
detect NTR-labelled cells. In a more clinically relevant context, another series of 
experiments will also be carried out to determine if a Clostridium tumour seeking strain 
expressing NfsA_Ec variants can also be tracked in vivo using 
18
F-HX4. Studies of these 
Clostridium strains will also assess the tumour response to prodrugs such as PR-104A. 
We are not yet certain that the NTRs we have generated from this directed evolution work 
are truly improved in the tumour environment, and on this point the intended inclusion in 
trials of Clostridium expressing NfsA_Ec wild type (which shows good purified protein 
activity and stable functional expression from HCT-116) is reassuring. An additional 
point of interest will be whether endogenous Clostridium NTRs are also able to reduce 
18
F-HX4 to a cell entrapped form. C. sporogenes has an NfsA_Ec homologue (19% 
amino acid identity and 34% similarity identified via blastP search) and C. sporogenes are 
sensitive to the 2-NI anti-parasitic prodrug benznidazole (Hof, 1989), which suggests that 
there is potential for some level of endogenous 2-NI reduction to occur. If 
18
F-HX4 
reduction due to C. sporogenes NTRs does occur to a level sufficient to be detected by 
PET, this could actually prove beneficial for the in vivo tracking of the Clostridium as it 
may increase the total 
18
F-HX4 Clostridium signal.  
8.5.3 The potential use of bacterial NTRs as vector reporter genes 
independent of GDEPT 
At this very early point in assessment of NTR/2-NI microPET imaging we cannot make 
predictions about the possible efficacy of this reporter gene/probe pair as compared to the 
clinically tested hNIS/
99m
Tc SPECT and HSV1-TK based PET imaging. However if it 
does prove to offer at least comparable sensitivity and accuracy to existing modalities, 
there are reasons to think there would be a place for this reporter/gene pair for imaging in 
a wider context. For example, it is likely that the addition of HSV1-tk for imaging 
purposes would be inappropriate for certain specific oncolytic viruses such as JX-594 
(Parato et al., 2011) and others in various stages of clinical and preclinical development 
(Haddad et al., 2012; McCart et al., 2004; Thorne et al., 2007; Zhang et al., 2007) where  
a portion of the viral tumour specificity is due to the deletion of its endogenous thymidine 
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kinase. In regards to hNIS, its endogenous expression in the stomach, bladder and thyroid 
means hNIS is not suited as a reporter gene for vectors directed towards these areas 
(Barton et al., 2003). In addition NTRs (~700 bp) are nearly four times smaller than hNIS 
(Barton et al., 2003), which could make NTRs more appropriate for insertion into the 
backbones of viruses with defined packaging limits, particularly in situations where some 
of the viral insert capacity is already taken up by expression of other therapeutic genes or 
reporter genes for optical imaging (Penheiter et al., 2012).  
8.6 Concluding remarks 
It is promising for our long-term goal of developing NTR based GDEPT that the NfsA 
family can efficiently metabolise PET-suitable imaging agents already in clinical use, and 
in the very near future our multi-disciplinary collaboration will be able to assess if this 
activity is sufficient to allow noninvasive microPET imaging of NfsA_Ec expression. 
Furthermore this thesis demonstrates that with enzyme engineering techniques and E. coli 
based screening we can successfully increase the abilities of NTRs to sensitise their E. 
coli over-expression host to multiple imaging agents and prodrugs. Determining the wider 
validity of our E. coli based screens has been challenging, but the recently completed 
generation of C. sporogenes spores expressing our NTRs will soon allow for an exciting 
assessment of both the therapeutic efficacy and noninvasive imaging capabilities of a 
number of our NfsA_Ec variants in a clinically relevant bacterial vector model.   
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Appendix 1: 
NfsA_Ck 
MTPTIDLIRGHRSIRHFTDEPISDAQRESIIAAARGTSSSSFLQCSSIIRITDKAMREALVPLTGGQKHV
AQAAEFWVFCADFNRHLQICPDAQLGLAEQLLLGTVDTAMMGQNALTAAESLGLGGVYIGGIRN
HIEAVTERLKLPKYVLPLFGLCLGWPADNPGVKPRLPAELVVHENHYQPVDAALLAQYDEQIAEY
YLTRDSNTRRDTWSDHIRRTIIKENRPFILDYLHKQGWATR 
NfsA_Kp 
MTPTIELLRSHRSIRHFTDAPVSDEQRAEIIASAQAASTSSFLQCTSIIRITDPALRERLVPLTGGQQHV
AQAAEFWVFCADFNRHLQICPQAQLGLAEQLLIGVVDTALLAQNALTAAESLGLGGVYIGGLRNSI
EAVTELLELPQHVLPLFGLCLGWPADNPDIKPRMPAAMLVHENRYQPLDNALLAEYDEQLAHYY
LSRGSNARRDTWSDHIRRTIVKESRPFILDYLHKQGWATR 
NfsA_Eca 
MIPTIDLLQRHRSIRAFTSQAVTDEQRHAIIASAQSASSSSFLQCSSIIRITDPAVRETLIHYTGEQAYV
AQAAEFWVFCADFHRHVEIFPQAETGLAEQLLIGCVDTAIMAQNALVAAESLGLGGVFIGGIRNRI
ADVTQLLQLPTLVIPLFGLCLGHPDAEPQLKPRMPTAMMLHENVYQPLDRDVLAQYDQQMVEYY
LQRTGSRRESWSEHVELTLKKELRPFMLDYLHQQGWAIR 
NfsA_Vf 
MNPVIDTILEHRSIRSFTNEPISKEQLDTIISAGIAASSSSLLQVNSIIRITDKEKRKALVELSGGQPYVE
GAAEFLVFCIDFQRHYEMNPEIKAEFTELTLIGAVDAGIMAQNCLLAAESMGLGGVYIGGLRTNAQ
GVDDLLELPKNTAVLFGMCLGYPNQAPQKKPRLSPDVIVHENSYQPLDKSKIDEYDEIMQSYYAT
RSTNQKQSSWSEQITGKLSQESRPHIKGYLNNKGLAIK 
NfsA_Vv 
MNAVIDTLLSHRSIRKFTDQAITPEQLDTIIRAGLAASSSSLLQVVSIIRITDPAKRQQLAELAGPQHY
VETAAEFLVFCIDYQRHATLNSEVQAGFTELTLIGAVDAGIMAQNCLLAAESMGLGGVYIGGLRN
KAAEVDALLELPPFSAVLFGMCLGHPDQDPDLKPRLPAEVILHENHYQPLDLNKVEQYDQTMLDY
YGKRSSNQKQASWSEQVTGKLAGESRPHILPYLHSKGLATK 
Frp_Vh 
 
MNNTIETILAHRSIRKFTAVPITDEQRQTIIQAGLAASSSSMLQVVSIVRVTDSEKRKQLAQFAGNQA
YIESAAEFLVFCIDYQRHATINPDVQADFTELTLIGAVDSGIMAQNCLLAAESMGLGGVYIGGLRNS
AAQVDKLLGLPENSAVLFGMCLGHPDQNPEVKPRLPAHVVVHENQYQELNLDDIQSYDQTMQAY
YASSTSNQKLSSWSQEVTGKLAGESRPHILPYLNSKGLAKR 
 
NfrA_Bs 
MNNTIETILNHRSIRSFTDQLLTAEEIDILVKSAQAASTSSYVQAYSIIGVSDPEKKRELSVLAGNQPY
VENNGHFFVFCADLHRHQKLAEEKGENISELLENTEMFMVSLIDAALAAQNMSVAAESMGLGICY
IGGIRNELDKVTEVLQTPDHVLPLFGLAVGHPANLSGKKPRLPKQAVYHENTYNVNADDFRDTMN
AYDQTISDYYRERTNGQREETWSDQILNFMKQKPRTYLNDYVKEKGFNKN 
NfsA_Bc 
MNTIIETILNHRSIRHYEDRPLSDEQIRLIVESAQAAATSHFVQAYTILGIQDPGRKQRLAELTGNRH
VGTCGHLLIFCADLHKHALAAEMEGVDAQDTLETTEKFMVALIDTALAAQNAALAAESMGLGIC
YVGGLRNRLPEVAELLKIPQYVLPLFAMTIGYPADPSAKKPRMAAEHVYFEDEYPADERLLRDLK
EYNETVSQYYTKRTDGKRNDTWTGQMAQFFKEPSRVFMKEFVEHQGFDKK 
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NfsA_Bt 
MNEMIHKMEQHVSVRKYKEESIPKDVVEKMVHAAQHAASSHFVQAYSVIYVTDQELKAKLAELS
GNRHVKDCAAFFVCCADLKRLEIACEKHSTEIKHEGVEDFIVATVDASLFAQNLALAAESLGYGIC
YIGGIRNNPREVSELLHLPDKVYPVFGMTVGVPDEEHGVKPRLPVAAVLHENGYDEQKYDELLNE
YDETMNAYYKERPSNKKNVTWTESMSSFMSKEKRMHMKEFLSERGLNKK 
NfsA_Ls 
MSDLIAQMQHHVSVRNFEATPLSAEVKQQLIAAAQSGSSSNFVQAFSIIEVTDLALRTEIATISNSAS
YVNQTGTFYVFVADLYRQASMLKAQGQSLAGIQNMEALLVASVDTTIAAEDMAVAAESLGLGIC
YIGGIRNDIARVAELLGLPEYTVPLFGLTVGIPKTKNQVKPRLPQINQVAQNQYPRAQFADLKQYD
QQIADYYANRGSNQQQADWTSKNLDFFSAPRRPEVGAFLKKQGFTLA 
Ycnd_Bs 
MNEVIKSLTDHRSIRSYTDEPVAKEQLDQIIQAVQSAPTSINGQQVTVITVQDKERKKKISELSGGQP
WIDQAPVFLLFCADFNRAKIALEDLNDIKMEITNGLESVLVGAVDAGIALGTATAAAESLGLGTVPI
GAVRGNPQELIELLELPKYVFPVSGLVIGHPADRSAKKPRLPQEAVNYQETYLNQDELTSYIQAYD
EKMSEYMNKRTNGKETRNWSQGIASYYERLYYPHIREMLEKQGFKVEK 
NfsB_Ck 
 
MDIVSVALKRYSTKAFDPSKQLTADEAEKLKTLLQYSPSSTNSQPWHFIVASTEEGKARVAKSAAG
NFVFNERKMLDASHVVVFCAKTAMDDAWLDRVVDQEDADGRFATPEAKAANNKGRRFFADLH
RRDLKDDDQWMAKQVYLNVGNFLLGVAAMGLDAVPIEGFDAAVLDAEFGLKEKGYTSLVVVPV
GHHSVEDFNAALPKSRLPQETTLTEV 
NfsB_Kp 
MDIVSVALKRYSTKAFDATKKLTAGEAEQLKTLLQYSPSSTNSQPWHFIVASTDEGKARVAKAAS
GTYVFNERKILDASHVVVFCAKTAMDDAWLQRVVDQEEADGRFATPDAKAANHKGRTFFADMH
RKELKDDDQWMAKQVYLNVGNFLLGVAAMGLDAVPIEGVDFAILDEEFDLKAQGYTSLVVVPV
GHHSVEDFNATLPKSRLPQSTTITEI 
NfsV_Vv 
MTIVQAAQSRYSTKAFDASRKLPEEKVAAVKELIRMSASSVNSQPWHFIVASSEEGKARIAKATQG
GFAFNERKILDASHVVVFCAKTSIDEAYLLDLLQSEDKDGRFADVEAKNGMHAGRSFFVNMHRFD
LKDAHHWMEKQVYLNVGTLLLGASAMEIDAVPIEGFDAKVLDEEFGLREKGFTSVVIVPLGYHSE
DDFNAKLPKSRWPAETVFTEI 
NfsB_Es 
MNLNEIIRTRHTSKAYDNSRKLTAEQQQELLDLLRFSPSSVNSQPWHFFAVTTEEGKAQILPALMD
ANQVKAKNAAMTVVFTIKEELNEAHLLQLLEKEQQDGRYDGEEARAANDKGRRFFVGLNSETPE
QQREWMTRQAYLALGFLLLGAAAMGLDATPIEGFHPEKMDEVLGLKEKGLRSVVVATIGYRSDA
DFNATLPKSRLDQDVVITQL 
NfsB_Vh 
MSHQIITDLNNRYTAKKYDEEKRISQEDMAIIKEAIRLSASSINSQPWKFIVIESDEAKQRFHDTFAN
MHQFNQPHAKAASHTILLAYDPKFTKEKFAKRVDAEVTSGHLPADMYDMFMGAYAFAEANTDE
NGYNGGWTKAQVYIALGNLLHTLARLGIDSTPMEGVDPTLIGEEFKAELDGHVCEVALAIGYHKD
GEDYNHGLPKARLNMDDVITTL 
YfkO_Bs 
MADLKTQILDAYNFRHATKEFDPNKKVSDSDFEFILETGRLSPSSLGLEPWKFVVVQNPEFREKLR
EYTWGAQKQLPTASHFVLILARTAKDIKYDADYIKRHLKEVKQMPQDVYEGYLSKTEEFQKNDL
HLLESDRTLFDWASKQTYIALGNMMTAAAQIGVDSCPVEGFQYDHIHRILEEEGLLENGSFDISVM
VAFGYRVRDPRPKTRSAVEDVVKWV 
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YdgI_Bs 
MIKTNDFMEIMKGRRSIRNYDPTVKISKEEMTEILEEATTAPSSVNAQPWRFLVIDSPEGKEKLAPL
ASFNQTQVTTSSAVIAVFADMNNGDYLEEIYSKAVELGYMPQEVKDRQIAALTAHFEKLPAQVNR
ETILIDGGLVSMQLMLTARAHGYDTNPIGGYDKENIAETFGLDKERYVPVMLLSIGKAADEGYASY
RLPIDKIAEWK 
AzoR_Vv 
MSRLLVLKSSILGDYSQSNKLVDEFINKFDQQDVVVRDLAQQPLPVLDFQVATALRASGDLSEAQ
QAIVDLSDQLIAEIKHADTLIIAAPMYNFTVPTQLKNWIDLIARAGVTFTYTEQGPKGLIEGKKAVV
VTTRGGIHKDAASDIITPYLKTVLGFVGITEVEFVYAEALNMGEDFASKGLASASEHLAALTA 
 
NemA_St 
MSSAKLFTPLKVGAITATSRVFMAPLTRLRSIEPGDIPTPLMAEYYRQRASAGLIISEATQISAQAKG
YAGAPGLHSDEQIAAWKKITQGVHAQGGHMAVQLWHTGRISHASLQPGGQAPVAPSAINAGTRT
SLRDENGQAIRVETSTPRALDTHEIPGIVNDFRQAIANAREAGFDLVELHSAHGYLLHQFLSPSSNH
RTDRYGGSVENRARLVLEVVDAGIKEWGADRIGIRLSPVGTFQNVDNGPNEEADALYLIEALGKR
GIAYLHMSEPDWAGGEPYSDAFREKVRARFHGPIIGAGAYTPEKAEDLIEKGLIDAVAFGRDYIAN
PDLVARLQRKAELNPQRPESFYGGGAEGYTDYPTL 
NemA_Kp 
MSEAKLFSPLKVGAVTVPNRVFMAPLTRLRSIEPGDIPTPLMGEYYRQRASSGLIITEATQISAQAK
GYAGAPGLHSPEQIAAWQKITAGVHAENGHIAVQLWHTGRISHSSLQPGGAAPVAPSALSAGTRTS
LRYENGHAIRVDTSMPRALETAEIPGIVNDFRQAVGNARDAGFDLVELHSAHGYLLHQFLSPSANQ
RTDQYGGSVENRARLVLEVVDAVSQEWSAERIGIRVSPIGSFQNVDNGPNEEEDALYLISELAKRGI
AYLHMSEPDWAGGKPYSEAFRQKVRDRFPGVIIGAGAYTVEKANDLINKGLIDAVAFGRDYIANP
DLVARLQKKAALNPQRPESFYGGGAEGYTDYPTL 
NemA_Vv 
MSKLFEPTQLKQLDLLNRVVMAPMTRARTSQPGNIPNQMMATYYKQRATAGLIISEATQISDDSQ
GYSFTPGVYTDEQVAGWKLVTQAVKSQGAAMFCQLWHVGRVSHPVFQKGEQPIAPSALAPVETK
VWIADEQGNGNMVDCVEPRAMTQADIDRVVSDFAYAAKRAIEAGFDGIEIHGGNGYLIDQFLRTN
SNHRTDNYGGTRENRLRFLLEVVDAVSKAIGANKVGVRLAPFITFKDMNCPDIVPTILDASKQLQA
RDIAYLHLSEADWDDAPVIPESFRIELREYFTNTIIVAGSYTQARADEVLEKGYADLVAFGRPFVSN
PDLVARLKHQQPLAELDGATLFGGNERGYTDYTALHV 
YwrO_Bs 
MKILVLAVHPHMETSVVNKAWTEELSQHDNITVRELYKEYPNEAIDVAKEQQLCEQYDRIVFQFP
FYWYGSPPLLKKWQDLVLTYGWAFGSEGNALHGKELMLAVSTGSEAEKYQAGGANHYSISELLK
PFQATSNLIGMKYLPPYVFYGVNDATAEDISLSAKRLAEYIQQPFV 
YwrO_Li 
MKTLVIIAHPNIENSRVNRVWKEALLKSTEEVAIHELYEVYPNWDIDVTFEQQQLQNYDKVIIQFPF
YWYSYPPLLKKWFDDVFSYGWAYGSKGDKMAGKKLALAVSIGDKKYNYKEDAPIGYSLDTLLTP
FRATINHIRADYRGAHTIYGSSFEVTDEEIVENAYVYANKFIKTLN 
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Appendix 2: 
 
Table A2-1 All possible degenerate codons which designated only the NfsA_Ec wild type 
amino acid residue or the indicated mutant residue. Mutations chosen for inclusion into a 
multi-mutant gene library are marked as red while other possible codons are marked as blue. 
Codons calculated using online tool (http://guinevere.otago.ac.nz/cgi-bin/aef/AA-Calculator.pl).  
 
 
 
 
Mutation R12X S
Fold improvement (EF5/F-miso/Both)1 (1.6/1.7/3.3)
Possible redundancy codon MGC
S40X T W
(1.6/1.7/3.3) (1.4/1.8/3.2) 
WCT TSG
S41X M Q Y C G C+Y G+C
(2.1/2.9/5.0) (2.1/2.6/4.7) (1.9/2.6/4.5) (1.9/2.6/4.5) (1.8/1.6/3.4)
none none TMT WGT RGT TVT DGT
F42 N I W A R H
(2.2/2.0/4.2) (1.9/2.2/4.1) (1.8/2.0/3.8) (2.0/1.6/3.6) (1.5/2.0/3.5) (1.8/1.6/3.4)
none WTC none none none none
L43 D E
(1.4/1.3/2.7) (1.3/1.1/2.4)
none none
C45 M E L H D
(2.2/2.0/4.2) (2.2/1.7/3.9) (2.0/1.7/3.7) (2.2/1.1/3.3) (1.7/1.1/2.8)
none none none none none
F83 D G A R
(1.7/2.1/3.8) (1.6/1.8/3.4) (1.7/1.3/3.0) (1.7/1.4/3.1)
none none none none
L103 V Q
(1.7/1.3/3.0) (1.6/1.1/2.7)
STW CWG
N134 A R W
(1.7/2.3/4.0) (1.8/1.9/3.7) (1.6/0.8/2.4)
none none none
H215 R K
(1.4/1.5/2.9) (1.3/1.6/2.9)
CRT none
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Appendix 3:  
 
Table A3-1Table of mutations found in random clones from NfsA_Ec mutant library 
designed to specify either the wild type amino acid residue or the designated mutation at each 
targeted site.  
 
Table A3-2 Table of mutations found in random clones from NfsA_Ec mutant library 
designed to be able to have any of the 20 common amino acid residues, or one stop codon, at sites 
41, 45, 83 and 134.  
 
 
Random Clone R12S S40T S41C S41Y F42I C45L C45M L103V N134A H215R
1    
2    
3   
4   
5   
6    
7   
8      
9  
10    
Random Clone 41 45 83 134
1 K H V STOP
2 P A S S
3 E Q C G
4 STOP D L R
5 V S P C
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